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Abstract 
Mononuclear and binuclear (unsubstituted and substituted) palladacycles based on 
benzylidene-2,6-diisopropylphenylamine, were designed and synthesised for evaluation as 
anti-cancer agents. The design of these complexes was based on the structure and properties 
of AJ5, a binuclear palladacycle with significant anti-cancer activity, but poor solubility. In an 
attempt to improve water solubility the Schiff base ligands, employed to prepare the 
palladacycles, were modified by introducing hydrophilic functional groups on the aldehyde 
starting material. Furthermore, the µ-chloro bridged palladacycles were cleaved with either the 
hydrophilic tertiary phosphine, 1,3,5-triaza-7-phosphaadamantane (PTA), or bis(tertiary 
phosphine) ligands as a further attempt at improving the water-solubility, whilst maintaining 
the anti-cancer activity. The synthesised complexes were fully characterised by a range of 
analytical techniques. The solubilities of the palladacycles were determined in water, dimethyl 
sulfoxide and water/dimethyl sulfoxide mixtures. None of the complexes were entirely water-
soluble, however, the substituted binuclear palladacycles were found to show the highest 
solubility in dimethyl sulfoxide, with some analogues exhibiting improved solubility, compared 
to AJ5. 
NMR spectra of the mononuclear palladacycles showed that these PTA-cleaved, mononuclear 
palladacycles exhibit fluxional behaviour, especially with regard to the isopropyl substituents 
on the imine ligand. This fluxionality manifests itself as varying degrees of resolution of the 
isopropyl signals in the proton NMR spectroscopy, leading to this signal having different 
shapes depending on the nature of the imine ligand. The variety of peak shapes observed for 
the methyl signals of the isopropyl groups were thought to be due to a reversible symmetric 
site-exchange and fortunately this could be simulated by way of a computational model 
developed in-house. The free energy of activation (ΔG#) and other thermodynamic parameters 
for the site-exchange process were calculated and found to correspond with aryl ring rotation. 
Slight deviations in the expected chemical shifts were attributed to concentration-dependent 
chemical exchange processes. Both molecular aggregation via PTA self-association and 
dimerisation by imine dissociation were proposed and shown to be plausible. Furthermore, we 
were able to show that the “ortho effect” accounts for the influence of the ortho-substituents 
on the free energy of activation. We were also able to attribute the ability for these species to 
undergo the proposed chemical exchange processes to the phosphorous ligand, PTA, 
specifically its small cone angle and nitrogen donor atoms. 




In vitro evaluation of the mono- and binuclear palladacycles was performed to determine their 
biological activity as anti-cancer agents against human breast adenocarcinoma MCF7 
(estrogen receptor positive) and MDA-MB231 (estrogen receptor negative) cell lines. These 
studies show that most of the complexes are cytotoxic, with the binuclear palladacycles 
showing better activity than the mononuclear palladacycles. IC50 values of some of the 
palladacycles were better than those of cisplatin (below 20 μM) and the IC50 values for the 
substituted-binuclear palladacycle, BTC2, were found to be comparable to those of AJ5. The 
complexes were found to induce DNA damage and apoptosis. DNA binding studies were 
carried out on the most active palladacycle in each series to determine the mode of action. 
DNA binding studies by electrophoresis, ultraviolet-visible-, circular dichroism- and nuclear 
magnetic resonance spectroscopy suggest that the palladacycles bind to DNA non-covalently, 
by a mode different to that of cisplatin. The most likely mode of DNA binding was identified as 
an electrostatic binding mode. Thus, the formation of an aquated cationic species was 
proposed to form via hydrolysis of the Pd-Cl bond. 






Monokernige en bikernige (ongesubstitueerde en gesubstitueerde) palladasikliese 
verbindings gebaseer op die bensilideen-2,6-diisopropielfenielamien ligand, is ontwerp en 
gesintetiseer vir evaluering as kankermiddels. Die ontwerp van hierdie komplekse is gebaseer 
op die struktuur en eienskappe van AJ5, ‘n bikernige palladasikliese verbinding wat 
beduidende aktiewiteit as ‘n kankermiddel toon, maar deur swak oplosbaarheid belemmer 
word. In ‘n poging om die wateroplosbaarheid te verbeter is die Schiff-basis ligande, wat 
gebruik is in die voorbereiding van die palladasikliese verbindings, gemodifiseer deur die 
byvoeging van hidrofiliese funksionele groepe op die aldehied uitgangstof. Die µ-chloor 
oorbrugde palladasikliese verbindings is daarna gesplits deur die hidrofiliese tersiêre fosfien, 
1,3,5-triasa-7-fosfaadamantaan (PTA), of bis(tersiêre fosfien) ligande, as ‘n verdere poging 
om die wateroplosbaarheid te verbeter sonder om die biologiese aktiewiteit te belemmer. Die 
gesintetiseerde komplekse is volledig gekarakteriseer met ‘n reeks analitiese tegnieke. Die 
oplosbaarheid van die gesplete palladasikliese verbindings is in water, dimetielsulfoksied en 
‘n mengsel van water/dimetielsulfoksied bepaal. Geeneen van die komplekse is in water 
oplosbaar nie, maar die gesubstitueerde, bikernige palladasikliese verbindings toon die 
hoogste oplosbaarheid in dimetielsulfoksied. ‘n Paar van die bikernige palladasikliese 
verbindings toon ook beter oplosbaarheid as AJ5. 
KMR spektra van die monokernige palladasikliese verbindings wys dat hierdie PTA-gesplete, 
monokernige palladasikliese verbindings fluksionele gedrag toon, veral ten opsigte van die 
isopropiel substituente op die imien ligand. Die fluksionele gedrag manifesteer as die mate 
waarin die resolusie van die isopropiel sein in die proton KMR voorkom. As gevolg hiervan 
word daar ‘n reeks verskillende vorms vir hierdie seine, afhangend van die aard van die imien 
ligand, gevind. Die verskillende piekvorms wat waargeneem is vir die isopropiel metiel seine 
word geag om deur simmetriese plek uitruiling veroorsaak te word. Dit kan gelukkig deur 
middel van ‘n interne teoretiese model gesimuleer word. Die aktiveringsenergie (ΔG#) en 
ander termodinamiese parameters vir die plek verruiling is bereken en gevind om ooreen te 
stem met ariel ring rotasie. Effense afwykings vanaf die verwagte chemiese sein verskuiwing 
word aan konsentrasie-afhanklike chemise uitruiling prosesse toegeskryf. Beider molekulêre 
aggregasie deur self-assosiasie van PTA en dimerisasie deur imien dissociasie is voorgestel 
en gewys om haalbaar te wees. Daar is gevind dat die “orto effek” die invloed van die orto 
substituente op die aktiveringsenergie kon verklaar. Ons kon ook die vermoë van hierdie 
komplekse om die voorgestelde chemise uitruiling prosesse te ondergaan aan die fosfien 
ligand, PTA, toeskryf, spesifiek die klein keel hoek en die stikstof skenkeratome. 




In vitro evaluering van die monokernige en bikernige palladasikliese verbindings is uitgevoer 
om hul biologiese aktiwiteit as kankermiddels teen menslike bors adenokarsinoom MCF7 
(estrogeen reseptor positief) en MDA-MB231 (estrogeen reseptor negatief) sellyne te bepaal. 
Hierdie studies toon dat die meeste van die komplekse sitotoksies is en dat die bikernige 
palladasikliese verbindings better aktiewiteit toon as die monokernige palladasikliese 
verbindings. Die IC50 waardes van ‘n paar van die komplekse is beter as dié van cisplatin 
(onder 20 μM) en die IC50 waardes van die gesubstitueerde, bikernige palladasikliese 
verbinding, BTC2, was vergelykbaar met dié van AJ5. Daar is gevind dat die komplekse DNS 
dubbelstring breke en apoptose veroorsaak. DNS bindingstudies is uitgevoer op die mees 
aktiewe palladasikliese verbindings in elkeen van hierdie reekse, om die manier van interaksie 
te bepaal. DNS bindingstudies met behulp van elektroforese, ultraviolet-sig-, 
sirkulêredichroïsme-, kern magnetise resonansie spektroskopie dui daarop dat die 
palladasikliese verbindings DNS op ‘n nie-kovalente wyse bind, deur ‘n manier anders as dié 
van cisplatin. Die mees waarskynlikste manier van DNS verbind is geidentifiseer as ‘n 
elektrostatiese binding wyse. Dus was die formasie van ‘n kationiese spesies voorgestel wat 
vorm deur die hidroliese van die Pd-Cl binding. 
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Me  methyl 
MeCN  acetonitrile 
m.p.  melting point 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
N7  number 7 nitrogen atom in guanine nucleoside base 
NCI  National Cancer Institute 
NCI-analysis non-covalent interaction analysis 
NMR  Nuclear Magnetic Resonance 
NSCLC  non-small cell lung cancer 
OMe  methoxy 
Ox  oxalate 
PDT  photodynamic therapy 
Ph  phenyl 
pKa  acid dissociation constant 
ppm  parts per million 
PTA  1,3,5-triaza-7-phosphaadamantane 
QTAIM  quantum theory of atoms in molecules 
RAPTA  ruthenium/arene/PTA 
ROS  reactive oxygen species 
RPMI  Roswell Park memorial Institute 
sac  saccharinate 
TB  tuberculosis 
terpy  2,2’:6’,2”-terpyridine 
TMS  tetramethyl silane 





Palladium and its complexes 
as potential anti-cancer agents 
 
1.1 Introduction 
The first record of cancer can be found in a copy of an ancient Egyptian textbook on trauma 
surgery, viz. the Edwin Smith Papyrus, dating back to approximately 3000 BC. Eight cases of 
tumours or ulcers of the breast were recorded in this textbook. According to the text, the 
tumours were removed by cauterisation and it states that there is no treatment for the disease 
[1]. In 2012, the GLOBOCAN project estimated that there were 14.1 million new cases of 
cancer worldwide, 32.6 million people living with cancer and 8.2 million cancer related deaths, 
which amounts to approximately 22 thousand deaths a day [2]. This is a significant increase 
from the 12.7 million new cancer cases, reported in 2008. Five centuries since its discovery, 
cancer is responsible for one in eight deaths. Worldwide, it causes more deaths than AIDS, 
TB and malaria combined [3]. 
Cancer is defined as a “group of diseases characterised by uncontrolled growth and spread 
of abnormal cells” [3]. The causes of cancer are numerous and can be classified into two 
groups, external- and internal factors. External factors, known as carcinogens, include: 
chemicals (tobacco smoke is the most well-known respiratory carcinogen [4]), radiation and 
viruses, whilst internal factors include: inherited genetic mutations, hormones and immune 
conditions. Most types of cancer develop over a long period of time and are the result of 
multiple factors. All types of cancer involve the mutation of the genes which control cell growth, 
-division and -death [1;3]. Generally, however, the risk of developing cancer increases with 
age and exposure to carcinogens. Treatments range from surgery, radiation and 
chemotherapy to hormone and immunotherapy [1;3]. 
Oncology is the study of cancer which includes the fields of anatomy, physiology, 
epidemiology and chemistry. It is one of the most rapidly evolving areas of modern medicine, 
as is evident from the 15% decrease in mortality due to cancer since the 1990’s [1]. 
This review will focus on the latter field, viz. chemistry, more specifically the use of palladium-
based chemical compounds as chemotherapeutic agents. 




1.1.1 Transition metals as anti-cancer agents 
The term chemotherapy was defined by Paul Ehrlich, when he used it to describe the use of 
chemicals to treat a disease; however, it was not until the late 1960’s that curing cancer with 
drugs was even considered to be possible [5]. Traditionally, chemotherapeutic agents were 
organic molecules, as inorganic metal-based compounds were known to be carcinogenic [6]. 
Nevertheless, Paracelsus, the founder of the field of toxicology, quoted the following: “Dosis 
facit venenum”. Translated, it means that the dose makes the poison. He theorised that 
harmful or poisonous materials in small doses could be beneficial [7;8]. Despite his theory, 
research in the field of inorganic and organometallic compounds as anti-cancer agents only 
gained interest after the discovery of cisplatin, the first platinum-containing anti-cancer agent. 
 
1.1.1.1 Cisplatin and platinum anti-cancer drugs 
In 1969, Rosenberg and co-workers discovered the potential anti-cancer properties of cisplatin 
(cis-[Pt(NH3)2Cl2]) during a study to determine the effects of electrical current on the cell 
division of E.coli. It was noted that cell division was inhibited, but that cell growth was not, 
resulting in long filamentous cells instead of rods (Figure 1.1). This type of cell division 
inhibition is a sought after property in anti-cancer agents. Further investigation showed that 
the observed inhibition was not due to the electrical current, but rather due to platinum from 
the electrodes which was forming [PtCl6]- by platinum hydrolysis. This led to testing of other 
platinum complexes for similar properties. The complexes were tested in mice with sarcoma 
180. It was found that cisplatin (Figure 1.2) was the most effective of the complexes, resulting 
in complete inhibition of the development of a solid tumour [9]. 
 
Figure 1.1: Normal rod-shaped E.coli (left) and filamentous E.coli (right) [9]. 
 
Following Rosenberg’s work, testing was continued at the United States National Cancer 
Institute where cisplatin entered clinical trials. In 1971, the first patient was treated. Cisplatin 
has since been used to treat various cancers, including head and neck, ovarian and testis 
cancer, with a large number of patients being completely cured after treatment. Currently, it is 
one of the most successful anti-cancer drugs on the market. The discovery and success of 
cisplatin led to increased interest in the use of metal compounds to treat cancer [10-13]. 





Figure 1.2: Chemical structure of cisplatin. 
 
Despite the increase in research in the field of platinum-based anti-cancer agents and the 
thousands of compounds being synthesised and evaluated as anti-cancer agents every year, 
only a limited number of platinum complexes have entered clinical trials and been approved 
for clinical use. The main problems with these new platinum compounds were severe toxicity, 
limited application and drug-resistance. This lack of advancement, coupled with limited 
application of the approved drugs due to toxicity, led to the ongoing search for new anti-cancer 
agents with increased specificity, reduced toxicity and the ability to overcome resistance [14]. 
 
1.1.1.2 Alternative transition metal anti-cancer drugs 
Over the years, many different transition metals have been tested as anti-cancer agents, 
including vanadium, iron, copper, ruthenium, palladium, silver and gold [14;15]. 
Among the more promising transition metal-based drugs are those of ruthenium, specifically, 
the ruthenium/arene/PTA or RAPTA (where PTA is 1,3,5-triaza-7-phosphaadamantane) 
complexes (Figure 1.3). Essentially, these complexes consist of an arene-capped ruthenium 
(II) centre and contain the water-soluble phosphine ligand, PTA. 
 
Figure 1.3: RAPTA complexes. 
 
First discovered by Dyson et al., these structures present an ideal scaffold for rational drug 
design [16]. Not only do they exhibit favourable pharmacokinetic properties, but their 
pharmacological properties are promising, as well [17]. As with many ruthenium complexes, 
the RAPTA complexes have a pH dependant mechanism which makes them highly selective 
for cancer cells in vitro and well tolerated in vivo. Despite having lower cytotoxicity than 
platinum-based drugs, the overall lower toxicity and controllable chemistry of these ruthenium 
complexes makes them very good candidates for clinical evaluation [18].




Another metal, notorious for its toxicity, yet surprising with respect to its therapeutic capability, 
is arsenic. The arsenic complex, arsenic trioxide (A2O3), was first reported to have anti-
leukemic properties in the 1800’s (Figure 1.4), whilst orally administered potassium arsenite 
(K3AsO3) was used in the 1950’s to treat chronic myelogenous leukaemia. Both drugs were 
later discarded in favour of more modern treatments. 
 
Figure 1.4: Chemical structure of arsenic trioxide. 
 
However, recently arsenic compounds have resurfaced in medicinal applications, driven by 
the discovery of the efficacy of arsenic trioxide against acute promyelocytic leukaemia (APL). 
In 2000, the Food and Drug Administration (FDA) approved arsenic trioxide for the treatment 
of relapsed and refractory APL [19;20] by intravenous administration. By 2003, a group at the 
University of Hong Kong reported the redevelopment of an oral preparation of arsenic trioxide, 
as an alternative to the current intravenous administration. Preliminary studies with the orally 
active drug showed results comparable to those of the intravenously administered form [20]. 
In contrast to the examples given above, research into palladium-based complexes has been 
rather disappointing in terms of progress beyond the laboratory. Based on the similarities in 
the physical and chemical properties of platinum and palladium and the proven near identical 
coordination chemistry of the Pd2+ and Pt2+ oxidation states, there is some degree of 
expectation for analogous complexes to have comparable properties. Aside from the early 
studies of palladium complexes, which proved rather insignificant with regards to anti-cancer 
activity, there are several examples of palladium(II) complexes with significantly lower toxicity 
than their platinum(II) counterparts and comparable activity throughout the literature. Recently, 
an example of a palladium complex with 10-fold higher activity than cisplatin was reported by 
ourselves [21;22]. Despite some promising results, there has been little to no progress beyond 
laboratory evaluation of these palladium complexes. To date, there are only a few 
photodynamic therapy palladium-based drugs in clinical trials [23]. 
 
1.1.2 (A closer look at) Palladium 
Although palladium is best known for its use as catalysts for a range of organic 
transformations, it has been shown to have promising biological activity. Radioactive 
palladium and palladium complexes with chlorophyll-type ligands have been successfully 
employed as brachytherapy- and photodynamic therapy agents against cancer, respectively 
[24]. 




Brachytherapy was discovered soon after the discovery of X-rays in 1895. It was Pierre Curie, 
who proposed that a small tube of radioactive radium be inserted directly into a tumour, thus 
inventing the term “brachytherapy” [25]. By the early 1970s, brachytherapy had been proven 
to be successful in increasing the life expectancy of cancer patients. Currently, brachytherapy 
is used as a less invasive form of radiation therapy, where small radioactive seeds 
(theraseeds) are implanted into the tumour (Figure 1.5) [26]. 
 
Figure 1.5: Image of a theraseed [26]. 
 
Radioactive palladium-103 (103Pd) seeds (Figure 1.6), were introduced in 1986 and are 
currently in clinical use as an alternative to radioactive iodine-125 (125I). The palladium-103 
isotope is a source of low energy photons, with a half-life of 17 days. This results in a 
significantly decreased dose with increasing distance from the source relative to that of higher 
energy photons, such as those generated by the decay of iodine-125. This ensures that the 
radiation is localised and that radiation exposure to people in contact with patients undergoing 
brachytherapy is limited. Furthermore, the short half-life of palladium-103 provides higher 
initial dose rates than iodine-125, which has a half-life of 60 days [27]. These differences make 
palladium-103 a safer alternative to iodine-125, with fewer complications; however, both are 
frequently used in treatments [28;29]. 
Photodynamic therapy (PDT) is a cancer treatment where an inactive form of the drug is 
administered and is then locally activated and controlled by light. The principle is to administer 
a non-toxic photosensitiser and then activate it at which point, it generates cytotoxic reactive 
oxygen species (ROS) which are responsible for cell death and necrosis. Damage is limited 
or localised as the drug is only activated in a specific target area. Selectivity of PDT drugs is 
usually based on differential drug accumulation within tumour- and normal tissues. PDT has 
been used to treat a range of different cancers. Palladium-bacteriopheophorbide (TOOKAD), 
shown in Figure 1.7, is a fast acting PDT drug which leads to vascular thrombosis and 
secondary tumour destruction, clearing the system within a few hours. This drug is currently 
involved in clinical trials, evaluating its efficacy against prostate cancer. Thus far, it has proven 
to be as safe and effective as current photosensitisers, with the added benefit of having a 
rapid clearance rate [30;31].






Figure 1.6: Diagram of palladium-103 theraseed design [32]. 
 
 
Figure 1.7: Chemical structure of TOOKAD. 
 
1.1.3. Platinum vs. palladium with respect to designing chemotherapeutics 
As mentioned previously, platinum and palladium have very similar physical and chemical 
properties, with the exception of their ligand exchange kinetics. The ligand exchange rate for 
palladium is 105 times faster than that of platinum. The most significant implication of this 
difference, in terms of designing chemotherapeutic agents, is that palladium species will be 
far more reactive in biological environments than their platinum analogues. 
Considering the similarities between platinum and palladium, especially their very similar 
coordination abilities, and the overall lower toxicity of palladium, it is plausible that palladium 
complexes could be used for synthesising analogues of existing platinum anti-cancer drugs 
which are more active and less toxic [33].




The next section will discuss some of the significant developments in the design of palladium 
anti-cancer drugs, as well as the more the promising complexes reported in the literature. The 
work discussed below is aimed at providing a timeline for the developments and discoveries 
in this field and to establish a guide for future investigators. This review is by no means a full 
account of all the palladium complexes designed as potential anti-cancer drugs. 
 
1.2 Palladium complexes as anti-cancer agents 
1.2.1 Palladium analogues of platinum drugs (1970s-1980s) 
Following the success of cisplatin, Cleare published a review in 1974, with the aim of 
encouraging research in the direction of inorganic coordination complexes [34]. The ideal anti-
cancer drug was defined as having selective toxicity for cancer cells. It was also pointed out 
that a drug such as this was yet to be discovered. In the review, it was speculated that 
palladium(II) complexes were too reactive to be effective in vivo, due to the significantly higher 
ligand exchange kinetics of palladium, as compared to platinum. This was based on the lack 
of activity of some reported palladium(II) analogues of active platinum(II) complexes when 
tested against Sarcoma 180 in Swiss white mice [35]. Even the more stable palladium 
complexes, with bidentate ligands, showed unimpressive results. The activity for these 
complexes was measured as the weight of a treated tumour compared with that of an 
untreated (control) tumour, also referred to as a T/C value (Table 1.1). T/C values below 50 
were considered to be significant, however, none of the tested complexes met this requirement 
[34]. 
Table 1.1: In vivo results for palladium(II) analogues of active platinum(II) complexes. 
Complex Dose range (mg/kg) Toxicity level (mg/kg) T/Ca 
cis-[Pd(NH3)2Cl2] 1.25-10 >10 83 
[Pd(en)Cl2] 5-40 >40 79 
[Pd(NH3)2mal] 25-200 150-200 55 
[Pd(en)mal] 25-100 >100 75 
[Pd(en)ox] 1.25-75 >40 104 
[Pd(NH3)2ox] 1.25-200 ~100 80 
Abbreviations: en: ethylenediamine; mal: malonate; ox: oxalate. aWeight of treated tumour compared to 
control tumour (expressed as a percentage). 




During the same period (1979), Graham and Williams [36] followed the research trends set by 
Furst [37] and Rosenberg [9] to consider the incorporation of group VIIIB metals into potential 
anti-cancer drugs. They studied the anti-bacterial, -cancer, -viral and fungicidal properties of 
several palladium and nickel complexes. Table 1.2 is an abbreviated table, showing the anti-
cancer screening data for the palladium complexes tested. From their results, they concluded 
that active palladium complexes do not follow the structural criteria, as determined for active 
platinum complexes. This is clear from entries 4-6, for compounds which do not have nitrogen 
donor atoms (with at least one active hydrogen) in their carrier ligands, as stipulated for 
designing active platinum drugs, yet these complexes are active. Entry 3 is another example 
of a complex which is biologically active, yet its octahedral geometry does not allow for metal-
metal stacking, a property thought to be essential for anti-cancer activity, based on cisplatin 
and other active platinum anti-cancer drugs. Furthermore, they were able to confirm that 
selectivity varies with the central metal ion, in the same way that it varies with nitrogen ligand 
substitution in the platinum species. Their most significant observation was that the neutral 
species was the active drug in the case of platinum complexes, whereas palladium complexes 
exchange ligands too quickly for the initial neutral complex to be the active species. Thus, the 
anions, PdCl62- and PdCl42-, were the more likely active species. This observation cleared up 
the misconception that palladium complexes are inferior to their platinum counterparts, as 
initially found by Cleare and Hoeschele [35]. This publication brought to light one of the issues 
still of concern today, the need to determine the nature of the active species under 
physiological conditions [36]. 
Further studies looking at the palladium analogues of cisplatin and its derivatives were 
reported in 1990 by Castan et al. [38]. By this time, a handful of palladium complexes with 
nitrogen-donor ligands, [Pd(L)(NO3)2] [where L = ethylenediamine (en), bipyridine (bipy) or 
1,2-diaminocyclohexane (DACH)], had been reported to have “noticeable” activity against 
sarcoma 180 [39], yet the overall results remained unsatisfactory in comparison to the 
platinum analogues. The authors ascribed these “disappointing results” to an inappropriate 
selection of ligands, suggesting that the ligands were not lowering the reactivity of the metal 
sufficiently for the complex to be active. Their hypothesis was that the high reactivity of 
palladium could be counteracted by relatively inert leaving groups and that cis-trans 
isomerisation could be prevented by suitable ligands, such as chelating ligands. In an attempt 
to prove their hypothesis, they tested platinum and palladium complexes with the general 
formula, N2ML, where N2, the inert ligand, was one mole of DACH or 2 moles of ammonia, M, 
the metal and L, the leaving group, was the dianion of 3-methyl orotic acid. The complexes 
were tested against leukemia cell lines, L1210 and P388, in CDF1 hybrid female (BALB/C x 
DBA/2) mice and sarcoma 180 cells in Swiss mice. The highest non-lethal dose (LD0) values 




and T/C values were reported, where T/C was defined as the median survival time of the 
treated mice (excluding the survivors) compared to the median life span of untreated mice, 
expressed as a percentage. In this case, a T/C percentage of 125 or greater indicated 
significant activity. The results are shown in an abbreviated table, Table 1.3. 











cis-Pd(NH3)2Cl2 100% at 1.95 75% at 12.5 1.6% at 25 0 at 50 




100% at 15.6 
55% at 1.9 
92% at 50 86% at 100 0 at 50 
Na2PdCl6 
100% at 7.8 
25% at 1.9 
36% at 50 2.5% at 50 0 at 50 
(NH4)2PdCl4 
100% at 15.6 
60% at 3.9 
49% at 50 11% at 50 0 at 50 
enH2PdCl4 
100% at 7.8 
76% at 1.9 
34% at 25 27% at 50 0 at 50 
(πC3H5PdCl)2 
100% at 1.9 
34% at 0.04 
0 at 12.5 40% at 12.5 Toxic at 12.5 
Pd(cyclopent)2Cl2 100% at 3.9 
14.7% at 50 
70.3% at 25 
4.0% at 50 




100% at 31.25 
31.2% at 50 
6.4% at 25 
13.3% at 50 




100% at 3.9 
11.1% at 50 
63.0% at 25 
0 at 50 
27.4 at 25 
 
Pt(cyclohex)2Cl2 100% at 1000 
63.3% at 50 
49.6% at 25 
0 at 50 
0 at 25 
 
Pd(asn)Cl2 
100% at 250 
27% at 1.9 
   
Pd(asn)2 
(pale yellow isomer) 
100% at 31 
64% at 1.9 
   
Pd(asn)2 
(lilac grey isomer) 
100% at 62.5 
54% at 1.0 
   
Abbreviations: en: ethylenediamine; cyclopent: cyclopentylamine; cyclohex: cyclohexylamine; asn: asparagine. 
aPercentage inhibition at μg/mL concentration. bPercentage inhibition at mg/kg/dose concentration. cPercentage 
inhibition at mg/kg/dose concentration. 
 
 




Table 1.3: In vivo anti-tumour activity of N2ML-type complexes against Sarcoma 180 [38]. 






















Abbreviations: 3-Me-orot: 3-methyl orotic acid. aMedian survival time of treated mice 
(excluding the survivors) compared to the median life span of untreated mice (expressed as 
a percentage). 
 
From Table 1.3, the complex reported by Gill in 1984 [39], [Pd(DACH)(NO3)2], had reasonable 
anti-tumour activity, despite the potential for isomerisation in aqueous media. Furthermore, 
[Pd(DACH)(3-Me-orot)], where 3-Me-orot = 3-methyl orotic acid, had significant activity with 
T/C values of 150 and 267, which is higher than that observed for Gill’s complex. Another 
observation was the significant drop in activity for the platinum analogues containing the 
orotate anion. This could be ascribed to the reduction in reactivity due to the strong chelating 
effects of the orotate anion. 
The low activity observed for [Pd(NH3)2(3-Me-orot)] was thought to be due to isomerisation 
from the cis isomer to the thermodynamically stable trans isomer, thus rendering the species 
inactive, in the same way that [Pd(NH3)2Cl2] is inactive compared to its platinum counterpart 
which is not plagued by the trans-effect. 
Despite this lack of activity and the very limited number of active palladium complexes, 
researchers were not discouraged, as Kirschner et al. had already proven that a palladium 
complex could have significant anti-cancer activity. In 1966, they published their paper, “Anti-
cancer and Potential Anti-viral Activity of Complex Inorganic Compounds” where they studied 
twenty-six inorganic compounds for their ability to alter cancer-producing viruses. They 




proposed that these compounds would target the protein and nucleic acid units in the virus, 
by coordination or chelation of the metal ion to atoms in these large macromolecules, thus 
altering the structure of the macromolecules and consequently the virus. They looked at 
platinum metals, as these are good sulphur coordinators, aluminium metals were considered 
for their oxygen-binding potential and iron and cobalt were selected as nitrogen coordinators. 
The ligands employed were chosen for their inherent biological activity. 
Five of the compounds showed significant anti-cancer activity and in each case, the activity of 
the complex was higher than that of the ligand. Na2[Pt(mp)2Cl4]·2H2O, Na2[Pd(mp)2Cl2]·H2O 
and [Pd(butp)3Cl]Cl (where mp = 6-mercaptopurine and butp = butylthiopurine) were among 
the active compounds. The results in Table 1.4 show that palladium can not only exhibit similar 
activity to its platinum analogues, but that palladium-based compounds as anti-cancer agents 
is a valid and worthwhile field of research [40]. 
Table 1.4: Anti-tumour activity results for active complexes with biologically active ligands, 6-mercaptopurine and 
butylthiopurine [40]. 




% tumour weight 
decrease 
Na2[Pt(mp)2Cl4]·2H2O 
























aSwiss mice used as host. bBDF1 mice used as host. 
 
1.2.2 Palladium and its lability solved (1990s) 
The work by Khan and co-workers, in 1991, generated the first genuine interest in palladium 
complexes as anti-tumour drugs [41]. As mentioned previously, the lability of palladium 
complexes posed a problem for application as anti-cancer agents. Khan and co-workers 
reasoned that if the palladium complexes could be stabilised enough to reach their biological 
targets, they could be tested as anti-tumour agents. Much the same as the approach by 
Castan et al. [38], they made use of chelating ligands, such as methionine (meth) and 
mercaptopyrimidine (mercaptopy), to reduce the lability of mixed ligand complexes of cis-
dichloromethioninepalladium(II). At this early stage of the investigation into palladium-based 
anti-tumour agents, the requirement for these complexes to be considered as potential anti-




tumour agents, was that they would have to exhibit half maximal inhibitory concentration (IC50) 
values of 10 μg/mL or lower. 
 
Figure 1.8: Chemical structure of [Pd(meth)(2mercaptopy)Cl]Cl. 
 
The anti-tumour activity of the six reported square planar complexes was evaluated by in vitro 
cytotoxicity against CHO (Chinese hamster ovary) and Hela (Epidermoid Carcinoma Cervix) 
cell lines. Based on the results, chloro2-mercaptopyrimidinemethioninepalladium(II)chloride 
{[Pd(meth)(2mercaptopy)Cl]Cl}, shown in Figure 1.8, proved to be the most cytotoxic with IC50 
values in the range of 6.25 μg/mL and 6.17 μg/mL for the CHO and Hela cell lines, respectively. 
This complex not only met the requirement, but showed that palladium complexes could 
indeed be powerful anti-tumour agents [6;41]. 
In the early 1990’s, Navarro-Ranninger and co-workers published a paper on the use of 
spermidine [(N-(3-aminopropyl)-1,4-diaminobutane), (sper)] as the ligand in palladium(II) 
complexes to be evaluated as potential anti-tumour agents [42]. Based on previous work, such 
as the examples discussed above, this chelating ligand was selected for its biological activity 
and the ability to reduce the reactivity of the palladium metal centre, as well as the potential to 
manipulate the cis-trans isomerisation to favour the formation of the active cis isomer. They 
were able to prove that [PdCl2(sperH)]2[PdCl4] and [(PdCl2)3(sper)2] (Complexes 1 and 2 in 
Figure 1.9) had similar or enhanced activity compared to cisplatin, against MDA-MB 468 
breast cancer cells, as shown in Table 1.5. 





Figure 1.9: Palladium complexes with spermidine ligands [42]. 
 
 
Figure 1.10: Electrophoresis gels showing changes in electrophoretic mobility of the oc and ccc forms of the pUC8 plasmid 
DNA. Lanes 7-9 are the controls, K2PdCl4, spermidine and cisplatin. (A) shows the results for [(PdCl2)3(sper)2] in lanes 
labelled a. (B) shows the results for [PdCl2(sperH)]2[PdCl4], with increasing Pd/nucleotide concentrations [42]. 
1 
2 




Table 1.5: In vitro testing results of palladium complexes with spermidine-type ligand [42]. 





a50% inhibition of cell growth. 
 
Furthermore, they investigated the drug-induced changes in DNA conformations, by studying 
changes in the electrophoretic mobility of covalently closed circular (ccc)- and open circular 
(oc) plasmid DNA (Figure 1.10). Both complexes induced changes in both the ccc and oc 
plasmids, but the change observed for [PdCl2(sperH)]2[PdCl4] is far more significant. The 
change in electrophoretic mobility is even more extensive than the change observed for 
cisplatin (lane 9) [42]. 
With these promising results in hand, they extended their study of these types of complexes, 
using both putrescine [(1,4-butanediamine), (put)] and spermine {[N,N’-bis(3-aminopropyl)-
1,4-butanediamine], (sperm)} as ligands. As shown in Figure 1.11, the ligands were used as 
bridging ligands to form binuclear complexes. These complexes were again evaluated against 
the MDA-MB 468 cell line. The ID50 values obtained for compounds 3-5 are considerably more 
favourable, compared to the value obtained for cisplatin (Table 1.6) [43]. 
Table 1.6: Anti-proliferative activity of Pd(II) putrescine and Pd(II) spermine complexes [43]. 
Complex ID50 values (μg/mL)a Dose (μM) 
[PutH2][PdCl4] (3) 0.39 1.60 
[Pd2Cl4(Put)2] (4) 0.37 0.70 
[PdCl2(Put)]+ [Pd2Cl4(Put)2] (5)  0.42 0.53 
[PdCl2(SpermH2)][PdCl4] (7) 7.25 11.51 
[Pd2Cl4(Sperm)] (6) 4.70 8.44 
K2PdCl4 1.79 5.50 
Cisplatin 0.80 2.50 
Abbreviations: Put: putrescine; Sperm: spermine. Compound structures are reported in Figure 1.11. 





Figure 1.11: Palladium complexes with putrescine and spermine ligands. 
 
As with the previous complexes, the drug-DNA interactions were investigated. UV-Vis- and 
CD spectroscopy, as well as electrophoresis, were used. Plasmid DNA was used for all of 
these assays, instead of linear DNA, which is more common in current literature on 
spectroscopic techniques for investigation DNA-binding studies. UV-Vis spectra showed that 
the complexes induced a hyperchromic effect, which is the opposite of the effect induced by 
the ligands. Similarly to cisplatin and K2PdCl4, [PdCl2(SpermH2)][PdCl4] and [Pd2Cl4(Sperm)] 
induced a bathochromic shift, as well. These observations pointed to drug-induced 
conformational changes in the secondary structure of the DNA, more specifically, a distortion 
of the base stacking. CD spectra showed shifted and decreased intensities for both the 
positive and negative ellipticity values. In this instance, the most significant changes were 
observed for [Pd2Cl4(Put)2] and [Pd2Cl4(Sperm)], along with the controls, K2PdCl4 and cisplatin. 
The changes point to the opening and rotation of the stacked bases in the DNA double helix. 
The electrophoresis data, however, showed no change in the electrophoretic mobility of the 
oc form, as was observed for the control compounds. This suggests that these compounds do 









previously with the control compounds. The complexes with putrescine as ligand, retarded the 
mobility of the ccc form of the pUC8 plasmid DNA. [Pd2Cl4(Put)2] had a higher retention of the 
ccc form than cisplatin. Based on these results, it was concluded that Pd(II) putrescine 
complexes altered both the secondary and tertiary structure of DNA. These changes are likely 
the formation of local microloops which result in partial uncoiling of the DNA helix. This 
suggested that the spermine and putrescine ligands result in the formation of different adducts. 
Navarro-Ranninger and co-workers made a significant contribution to research in this area by 
showing just how significant the correct choice of ligand is and how extensive the effects can 
be in terms of drug-DNA interaction and anti-proliferative activity. Another important 
observation was made in that the spectroscopic data suggest that both the Pd(II) putrescine 
and the Pd(II) spermine complexes produced similar degrees of modification in the DNA, whilst 
the in vitro assays showed that the Pd(II) putrescine complexes possessed higher anti-
proliferative activity. The in vitro and in vivo data cannot necessarily be correlated, as there 
are numerous factors which could cause these differences, but it should again become clear 
that testing potential anti-cancer activity by only one assay or method is insufficient to obtain 
a true indication of the anti-cancer potential of a compound [43]. 
Realising the importance of ligand choice, Higgins III et al. [44] followed the work by Newkome 
[45] and others, from as early as 1985, where bidentate bipyridines were observed to form 
palladacyclic complexes capable of binding to DNA [45]. Based on this literature, 
phenanthroline ligands were investigated for their planarity, as a planar ligand may result in a 
planar complex capable of intercalating into the DNA double helix. This ability to intercalate 
into the DNA helix was a sought after property for potential anti-cancer agents at the time 
[44;46]. Figure 1.12 depicts the intercalation of ethidium bromide, a well-known DNA-
intercalating agent, into the DNA helix. 
 
Figure 1.12: Planar structure of ethidium bromide (left) and diagram showing the intercalation of ethidium bromide into 
the DNA double helix (right) [47]. 




When investigating their own complexes with phenanthroline-type ligands in 1989, Higgins III 
et al. discovered a unique palladacycle compound, complex 8 (Figure 1.13) [48]. Complex 8 
is a mononuclear palladacycle with 2-arylphenanthroline as ligand. Evaluation of this complex 
against a tumour panel showed “potent” anti-cancer activity (Table 1.7) [44;46]. 
After their initial success, they continued their investigation into the use of amine ligands in 
1993, where they studied various amines for their bridge opening abilities, thus forming 
mononuclear complexes from binuclear bridged palladacycles [44]. 
 
Figure 1.13: Unique palladacycle complex, complex 8, and the follow up complex 9 (where L = pyridine for 9a and iPr-NH2 
for 9b), both reported by Higgins III et al. [44]. 
 
Table 1.7: Anti-cancer activity of complex 8 and complex 9 [44]. 
Human Cancer 
Cell Line 
IC50 value (μM) 
Complex 8 Complex 9a Complex 9b 
SW6020 5 44 30 
SW1116 7 44 26 
SW403a 6 - - 
ZR75-1 7 50 9 
HT1376 8 8 9 
SK-OV-3 7 20 10 
aNo data obtained. 
 
Their choice of mononuclear target compounds over the dimeric species was based on 
solubility considerations. The limited solubility of the dimeric complexes in most organic 
solvents forced them to consider lower molecular weight species. Therefore, they considered 
the mononuclear analogues, as these lower molecular weight complexes were more likely to 
be soluble. The use of amines was based on earlier work where these ligands produced 
complexes with DNA binding ability, which could lead to anti-tumour activity, as well as their 
potential to increase solubility. Both aromatic and aliphatic amines were used. Most of the 
9a/b 
8 




complexes were found to have improved solubility and two of these complexes were found to 
be water-soluble. When evaluated for their cytotoxicity against a number of cancer cell lines, 
most of the complexes displayed IC50 values in the range of 10 μg/mL across the panel, 
making them effective, but not necessarily selective for different cells, be it various cancerous 
cell lines or healthy cells. However, the complexes derived from N,N-dimethylbenzyl amine, 
complex 9a and 9b (where L = pyridine for 9a and L = iPr-NH2 for 9b), displayed differential 
cytotoxicity. A 3-5 fold difference in activity was observed between the HT1376 and the 
SW6020 cell lines, making these the most promising leads for the design of an effective yet 
less toxic drug [44]. 
 
1.2.3 Cis and trans isomers (early 2000s) 
In 2001, Al-Allaf and Rashan synthesised a large number of novel palladium complexes in 
both their cis and trans forms. A variety of ligands were employed, including pyrazoles, DMSO 
and ferrocenylphenylphosphanes. The complexes were tested against a series of tumour cell 
lines and solid tumours. The results showed that trans-palladium complexes are generally 
more cytotoxic than their cis-palladium and -platinum analogues. Some of these complexes 
were also more active in vitro, than cisplatin, carboplatin and oxaliplatin [49]. This followed on 
the earlier work by Tusek-Bozic and co-workers, who reported trans-palladium complexes with 
mono- and diethylphosphonate ligands for improved solubility, as potential anti-cancer agents. 
Their results showed that the trans-palladium complexes have improved activity with respect 
to their cis analogues. A representative structure is shown in Figure 1.14 [46;50;51]. 
 
Figure 1.14: Representative structure in early work on active trans-palladium complexes as anti-tumour agents. 
 
Abu-Surrah and co-workers reported on a chiral trans-palladium complex with a bulky amine 
ligand, endo-(1R)-1,7,7-trimethylbicyclo[2-2-1]-heptan-2-amine [52], the year after the 
extensive work by Al-Allaf and Rashan [49]. This complex was evaluated against three cell 
lines, L929 (murine fibrosarcoma), K562 (human myelogenous leukemia) and HeLa (human 
cervical carcinoma) cells. The results again showed similar activity to the standard platinum 
drugs, cisplatin, carboplatin and oxaliplatin [46;52]. 




It is well known that trans-platinum complexes are generally inactive as anti-cancer agents; 
hence the early studies of palladium complexes considered cis isomers, assuming the same 
structure rules applied to palladium, yet here clear violations of these rules were observed. 
The trans-palladium species not only outperformed their cis isomers, but also the cis-platinum 
analogues. From these results, it was clear that the known structure-activity rules for designing 
active platinum drugs did not apply to palladium drugs. This also suggested that palladium 
drugs may have a different mode of action to platinum drugs. 
 
1.2.4 Significant complexes and their influence on palladium drug design (2000-2015) 
Research leading up to the early 2000s proved that the structure-activity relationship for active 
platinum complexes cannot be applied in the design of active palladium anti-cancer drugs. 
However, based on the early research, it is clear that chelating or strongly binding ligands are 
necessary for reducing the reactivity of the metal centre in order to obtain an active compound. 
Aside from this requirement, researchers could try almost anything. In the following sections, 
we report some of the more successful designs. 
In 2003, Rodrigues et al. reported palladacycles with the bisphosphinic ligand, dppe [11]. The 
dppe ligand was used to decrease the lability of palladium and to stabilise the complex. This 
should allow for the use of lower dosages and consequently lower toxicity. These complexes 
showed promise as anti-tumour agents against a syngeneic B16F10 murine melanoma model, 
both in vitro and in vivo. The novel palladacycles were classified as ionic mononuclear 
[Pd(C,N-cycle)(dppe)Cl], molecular mononuclear [Pd(C2,N-cycle)(dppe)Cl] and binuclear 
[Pd2(C,N-cycle)2(μ-dppe)Cl2] complexes. 
 








In vitro evaluation of the compounds against B16-Nex2 cells (subline of B16F10 murine 
melanoma model) showed that complexes 10, 11a and 11b (where 11a and 11b were the 
S(-) and R(+) enantiomers, respectively) were highly active, resulting in 100% tumour cell 
death at concentrations below 1.25 μM (Figure 1.15), whilst the other complexes required 
concentrations above 10 μM to produce the same effect. When these three complexes were 
evaluated in vivo, only complex 11a showed anti-tumour activity; however, it is important to 
note that none of the complexes were toxic to the host mice, even at a dosage of 
60 μM/animal/week (where a 1 mM stock solution of 11a was prepared in 1% DMSO in 50 
mM phosphate buffer and further dilution was achieved with phosphate-buffered saline). 
Evaluation of the other complexes in vivo, showed that two of the less active complexes 
(based on the in vitro work), [Pd(o-NC5H4)(Cl)C=C(Ph)(dppe)Cl] and [Pd(CH2-
N(CH3)2(Cl)C=C(Ph)(dppe)], were active and showed similar activity to complex 11a. Further 
investigation of these three active complexes showed that all three induced an apoptosis-like 
effect in the tumour cells via a caspase-1 and caspase-3 independent pathway. 
The binuclear complex 11a showed good activity in both in vitro and in vivo testing with 100% 
cell death occurring at a concentration lower that 1.25 μM [11]. Interestingly, however, the two 
mononuclear palladacycles showed very little activity in vitro, yet in vivo they showed 
significantly improved activity. 
Circular dichroism spectroscopy, a spectroscopic technique used to elucidate changes in 
secondary structure of macromolecules upon interaction with potential drug complexes, was 
used to determine if the complexes interacted with DNA. Complex 11a was found to interact 
with plasmid DNA, inducing changes in the CD spectrum, as shown in Figure 1.16. These 
changes suggested that the complex intercalated between base pairs in the DNA double helix. 
This work emphasises the potential of palladacycles with dppe ligands as highly active anti-
tumour agents, both in vitro and in vivo [11]. 





Figure 1.16: CD spectra of DNA and complex 11a [11]. 
 
Ray et al. reported on palladium N-heterocyclic carbene (NHC) complexes with 1-benzyl-3-
tert-butylimidazol-2-ylidene as the ligand. Their motivation was two-fold. Firstly, NHC 
complexes have proven to be very successful in the field of catalysis. Secondly, the usefulness 
of NHC ligands in potential anti-cancer drugs was assumed based on previous success of 
palladium complexes with amine- and pyridine ligands which showed considerable anti-
proliferative properties against tumour cells. Their NHC compounds were modelled on the 
potent anti-cancer pro-drug, trans-(pyridine)2PtCl2, [53] where the pyridine ligands were 
replaced by a more electron-donating NHC ligand, to further stabilise the highly reactive 
palladium centre. 
 
Figure 1.17: Palladium-NHC complexes synthesised by Ray et al. [53]. 
 
These Pd-NHC complexes (Figure 1.17) showed promising anti-cancer activity against HeLa 
cells. At a concentration of 10 μM, complex 12 inhibited proliferation by 35%, whilst complex 
13 resulted in 85% inhibition of tumour proliferation. Complex 13 also exhibited anti-
proliferative activity that was far more effective than that of cisplatin (Table 1.8) in the following 








Table 1.8: In vitro assay results for complex 1b compared to cisplatin [53]. 
Compound 
IC50 (μM) 
HeLa MCF7 HCT116 
13 4 ± 0.2 1 ± 3 0.8 ± 0.05 
Cisplatin 8 ± 1 15 ± 2 16 ± 3 
 
The observation that complex 13 was more active than complex 12 could be ascribed to the 
more electron-rich metal centre of complex 13, as compared to that of complex 12. This was 
due to the coordination of two NHC ligands in the case of complex 13, whilst complex 12 only 
had one of these electron donating ligands [53]. This work has continued since and in 2013, 
a very promising example of substituted Pd-NHC complex was reported by Haque et al. 
(Figure 1.18). Evaluation of this complex against colorectal cancer cell lines (HCT116) showed 
high levels of activity at very low concentrations (6.6 μM) [46;54]. 
 
Figure 1.18: Substituted NHC-Pd complex reported by Haque et al. [54]. 
 
With current trends in anti-cancer research moving in the direction of orally active drugs, there 
is a greater need to improve the overall solubility of many of these palladium complexes, and 
more specifically, the water solubility. In 2013, Guerrero et al. reported novel palladium 
complexes with the water-soluble phosphine, PTA, and its derivative, 3,7-diacetyl-1,3,7-triaza-
5-phosphabicyclo[3.3.1]nonane (DAPTA) [55]. These ligands were chosen based on the 
success of the RAPTA complexes, with these ligands. Thus, trans-platinum and –palladium 
complexes were synthesised using these water-soluble ligands. Thionate moieties were also 
incorporated, based on the authors’ previous success with such ligands in water-soluble gold 
and platinum complexes [56]. The complexes shown in Figure 1.19 were found to be poorly 
water-soluble (0.1-0.8 mg/mL), with the exception of two of the palladium complexes which 
were moderately water-soluble. These were trans-[Pd(S-methylpyrimidine-2-
thionate)2(DAPTA)2  (complex 16) and trans-[Pd(S-methylpyrimidine-2-thionate)2(PTA)2 
(complex 14) with 12.6 mg/mL and 23.4 mg/mL solubility in water, respectively. All of the 




complexes were evaluated as anti-cancer agents against human ovarian cancer cell lines, 
A2780 and A2780cisR (cisplatin-resistant). The palladium complexes had activity comparable 
to that of cisplatin against A2780; however, remarkably high cytotoxicity was observed when 
tested against A2780cisR, thus, exhibiting the ability of these palladium complexes to 
overcome cisplatin resistance [55]. 
 
Figure 1.19: PTA-based palladium complexes as potential water-soluble anti-cancer agents [55]. 
 
Still focusing on the solubility of potential drugs, Albert et al. investigated the efficacy of doubly 
cyclopalladated diimines with linker molecules, N(CH2)2N and N(CH2)2O(CH2)2O(CH2)2N 
(complexes 18 and 19 in Figure 1.20, respectively) [57]. These linkers varied in length and 
flexibility, but more importantly, they differed in their hydrophilicity and lipophilicity. The diimine 
palladacycles were evaluated against a panel of adenocarcinoma cell lines: HCT116 (colon), 
MCF7 (breast) and MDA-MB231 (breast). Interestingly, complexes with the shorter linker, 
N(CH2)2N, were inactive (IC50 values >100 μM), whilst those with the longer oxygen-containing 









Figure 1.20: Doubly cyclopalladated diimines with linker molecules, where R = p-Cl, p-OMe, p-NO2 and o-Cl [57]. 
 
The authors correlated the biological results to the chemical structures. The significantly higher 
activity observed for the longer linker was firstly ascribed to the flexibility of the linker, which 
would allow the formation of flexible adducts with DNA. This is the same rationalisation applied 
to the high activity observed for polymetallic species, such as the trinuclear platinum drug, 
BBR3464 [({trans-PtCl(NH3)2-(µ-trans-[Pt(NH3)2(CH2)6NH2)2]})4+], which is currently 
undergoing clinical evaluation [57]. The second reasoning for the significant activity is the 
presence of the oxygen atoms, which allow hydrogen-bond formation and consequently 
enhanced hydrophilicity. Furthermore, the activity of chemotherapeutic agents has been linked 
to the cellular accumulation within cancer cells, where higher accumulation leads to enhanced 
cytotoxicity and lower toxicity. This accumulation is related to the lipophilicity, which is an 
indication of the amount of drug which can enter the cell. It is also well known that the balance 
between hydrophilicity and lipophilicity is important, which, in this instance, is obtained by the 
presence of the oxygen atoms in the linker molecule. 
Further evaluation of these complexes showed that they were less effective at uncoiling DNA 
than cisplatin. This suggested that there may be an alternative mode of action to that of 
cisplatin, or a different target than DNA [57]. 
Recently, a very promising binuclear palladacycle, AJ5, was identified and evaluated by our 
group (Figure 1.21). Originally designed as a catalyst, this complex was evaluated against 
human breast cancer cell lines, MCF7 and MDA-MB231, and melanoma cell lines, ME1402, 
WM1158 and 501 mel. In each instance, AJ5 outperformed cisplatin [21;22]. 
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Figure 1.21: Promising palladacycle, AJ5. 
 
Initially, AJ5 was evaluated against malignant melanoma cell lines, as this is an aggressive 
and notoriously difficult cancer to treat. It is also one of the more prevalent cancers in South 
Africa. In vitro testing showed that AJ5 was more effective at inhibiting the cancerous cell lines 
compared to the normal non-malignant fibroblast cell lines, FGO, DNB and CT1 (Table 1.9). 
It was noted that at a concentration of 0.4 μM, AJ5 killed 90% of the melanoma cells whilst 
70% of the fibroblast cells survived. This is important since many of the severe side effects 
caused by chemotherapeutic agents are due to the high concentrations required to kill cancer 
cells. Furthermore, comparison of the IC50 values of AJ5 and cisplatin, 0.2 μM and 10 μM 
respectively, showed that AJ5 was approximately 50 fold more active than cisplatin. Taken 
together, this means that AJ5 is likely to be far less toxic than cisplatin due to its high potency 
and degree of selectivity for cancerous cells over non-malignant tissue. 
Table 1.9: IC50 results for AJ5 [21]. 
Cell line IC50 (μM) 
ME1402 0.1945 
WM1158 0.2008 





Investigations into the mode of action of AJ5 showed that it induced both apoptosis and the 
formation of autophagosomes. While apoptosis is a recognised mechanism of cell death, 
autophagy, a catabolic process which involves the degradation and recycling of 
macromolecules and organelles, was thought to be a mode of survival, delaying the onset of 
apoptosis. However, there have been a number of reports showing that autophagy can be a 
mode of cell death as well. To test this, autophagy was inhibited in the AJ5-treated cells. There 
AJ5 




was a significant decrease in the levels of PARP cleavage (an indicator of apoptosis) and the 
level of cell death, thus, confirming that AJ5-induced autophagy is a mode of cell death. 
Following the in vitro assays, in vivo assays were performed on nude mice. Cisplatin (CDDP) 
was used as a control. AJ5 was found to reduce the tumour growth in these melanoma-
bearing mice. Increased levels of apoptosis and autophagy were also observed. Figure 1.22 
shows the autophagosomes observed in tumour sections taken from the melanoma-bearing 
mice. Furthermore, the treated mice showed no obvious side effects, suggesting that AJ5 was 
less toxic than cisplatin, as predicted from the in vitro results [21]. 
To probe the scope of this drug, AJ5 was also evaluated against breast cancer. As stated 
earlier, AJ5 exhibited far better results than cisplatin. Not only was AJ5 more active against 
the cancerous cell lines (MCF7 and MDA-MB231) than the normal fibroblast cells (FGO and 
DNB), but it was also more effective against the more resistant and difficult to treat cell line, 
MDA-MB231. The mode of cell death was once again found to be both apoptosis and 
autophagy [22]. 
 
Figure 1.22: Representative transmission electron photomicrographs of tumour sections from melanoma-bearing mice 
showing autophagosomes, indicated by black arrows. Note the CDDP vehicle is a sodium chloride solution, whilst the AJ5 
vehicle is dimethyl sulfoxide (DMSO) [58]. 
  





From this brief overview, it is clear that cancer is a serious disease which is still affecting a 
large percentage of the world population, as it has been for the past five centuries. It should 
also be noted that significant progress has been made in the field of chemotherapy with the 
most notable of these being the discovery of cisplatin in 1965. A 15% decrease in mortality 
since the 1990’s emphasises this progress. However, problems such as toxicity and tumour 
cell resistance continue to hamper successful treatments. As shown here, palladium 
complexes have potential as viable alternatives to the current drugs, both in terms of reduced 
toxicity and the ability to overcome cisplatin/platinum drug resistance. The literature provides 
a vast library of these palladium complexes, including some very promising examples where 
the palladium complexes are significantly more active than cisplatin, yet not as toxic. Despite 
the overwhelming number of promising palladium complexes in the literature, there has been 
limited success with these complexes beyond the laboratory. This lack of advancement has 
been ascribed to the absence of data regarding the mode of action of these drugs. This need 
for more in-depth information justifies the ongoing research in this field. 
 
1.4 Aims and objectives 
Palladacycles have been found to be active in vitro as anti-cancer agents, especially those 
with methyl amino functionalities [44]. There are also reports of dppe-bridged palladacycles 
which are effective against certain cancers [11;59]. Our group has recently started testing 
palladacycles with imine functionalities as possible anti-cancer drugs [21;22]. Some of the 
binuclear complexes developed have shown promise. Palladium and platinum are both group 
10 transition metals. Although they form similar structures, the reactivities vary greatly, 
particularly in that palladium complexes are less toxic than platinum complexes [11;59]. 
However, a major problem with these types of complexes is solubility, even more so, solubility 
in aqueous media [44]. 
The aim of this project was to synthesise novel water-soluble palladacycles for testing as anti-
cancer agents. In an attempt to improve water solubility, the Schiff base ligands were modified 
by introducing hydrophilic functional groups on the aldehyde starting materials. The bridged 
palladacycles were then cleaved with the hydrophilic tertiary phosphine, 1,3,5-triaza-7-
phosphaadamantane (PTA) or bis(tertiary phosphine) ligands [60]. 
The new palladacycle complexes were tested for their efficacy as anti-cancer agents in vitro. 
The tests were against mammalian breast cancer cell lines, MCF7 and MDA-MB231. Cell 




viability tests were also done in the presence of the most promising complexes. In addition, 
DNA binding studies using the some of the prepared palladacycles were conducted. 
 
1.5 Thesis outline 
Chapter 1 – Palladium and its complexes as potential anti-cancer agents 
This review provides a brief timeline of the significant developments in the design 
of palladium anti-cancer drugs, as well as the most promising palladacycle 
complexes reported in the literature. 
Chapter 2 – Mononuclear palladacycles: Synthesis and characterisation 
This chapter introduces palladacycle chemistry and its biological application. It 
also discusses the significance of mononuclear palladacycles as anti-cancer 
agents, as well as the synthesis and characterisation of the novel mononuclear 
PTA-based palladacycles. 
Chapter 3 – NMR spectroscopic study of PTA-based palladacycles 
The symmetric site-exchange and concentration effects of the PTA-based 
palladacycles were investigated by NMR spectroscopy. The study is discussed in 
this chapter. 
Chapter 4 – Binuclear palladacycles: Synthesis and characterisation 
This chapter discusses the significance of binuclear palladacycles as anti-cancer 
agents, as well as the synthesis and characterisation of the binuclear 
palladacycles. 
Chapter 5 – Biological evaluation and DNA binding studies of synthesised palladacycles 
All biological results and DNA binding study results are reported and discussed in 
this section. 
Chapter 6 – Conclusions and future work 
Some general conclusions and suggestions for future work are provided in this 
final chapter. 
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Synthesis and Characterisation 
 
2.1 Introduction 
Palladacycles are defined as any palladium compound containing at least one palladium-
carbon sigma bond which is intramolecularly stabilised by one or two neutral two-electron 
donors (including nitrogen, phosphorous, oxygen and sulfur), whilst the organic moiety acts 
as a carbon-anionic four- or six-electron donor ligand. These complexes were first reported by 
Cope et al. [1], who synthesised such species by cyclopalladation of azobenzene derivatives 
[2-4]. Palladacycles can be classified as one of two types with those being either anionic four-
electron donors or anionic six-electron donors, as shown in Figure 2.1. 
 
Figure 2.1: General structure of C-anionic four-electron donor (left) and C-anionic six-electron donor (right) type 
palladacycles, where X is an anionic ligand and Y is a two-electron donor [2]. 
 
After the initial discovery by Cope et al. [1], a number of years passed before palladacycles 
became a popular area of research. This occurred when Herrmann et al. produced a 
palladacycle of the tri-o-tolyl-phosphane ligand as a precatalyst for Heck and other cross-
coupling reactions catalysed by palladium [5]. This discovery increased interest from the 
chemical industry as palladacycles could be used to elaborate lower value substrates which 
were currently in use. Since then, palladacycles have become synonymous with Heck and 
other C-C coupling reactions [2;4]. However, in the last four decades, a wide range of 
palladacycles have been synthesised and studied for diverse applications. Thus, the chemistry 
of these complexes is fairly well understood and documented [2]. 
 
2.1.1 Palladacycle chemistry 
The rich chemistry associated with palladacycles is due to the facile redox interchange 
between the palladium(II) and palladium(0) oxidation states. Another contributing property is 
the compatibility of palladacycles with most functional groups, which sets them apart from 




several other transition metal complexes [4]. Complimenting this rich chemistry are properties 
such as stability and robustness, availability, ease of handling and versatility, making these 
complexes attractive to industry and the research community. Besides these assets, 
palladacycles are also easily and rapidly synthesised [2;4]. 
There are a number of methods used to synthesise palladacycles, including C-H bond 
activation, transmetallation and oxidative addition. Of these, C-H bond activation, which often 
involves orthopalladation, is the simplest and most direct method. It is also the method which 
was employed to synthesise the series of mononuclear palladacycles reported here. It usually 
involves the use of a tetrachloropalladated salt and a base, or palladium acetate and acetic 
acid or benzene. The resultant palladacycles are usually five- or six-membered chelate rings 
[4]. 
 
2.1.2 Biological application of palladacycles 
The appeal of palladacycles for medicinal and biological applications arises from their rich 
chemistry, ease of synthesis and handling (due to the stability), as well as the potential for 
rapid library development. These properties are especially significant when one considers the 
application of these complexes in cancer treatment, where there is still no clear structure-
activity guideline for palladacycles. 
By using existing information on palladacycle synthesis and chemistry, a large number of 
complexes can be generated in a short period of time, allowing more time for biological 
evaluation of the complexes. The stability allows for simple long term storage and ease of 
testing [4]. Furthermore, there are a number of articles which compare palladacycles to their 
platinum analogues and often the use of palladacycles has been shown to be more 
advantageous. The choice of cyclometallated- over non-cyclometallated palladium complexes 
is due to the former’s increased stability, slower reaction kinetics and consequently lower 
toxicity, as non-cyclometallated complexes of palladium were found to be highly labile in 
biological fluids [4]. 
As described in the previous chapter, palladacycles can be either mononuclear, binuclear or 
multinuclear complexes. In this chapter, we focus on mononuclear palladacycles. 
The consideration of mononuclear over binuclear palladacycles is mainly driven by the need 
to improve solubility. In 1993, Higgins et al. prepared dimeric palladacycles for testing as anti-
cancer agents; however, the limited solubility led them to consider mononuclear analogues 
[2]. Since the mononuclear analogues have lower molecular weights, it was reasoned that 




these palladacycles would be more soluble. The authors made use of various amines to cleave 
the chloro-bridged dimeric species, obtaining much more soluble mononuclear analogues 
(Scheme 2.1). However, it was found that the mononuclear species were not water-soluble, 
but were quite stable in organic solvents. The mononuclear palladacycles were tested against 
a tumour panel of human carcinomas and most complexes exhibited uniform cytotoxicity for 
all cell lines in the range of 10 μg/mL [2]. 
 
Scheme 2.1: General synthetic scheme for dimeric and monomeric palladacycles prepared by Higgins III et al. Where X = 
Cl or OAc and L = amine [2]. 
 
Despite the improved solubility, most mononuclear palladacycles have been reported to be 
less cytotoxic than their dimeric analogues. One of the many examples of this trend was 
presented by Karami et al. in 2012 [6]. The IC50 values of the two mononuclear complexes, 
Pd(C,N)-C6H4CH2NH(Et)Cl(Py) and Pd(C,N)-C6H4CH2NH(t-Bu)Cl(PPh3) were approximately 
two-fold higher than those for the binuclear analogue, Pd2(C,N-dmba)2(μ-dppe)(Cl)2 [6], as 
shown in the Table 2.1. 
Table 2.1: IC50 values (μM ± SD) of palladacycles against tumour panel, as reported by Karami et al. [6]. 
Complex Hela HT-29 K562 MDA-MB-468 
Pd(C,N)-C6H4CH2NH(Et)Cl(Py) 7.5 ± 0.60 4.3 ± 0.04 3.7 ± 0.04 2.4 ± 0.05 
Pd(C,N)-C6H4CH2NH(t-Bu)Cl(PPh3) 7.7 ± 0.40 5.3 ± 0.28 3.3 ± 0.04 3.3 ± 0.05 
Pd2(C,N-dmba)2(μ-dppe)(Cl)2 2.1 ± 0.05 2.2 ± 0.04 1.4 ± 0.06 2.3 ± 0.01 
 
As stated in the aims, the series of mononuclear palladacycles reported here was based on a 
dimeric palladacycle (AJ5) which had been previously synthesised in our laboratory [7] and 
has been shown to exhibit significant anti-cancer activity. However, its activity is hindered by 
poor solubility. Since AJ5 is not water-soluble and dimeric palladacycles are known for their 
poor solubility, it was decided to synthesise mononuclear analogues, using the rationale 
proposed by Higgins et al. that lower molecular weight products are more soluble. Hence, the 
aim was to replace the dppe ligand with a water-soluble tertiary phosphine, 1,3,5-triaza-7-
phosphaadamantane (PTA) (Figure 2.2) [8]. The decision to use PTA, rather than the more 
directly comparable triphenylphosphane, PPh3, was based on the trend of reduced cytotoxicity 
for mononuclear palladacycles relative to their dimeric analogues, as discussed above. PTA 
is not only a water soluble phosphine, but it is non-toxic and biocompatible, which may lead to 
a less significant reduction in cytotoxicity or even improved cytotoxicity [9]. Additionally, it was 




set out to investigate the effects of various ortho substituents (R) on solubility and efficacy of 
these complexes. 
 
Figure 2.2: Structure of AJ5 (left) and mononuclear analogues (right) where R = 2-H, 2-Cl, 2-Br, 2-Me, 4-Me, 2-F, 2-NO2 or 
2-OMe. 
 
2.2 Synthetic route 
The series of mononuclear palladacycles was synthesised in a three-step process. The 
monosubstituted ligands were synthesised by Schiff base condensation of 2,6-
diisopropylaniline with various monosubstituted benzaldehydes. These Schiff base ligands 
were cyclopalladated by the reaction of the ligands with the palladium precursor, 
bis(acetonitrile)palladium dichloride, [(MeCN)2PdCl2]. An excess of sodium acetate was used 
as the base. The resulting μ-chloro bridged palladacycles were then cleaved by the addition 
of a basic tertiary phosphine, PTA, producing the desired mononuclear palladacycle target 
molecules for anti-cancer testing. 
The synthesised complexes were characterised by FT-IR- and NMR (1H, 13C and 31P) 
spectroscopy, mass spectrometry and microanalysis, as well as melting point- and single 
crystal analysis, where applicable. In addition, the solubilities were determined in water, 
dimethyl sulfoxide and a water/dimethyl sulfoxide mixtures. 
 
2.3 Results and Discussion 
2.3.1 Preparation of Schiff base ligands 
The Schiff base ligands were synthesised as described by Mungwe et al. [7]. The ligands were 
prepared by reacting various monosubstituted benzaldehydes with 2,6-diisopropylaniline in 
dry ethanol, as shown in Scheme 2.2. 






Scheme 2.2: Synthetic scheme for Schiff base ligands. 
 
The ligands, L1-L5, have been prepared previously by our group [10;11] and L6 and L7 have 
been reported previously [12;13]. The synthetic method employed in this project produced 
higher yields for L6 and an alternative synthetic method for the previously reported L7. L8, 
however, is a novel ligand. The ligands were isolated as yellow crystalline solids in low to high 
yields (29-81%). The ligands were found to be stable both in the solid state, as well as in 
solution. As reported [7], the ligands were soluble in polar organic solvents. 
The ligands were characterised by various analytical techniques and these are discussed 
below. Table 2.2 contains some general characterisation data for comparison of the various 
analogues. 
FT-IR spectroscopy was used to determine whether the imine had been formed successfully. 
The strong aldehyde carbonyl (C=O) stretch band for an aldehyde conjugated with a phenyl 
ring occurs in the region 1700-1660 cm-1 [14]. The imine C=N stretch occurs in the region 
1690-1640 cm-1 and has variable-intensity absorption. The disappearance of the C=O band 
and the appearance of the C=N band was monitored using FT-IR spectroscopy. In all cases, 
there were no bands in the νC=O region and a medium to strong band in the νC=N region, as 
shown in the spectrum below (Figure 2.3) [14]. The νC=N bands of the various ligands prepared, 
occurred between 1640-1625 cm-1. 
L1: R = 2-H L2: R = 2-Cl 
L3: R = 2-Br L4: R = 2-Me 
L5: R = 4-Me L6: R = 2-F 
L7: R = 2-NO2 L8: R = 2-OMe 





Figure 2.3: FT-IR spectrum of L1 (4000-600 cm-1). 
 
Table 2.2: Analytical data for ligands, L1-L8. 
Ligand FT-IR (νC=N, cm-1)a ESI-MS (m/z) [M+H]+ Melting point (˚C)b 
L1* 1638 266 63-64 
L2* 1626 301 52-53 
L3* 1627 345 78-79 
L4 1629 280 62-66 
L5* 1636 280 93-94 
L6 1631 284 75-79 
L7 1643 311 63-66 
L8 1638 296 124-128 
aIR spectra were recorded neat using an ATR accessory. bMelting points were recorded in glass capillaries 
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1H NMR spectra of the ligands showed the imine signal in the region 8.22-8.76 ppm as a 
singlet. It is easily identified as the signal which occurs furthest downfield. No aldehyde or 
amine signals were present in the 9.00-10.0 ppm and 0.50-4.00 ppm regions, respectively. 
The complexity of the aromatic region (overlapping multiplets), also confirms the formation of 
the ligand. The septet observed at approximately 3.00 ppm represents the methine protons of 
the isopropyl substituents and the doublet at approximately 1.20 ppm represents the methyl 
groups of the isopropyl moieties. The presence of only one methine and one methyl signal 
suggest that the two isopropyl groups are in the same chemical environment. Hence, there is 
free rotation of the 2,6-diisopropylaniline group and the two isopropyl groups, around the N-C 
bond and the C-C bonds, as shown in Figure 2.4. 
Table 2.3 contains the 1H NMR spectroscopy data for the Schiff base ligands. From the data, 
it is clear that the imine signal shifts relative to the substituent on the benzene ring. The 
difference in the chemical shift of the 2-methyl and 4-methyl protons indicates that the para 
position (4) is more shielded from the effects of the imine than the ortho position (2). The more 
electronegative halogen analogues (L2, L3 and L6) show imine signals which are shifted more 
downfield compared to the chemical shift of the unsubstituted analogue (L1). The electron-
withdrawing nitro group caused a downfield shift, as was expected; however, the methoxy 
group (L8) was expected to cause a shift similar to that of the methyl group or an even further 
upfield shift, as it is a donating group, yet the observed chemical shift is close to that of the 
nitro analogue (L7). Although unexpected, literature reports showed that methoxy substituents 
can be electron withdrawing or electron donating, depending on the electronic interactions in 
the system [15]. 
 
Figure 2.4: Free rotation of 2,6-diisopropylaniline moiety in ligands. 


















L1* 8.22 (s, 1H) 
7.92-7.95 (m, 2H, H2,6); 7.52-7.54 (m, 3H, H3,4,5); 
7.09-7.20 (m, 3H, H10,11) 
 
2.99 (sept, 2H, 
3JH-H 6.9 Hz) 
 
1.19 (d, 12H, 
3JH-H 6.9 Hz) 
L2* 8.76 (s, 1H) 
8.27-8.29 (m, 1H, H3); 7.44-7.48 (m, 3H, H4,5,6); 
7.12-7.20 (m, 3H, H10,11) 
 
2.98 (sept, 2H, 
3JH-H 6.9 Hz) 
 
1.20 (d, 12H, 
3JH-H 6.8 Hz) 
L3* 8.60 (s, 1H) 
8.27 (dd, 1H, 3JH-H 7.8 Hz, 4JH-H 1.9 Hz, H3); 7.66 (dd, 1H, 3JH-H 8.1 
Hz, 4JH-H 1.3 Hz, H6); 7.44-7.49 (m, 1H, H4); 7.35-7.40 (m, 1H, H5); 
7.12-7.22 (m, 3H, H10,11) 
 
2.99 (sept, 2H, 
3JH-H 6.9 Hz) 
 
1.21 (d, 12H, 
3JH-H 6.9 Hz) 
L4* 8.52 (s, 1H) 
8.11 (dd, 1H, 3JH-H 7.6 Hz, 4JH-H 1.4 Hz, H6); 7.34-7.44 (m, 2H, H4,5); 
7.27-7.29 (m, 1H, H3); 7.11-7.20 (m, 3H, H10,11) 
 
3.02 (sept, 2H, 
3JH-H 7.0 Hz) 
2.56 (2, 3H) 
1.20 (d, 12H, 
3JH-H 7.0 Hz) 
L5* 8.18 (s, 1H) 
7.87 (d, 2H, 3JH-H 8.0 Hz, H2,6); 7.37 (d, 2H, 3JH-H 7.8 Hz, H3,5); 7.13-
7.22 (m, 3H, H10,11) 
 
3.04 (sept, 2H, 
3JH-H 6.8 Hz) 
2.49 (s, 3H) 
1.22 (d, 12H, 
3JH-H 6.8 Hz) 
L6 8.53 (s, 1H) 
8.21-8.27 (m, 1H, H3); 7.47-7.52 (m, 1H); 7.27-7.33 (m, 1H); 7.10-
7.20 (m, 4H, H10,11) 
 
2.98 (sept, 2H, 
3JH-H 6.9 Hz) 
 
1.20 (d, 12H, 
3JH-H 6.9 Hz) 
L7 8.65 (s, 1H) 
8.35 (dd, 1H, 3JH-H 7.8 Hz, 4JH-H 1.6 Hz); 8.13 (dd, 1H, 3JH-H 8.2 Hz, 
4JH-H 1.3 Hz); 7.78-7.83 (m, 1H); 7.65-7.71 (m, 1H); 7.12-7.22 (m, 
2H); 7.06 (d, 1H, 3JH-H 7.6 Hz) 
 
3.03 (sept, 2H, 
3JH-H 6.9 Hz) 
 
1.22 (d, 12H, 
3JH-H 6.8 Hz) 
L8 8.76 (s, 1H) 
8.32 (dd, 1H, 3JH-H 7.6 Hz, 4JH-H 1.8 Hz); 7.58-7.61 (m, 1H); 7.28 (d, 
1H, 3JH-H 7.6 Hz); 7.20-7.23 (m, 2H); 7.10 (d, 1H, 3JH-H 8.2 Hz) 
3.88 (s, 3H) 
3.02 (sept, 2H 
 3JH-H 7.0 Hz) 
 
1.20 (d, 12H, 
3JH-H 6.5 Hz) 
*Data from previously published results [10;11]. Spectra run in CDCl3 at 25 °C. Chemical shifts reported in ppm, referenced relative to residual solvent peak. Superscript numbering 
denotes proton assignments as per Figure 2.4.
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Electrospray ionisation mass spectrometry (ESI-MS) was used as further confirmation that the 
correct product was formed. The spectra show a large base peak and in some cases, a few 
smaller peaks. The base peak corresponds to the molecular ion, [M+H]+, of the ligand, as 
shown in Figure 2.5. The isotopic clusters result from nitrogen and its isotopes, as well as the 
various halogen isotopes in the case of the ortho-halogenated analogues. Comparison of the 
fragmentation pattern for the [M+H]+ fragment with the simulated pattern showed that the 
assignment of the fragment was correct. 
 
Figure 2.5: Mass spectrum of L7 and simulated fragment pattern for [M+H]+ fragment. 
AV052
m/z












A crystal structure was obtained for L7, the nitro analogue. The crystals were obtained by 
recrystallisation from DCM layered with cold methanol at low temperature (-16 °C). The crystal 
structure was determined by single crystal X-ray diffraction. 
The asymmetric unit (ASU) contains two molecules, A and B, as shown in Figure 2.6, which 
have slight structural differences. The planes of the aromatic rings in A are almost 
perpendicular, whilst the angle between those in B is much smaller. This is evident from the 
torsion angle C1-C7-N2-C8 (τ), which is different for A (τA = 177.6(1)˚) and B (τB = -173.3(1)˚). 
These structural differences result in different orientations and different packing. Alternating 
columns of A and B are observed in the crystal packing (Figure 2.7) as an ⋯ABAB⋯ array of 
offset columns which repeat along the c-axis. The crystal structure also shows a complex 
network of C-H⋯O and C-H⋯N inter- and intramolecular hydrogen bonds. Molecules A and B 
are linked by two intermolecular C-H⋯O bonds, C3A-H3A⋯O1B and C4B-H4B⋯O2A. Further 
numerical data on the hydrogen bonds can be found in Table 2.4. Additionally, there is an 
O1A···O1B intermolecular interaction between the nitro groups of A and B molecules, with a 
bond distance of 2.900(1) (Figure 2.7). Other crystallographic data can be found in Table 2.5 
and geometric parameters can be found in Appendix 1, Tables A1.1 and A1.2. 
 
Figure 2.6: Asymmetric unit (ASU) for Schiff base ligand, L7, with thermal ellipsoids rendered at the 50% probability level. 
H atoms are rendered as spheres with arbitrary fixed radii. Selected non-H atoms are labelled. 
 





Figure 2.7: Crystal packing showing alternating columns of A and B along the c-axis and the O1A···O1B intermolecular 
interaction. Hydrogen atoms have been omitted for clarity. 
 
Table 2.4: Numerical details of the hydrogen bonds in L7. 
D-H···A D-H (Å) H···A (Å) D···A (Å) D-H···A (⁰) 
C3A—H3A···O1Bi 0.95 2.40 3.269(2) 152 
C7A—H7A···O2A 0.95 2.47 2.928(2) 110 
C14A—H14A···N2A 1.00 2.48 2.969(2) 109 
C14B—H14B···O2B 1.00 2.57 3.572(2) 178 
C15B—H15D···N2B 0.98 2.56 3.180(2) 121 
C17A—H17A···N2A 1.00 2.38 2.805(2) 104 
C17B—H17B···N2B 1.00 2.42 2.814(2) 103 
C18B—H18I···O2Bii 0.98 2.57 3.295(2) 131 
C19B—H19G···O2Biii 0.98 2.60 3.514(2) 155 
Note: D-H = proton donor group, A = proton acceptor atom; 
Symmetry codes: (i) -x+1, -y+1, -z; (ii) x, y+1, z; (iii) -x+2, -y+2, -z. 




Table 2.5: Crystallographic data for L7. 
Parameter L7 
Chemical formula C19H22N2O2 
Formula weight 310.39 
Temperature (K) 100(2) 
Wavelength (Å) 0.71073 
Crystal system Triclinic 
Space group P-1 
a (Å) 9.0009(13) 
b (Å) 10.1457(14) 
c (Å) 19.758(3) 
α (°) 100.105(2) 
β (°) 95.811(2) 
γ (°) 105.637(2) 
V (Å3) 1689.4(4) 
Z 4 
Dcalc [Mg/m3] 1.220 
Absorption coefficient (mm-1) 0.080 
F(000) 664 
Final R indices [I>2σ(I)] R1 = 0.0451, wR2 = 0.1010 
Reflections collected 20633 
Completeness to θmax (%) 91.6 
Goodness-of-fit on F2 1.040 
Largest difference peak and hole (e Å-3) 0.287, -0.216 
 
 
2.3.2 μ-Chloro palladacycles 
Cyclopalladation of the Schiff base ligands, via electrophilic C-H bond activation was carried 
out to obtain μ-chloro palladacycles. The synthesis was performed as described by Mungwe 
et al. [7], using two equivalents of Schiff base ligand, two equivalents of 
bis(acetonitrile)palladium dichloride and four equivalents of sodium acetate to form one 
equivalent of bridged palladacycle (Scheme 2.3). The duration of the reaction depended on 
the nature of the Schiff base ligand [7]. 






Scheme 2.3: Synthetic scheme for µ-chloro palladacycles. 
 
The chloro-bridged palladacycles, B1-B5, have been reported previously [10;11], whilst B6-
B8 are novel. The complexes were isolated as yellow solids (amorphous or crystalline), except 
for the nitro analogue which is an orange solid. The yields were in the range of 33-89%. The 
palladacycles are stable in both the solid state and in solution. All analogues were found to be 
soluble in chlorinated organic solvents, but B2 and B3 were found to be only sparingly soluble. 
Characterisation of the palladacycles involved the use of various analytical techniques, as will 
be discussed below. 
FT-IR spectroscopy was used to determine if the cyclopalladation had occurred. The imine 
νC=N stretch of the bridged palladacycle is expected to shift to a lower wavenumber if 
coordination occurs. If the coordination of the nitrogen atom to the palladium is through its 
lone pair, the shift is expected to be small, approximately 30 cm-1. However, if coordination 
through the C=N double bond, via a ƞ2 interaction, would result in a larger shift [16]. For all the 
bridged complexes, there was only one medium to strong band in the νC=N region, as shown 
in the spectrum below [14]. The νC=N bands of the various complexes occur at lower 
wavenumbers, approximately 30-40 cm-1 lower than those of the ligands, confirming that the 
coordination to the palladium metal centre is through the nitrogen lone pair (Table 2.6). 
As shown in the Table 2.6, melting points determined for the bridged palladacycles are 




B1: R = 2-H B2: R = 2-Cl 
B3: R = 2-Br B4: R = 2-Me 
B5: R = 4-Me B6: R = 2-F 
B7: R = 2-NO2 B8: R = 2-OMe 




Table 2.6: Analytical data for bridged palladacycles, B1-B8. 
Complex FT-IR (νC=N, cm-1)a Melting point (˚C)b 
B1* 1599 317-320 
B2* 1594 330-332 
B3* 1584 300-302 
B4* 1594 303-305 
B5* 1597 305-307 
B6 1605 >250 
B7 1600 >250 
B8 1593 >250 
aIR spectra were recorded neat using an ATR accessory. bMelting points were recorded in glass 
capillaries and are reported as uncorrected. *Data from previously published results [11]. 
 
1H NMR spectroscopic results (Table 2.7) showed the imine signal as a singlet in the region 
7.69-8.72 ppm. The imine signal was shifted slightly upfield (0.4-0.7 ppm), relative to the free 
ligand, again indicating that the coordination occurs through the nitrogen atom lone pair and 
not through the imine double bond. It is known that if the coordination was through the double 
bond, the shift would have been larger, by approximately 2 ppm [17]. This confirms what was 
observed from the FT-IR spectroscopic data, which also suggested coordination through the 
lone pair. Additionally, the isopropyl methine signal was shifted downfield compared to the 
ligand and the signal was no longer a septet, but a multiplet, integrating for four protons. The 
methyl signal had changed significantly; the doublet which integrated for twelve protons was 
now observed as two doublets, which integrated for twelve protons each. This, as well as the 
change in the methine signal, indicated that these groups were no longer equivalent. Hence, 
the free rotation observed in the free ligand was now restricted in the complex. 
In the free ligand, it is expected that there is free rotation about the N-C bond and the two  
C-C bonds of the isopropyl moieties. If all bonds were restricted, there would be two methine 
signals and four methyl signals. However, this is not the case. Should the N-C bond have free 
rotation whilst the C-C bonds are restricted (Figure 2.8, left), we expect one methine signal 
and two methyl signals. If the opposite were the case, we expect two methine signals and two 
methyl signals. The latter is most likely (Figure 2.8, right). This is supported by the significant 
difference in chemical shifts for the methyl groups (indicating significantly different chemical 
environments). Hence, it is proposed that the N-C bond does not rotate, but the C-C bonds 
do, therefore making the methines inequivalent - evident from the differences in coupling 
constants within what appears to be a septet, but is in fact two overlapping signals. 





Figure 2.8: Possible restrictions to rotation in the bridged palladacycles indicated as bold red bonds. 
 
As for the ligands, the difference in chemical shift of the 2-methyl and 4-methyl protons 
(2.28-2.40 ppm) indicates that the para position is once again more shielded from the effects 
of the imine compared to the ortho position. The imine proton signals of the more 
electronegative halogen analogues (B2, B3 and B6) and the nitro analogue (B7) are shifted 
more downfield than the unsubstituted analogue (B1), as was expected. The methoxy 
analogue (B8) behaves the same as in the ligand, behaving more like an electron withdrawing 
group than an electron donating group. 
ESI-MS was used as further confirmation that the correct product was formed. The spectra 
showed a large base peak and in some cases, a few smaller peaks (Figure 2.9). The base 
peak corresponded to the [(M/2)-Cl+MeCN]2+ ion fragment, as shown in Figure 2.10. The 
coordination of acetonitrile in place of the chlorine ion (or the acetate ion for acetate-bridged 
palladacycles) is a phenomenon which has been reported previously by Tjosaas et al., who 
reported dimerisation and acetonitrile/acetate exchange occurring in acetonitrile solutions [18]. 
In some cases, the [M-Cl]+ ion fragment (Figure 2.9) can also be observed. The isotopic 
clusters observed in Figure 2.9 result from palladium, nitrogen and chlorine isotopes. 
Palladium has six naturally occurring stable isotopes, whilst nitrogen and chlorine each have 
two stable isotopes. The simulated fragment patterns correspond to the observed fragments, 
however, the [M-Cl]+ fragment is overlapped with another fragment, making the comparison 
more complex. 


















B1* 7.75 (s, 2H) 
7.28-7.35 (m, 4H, H2,3); 7.19-7.21 (m, 6H, H10,11,12); 
7.05-7.09 (m, 4H, H4,5) 
 3.53 (m, 4H)  
1.39 (d, 12H, 3JH-H 6.6 Hz); 
1.15 (d, 12H, 3JH-H 6.6 Hz) 
B2* 8.13 (s, 2H) 
7.31-7.36 (m, 2H, H3); 7.19-7.22 (m, 4H); 
6.97-7.08 (m, 6H) 
 3.49 (m, 4H)  
1.39 (d, 12H, 3JH-H 6.6 Hz); 
1.18 (d, 12H, 3JH-H 6.6 Hz) 
B3* 8.13 (s, 2H) 
7.31-7.34 (m, 2H, H3); 7.17-7.22 (m, 6H, H10,11,12); 
7.10-7.13 (m, 2H, H4); 6.85-6.90 (m, 2H, H5); 
 3.49 (m, 4H)  
1.39 (d, 12H, 3JH-H 6.6 Hz); 
1.18 (d, 12H, 3JH-H 6.6 Hz) 
B4* 8.01 (s, 2H) 
7.31-7.33 (m, 2H, H3); 7.20-7.22 (m, 4H); 
6.80-7.03 (m, 6H) 
 3.54 (m, 4H) 2.40 (s, 6H) 
1.39 (d, 12H, 3JH-H 5.9 Hz); 
1.16 (d, 12H, 3JH-H 6.4 Hz) 
B5* 7.69 (s, 2H) 
7.30-7.35 (m, 2H,H2); 7.16-7.21 (m, 6H, H10,11,12); 
7.01 (s, 2H, H5); 6.88 (d, 2H, 3JH-H 7.5 Hz, H3) 
 3.53 (m, 4H) 2.28 (s, 6H) 
1.39 (d, 12H, 3JH-H 6.6 Hz); 
1.15 (d, 12H, 3JH-H 7.0 Hz) 
B6 8.02 (s, 2H) 
7.31-7.36 (m, 2H); 7.19-7.22 (m, 4H); 7.03-7.11 (m, 2H); 





1.40 (d, 12H, 3JH-H 6.6 Hz); 
1.18 (d, 12H, 3JH-H 6.8 Hz) 
B7 8.72 (s, 2H) 
7.87 (d, 2H, 3JH-H 8.1 Hz); 7.55-7.58 (m, 2H); 





1.39 (d, 12H, 3JH-H 6.5 Hz); 
1.19 (d, 12H, 3JH-H 6.8 Hz) 
B8 8.06 (s, 2H) 
7.27-7.32 (m, 2H); 7.17-7.19 (m, 4H); 6.97-7.03 (m, 2H); 
6.78 (d, 2H, 3JH-H 7.8 Hz); 6.53 (d, 2H, 3JH-H 8.4 Hz) 




1.39 (d, 12H, 3JH-H 6.8 Hz); 
1.16 (d, 12H, 3JH-H 6.8 Hz) 
*Data from previously published results [10;11]. Spectra run in CDCl3 at 25 °C. Chemical shifts reported in ppm, referenced relative to residual solvent peak. Superscript 
numbering denotes proton assignments as per Figure 2.4.
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Figure 2.9: Mass spectrum of B6 with insets of zoomed in spectra showing the [(M/2)-Cl+MeCN]2+ cluster (green) and the [M-Cl]+ cluster (purple), as well as simulated fragment patterns. 
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Figure 2.10: [(M/2)-Cl+MeCN]2+ ion fragment. 
 
Single crystals of B6, the fluoro analogue, were obtained by slow evaporation of a 
DCM/hexane solution at room temperature. The resultant yellow crystals were analysed by 
single crystal X-ray diffraction. 
 
Figure 2.11: Complete molecular structure for dinuclear palladacycle, B6, with thermal ellipsoids rendered at 50% 
probability level. The atoms in the ASU have been labelled. H atoms are rendered as spheres with arbitrary fixed radii. 
 
The chloro-bridged palladacycle, C38H42Cl2F2N2Pd2, has half a molecule in the asymmetric unit 
and the dinuclear molecule resides on a crystallographic inversion centre (Figure 2.11). The 
symmetry around the palladium centres is a distorted square planar geometry. Several atoms 
of the isopropyl moieties are disordered over two positions. The disorder is most likely via 
fluxional motion about a carbon (sp2)-carbon (sp3) bond axis. The carbon atoms in the major 
component of the disorder are labelled C15 and C16, as shown in Figure 2.11, whilst the minor 
component is labelled C21 and C22 (not shown in the figure for the sake of clarity). The major 
and minor components have site occupancy factors of 0.76(3) and 0.24(3), respectively. The 
molecules in the crystal structure associate via centrosymmetric hydrogen bonded rings with 




Etter notation R22(10) [19]. These hydrogen bonds link the molecules to form infinite chains 
along the diagonal of the ab plane (Figure 2.12). Table 2.8 contains the numerical details of 
the C-H···F hydrogen bonds involved in the association of the molecules. 
 
Figure 2.12: Structure of B6 showing infinite chain, where the atoms in the chain are depicted as balls. 
 
The nature of C-H···F interactions in molecular crystals has been studied extensively. It has 
previously been found that these interactions act as weak hydrogen bonds when the fragments 
involved are neutral [20], as in the case of B6. C-H···F interactions are important in organising 
molecules in the crystal lattice often forming dimers and chains [21]. Although these 
interactions are weak, they can be as important as C-H···O and C-H···N hydrogen bonds in 
stabilising specific crystal structures [22]. 
CSD database screening found that C-H···F interactions have a mean distance of 2.6 Å and 
the mean F···H-C angle was found to be approximately 135 °C [23]. Similar C-H···F hydrogen 
bonding has been reported for the crystal structure of bis(µ2-chloro)-bis(2-(((2,6-
diisopropylphenyl)imino)methyl)-5-fluorophenyl)-di-palladium(II) (Literature compound A), 
where the C-H···F hydrogen bonding interactions form an infinite chain [24]. This data is 
included in Table 2.8. From the table, it is clear that the hydrogen bonding observed for B6 is 
very similar to that of the Literature compound A, with the literature example being a slightly 
weaker bond, as indicated by the slightly longer C···F bond length. Furthermore, the hydrogen 
bond distance and angle fit the mean values reported. 
Table 2.8: Numerical details of the C-H···F hydrogen bonds in B6 and the Literature compound A [24] 
Compound D-H···A D-H (Å) H···A (Å) D···A (Å) D-H···A (⁰) 
B6 C7-H7···F1i 0.95 2.46 3.282(2) 145 
Literature 
compound A 
C9-H9B···F1ii 0.96 2.52 3.359(4) 145 
Note: D-H = proton donor group, A = proton acceptor atom; 
Symmetry codes: (i) −x+1, −y+1, −z; (ii) 1-x, 0.5+y, 0.5-z. 




Two of the previously reported bridged palladacycles, B1 and B2, were found in the CSD 
[7;25]. Table 2.9 contains all the coordination bond distances and bond angles for these two 
palladacycles, as well as B6. 
From the table, it is appears as though the Pd(1)-N(1) bond distance increases with more 
electron withdrawing ortho-substituents (2-Cl in B2 and 2-F in B6, if the large error is taken 
into account), thus, electron withdrawing substituents tend to weaken (lengthen) the bond as 
they draw electron density out of the metallocyclic ring system, whilst the unsubstituted 
complex (2-H in B1) has a slightly longer bond length, as the proton does not draw electron 
density out of the metallocyclic ring system. The same trend is observed for the Pd(1)-C(6) 
and C(7)-N(1) bonds. Thus, electron withdrawing ortho-substituents appear to weaken the 
coordination bonds. The bond angles clearly illustrate the distorted square planar geometry of 
the palladium centres, with all the angles being close to 90° or 180°. 
Table 2.9: Selected bond distances (Å) and bond angles (°) [7;25]. 
Complex B1* B2* B6 
Pd(1)-N(1) 2.022(1) 2.028(5) 2.03(1) 
Pd(1)-C(6) 1.965(1) 1.979(6) 1.98(2) 
C(7)-N(1) 1.279(2) 1.288(8) 1.292(2) 
Pd(1)-Cl(1) 2.326(5) 2.447(2) 2.319(4) 
Pd(1)-Cl(A) 2.451(5) 2.329(2) 2.445(5) 
Pd(1)···Pd(A) 3.457 3.477 3.450 
N(1)-Pd(1)-C(6) 81.13(7) 81.5(2)1 81.37(7) 
N(1)-Pd(1)-Cl(1) 176.1(4) 176.3(2) 176.7(4) 
N(1)-Pd(1)-Cl(A) 96.59(4) 96.9(2) 96.06(4) 
C(6)-Pd(1)-Cl(1) 94.98(5) 94.9(2) 95.33(5) 
C(6)-Pd(1)-Cl(A)  178.2(2) 177.3(5) 
Cl(1)-Pd(1)-Cl(A) 87.31(2) 86.59(6) 87.3(2) 
*Previously reported data [7;25]. 1Note that the bond angle was incorrectly reported as 178.2(2), but it was 
measured and found to be 81.5(2) [7]. 
  




Table 2.10: Crystallographic data for B6. 
Parameter B6 
Chemical formula C38H42Cl2F2N2Pd2 
Formula weight 848.44 
Temperature (K) 100(2) 
Wavelength (Å) 0.71073 
Crystal system Triclinic 
Space group P-1 
a (Å) 9.6171(4) 
b (Å) 9.8094(5) 
c (Å) 10.6917(5) 
α (°) 96.677(1) 
β (°) 111.131(1) 
γ (°) 94.141(1) 
V (Å3) 927.31(7) 
Z 1 
Dcalc [Mg/m3] 1.519 
Absorption coefficient (mm-1) 1.152 
F(000) 428 
Final R indices [I>2σ(I)] R1 = 0.0215, wR2 = 0.0497 
Reflections collected 11297 
Completeness to θmax (%) 91.2 
Goodness-of-fit on F2 1.020 
Largest difference peak and hole (e Å-3) 0.395, -0.421 
 
Additional structural data can be found in Table 2.10 and geometric parameters can be found 
in Appendix 1, Tables A1.3 and A1.4. 




2.3.3 Mononuclear palladacycles 
The binuclear μ-chloro palladacycles were reacted with the water-soluble tertiary phosphine, 
PTA, to obtain mononuclear palladacycles. The reaction conditions are shown in Scheme 2.4. 
The mononuclear palladacycles are all novel and were characterised completely, using a wide 
range of analytical techniques. They were isolated as yellow solids (crystalline or amorphous) 




Scheme 2.4: Reaction scheme for cleavage of dimeric palladacycles to obtain mononuclear species. 
 
FT-IR spectroscopy was used to determine whether the chloro-bridged palladacycle was 
cleaved successfully. The νC=N stretch of the cleaved, mononuclear palladacycle is expected 
to shift to a higher wavenumber due to coordination of the two electron donor phosphine 
ligand. This is due to the better sigma-donor ability of the phosphine compared to that of the 
chloride. This consequently increases the electron density on the metal centre, which then 
leads to increased back-donation from the metal to the ligands. Since the phosphine is a better 
pi-acceptor ligand than the imine, there is less back-donation to the imine. Therefore, the imine 
bond is stronger and the corresponding shift to higher wavenumbers is observed [26,27]. For 
all the bridged complexes, there was only one medium to strong band in the νC=N region [14]. 
The νC=N bands of the various mononuclear palladacycles occur at slightly higher 
wavenumbers than those of the bridged complexes (Table 2.11).
C1: R = 2-H C2: R = 2-Cl 
C3: R = 2-Br C4: R = 2-Me 
C5: R = 4-Me C6: R = 2-F 
C7: R = 2-NO2 C8: R = 2-OMe 




Table 2.11: Analytical data for mononuclear palladacycles, C1-C8. 
Complex FT-IR (νC=N, cm-1)a 
ESI-MS (m/z) 
[M-Cl]+ 
Melting point (˚C)b 
C1 1606 527 222-226 
C2 1600 563 215-219 
C3 1599 607 173-178 
C4 1601 541 197-202 
C5 1608 541 198-202 
C6 1605 545 219-222 
C7 1599 572 216-221 
C8 1597 557 203-207 
aIR spectra were recorded neat using an ATR accessory. bMelting points were recorded in glass 
capillaries and are reported as uncorrected. 
 
Studying these complexes with 1H NMR spectroscopy produced some interesting results of 
which the salient points are summarised in Table 2.12. In all the PTA complexes, the imine 
signal occurs in the region of 7.90-8.80 ppm. This is slightly downfield when compared to that 
of the chloro-bridged complexes. This can, once again, be explained by the fact that the 
phosphine is a better sigma donor than the chloride ligand, thus leading to increased electron 
density on the metal centre and subsequent back-donation. Since the imine has more double 
bond character (due to its reduced pi-acceptor ability relevant to the presence of the 
phosphine), it experiences greater anisotropic effects [14;26;27]. The most likely explanation 
for this is that the better sigma-donor ability of the phosphine ligand compared to the chloride 
ligand, leads to an increase in the delocalisation of electron density in the metallocyclic ring, 
resulting in a greater degree of deshielding of the imine protons. Furthermore, the imine signal 
occurs as a doublet. This is due to 4JH-P coupling between the imine proton and the 
phosphorous atom of the PTA ligand. 
Cleavage of the μ-chloro bridge leads to changes in the aromatic region of the NMR spectrum, 
producing many multiplets with fine splitting. An additional multiplet occurs in the region of  
4.5-4.6 ppm. This signal integrates for the twelve protons associated with PTA. Free PTA has 
a singlet and a doublet at 4.61 ppm and 4.05 ppm; however, upon coordination it appears as 
though these signals shift and have some degree of overlap. As with the bridged complex, the 
methine signal is a multiplet, integrating for two protons. Again the multiplet is due to 
overlapping septets with very similar shifts. The methyl signals vary in multiplicity. Some 
analogues produced the expected two doublets, as was observed for the chloro-bridged 
palladacycles, whilst others showed signals with varying extents of broadening. C4, the  




2-methyl analogue, showed a signal which resembles a broad singlet instead of the two 
doublets. These varyingly broad signals were unexpected and once again indicated a variation 
in the degree of bond rotation. This phenomenon is not observed in the analogous 
triphenylphosphane and trimethylphosphane series [10;11]. On closer investigation it was 
observed that these complexes exhibit dynamic motion in solution, in other words, the varying 
degrees of signal broadening observed are likely due to a dynamic phenomenon such as a 
chemical exchange process. This was explored further using variable temperature NMR, the 
details of which are discussed in Chapter 3. 
Figure 2.14: 13C NMR spectrum of C1. 
 
13C NMR spectroscopy (Figure 2.14) also showed the imine carbon as the most downfield 
signal. As with the 1H NMR spectra, these spectra showed heteronuclear splitting. The imine 
carbon signal (177 ppm) is a doublet due to three-bond coupling between 13C and 31P (3JC-P) 
which is of the order 3.1-4.5 Hz. The signals for the PTA carbons occur as two doublets, due 
to heteronuclear coupling of these carbons to phosphorous. The signal at approximately 70 
ppm represents the N-CH2-N carbon atom with 3JC-P, whilst the doublet at 52 ppm represents 
the N-CH2-P carbon atom with 1JC-P. 
 
 C1 C2_300.esp























































































































































7.99 (d, 1H, 
4JH-P 7.6 Hz) 






 1.07-1.39 (br s, 12H) 
C2 
8.48 (d, 1H, 
4JH-P 7.6 Hz) 







1.33 (d, 6H, 3JH-H 6.9 Hz) 
1.16 (d, 6H, 3JH-H 6.8 Hz) 
C3 
8.48 (d, 1H, 
4JH-P 7.6 Hz) 
7.31-7.34 (m, 1H, H3); 7.25-7.28 (m, 1H); 







1.33 (d, 6H, 3JH-H 6.8 Hz) 
1.17 (d, 6H, 3JH-H 6.9 Hz) 
C4 8.31 (s, 1H) 
7.26-7.27 (m, 2H); 7.16-7.19 (m, 4H); 








1.05-1.40 (br s, 12H) 
C5 
7.93 (d, 1H, 
4JH-P 7.8 Hz) 
7.36 (d, 1H, 3JH-H 7.6 Hz, H3); 7.21-7.24 (m, 
1H, H11); 7.17 (s, 1H); 7.12-7.14 (m, 2H); 








1.13-1.29 (m, 12H) 
C6 
8.33 (dd, 1H, 4JH-P 
7.6 Hz, 4JH-F 0.7 Hz) 
7.24-7.35 (m, 2H, H3,11); 7.16-7.19 (m, 2H); 







1.33 (d, 6H, 3JH-H 6.6 Hz) 
1.15 (d, 6H, 3JH-H 6.8 Hz) 
C7 
8.80 (d, 1H, 
4JH-P 7.8 Hz) 
7.84 (dd, 1H, 3JH-H 8.1 Hz, 4JH-H 1.0 Hz, H3); 
7.52-7.56 (m, 1H, H5); 7.41-7.46 (m, 1H, H4); 







 1.17-1.32 (br m, 12H) 
C8 
8.41 (d, 1H, 
4JH-P 7.5 Hz) 
7.26-7.30 (m, 1H); 7.21-7.24 (m, 2H); 7.14-
7.17 (m, 2H); 6.84-6.88 (m, 1H, H5); 6.67-








1.32 (br d, 6H, 3JH-H 6.8 Hz); 
1.15 (br d, 6H, 
3JH-H 6.8 Hz) 
Spectra recorded in CDCl3 at 25 °C. Chemical shifts reported in ppm, referenced relative to residual solvent peak. Superscript numbering denotes proton assignments as per 
Figure 2.4.
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31P NMR spectra show singlets at approximately -47 ppm (Table 2.13). This is a significant 
shift from the free PTA signal at -102 ppm. Similar shifts were observed for other palladium 
compounds upon coordination of PTA [28;29]. 
Table 2.13: 31P NMR shifts of mononuclear palladacycles, C1-C8. 










To further probe this large chemical shift, the 31P NMR spectroscopic signals for analogous 
group 10 metal-PTA compounds from the literature were compared (Table 2.14). Additionally, 
the M-P bond length from the crystal structures of the analogous protonated compounds, 
[M(PTAH)4]Cl4, were compared. These values are reported in Table 2.15. 
Table 2.14: Group 10 metal-PTA compounds from the literature and their 31P NMR shifts [28;30;31]. 
PTA compound 
31P NMR shift (D2O) 
(ppm) 
Change in chemical shift relative 
to free PTA (ppm) 
PTA -96 0 
Ni(PTA)4 -46 50 
Pd(PTA)4 -59 37 
Pt(PTA)4 -75 with Pt satellites(JPt-P = 3590 Hz)  21 
cis-PdCl2(PTA)2 -23 73 
cis-PtCl2(PTA)2 -51 with Pt satellites(JPt-P = 3350 Hz) 45 
 
Table 2.15: M-P bond lengths for reported [M(PTAH)4]Cl4 structures from the literature [30;32]. 
PTA compound M-P bond distance (Å) Electron density on M (gcm-1) 
[Ni(PTAH)4]Cl4 2.133(2) 8.90 
[Pd(PTAH)4]Cl4 2.203(3) 12.0 
[Pt(PTAH)4]Cl4 2.254(3) 21.5 




From the tables above, it is clear that the group 10 metal to which the PTA ligand coordinates 
has a significant influence on the 31P NMR chemical shift of the compound and the M-P bond 
length. 
Coordination of the two electron donor, PTA, increases the electron density on the metal, 
resulting in increased back donation. The larger the extent of back donation, the longer the 
bond length and consequently, the weaker the M-P bond. Therefore, the high electron density 
on platinum leads to a greater extent of back donation and results in a weaker M-P bond. 
Furthermore, from the 31P NMR chemical shifts, it appears as though the degree of deshielding 
of the phosphorous correlates with the extent of back donation. Since nickel has a lower 
electron density than platinum, there is less back donation to the PTA ligands and thus, there 
is lower electron density on the phosphorous atoms. Consequently, there is a lower degree of 
shielding of the phosphorous nuclei from the magnetic field, hence, the large downfield shift 
observed in the 31P NMR spectra. 
Having determined that the large downfield shift in the 31P NMR spectra is most likely due to 
the higher electron density on palladium, the next step was to compare the 31P NMR spectra 
for the PTA complexes with the previously reported PPh3 and PMe3 analogues. The extent of 
the deshielding (55 ppm downfield shift) observed for the PTA complexes was close to that 
observed for PMe3 (57-58 ppm) and larger than that observed for PPh3 (47 ppm) [8;9]. Thus, 
similarly to PMe3, PTA is a better sigma donor than PPh3 due to its higher basicity, where the 
pKa’s of PMe3, PTA and PPh3 are 8.65, 5.68 and 2.73, respectively [8;33]. Therefore, 
coordination of the PTA ligand increases the electron density on the palladium centre, leading 
to increased back donation and consequent deshielding of the phosphorous atoms in the PTA 
complexes, as explained above. 
 
ESI-MS was again used as further confirmation that the correct products had been isolated. 
Mass spectra showed the [M+H]+ and [M-Cl]+ ion fragments for all the analogues (Figure 2.15). 
C2-C8 also showed the [M-Cl-PTA+MeCN]+ ion fragment, as shown in Table 2.16. Some of 
the analogues also show two dimeric ion fragments in the region of 800-1200 m/z. This 
dimerisation occurs during the ionisation process and has been reported previously [18]. 
Again, isotope clusters were observed and were indicative of the atoms present in the 
fragment. Furthermore, the simulated fragmentation patterns matched the observed 
experimental fragments for all cases, except the [M+H]+ fragment, which is overlapped with a 
second fragment, thus the fragmentation pattern is obscured. 
 




Table 2.16: Ion fragments detected by ESI-MS for mononuclear palladacycles, C1-C8. 
Complex [M+H]+ [M-Cl]+ [M-Cl-PTA+MeCN]+ 
C1 564 527 - 
C2 599 563 447 
C3 643 607 491 
C4 579 541 425 
C5 579 541 425 
C6 583 545 429 
C7 610 572 456 
C8 595 557 441 
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Solubility of the compounds was tested in water, DMSO and a DMSO/water mixture. 
Quantitative testing was done by adding the respective solvent, water or DMSO, to a known 
mass of the complex, drop-wise, until dissolution was achieved. This was continued until the 
solid dissolved (clear solution) or until a maximum of 10 mL was reached. None of the 
complexes were completely water-soluble by this method. To obtain a relative solubility in a 
DMSO/water mixture, water was added drop-wise to the complex, dissolved in DMSO, until 
the complex precipitated out (turbid solution). The results are reported as the minimum 
percentage of DMSO required for the complex to remain dissolved in a DMSO/water solution. 
Table 2.17 shows the results of this study. 






Minimum %DMSO in 
DMSO/water solution 
AJ5 0 4.38 57 
C1 0 8.32 66 
C2 0 1.91 72 
C3 0 2.34 72 
C4 0 6.72 69 
C5 0 12.3 49 
C6 0 10.6 68 
C7 0 0.459 57 
C8 0 6.32 58 
 
Based on the results in Table 2.17, these complexes are not water-soluble. Complexes C4 
and C6 show the highest solubility in DMSO, whilst complex C5 shows the highest tolerance 
for water, requiring only 11% DMSO in an aqueous medium to remain dissolved. When 
compared to AJ5, C7 is more soluble in DMSO; however, the tolerance for water is 
significantly lower and C5, has higher water tolerance than AJ5, but it is far less soluble in 
DMSO. 
 
Suitable crystals of C1, C2 and C4 were obtained by slow evaporation of  
DCM/diethyl ether solutions at room temperature. The resultant yellow crystals were analysed 
by single crystal X-ray diffraction and the experimental data are recorded in Table 2.18. 
Additional geometric parameters can be found in Appendix 1, Tables A1.5 – A1.10. 
 




Table 2.18: Crystallographic data for C1, C2 and C4. 
Parameter C1 C2 C4 
Chemical formula C25H34ClN4PPd C25H33Cl2N4O0.05PPd C26H37ClN4O0.5PPd 
Formula weight 563.38 598.56 586.41 
Temperature (K) 100(2) 100(2) 173(2) 
Wavelength (Å) 0.71073 0.71073 0.71073 
Crystal system Monoclinic Monoclinic Triclinic 
Space group P21/n P21/c P-1 
a (Å) 19.101(3) 12.1991(4) 13.3048(9) 
b (Å) 13.413(2) 23.1995(8) 13.7674(10) 
c (Å) 19.575(3) 18.2034(6) 17.0288(12) 
α (°) 90.00 90.00 104.843(1) 
β (°) 94.160(2) 93.563(2) 105.172(1) 
γ (°) 90.00 90.00 109.699(1) 
V (Å3) 5001.8(15) 5141.8(3) 2622.8(3) 
Z 8 8 4 
Dcalc [Mg/m3] 1.496 1.546 1.485 
Absorption coefficient (mm-1) 0.933 1.013 0.894 
F(000) 2320 2451 1212 
Final R indices [I>2σ(I)] 
R1 = 0.0374, 
wR2 = 0.0751 
R1 = 0.0199, 
wR2 = 0.0507 
R1 = 0.0304, 
wR2 = 0.0698 
Reflections collected 31961 170673 32275 
Completeness to θmax (%) 91.5 94.5 91.2 
Goodness-of-fit on F2 1.028 1.060 1.031 
Largest difference peak and hole 
(e Å-3) 
0.613, -0.565 0.607, -0.493 0.600, -0.518 
 
The asymmetric units of all three compounds contain two molecules each due to slight 
structural differences, including differences in bond lengths and angles, as well as disorder of 
the isopropyl groups for C2 and C4. The geometry around the palladium centres is distorted 
square planar, with the phosphine ligand trans to the imine nitrogen and the angle between 
the planes of the two aromatic rings varying between 73.60° and 88.41°. 
For C1 (Figure 2.16), the structural differences are evident from the torsion angle C1-C7-N1-
C8 (τ), which is different for the two molecules, A (τA = 178.8(2)˚) and B (τB = 177.0(2)˚). These 
differences result in different orientations and different packing. C1 shows interesting packing 




of the two molecules, as shown in Figure 2.17, where A (green) and B (purple), form alternating 
rows along the diagonal of the ac plane. 
 
Figure 2.16: Asymmetric unit of C1, with thermal ellipsoids rendered at the 50% probability level. H atoms are rendered 
as spheres with arbitrary fixed radii. Selected non-H atoms are labelled. 
 
Similarly, a 1.1° difference in the C1-C7-N1-C8 torsion angle of the two symmetry-independent 
molecules was also observed in C2 (Figure 2.18). Additionally, there was disorder of several 
atoms in the isopropyl moiety of molecule A, whilst no disorder was observed in molecule B. 
The disorder is most likely a result of fluxional motion about a carbon (sp2)-carbon (sp3) bond 
axis. The carbon atoms in the major component of the disorder are labelled C15A and C16A, 
whilst the carbon atoms in the minor component are labelled C15C and C16C. The major and 
minor components have site-occupancy factors of 0.72(2) and 0.28(2), respectively. 
The packing of C2 shows an ⋯ABAB⋯ array along the a-axis, similar to that observed for L7 
and C1. Furthermore, an intermolecular hydrogen bond between a PTA nitrogen and a 
molecule of water was observed (Figure 2.19), the details of which are reported in Table 2.17. 
Note that the hydrogen atoms on the water molecule involved in this hydrogen bond could not 
be modelled satisfactorily, thus only an oxygen atom is displayed in the ASU (Figure 2.18). 
Consequently, some of the bond lengths and angles pertaining to the hydrogen bond could 




not be measured. From the literature, it is known that these O-H···N hydrogen bonds are 
common in compounds containing PTA ligands [34]. 
 
Figure 2.17: Crystal packing of C1 showing alternating molecules A (green) and B (purple). Viewed down the b-axis. 
 
 
Figure 2.18: Asymmetric unit of C2, with thermal ellipsoids rendered at the 50% probability level. H atoms have been 
omitted for clarity. Selected non-H atoms are labelled. 





Figure 2.19: Hydrogen bond between PTA nitrogen of C2 and an entrapped water molecule. Hydrogens have been 
omitted for clarity. 
 
Table 2.19: Numerical details of the O-H···N hydrogen bond in C2 and C4. 
Compound D-H···A D-H (Å) H···A (Å) D···A (Å) D-H···A (⁰) 
C2 O1-H···N2Ai - - 2.89(1) - 
C4 O1-H2···N2Bii 0.901 2.01 2.90(4) 167 
Note: D-H = proton donor group, A = proton acceptor atom; Symmetry codes: (i) 1−x, 1−y, 2−z; (ii) -1+x, y, z. 
 
C4, shown in Figure 2.20, is very similar to C2, with a difference of 5.1˚ in the torsion angle 
C1-C7-N1-C8 (τ) for molecule A and B. Disorder is observed in the isopropyl moiety of 
molecule B, with major and minor components assigned as C15B, C16B and C15C, C16C. 
Site occupancy factors are 0.853(6) for the major component and 0.147(6) for the minor 
component. As for C2, the disorder is most likely due to fluxional motion about a carbon (sp2)-
carbon (sp3) bond axis. Packing is similar to C1 and C2, but the ⋯ABAB⋯ array repeats along 
the c-axis. 




As for C2, there is an intermolecular hydrogen bond between a nitrogen of a PTA ligand and 
an entrapped water molecule, as shown in the Figure 2.21. The details of this bond are 
recorded in Table 2.19. 
 
Figure 2.20: Asymmetric unit of C4, with thermal ellipsoids rendered at the 50% probability level. H atoms have been 
omitted for clarity. Selected non-H atoms are labelled. 
 
 
Figure 2.21: Hydrogen bond between PTA nitrogen of C4 and an entrapped water molecule. Hydrogens have been 
omitted for clarity and the oxygen atoms of the water molecules are represented as balls. 




Next, the coordination bond lengths in the three palladacycles were considered and compared 
with analogous literature compounds. 
The coordination bond lengths for C1, C2 and C4 are recorded in Table 2.20, followed by that 
of analogous PPh3 palladacycles from the literature. All structures referred to in Table 2.20 
are represented in Figure 2.22. 
 
Figure 2.22: Novel and reported palladacycles with similar coordination spheres [10;11]. R = 2-H, 2-Cl, 2-Me and 4-Me 
and PX3 = PTA and PPh3. 
 
Table 2.20: Bond lengths for C1, C2, C4 and analogous palladacycles from the literature, represented in Figure 2.22. 
Complex Pd-N1 (Å) Pd-P (Å) Pd-C6 (Å) Pd-Cl (Å) C7-N1 (Å) 
C1 
















































Literature Compound C 
PX3 = PPh3; R = 4-Me 
2.102(3) 2.2520(9) 2.011(3) 2.3647(7) 1.285(5) 
*No errors reported in the references [10;11]; ABond distance for molecule A in the ASU; BBond distance for 
molecule B in the ASU. 
 
From the Table 2.20, it is clear that the substituent on the aromatic ring influences the Pd-N1, 
Pd-P and Pd-C6 bond lengths. Unfortunately, the crystal data for C4 was collected at a much 
higher temperature, so the bond lengths could not be compared. However, comparing the 
unsubstituted complex, C1, and the chloro-analogue, C2, revealed that the electron 
withdrawing substituent results in shorter Pd-N1 and Pd-C6 bonds and a longer Pd-P bond. 
However, a clear trend in terms of the electronic effects of the substituents cannot be 
established from the three complexes reported here. Furthermore, it was noted that the 
phosphine ligand has a significant influence on the Pd-P bond distance, with the bond lengths 




for the PPh3 complexes being longer and therefore, weaker as compared to the bond lengths 
in the PTA compounds, where the bond is approximately 0.03 Å shorter. The shorter Pd-P 
bond distance in the PTA analogues could be due to less steric strain, as the cone angle of 
PTA is considerably smaller than that of PPh3. Overall, the coordination bonds appear very 
similar for the novel palladacycles, C1, C2 and C4, and the reported PPh3 analogues, 
Literature compounds B and C. 
 
2.4 Conclusions 
Novel PTA-based palladacycles were synthesised and fully characterised. The complexes 
were found to have dynamic motion in solution, as shown in the 1H and 13C NMR spectra. 
None of the complexes were water-soluble and no clear trend was observed for the influence 
of the ortho-substituents on the solubility. Crystal structures of some of the complexes showed 
two molecules in the asymmetric unit due to slight structural differences. Preliminary studies 
into improving the solubility of the complexes showed that simply reducing the molecular 
weight and including a water-soluble ligand is not sufficient, and more work needs to be done 
in this respect. 
 
2.5 Materials and Methods 
Reagents were obtained from Sigma Aldrich, Kimix and Merck. The palladium precursor, 
bis(acetonitrile)palladium dichloride, was prepared by refluxing PdCl2 in excess acetonitrile for 
3-4 hours, followed by filtration and drying [35]. Reactions were performed under nitrogen in 
sealed Schlenk tubes. All solvents for syntheses were distilled before use or dried over 
ZANTECH Alusorb ZT200 2-5 mm sieves in Innovative Technology PS-Micro solvent purifiers. 
Novel compounds were characterised using the following analytical techniques: FT-IR-, NMR 
spectroscopy (1H, 13C, 31P), mass spectrometry, microanalysis, melting point determinations, 
solubility and single crystal XRD structure determination where applicable. 
FT-IR spectra were recorded on a Thermo Nicolet AVATAR 330 instrument equipped with a 
smart performer ATR. Samples were recorded neat. NMR (1H: 300 and 400 and 600 MHz; 
13C: 300, 400 and 600 MHz, 31P: 300 and 600 MHz) spectra were recorded on Varian NMR 
spectrometers at 273 K and chemical shifts are referenced to the residual protons of the 
deuterated solvents and external tetramethyl silane (TMS) of 1H and 13C NMR spectra, whilst 
31P NMR spectroscopy chemical shifts are referenced relative to external 85% phosphoric acid 




(H3PO4). Chemical shifts (δ) and coupling constants (J) are reported in ppm and Hertz (Hz), 
respectively. The data in brackets are as follows: multiplicity, number of atoms (as per 
integration), coupling constants and assignment of atoms (where ‘,’ denotes ‘and’ and 
‘/’denotes ‘or’). The following abbreviations were used to describe multiplicity of signals: s = 
singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = multiplet and br = broad signals. 
ESI-MS (positive ion mode) analyses were performed on either a Waters API Quattro Micro 
or a Waters API Q-TOF Ultima instrument by direct injection of sample with acetonitrile as 
solvent. Fragmentation patterns were simulated using IsoPro 3.0 MS/MS Software [36]. 
Microanalysis was done at the University of Cape Town, Department of Chemistry on a 
Thermo Elemental Analyser CHNS-O instrument. Melting points were determined using a 
Stuart Scientific SMP3 melting point apparatus and are reported as uncorrected. 
Quantitative solubilities of the mononuclear PTA-based palladacycles, in water and DMSO, 
were determined by adding the solvent drop-wise to a known mass of compound until the 
compound dissolved or remained insoluble at a maximum volume of 10 mL. Relative 
solubilities in DMSO/water mixtures were obtained by adding water drop-wise to a solution of 
the complex in DMSO, until the complex precipitated out, making the solution turbid. 
For the X-ray structural determination, single crystals were mounted on nylon loops. Single 
crystal X-ray diffraction data were recorded using a Bruker Apex2 diffractometer with graphite 
monochromated Mo-Kα radiation (λ = 0.71073 Å). An Oxford Cryostream cooling system was 
used to record data sets at 100 and 173 K. Data reduction and absorption corrections were 
carried out with the Bruker software packages SAINT and SADABS [37;38]. Crystal structures 
were solved and refined using SHELXS97and SHELXL97, respectively [39]. Molecular 
graphics from Mercury 3.7 were used [40]. Additional geometric parameters can be found in 
Appendix 1. *Note that single crystal X-ray diffraction data was recorded and solved by Dr. 
Vincent Smith and Prof. Delia Haynes from Stellenbosch University and Prof. Ilia Guzei from 
the University of Wisconsin, Madison. 
 
Synthesis of monofunctional imine ligands (L1-L8) 
Benzylidene-2,6-diisopropylphenylamine (L1) 
L1 was synthesised by stirring a solution of 2,6-diisopropylaniline (1.07 mL, 5.64 mmol) in dry 
ethanol (10 mL) in a Schlenk tube. Benzaldehyde (0.573 mL, 5.64 mmol) was added to the 
solution and the resulting yellow solution was stirred for 24 hours in an oil bath at ± 28 °C. The 
solvent was removed on a rotary evaporator to obtain a yellow oily residue. The residue was 
dissolved in dichloromethane (15 mL) and the solution was washed with water (10 x 15 mL 




portions). The yellow organic layer was dried over anhydrous magnesium sulphate after which 
the magnesium sulphate was removed by filtration. The solvent was then removed from the 
yellow filtrate to obtain a yellow oily residue. The product was recrystallised from the residue 
by dissolving the residue in dichloromethane (2-3 mL) and then layering with cold methanol at 
low temperature. The solution was kept at low temperature (-16 °C) overnight. Yellow crystals 
which subsequently formed were isolated by vacuum filtration and rinsing with cold methanol. 
The yellow crystals were air dried. Yield: 0.648 g, 43%. FT-IR (νC=N, cm-1) 1638. 
 
2-Chlorobenzylidene-2,6-diisopropylphenylamine (L2) 
L2 was synthesised according to the method above using 2-chlorobenzaldehyde instead of 
benzaldehyde. Yield: 0.909 g, 54%. FT-IR (νC=N, cm-1) 1626. 
 
2-Bromobenzylidene-2,6-diisopropylphenylamine (L3) 
L3 was synthesised according to the method above using 2-bromobenzaldehyde instead of 
benzaldehyde. Yield: 1.556 g, 80%. FT-IR (νC=N, cm-1) 1627. 
 
2-Methylbenzylidene-2,6-diisopropylphenylamine (L4) 
L4 was synthesised according to the method above using 2-methylbenzaldehyde instead of 
benzaldehyde. Yield: 0.911 g, 57%. FT-IR (νC=N, cm-1) 1629. 
 
4-Methylbenzylidene-2,6-diisopropylphenylamine (L5) 
L5 was synthesised according to the method above using 4-methylbenzaldehyde instead of 
benzaldehyde. Yield: 1.237 g, 79%. FT-IR (νC=N, cm-1) 1636. 
 
2-Fluorobenzylidene-2,6-diisopropylphenylamine (L6) 
L6 was synthesised by stirring a solution of 2,6-diisopropylaniline (1.07 mL, 5.64 mmol) in dry 
ethanol (10 mL) in a Schlenk tube. 2-Fluorobenzaldehyde (0.605 mL, 5.64 mmol) was added 
to the solution. The resulting yellow solution was stirred for 24 hours in an oil bath at ± 28 °C. 
The solvent was removed to obtain yellow oily residue. The residue was dissolved in 
dichloromethane (15 mL). The solution was washed with water (10 x 15 mL portions). The 
yellow organic layer was dried over anhydrous magnesium sulphate. The magnesium 
sulphate was removed by filtration. The solvent was removed from the yellow filtrate to obtain 




a yellow oily residue. The product was recrystallised by dissolving the residue in 
dichloromethane (2-3 mL) and then layering the solution with cold methanol at low temperature 
(-16 °C). The solution was kept at low temperature (-16 °C) overnight. Yellow needle-like 
crystals were isolated by vacuum filtration and rinsing with cold methanol. The crystals were 
air dried. Yield: 1.30 g, 81%. FT-IR (νC=N, cm-1) 1631. m.p.: 74.9-79.0 °C. 1H NMR (299.74 
MHz, CDCl3): δ 8.53 (s, 1H, CH=N); δ 8.21-8.27 (m, 1H, Ph); δ 7.47-7.52 (m, 1H, Ph); δ 7.27-
7.33 (m, 1H, Ph); δ 7.10-7.20 (m, 4H, Ph); δ 2.98 (sept, 2H, 3JH-H 6.9 Hz, 
iPr-CH); δ 1.20 (d, 
12H, 3JH-H 6.9 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 161.12 (CH=N); δ 155.63 (d, 
JC-F 4.5 Hz, CAr-F); δ 149.27 (CAr); δ 137.52 (CAr); δ 132.96 (d, JC-F 8.9 Hz, CAr); δ 127.69 (d, 
JC-F 2.5 Hz, CAr); δ 124.54 (d, JC-F 3.8 Hz, CAr); δ 124.29 (CAr); δ 123.03 (CAr); δ 116.10 (CAr); 
δ 115.82 (CAr); δ 27.93 (
iPr-CH); δ 23.46 (iPr-CH3). ESI-MS: [M+H]+ 284.18. 
 
2-Nitrobenzylidene-2,6-diisopropylphenylamine (L7) 
L7 was synthesised according to the method above using 2-nitrobenzaldehyde instead of 2-
fluorobenzaldehyde. Yield: 0.507 g, 29%. FT-IR (νC=N, cm-1) 1643. m.p.: 63.2-65.7 °C. 1H NMR 
(299.74 MHz, CDCl3): δ 8.65 (s, 1H, CH=N); δ 8.35 (dd, 1H, 3JH-H 7.8 Hz and 4JH-H 1.6 Hz, Ph); 
δ 8.13 (dd, 1H, 3JH-N 8.2 Hz and 4JH-H 1.3 Hz, Ph); δ 7.78-7.83 (m, 1H, Ph); δ 7.65-7.71 (m, 
1H, Ph); δ 7.12-7.22 (m, 2H, Ph); δ 7.06 (d, 1H, 3JH-H 7.6 Hz, Ph); δ 3.06 (sept, 2H, 3JH-H 6.9 
Hz, iPr-CH); δ 1.22 (d, 12H, 3JH-H 6.8 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 158.24 
(CH=N); δ 149.30 (CAr); δ 148.28 (CAr); δ 137.51 (CAr); δ 133.79 (CAr); δ 131.35 (CAr); δ 131.03 
(CAr); δ 129.69 (CAr); δ 124.68 (d, 2JC-N 12.0 Hz, CAr); δ 123.13 (CAr); δ 122.77 (CAr); δ 27.94 
(iPr-CH); δ 23.51 (iPr-CH3). ESI-MS: [M+H]+ 311.18. 
 
2-Methoxybenzylidene-2,6-diisopropylphenylamine (L8) 
L8 was synthesised according to the method above using 2-methoxybenzaldehyde instead of 
2-fluorobenzaldehyde. Yield: 0.879 g, 53%. FT-IR (νC=N, cm-1) 1638. m.p.: 124-129 °C. 1H NMR 
(599.98 MHz, CDCl3): δ 8.76 (s, 1H, CH=N); δ 8.32 (dd, 1H, 3JH-H 7.6 Hz and 4JH-H 1.8 Hz, Ph); 
δ 7.58-7.61 (m, 1H, Ph); δ 7.28 (d, 2H, 3JH-H 7.6 Hz, Ph); δ 7.20-7.23 (m, 2H, Ph); δ 7.10 (d, 
1H, 3JH-H 8.2 Hz, Ph); δ 3.88 (s, 3H, -OCH3); δ 3.02 (sept, 2H, 3JH-H 7.0 Hz, 
iPr-CH); δ 1.20 (d, 
12H, 3JH-H 6.5 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 159.48 (CH=N); δ 158.46 
(CAr); δ 150.01 (CAr); δ 137.78 (CAr); δ 132.56 (CAr); δ 127.28 (CAr); δ 124.63 (CAr); δ 123.85 
(CAr); δ 122.89 (CAr); δ 120.87 (CAr); δ 111.19 (CAr); δ 55.59 (-OCH3); δ 27.85 (
iPr-CH); δ 23.50 
(iPr-CH3). ESI-MS: [M+H]+ 296. 
 




Synthesis of μ-chloro palladacycles (B1-B8) 
[PdCl(C6H4)CH=N{2,6-iPr2-C6H3}]2 (B1) 
B1 was synthesised by stirring a solution of bis(acetonitrile)palladium dichloride (0.100 g, 
0.386 mmol) in DCM (10 mL) in a Schlenk tube. L1 (0.102 g, 0.386 mmol) and sodium acetate 
(0.063 g, 0.77 mmol) were added to the solution. The resulting dark red solution was stirred 
for 18 hours in an oil bath at ± 28 °C. The solvent was removed to obtain yellow solid residue. 
The residue was dissolved in DCM (20 mL) and the solution was filtered through celite. The 
solvent was removed from the filtrate on a rotary evaporator to obtain an oily residue. The 
product was recrystallised from the residue by dissolving it in DCM and then layering the 
solution with hexane at room temperature. The solution was kept at room temperature 
overnight after which a yellow solid was isolated by vacuum filtration and rinsing with hexane. 
The solid was air dried. Yield: 0.118 g, 76%. FT-IR (νC=N, cm-1) 1599. 
 
[PdCl(2-Cl-C6H3)CH=N{2,6-iPr2-C6H3}]2 (B2) 
B2 was synthesised according to the method above using L2 instead of L1. Yield: 0.112 g, 
66%. FT-IR (νC=N, cm-1) 1594. 
 
[PdCl(2-Br-C6H3)CH=N{2,6-iPr2-C6H3}]2 (B3) 
B3 was synthesised according to the method above using L3 instead of L1 and reacting for 
only 6 hours. Yield: 0.166 g, 89%. FT-IR (νC=N, cm-1) 1584. 
 
[PdCl(2-Me-C6H3)CH=N{2,6-iPr2-C6H3}]2 (B4) 
B4 was synthesised according to the method above using L4 instead of L1 and reacting for 
24 hours. Yield: 0.090 g, 56%. FT-IR (νC=N, cm-1) 1594. 
 
[PdCl(4-Me-C6H3)CH=N{2,6-iPr2-C6H3}]2 (B5) 
B5 was synthesised according to the method above using L5 instead of L1 and using 0.308 
mmol of ligand and precursor and 0.616 mmol of sodium acetate. Yield: 0.075 g, 58%. FT-IR 
(νC=N, cm-1) 1597. 
  





B6 was synthesised by stirring a solution of bis(acetonitrile)palladium dichloride (0.100 g, 
0.386 mmol) in dichloromethane (10 mL) in a Schlenk tube. L6 (0.109 g, 0.386 mmol) and 
sodium acetate (0.063 g, 0.772 mmol) were added to the solution. The resulting orange 
solution was stirred for 24 hours in an oil bath at ± 28 °C. The solvent was removed to obtain 
yellow solid residue. The residue was dissolved in dichloromethane (20 mL). The solution was 
filtered through celite. The solvent was removed from the yellow filtrate to obtain a yellow oily 
residue. The product was recrystallised from the residue by layering with hexane at room 
temperature. The solution was kept at room temperature overnight. A yellow solid was isolated 
by vacuum filtration and rinsed with hexane. The solid was air dried. Yield: 0.053 g, 32%. FT-
IR (νC=N, cm-1) 1604. m.p.: >250 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.02 (s, 2H, CH=N); δ 
7.31-7.36 (m, 2H, Ph); δ 7.19-7.22 (m, 4H, Ph); δ 7.03-7.11 (m, 2H, Ph); δ 6.94-6.97 (m, 2H, 
Ph); δ 6.71-6.77 (m, 2H, Ph); δ 3.42-3.55 (m, 4H, iPr-CH); δ 1.39 (d, 12H, 6.8 Hz, iPr-CH3); δ 
1.18 (d, 12H, 6.8 Hz, iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 171.30 (CH=N); δ 161.35 
(CAr); δ 157.87 (CAr); δ 156.21 (CAr); δ 144.25 (CAr); δ 141.45 (CAr); δ 132.91-133.12 (m, CAr); 
δ 129.56 (CAr); δ 128.00 (CAr); δ 123.31(CAr); δ 111.32 (d, 2JC-F 19.1 Hz, CAr); δ 28.25 (
iPr-CH); 
δ 24.45 (iPr-CH3); δ 22.97 (
iPr-CH3). ESI-MS: [M-Cl]+ 813.11, [(M/2)-Cl+MeCN]2+ 429.01. Anal. 
Found: C, 53.4; H, 4.97; N, 2.48. Calc. for C38H42N2F2Cl2Pd2: C, 53.8; H, 4.99; N, 3.30. 
 
[PdCl(2-NO2-C6H3)CH=N{2,6-iPr2-C6H3}]2 (B7) 
B7 was synthesised according to the method above using L7 instead of L6. Yield: 0.054 g,  
50%. FT-IR (νC=N, cm-1) 1596. m.p.: >250 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.72 (s, 2H, 
CH=N); δ 7.87 (d, 2H, 3JH-H 8.1 Hz, Ph); δ 7.55-7.58 (m, 2H, Ph); δ 7.36-7.41 (m, 2H, Ph); δ 
7.23-7.28 (m, 6H, Ph); δ 3.40-3.49 (m, 4H, iPr-CH); δ 1.39 (d, 12H, 6.5 Hz, iPr-CH3); δ 1.19 
(d, 12H, 6.8 Hz, iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 174.90 (CH=N); δ 157.87 (CAr); 
δ 146.17 (CAr); δ 144.23 (CAr); δ 141.17 (CAr); δ 139.49 (CAr); δ 137.81 (CAr); δ 131.16 (CAr); δ 
128.50 (CAr); δ 123.51(CAr); δ 121.17 (CAr); δ 28.47 (
iPr-CH); δ 24.44 (iPr-CH3); δ 22.92 (
iPr-
CH3). ESI-MS: [M-Cl]+ 867.10, [(M/2)-Cl+MeCN]2+ 456.09. Anal. Found: C, 47.5; H, 4.50; N, 
5.03. Calc. for C38H42N4 O4Cl2Pd2·CH2Cl2: C, 47.4; H, 4.49; N, 5.67. 
 
[PdCl(2-OMe-C6H3)CH=N{2,6-iPr2-C6H3}]2 (B8) 
B8 was synthesised according to the method above using L8 instead of L6. Yield: 0.120 g,  
71%. FT-IR (νC=N, cm-1) 1593. m.p.: >250 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.06 (s, 2H, 
CH=N); δ 7.27-7.32 (m, 2H, Ph); δ 7.17-7.19 (m, 4H, Ph); δ 6.97-7.03 (m, 2H, Ph); δ 6.78 (d, 
2H, 3JH-H 7.8 Hz, Ph); δ 6.53 (d, 2H, 3JH-H 8.4 Hz, Ph); δ 3.77 (s, 6H, -OCH3); δ 3.47-3.60 (m, 




4H, iPr-CH); δ 1.39 (d, 12H, 3JH-H 6.8 Hz, 
iPr-CH3); δ 1.16 (d, 12H, 6.8 Hz, 
iPr-CH3). 13C{1H} 
NMR (CDCl3, 75.38 MHz): δ 173.04 (CH=N); δ 158.27 (CAr); δ 157.36 (CAr); δ 144.77 (CAr); δ 
141.75 (CAr); δ 133.78 (CAr); δ 132.70 (CAr); δ 127.48 (CAr); δ 126.26 (CAr); δ 123.10 (CAr); δ 
106.72 (CAr); δ 55.33 (-OCH3); δ 28.11 (
iPr-CH); δ 24.50 (iPr-CH3); δ 23.01 (
iPr-CH3). ESI-MS: 
[(M/2)-Cl+MeCN]2+ 441.1. Anal. Found: C, 52.8; H, 5.95; N, 2.98. Calc. for 
C40H48N2O2Cl2Pd2·2H2O: C, 52.9; H, 5.77; N, 3.08. 
 
Cleavage of μ-chloro palladacycles with monodentate phosphine, PTA, to 
produce the phosphine containing palladacycles, (C1-C8) 
[Pd(PTA)(C6H4)CH=N{2,6-iPr-C6H3}Cl] (C1) 
C1 was synthesised by stirring a solution of B1 (0.060 g, 0.074 mmol) in dichloromethane (5 
mL) in a Schlenk tube. PTA (0.023 g, 0.15 mmol) was added. The solution was stirred for 2 
hours in an oil bath at ± 28 °C. The solvent was removed on a rotary evaporator to obtain a 
yellow oily residue. The product was recrystallised by layering a dichloromethane solution with 
ether at room temperature. The solution was kept at room temperature overnight. The yellow 
crystals were isolated by vacuum filtration and rinsed with ether. The crystals were air dried. 
Yield: 0.118 g, 89%. FT-IR (νC=N, cm-1) 1606. m.p.: 222-226 °C. 1H NMR (299.74 MHz, CDCl3): 
δ 7.99 (d, 1H, 4JH-P 7.6 Hz, CH=N); δ 7.46-7.48 (m, 1H, Ph); δ 7.16-7.35 (m, 6H, Ph); δ 4.53-
4.64 (m, 12H, PTA); δ 3.16-3.29 (m, 2H, iPr-CH); δ 1.07-1.39 (br s, 12H, iPr-CH3). 13C{1H} 
NMR (CDCl3, 75.38 MHz): δ 176.91 (d, 3JC-P 4.5 Hz, CH=N); δ 157.99 (d, JC-P 4.5 Hz, CAr); δ 
147.81 (CAr); δ 144.23 (CAr); δ 140.81 (CAr); δ 136.27 (d, JC-P 9.5 Hz, CAr); δ 131.91 (d, JC-P 4.5 
Hz, CAr); δ 130.05 (CAr); δ 127.19 (CAr); δ 124.97 (CAr); δ 122.86 (CAr); δ 73.25 (d, 3JC-P 6.4 Hz, 
N-CH2-N); δ 52.43 (d, 1JC-P 16.5 Hz, P-CH2-N); δ 28.36 (
iPr-CH); δ 24.43 (iPr-CH3); δ 23.00 
(iPr-CH3). 31P{1H} NMR (121.34 MHz, CDCl3): δ -47.02 (s). ESI-MS: [M+H]+ 564.1; [M-Cl]+ 
527.2. Anal. Found: C, 53.4; H, 6.08; N, 9.29. Calc. for C25H34N4PClPd: C, 53.3; H, 6.08; N, 
9.94. Solubility: DMSO 4.65 mg/mL; 51% DMSO in water. 
 
[Pd(PTA)(2-Cl-C6H3)CH=N{2,6-iPr2-C6H3}Cl] (C2) 
C2 was synthesised as above, using B2 as the reagent and the amounts as indicated here: 
B2 (0.080 g, 0.0910 mmol) and PTA (0.029 g, 0.182 mmol). Yield: 0.119 g, 88%. FT-IR (νC=N, 
cm-1) 1600. m.p.: 215-219 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.48 (d, 1H, 4JH-P 7.6 Hz, 
CH=N); δ 7.13-7.30 (m, 6H, Ph); δ 4.52-4.63 (m, 12H, PTA); δ 3.14-3.27 (m, 2H, iPr-CH); δ 
1.33 (d, 6H, 3JH-H 6.9 Hz, 
iPr-CH3); δ 1.16 (d, 6H, 3JH-H 6.8 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 
75.38 MHz): δ 175.21 (d, 3JC-P 4.5 Hz, CH=N); δ 160.19 (d, JC-P 3.8 Hz, CAr); δ 144.44 (d, JC-P 




8.3 Hz, CAr); δ 140.76 (d, JC-P 1.3 Hz, CAr); δ 134.85 (CAr); δ 134.73 (CAr); δ 134.43 (CAr); δ 
133.21 (d, JC-P 4.5 Hz, CAr); δ 127.41 (CAr); δ 125.82 (CAr); δ 122.94 (CAr); δ 73.24 (d, 3JC-P 7.0 
Hz, N-CH2-N); δ 52.41 (d, 1JC-P 15.9 Hz, P-CH2-N); δ 28.42 (
iPr-CH); δ 24.52 (iPr-CH3); δ 22.87 
(iPr-CH3). 31P{1H} NMR (121.34 MHz, CDCl3): δ -47.61 (s). ESI-MS: [M+H]+ 599.1; [M-Cl]+ 
563.1; [M-Cl-PTA+MeCN]+ 447.1. Anal. Found: C, 50.0; H, 5.54; N, 9.49. Calc. for 




C3 was synthesised as above, using B3 as the reagent and the amounts as indicated here: 
B3 (0.130 g, 0.134 mmol) and PTA (0.042 g, 0.268 mmol). Yield: 0.061 g, 36%. FT-IR (νC=N, 
cm-1) 1599. m.p.: 173-178 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.48 (d, 1H, 4JH-P 7.6 Hz, 
CH=N); δ 7.31-7.34 (m, 1H, Ph); δ 7.25-7.28 (m, 1H, Ph); δ 7.18-7.22 (m, 3H, Ph); δ 7.07-
7.13 (m, 1H, Ph); δ 4.52-4.63 (m, 12H, PTA); δ 3.14-3.28 (m, 2H, iPr-CH ); δ 1.33 (d, 6H, 3JH-
H 6.8 Hz, 
iPr-CH3); δ 1.17 (d, 6H, 3JH-H 6.9 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 
177.08 (d, 3JC-P 3.8 Hz, CH=N); δ 159.88 (d, JC-P 3.8 Hz CAr); δ 145.36 (CAr); δ 143.91 (CAr); δ 
140.33 (CAr); δ 135.01 (d, JC-P 9.5 Hz, CAr); δ 132.92 (d, JC-P 5.1 Hz, CAr); δ 128.69 (CAr); δ 
126.99 (CAr); δ 123.02 (CAr); δ 122.52 (CAr); δ 72.81 (d, 3JC-P 7.0 Hz, N-CH2-N); δ 51.97 (d, 1JC-
P 15.9 Hz, P-CH2-N); δ 28.02 (
iPr-CH); δ 24.12 (iPr-CH3); δ 22.43 (
iPr-CH3). 31P{1H} NMR 
(161.90 MHz, CDCl3): δ -47.89 (s). ESI-MS: [M+H]+ 643.0; [M-Cl]+ 607.1; [M-Cl-PTA+MeCN]+ 
491.0. Anal. Found: C, 46.5; H, 6.38; N, 9.14. Calc. for C25H33N4PClBrPd: C, 46.8; H, 5.18; N, 
8.72. Solubility: DMSO 3.03 mg/mL; 67% DMSO in water. 
 
[Pd(PTA)(2-Me-C6H3)CH=N{2,6-iPr2-C6H3}Cl] (C4) 
C4 was synthesised as above, using B4 as the reagent and the amounts as indicated here: 
B4 (0.075 g, 0.0892 mmol) and PTA (0.028 g, 0.178 mmol). Yield: 0.076 g, 74%. FT-IR (νC=N, 
cm-1) 1601. m.p.: 197-202 °C. 1H NMR (599.98 MHz, CDCl3): δ 8.31 (s, 1H, CH=N); δ 7.26-
7.27 (m, 2H, Ph); δ 7.16-7.19 (m, 4H, Ph); δ 6.96 (d, 1H, 3JH-H 7.3 Hz, Ph); δ 4.53-4.61 (m, 
12H, PTA); δ 3.21-3.28 (m, 2H, 3JH-H 6.9 Hz, 
iPr-CH); δ 2.47 (s, 3H, CH3); δ 1.05-1.40 (br s, 
12H, iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 174.53 (CH=N); δ 159.05 (CAr); δ 145.52 
(CAr); δ 144.79 (CAr); δ 140.89 (CAr); δ 140.11 (CAr); δ 134.33 (CAr); δ 132.43 (CAr); δ 127.15 
(CAr); δ 127.11 (CAr); δ 122.94 (CAr); δ 73.25 (d, 3JC-P 6.4 Hz, N-CH2-N); δ 52.27 (d, 1JC-P 15.3 
Hz, P-CH2-N); δ 28.32 (
iPr-CH); δ 24.11 (iPr-CH3); δ 20.45 (CH3). 31P{1H} NMR (121.34 MHz, 
CDCl3): δ -48.64 (s). ESI-MS: [M+H]+ 579.1; [M-Cl]+ 541.2; [M-Cl-PTA+MeCN]+ 425.1. Anal. 




Found: C, 52.6; H, 6.27; N, 9.23. Calc. for C26H36N4PClPd·H2O: C, 52.4; H, 6.43; N, 9.41. S 
Solubility: DMSO 0.43 mg/mL; 51% DMSO in water. 
 
[Pd(PTA)(4-Me-C6H3)CH=N{2,6-iPr2-C6H3}Cl] (C5) 
C5 was synthesised as above, using B5 as the reagent and the amounts as indicated here: 
B5 (0.100 g, 0.119 mmol) and PTA (0.037 g, 0.238 mmol). Yield: 0.076 g, 56%. FT-IR (νC=N, 
cm-1) 1608. m.p.: 198-202 °C. 1H NMR (299.74 MHz, CDCl3): δ 7.93 (d, 1H, 4JH-P 7.8 Hz, 
CH=N); δ 7.36 (d, 1H, 3JH-H 7.6 Hz, Ph); δ 7.21-7.24 (m, 1H, Ph); δ 7.17 (s, 1H, Ph); δ 7.12-
7.14 (m, 2H, Ph); δ 7.01-7.04 (m, 1H, Ph); δ 4.53-4.63 (m, 12H, PTA); δ 3.15-3.28 (m, 2H, iPr-
CH); δ 2.44 (s, 3H, CH3); δ 1.13-1.29 (m, 12H, 
iPr-CH3). 13C{1H} NMR (CDCl3, 100.57 MHz): 
δ 176.40 (d, 3JC-P 4.0 Hz, CH=N); δ 157.89 (CAr); δ 145.06 (CAr); δ 144.31 (CAr); δ 142.54 (d, 
JC-P 5.0 Hz, CAr); δ 140.91 (CAr); δ 137.56 (d, JC-P 10.1 Hz, CAr); δ 129.86 (CAr); δ 127.10 (CAr); 
δ 125.57 (CAr); δ 122.83 (CAr); δ 73.29 (d, 3JC-P 7.0 Hz, N-CH2-N); δ 52.43 (d, 1JC-P 16.1 Hz, P-
CH2-N); δ 28.36 (
iPr-CH); δ 24.41 (CH3); δ 22.98 (
iPr-CH3); δ 22.46 (
iPr-CH3). 31P{1H} NMR 
(121.34 MHz, CDCl3): δ -47.58 (s). ESI-MS: [M+H]+ 579.1; [M-Cl]+ 541.2; [M-Cl- PTA+MeCN]+ 
425.1. Anal. Found: C, 53.0; H, 6.25; N, 9.20. Calc. for C26H36N4PClPd·H2O: C, 52.4; H, 6.43; 
N, 9.41. Solubility: DMSO 0.43 mg/mL; 51% DMSO in water. 
 
[Pd(PTA)(2-F-C6H3)CH=N{2,6-iPr2-C6H3}Cl] (C6) 
C6 was synthesised as above, using B6 as the reagent and the amounts as indicated here: 
B6 (0.073 g, 0.0860 mmol) and PTA (0.027 g, 0.172 mmol). Yield: 0.066 g, 66%. FT-IR (νC=N, 
cm-1) 1605. m.p.: 219-222 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.33 (dd, 1H, 4JH-P 6.9 Hz and 
4JH-F 0.7 Hz, CH=N); δ 7.24-7.35 (m, 2H, Ph); δ 7.16-7.19 (m, 2H, Ph); δ 7.04-7.08 (m, 1H, 
Ph); δ 6.83-6.89 (m, 1H, Ph); δ 4.53-4.64 (m, 12H, PTA); δ 3.12-3.26 (m, 2H, iPr-CH); δ 1.33 
(br d, 6H, 3JH-H 6.6 Hz, 
iPr-CH3); δ 1.15 (br d, 6H, 3JH-H 6.8 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 
75.38 MHz): δ 171.49 (d, 3JC-P 3.8 Hz, CH=N); δ 163.15 (CAr); δ 160.19-160.30 (m, CAr); δ 
159.65 (CAr); δ 144.35 (CAr); δ 140.81 (CAr); δ 134.79 (d, JC-P 4.5 Hz, CAr); δ 131.96 (dd, JC-P 
8.9 Hz and JC-P 3.2 Hz, CAr); δ 127.36 (CAr); δ 122.91 (CAr); δ 111.91 (d, JC-P 20.4 Hz, CAr); δ 
73.25 (d, 3JC-P 7.0 Hz, N-CH2-N); δ 52.49 (d, 1JC-P 16.5 Hz, P-CH2-N); δ 28.40 (
iPr-CH); δ 24.47 
(iPr-CH3); δ 22.93 (
iPr-CH3). 31P{1H} NMR (121.34 MHz, CDCl3): δ -46.91 (s). ESI-MS: [M+H]+ 
583.1; [M-Cl]+ 545.1; [M-Cl-PTA+MeCN]+ 429.1. Anal. Found: C, 51.6; H, 5.52; N, 8.65. Calc. 
for C25H33N4FPClPd: C, 51.6; H, 5.72; N, 9.64. Solubility: DMSO 0.43 mg/mL; 51% DMSO in 
water. 
 





C7 was synthesised as above, using B7 as the reagent and the amounts as indicated here: 
B7 (0.065 g, 0.0720 mmol) and PTA (0.023 g, 0.144 mmol). Yield: 0.057 g, 65%. FT-IR (νC=N, 
cm-1) 1599. m.p.: 216-221 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.80 (d, 1H, 4JH-P 7.8 Hz, 
CH=N); δ 7.84 (dd, 1H, 3JH-H 8.0 Hz and 4JH-H 1.0 Hz, Ph); δ 7.52-7.56 (m, 1H, Ph); δ 7.41-
7.46 (m, 1H, Ph); δ 7.27-7.32 (m, 1H, Ph); δ 7.18-7.21 (m, 2H, Ph); δ 4.53-4.63 (m, 12H, PTA); 
δ 3.09-3.23 (m, 2H, iPr-CH ); δ 1.17-1.32 (br m, 12H, iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 
MHz): δ 174.22 (d, 3JC-P 3.8 Hz, CH=N); δ 161.97 (CAr); δ 148.71 (CAr); δ 144.22 (CAr); δ 141.49 
(d, JC-P 9.5 Hz, CAr); δ 140.52 (CAr); δ 139.55 (CAr); δ 132.01 (d, JC-P 4.5 Hz, CAr); δ 127.72 
(CAr); δ 123.00 (CAr); δ 120.72 (CAr); δ 73.22 (d, 3JC-P 7.0 Hz, N-CH2-N); δ 52.41 (d, 1JC-P 15.9 
Hz, P-CH2-N); δ 28.58 (
iPr-CH); δ 24.38 (iPr-CH3); δ 22.88 (
iPr-CH3). 31P{1H} NMR (121.34 
MHz, CDCl3): δ -48.15 (s). ESI-MS: [M+H]+ 610.1; [M-Cl]+ 572.1; [M-Cl-PTA+MeCN]+ 456.1. 
Anal. Found: C, 49.1; H, 5.53; N, 11.6. Calc. for C25H33N5O2PClPd: C, 49.4; H, 5.47; N, 11.5. 
Solubility: DMSO 0.368 mg/mL; 76% DMSO in water. 
 
[Pd(PTA)(2-OMe-C6H3)CH=N{2,6-iPr2-C6H3}Cl] (C8) 
C8 was synthesised as above, using B8 as the reagent and the amounts as indicated here: 
B8 (0.060 g, 0.0688 mmol) and PTA (0.022 g, 0.138 mmol). Yield: 0.054 g, 67%. FT-IR (νC=N, 
cm-1): 1597. m.p.: 203-207 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.41 (d, 1H, 4JH-P 7.5 Hz, 
CH=N); δ 7.26-7.30 (m, 1H, Ph); δ 7.21-7.24 (m, 1H, Ph); δ 7.14-7.17 (m, 2H, Ph); δ 6.84-
6.88 (m, 1H, Ph); δ 6.67-6.70 (m, 1H, Ph); δ 4.54-4.63 (m, 12H, PTA); δ 3.81 (s, 3H, CH3); δ 
3.17-3.31 (m, 2H, iPr-CH); δ 1.32 (br d, 6H,3JH-H 6.8 Hz, 
iPr-CH3); δ 1.15 (br d, 6H,3JH-H 6.8 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 173.13 (CH=N); δ 159.73 (CAr); δ 159.32 (CAr); 
δ 144.43 (CAr); δ 140.62 (CAr); δ 135.06 (CAr); δ 133.50 (d, JC-P 3.2 Hz, CAr); δ 128.17 (d, JC-P 
8.9 Hz, CAr); δ 126.53 (CAr); δ 122.32 (CAr); δ 107.09 (CAr); δ 72.81 (d, 3JC-P 7.0 Hz, N-CH2-N); 
δ 55.06 (CAr); δ 51.98 (d, 1JC-P 15.9 Hz, P-CH2-N); δ 27.84 (
iPr-CH); δ 24.08 (iPr-CH3); δ 22.52 
(iPr-CH3). 31P{1H} NMR (121.34 MHz, CDCl3): δ -48.08 (s). ESI-MS: [M+H]+ 595.1; [M-Cl]+ 
557.2; [M-Cl-PTA+MeCN]+ 441.1. Anal. Found: C, 52.5; H, 6.09; N, 9.46. Calc. for 
C26H36N4OPClPd: C, 52.6; H, 6.11; N, 9.44. Solubility: DMSO 4.07 mg/mL; 62% DMSO in 
water. 
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Nuclear magnetic resonance (NMR) spectroscopy is a common, yet powerful analytical tool 
for determining the molecular structure of matter. NMR spectroscopy is a fairly versatile 
technique and can be used to investigate the structure of both small molecules and high 
molecular weight macromolecules. It is used to determine the way in which proteins fold and 
to examine phase changes [1]. NMR spectroscopy allows one to determine the number of 
magnetically distinct atoms of a specific type (1H, 13C and others) present in a sample and 
provides information about the environment of each type of atom, as well as changes occurring 
in the environment on the spectral timescale. Most other spectroscopic techniques (infrared- 
and ultraviolet-visible spectroscopy) cannot detect dynamic motion in molecules as the 
frequency at which the spectra are recorded is too high, relative to the frequency of the motion, 
resulting in a seemingly static spectrum [2;3]. The combination of IR- and NMR spectroscopy, 
as analytical techniques, is often sufficient to determine a structure completely [3]. This was 
clearly shown in the use of these techniques for the characterisation of the PTA-based 
palladacycles in Chapter 2. This chapter will focus on the use of NMR spectroscopy to 
investigate the kinetics of a dynamic NMR process observed for the PTA-based palladacycles, 
in which the methyl signals of the diisopropyl moieties showed spectral broadening as a result 
of the fluxional behaviour of these moieties. Hence, a short introduction to dynamic NMR 
spectroscopy and chemical exchange is provided. 
 
3.1.1 Dynamic NMR spectroscopy 
The chemical shift of a nucleus is sensitive to changes in the chemical environment around it. 
Dynamic NMR spectroscopy systems are systems in which changes in the spectra (changes 
in various chemical shifts) are observed due to dynamic phenomena, such as chemical 
exchange (either inter- or intra-molecular) [2;4-6]. The use of NMR spectroscopy to study 
dynamic phenomena in chemistry has seen rapid growth and development in the past few 




years. The most common applications are the study of internal mobility of a molecule, including 
restricted rotation about a bond, ring inversions, and reversible rearrangements [7]. 
Molecular motion occurs over a wide range of timescales. NMR spectroscopy can be used to 
detect molecular motion occurring in the timescale range from picoseconds to seconds. The 
influence on the observed spectrum depends on the nature of the motion and the timescale in 
which it occurs. Below follows a short discussion on the types of motion and their influence on 
NMR spectra [1]. 
 
3.1.2 Molecular motion 
Molecular motion can be divided into the following groups: molecular vibration, local rotation, 
chemical exchange, molecular rotation and molecular translations. 
The most common types of motion are molecular vibration and local rotations. All atoms in a 
molecule vibrate around their mean position, the smaller the atom and molecule, the faster 
the vibration [1]. Molecular vibrations are typically on the picosecond timescale. This motion 
is faster than the spectral timescale and therefore has no effect on the NMR spectrum. Local 
rotations, such as the rotation of a methyl group (Figure 3.1) also occur on the picosecond 
timescale, unless the rotation is hindered in which case it may be slowed to the micro- or 
millisecond timescale. In some cases, the rotation may be prevented completely. As with 
molecular vibration, the chemical shift of the mean position for these atoms is usually observed 
as the motion is generally too fast to be observed by NMR spectroscopy [1]. 
  
Figure 3.1: Diagrams of molecular vibration and local rotation [1]. 
 
Chemical exchange is a motional process including the formation and breaking of bonds (in 
chemical reactions) and conformational exchange. These processes occur over a wide range 
of timescales (nanoseconds to seconds). During chemical reactions, the intermolecular 
exchange of a nucleus between two molecules can be monitored, whilst for conformational 
exchange, the intramolecular exchange of a nucleus between two conformations can be 
monitored (Figure 3.2) [6;8]. Examples include internal cyclisation and cis-trans isomerisation. 





Figure 3.2: Diagram of intramolecular chemical exchange [6]. 
 
Molecular rotations and translations occur in solution. These are random rotations or 
movements through space which change the anisotropic spin interactions (e.g. direct dipole-
dipole coupling), hence allowing the motion to be detected by NMR spectroscopy. 
Of the types of molecular motion mentioned above, chemical exchange is most commonly 
observed to influence a NMR spectrum [1;8]. This will be discussed in detail in the next section. 
 
3.1.3 Chemical exchange 
As stated above, chemical exchange is a motional process which involves the breaking and 
forming of bonds, as well as changes in conformation. The advantage of using NMR 
spectroscopy to study these dynamic systems is that the chemical exchange process can be 
detected, even if the system is at equilibrium. This is not the case for other analytical 
techniques, which require non-equilibrium states of the chemical system in order to detect a 
form of chemical exchange [2;9]. 
During chemical exchange, the nucleus of an atom experiences two or more different chemical 
environments. As the nucleus is exposed to one environment and then another, the chemical 
shift is influenced and the changes can be observed in the NMR spectrum as a variety of line 
shapes, depending on the rate of exchange [2;4;5]. Examples of several exchange reactions 
are tabulated below (Table 3.1) [9]. 
Table 3.1: Examples of chemical exchange processes [9]. 
Intermolecular chemical exchange Intramolecular chemical exchange 
Binding of ligand to macromolecule Unfolding of protein and motion of side chains 
Protonation/deprotonation equilibria 
of ionisable groups 
Helix-coil transitions of DNA and RNA 
Exchange of labile protons with solvent Conformational exchange 
Enzyme catalysed reactions Tautomerisation 
 




3.1.3.1 Conformational exchange 
One of the most commonly reported examples of chemical exchange is the intramolecular 
conformational change occurring in dimethylformamide. This type of chemical exchange is a 
two-site exchange. In this example, the C-N bond has partial double bond character due to 
the lone pair on the nitrogen which is delocalised into the carbonyl bond, as shown in  
Figure 3.3. The exchange or rotation of the methyl groups around this partial double bond can 
be detected by NMR spectroscopy, as the two sites are not chemically equivalent (since the 
molecule is not symmetrical); hence the magnetic field experienced by the nuclei differs and 
changes when the two groups exchange sites. These changes are observed as changes in 
the chemical shifts and line shapes of the NMR spectroscopic signals [1;9]. 
 
Figure 3.3: Resonance structures of dimethylformamide. 
 
This process is usually represented as shown below, where A and B are the two conformations 
(CH3* ‘E’ or ‘Z’ with oxygen) and k is the rate constant. 
 
If k is dependent on temperature, increasing the temperature results in faster exchange and 
consequently, the coalescence of the NMR spectroscopic signals [9]. The difference in the 
chemical shift frequencies relative to the rate of exchange determines the effect of the 
exchange on the NMR spectrum [1;4;5;10]. The effects can be divided into two types, slow 
intermediate exchange and fast intermediate exchange. 
Slow intermediate exchange 
Slow-intermediate exchange is infrequent, rather than slow. The site-exchange causes 
changes in the precessing frequency of the nuclear spin. This leads to dephasing of the 
transverse magnetisation and consequent decay of the signal. Since the rate of exchange is 
smaller than the frequency difference, only slight motional broadening is observed. The faster 
or more frequent the exchange, the faster the decay. This leads to broader NMR spectroscopic 
signals which start to overlap. [1;4;5;11]. The point at which the signals coalesce is called the 
crossover point (Figure 3.4). 
  




Fast intermediate exchange 
Fast exchange is considered to be past the point of coalescence (crossover point) of the 
signals. As the exchange occurs more frequently, the decay slows down due to a decreased 
rate of dephasing, hence reducing the NMR spectroscopic signal width (Figure 3.4). The 
exchange between the sites occurs so quickly that an average precession frequency is 
experienced, rather than two different frequencies. The signal still experiences motional 
broadening due to the exchange, but the broadening is of the same magnitude as that of the 
natural line width and the inhomogeneity of the magnetic field [1;4;5;11]. 
 
Figure 3.4: Example of intermediate two-site exchange process of dimethylformamide [12]. 
 
The example in Figure 3.4 is a very simple two-site exchange where the signals show no 
scalar (J) coupling, as the exchanging signals are the methyl groups of dimethylformamide. 
There are more complex systems where the exchanging signals show J coupling, an example 
of which is N,N-dimethyl-4-nitrosoaniline (Figure 3.5) [9;13]. The signals shown in Figure 3.5 
are those of the aromatic protons. Each of the four aromatic protons is observed as a doublet 
at low temperature, however, as the temperature increases and the nitroso group flips from 
side to side more frequently, the signals broaden until there are only two signals, a broad flat 
singlet (2300 Hz) which accounts for one proton and a sharp doublet (2000 Hz) which 
accounts for the remaining three protons. The scalar coupling and involvement of more than 
two signals makes interpretation and modelling of such systems more complex. 




These systems (both the simple and more complex systems) can be modelled by kinetic 
computational methods and further data may also be gained from the NMR spectra, such as 
rates of exchange and activation parameters for the exchange process. These methods are 
well documented in a number of books and reviews on dynamic NMR spectroscopy, therefore, 
they will not be discussed here [1;9;13;14]. The above theory and techniques were applied to 
analyse the changes observed in the NMR spectra previously reported in Chapter 2. 
 
Figure 3.5: Site-exchange process in N,N-dimethyl-4-nitrosoaniline [11]. 
 
3.2 Results and Discussion 
As mentioned in Chapter 2, the 1H NMR spectra of the PTA-based palladacycles (Figure 3.6) 
produced interesting results, particularly regarding the isopropyl methyl signals. One would 
expect the methyl groups to appear as two doublets in the 1H NMR spectra, as was the case 
for analogous triphenylphosphane (PPh3) and trimethylphosphane (PMe3) palladacycle 
structures (Figure 3.7) [15;16]. The representation of the methyl signals as two doublets 
implies that the protons are in two distinct chemical environments due to restricted rotation 
about the N-C bond between the imine nitrogen and the carbon on the 2,6-diisopropylaniline 
ring. However, the resonance signals of the corresponding PTA complexes ranged from fully 
resolved doublets to broad singlets (Figure 3.8), which were not observed for the analogous 
PPh3 and PMe3 complexes. The cause and possible mechanism for the observed broadening 
of these signals were investigated. 










Figure 3.6: Series of PTA-based mononuclear palladacycles with various R groups. 
 
 
Figure 3.7: Trimethyl- and triphenylphosphane analogues of PTA-based palladacycles. 
 
Since the differences in the observed signals are due to dynamic motion, it was decided to 
use variable temperature NMR spectroscopy in an attempt to understand the dynamic 
behaviour of these complexes. NMR spectra and relevant data not discussed in the following 
sections are included in Appendix 2. Variable temperature data are included in Section A2.1 
and computational data are included in Section A2.2. 
C1: R = 2-H C2: R = 2-Cl 
C3: R = 2-Br C4: R = 2-Me 
C5: R = 4-Me C6: R = 2-F 
C7: R = 2-NO2 C8: R = 2-OMe 





Figure 3.8: 1H NMR spectra of C1-C8 in CDCl3 at 25 °C, showing varying degrees of broadening in isopropyl group methyl 
signals between 1.00 and 1.50 ppm. 
 
3.2.1 Variable temperature NMR spectroscopy 
Variable temperature NMR spectroscopy can be used to monitor the rate of dynamic molecular 
motion of a molecule, by adjusting the temperature either up or down. Thus, the first step in 
the investigation was to record the NMR spectra over a wide range of temperatures, from 
-50 °C to 120 °C, using deuterated chloroform (CDCl3) and deuterated tetrachloroethane 
(TCE-d2) as solvents. 
Figures 3.9 and 3.10 show the array of NMR spectra recorded for C2, the 2-chloro analogue. 
At low temperature, the methyl signals of the isopropyl substituents were observed as two 
doublets (1.16 and 1.33 ppm). Increasing the temperature resulted in the coalescence of the 
two doublet signals into one broad doublet (20-25 °C). Further temperature increases led to 
the signals coalescing to a broad singlet at approximately 50 °C. Finally, the signal split into a 
single doublet at 75-100 °C, indicating that the methyl sites were magnetically equivalent at 
this temperature. Accompanying the change in the signal shape was a gradual downfield shift, 
suggesting that the methyl groups experience a degree of deshielding. Similarly, the 1H NMR 
imine signal which starts off as a broad doublet at low temperature appears to become broader 













with further increases in temperature. The change in imine signal shape may also be due to 
weakening and eventual loss of the 4JH-P coupling. As observed for the isopropyl methyl 
signals, the imine signal also shifts slightly downfield with increasing temperature. 
Furthermore, some changes were observed in the fine structure and/or chemical shifts of the 
isopropyl methine signal at 3.00-3.20 ppm and the PTA signal at 4.40-4.55 ppm. Relatively 
small changes were observed in the aromatic signals. Similar changes were observed in the 
variable temperature 1H NMR spectra of C4, the 2-methyl analogue, (Figure 3.11) and the 
other PTA-based palladacycles (A2.1-A2.8). 
Once it was confirmed that these changes were observed for all of the PTA-based analogues, 
the reversibility of the dynamic event was tested. This was done by recording the 1H NMR 
spectrum of C2 at 25 °C (1), followed by heating the sample to 100 °C, and then recording the 
1H NMR spectrum at 25 °C again once the sample had cooled down (2). The final step was to 
cool the sample to -50 °C and then record the 1H NMR spectrum at 25 °C for a third and final 
time once the sample had warmed up sufficiently (3). The three spectra recorded at 25 °C 
were compared and found to be qualitatively unchanged (Figure A2.9). Thus, it was concluded 
that the observed dynamic event is reversible. 
 
Figure 3.9: 1H NMR spectroscopic array of C2 in TCE-d2 (0 to 100 °C). Red arrow shows broadening signals and grey areas 
















Figure 3.10: 1H NMR spectroscopic array of C2 isopropyl methyl signals in TCE-d2 (0 to 100 °C), showing change in signal 
shape and chemical shift. Inset: Chemical structure of C2 showing possible rotation about the N-C bond. 
 
 
Figure 3.11: 1H NMR spectroscopic array of C4 in CDCl3 (-50 to 40 °C). Red arrow shows broadening signals and grey areas 
























As stated previously, a chemical exchange process involves the nucleus of an atom 
experiencing two or more different chemical environments. As the nucleus is exposed to one 
environment and then another, the chemical shift is influenced and the changes can be 
observed in the NMR spectrum as a variety of line shapes, depending on the rate of exchange 
[2;4;5]. Based on the changes observed in the variable temperature spectra of the 
palladacycles in the current study, two possible chemical exchange processes were proposed 
(Scheme 3.1), a site-exchange event which results in the broadening of the methyl signals of 
the isopropyl groups and possibly the imine proton signal (indicated by red arrows on spectra 
i.e., possible rotation about the N-C bond, as indicated in Figure 3.10) and a bond breaking or 
bond forming event which results in fine structure and chemical shift changes of certain signals 
(indicated as grey areas on spectra i.e., possible PTA ligand dissociation). The proposed 
processes may or may not be linked. Each of these processes are discussed in Sections 3.2.2 
and 3.2.3, respectively. 
 
Scheme 3.1: Possible chemical exchange processes occurring in solution. 
 
3.2.2 Proposed intramolecular two-site exchange process 
Since the only signals displaying a variety of line shapes were the isopropyl methyl signals 
and the imine proton signal and the changes in the imine signal could be due to loss of 4JH-P 
rather than an exchange event, a symmetric two-site exchange process was proposed. This 
is a chemical exchange process where an isolated nuclear spin is exposed to two different 
chemical environments, with different chemical shifts, but the molecule is identical in both 
environments [1]. 
An example of how the 1H NMR resonance signals change as a function of temperature for a 
symmetric two-site exchange is shown in Figure 3.12 [12]. The methyl signals of the isopropyl 
groups, shown in Figures 3.9 and 3.10, exhibit similar behaviour, where the two doublets (at 
low temperature) first condense and then become more resolved again at higher temperature. 
However, if only symmetric two-site exchange was taking place it is expected that the 












isopropyl methyl doublets in the regime of slow exchange. Yet, in the case of the PTA-based 
palladacycles, it was observed that the isopropyl methyl doublets shift downfield as 
temperature increases, indicating that another exchange process or some other reaction is 
taking place in addition to the site-exchange. Since the processes are not necessarily linked, 
the next section focuses only on the site-exchange process, whilst the second or additional 
process will be addressed in later sections. 
 
Figure 3.12: Variable temperature 1H NMR spectra of dimethylformamide showing increasing exchange from the top to 
the bottom (left) [12] and general scheme showing symmetric site-exchange process as a function of Energy, where ΔG# 
is the energy barrier to rotation (right). 
 
3.2.2.1 Symmetric two-site exchange model 
The symmetric two-site exchange of the isopropyl methyl signals about the N-C bond was 
modelled using an in-house program, NMRfitv12, which was written by one of our 
collaborators, Dr. Gerber and his research group. The calculations employed in the program 
are based on the work by Vallurupalli [17]. Such calculations are reported extensively in the 
literature and are fairly well understood, therefore, the calculation details are not discussed 
here [1;4;5;9;18;19]. Although the program does not explicitly model symmetric site-exchange, 
the forward and reverse rate constants must be the same for such a process. Whilst 
significantly different rate constants mean that the site-exchange is not symmetric, viz. there 
is more than one stable conformer of the molecule. Further details of the program, NMRFitV12, 
can be found in the thesis of O’Kennedy [20]. The NMR line fit plots for the calculated data 
relative to the experimental data are shown in Figure 3.13. 
At 0 °C, the methyl signals were observed as two doublets at 1.13 and 1.28 ppm. These 
signals represented a static system, where no site-exchange occurred. The spectrum at 
10 °C showed broadening of the doublets and a very slight downfield shift to approximately 
1.14 and 1.30 ppm. At 20 °C, it can be seen that the doublets had broadened quite significantly 















and the signals were shifted to 1.15 and 1.31 ppm. The signal observed as two doublets at 
0 °C appears as a broad doublet at 25 °C with a chemical shift of 1.23 ppm. This shift was 
slightly downfield from the average shift of the original doublets. Jumping to 50 °C, the signal 
was observed as a broad singlet at approximately 1.25 ppm. The broad singlet represented a 
system where the methyl sites are exchanging fast enough that an average signal of the two 
sites was observed. Increasing the temperature further was expected to increase the 
rotation/exchange beyond the detectable limit for NMR time-scale, thus the methyl signals are 
expected to collapse into a single doublet, representing two equivalent sites. The 75 °C and 
100 °C spectra clearly showed this process, where the broad doublet became more resolved 
as the temperature was increased further. 
The experimental data fit the model well with the exception of some minor peaks resulting 
from residual solvent impurities in the experimental spectra (1.2-1.4 ppm). The corresponding 
forward and reverse rate constants are reported in Table 3.2 and were found to be similar for 
each temperature, thus confirming the symmetric nature of the site-exchange. 
Table 3.2: Forward and reverse rate constants, k1 and k2, for C2 at various temperatures. 
Temperature (°C) k1 (s-1) k2 (s-1) 
0 11.29 10.86 
10 15.54 16.08 
20 25.96 26.54 
25 61.90 55.64 
50 164.7 162.2 
75 255.9 264.9 
100 2511 2518 
 








Figure 3.13: Excel plots showing correlation between experimental and calculated spectra of C2 in TCE-d2. 




3.2.2.2 Determining the nature of the symmetric site-exchange 
Having established that a symmetric site-exchange occurs in solution, the nature of the site- 
exchange was investigated. The aim of the investigation was to determine if the mechanism 
of interconversion leading to the observed broadening in the isopropyl methyl signals 
correlates with rotation about the N-C bond. 
Therefore, the study was extended by calculating the rotational energy barrier. The enthalpy 
(ΔH#), entropy (ΔS#) and free energy of activation (ΔG#) were calculated using the obtained 
rate constants to construct Eyring plots which depicts the reaction rate constant as a function 
of temperature (Equation 3.1) [2;14]. Eyring plots for all complexes yielded linear trends 
(Figures 3.14 and A2.10-2.16). The enthalpy (ΔH#) and entropy (ΔS#) of activation were 
calculated from the slopes and intercepts of these graphs (Equations 3.2 and 3.3) and were 
listed in Table 3.3. The activation energy (ΔG#) was then calculated using Equation 3.4 and 
tabulated (Table 3.3). 
Equation 3.1: Eyring equation. 
 
Equation 3.2: Slope of the Eyring plot. 
 
Equation 3.3: Intercept of the Eyring plot. 
 




























∆𝐺# = ∆𝐻 − 𝑇∆𝑆 





Figure 3.14: Eyring plot of C2 in TCE-d2. 
 
Table 3.3: Calculated thermodynamic data from the Eyring plots of C1-C8 in CDCl3. 
Complex ΔH# (kJ.mol-1) ΔS# (kJ.mol-1K-1) ΔG# (kJ.mol-1) 
C1 (2-H) 32.21 ± 0.9254 -0.1018 ± 0.003342 60.01 ± 1.838 
C2 (2-Cl) 42.61 ± 0.6119 -0.09395 ± 0.001986 68.27 ± 1.155 
C4 (2-Me) 39.74 ± 0.9803 -0.06635 ± 0.003577 57.87 ± 1.957 
C5 (4-Me) 35.51 ± 0.8289 -0.09071 ± 0.002950 60.29± 1.635 
C6 (2-F) 37.63 ± 0.8921 -0.09885 ± 0.003026 64.63 ± 1.719 
C7 (2-NO2) 35.88 ± 1.236 -0.09355 ± 0.004227 61.43 ± 2.390 
C8 (2-OMe) 39.87 ± 1.198 -0.09089 ± 0.004057 64.69 ± 2.306 
*No thermodynamic data were obtained for C3, as the thermodynamics of this compound are too slow 
and therefore cannot be detected by NMR. 
 
The Eyring plots showed that the experimental data lie within the 95% confidence band for all 
complexes that were modelled [14]. The linear Eyring plots confirmed that the observed 
broadness of the isopropyl methyl signals resulted from a symmetric site-exchange. 
Since one of the most likely mechanisms by which the isopropyl methyl groups can exchange 
is the rotation of the 2,6-diisopropylaniline aryl ring about the N-C bond, the literature was 
consulted in order to evaluate this proposal. A search for aryl ring rotation did not yield many 
results, however, the most relevant examples are included in Table 3.4. The literature 




R2 = 0.9944 
B = 16.59 ± 0.6857 
A = -5526 ± 207.0 
Dataset: 95% Confidence limit (+) 
Dataset: 95% Confidence limit (-) 
Function: A*x+B 




The rotational energy barriers for the PTA-palladacycles were found to be in the range of 
58-68 kJ/mol. When comparing the rotational energy barrier of the C6F6 aryl ring with larger 
groups involving aryl rings, it is clear that the energy barrier tends to increase with the size of 
the moiety that is rotating. Based on the examples in Table 3.4, the range of energy barriers 
for aryl ring rotations or moieties containing aryl rings is 48-87 kJ/mol. If the large size of the 
rotating moiety in the last entry is regarded as being too large for comparison with the  
2,6-diisopropylaniline moiety in the PTA-palladacycle system, the range can be refined to 
approximately 48-56 kJ/mol. This matches the observed rotational energy barriers quite well. 
Thus, based on the rotational energy barriers, it was quite possible that aryl ring rotation about 
the N-C bond occurs in solution [21-23]. 
Table 3.4: Comparison of rotational energy barriers from the literature. 
Structure showing rotating moieties ΔG# (kJ/mol) 
 
48 
(C-C; red arrows) 
56 






72 – 87 
[23] 
 
Variable temperature 1H, 13C and 31P NMR spectra were collected for C2 (Figures 3.15-3.18), 
to determine if all of the NMR signals, not just the isopropyl methyl signals, could corroborate 
the above finding. 
 





Figure 3.15: 1H NMR spectroscopic array (25-120 °C) of C2 in TCE-d2. 
 
 
Figure 3.16: 13C NMR spectroscopic array (25-85 °C) of C2 in TCE-d2. 





Figure 3.17: 13C NMR spectroscopic array (50-100 °C) of C2 in TCE-d2 showing the expected broadening and an upfield 
shift in the imine carbon signal. 
 
 
Figure 3.18: 31P NMR spectroscopic array (25-120 °C) of C2 in TCE-d2 with inset of zoomed-in region. 




The 1H NMR spectra (Figure 3.16) showed that the isopropyl methyl signals coalesce from 
two doublets to a broad singlet and shift approximately 0.085 ppm downfield. The multiplet 
observed for the methine groups is in fact two overlapping septets (as determined by the 
presence of two different coupling constants) which have almost identical chemical shifts, as 
determined in Chapter 2. No clear change in the multiplicity of these signals was observed 
with increasing temperature, but the downfield shift was observed to be 0.11 ppm. The PTA 
signal showed fine structural changes and a 0.06 ppm downfield shift. There were also some 
changes to the fine structure of the aromatic signals. The imine signal showed coalescence 
from a doublet to a singlet and a 0.04 ppm downfield shift. 
From the variable temperature 13C NMR spectra (Figures 3.17 and 3.18), the methyl signals 
show slight broadening and a relatively small upfield shift. The CH signal shifts downfield by 
0.9 ppm shift and no change in multiplicity was observed. Since the CH signals in the 1H NMR 
spectra overlap quite closely, the CH signals in the 13C NMR spectrum are presumed to be so 
close that they overlap perfectly and are observed as a singlet, as was the case for the 
µ-chloro palladacycles and the PPh3- and PMe3 analogues, where the N-C bond was restricted 
and the methyl signals were inequivalent and only one CH signal was observed [15;16]. The 
P-CH2-N doublet showed a decrease in the coupling constant and a downfield shift of 0.59 
ppm. The N-CH2-N doublet overlapped with the solvent peak, but at lower temperatures, the 
signal could be observed just upfield of the solvent signal. A 0.22 ppm downfield shift was 
observed with increasing temperature, before the signal was completely masked by the 
solvent signal. Unfortunately, the multiplicity could not be determined due to the overlap with 
the solvent signal. The changes observed in the PTA signals suggest that there are slight 
changes in the chemical environment around the PTA ligand. The aromatic region did not 
show any large shifts, however, the three signals that initially showed JC-P coupling seem to 
lose the coupling with increasing temperature. Finally, the imine signal shows coalescence 
from a clear doublet to a broad unresolved doublet. 
The variable temperature 31P NMR spectra (Figure 3.18) show one signal at approximately  
-47.5 ppm which broadens slightly with increasing temperature and shifts slightly downfield. 
Taken together, the NMR spectral arrays show the isopropyl methine and methyl signals were 
each represented by two signals at lower temperatures, thus confirming that the two sites are 
inequivalent when there is no site-exchange. Furthermore, the broadening of the isopropyl 
methyl signals with increasing temperature and the absence of broadening and significant 
changes in other signals (aside from the imine signal) suggested that the site-exchange occurs 
via rotation about the C-N bond, as determined from the rotational energy barriers. Loss of 
4JH-P coupling in the imine signal with increasing temperature was also observed in both the 




1H and 13C NMR spectra. However, these changes cannot be accounted for by simply having 
aryl ring rotation as proposed earlier. As stated previously, the changes in the imine signal 
may be caused by a bond breaking process, rather than a simple site-exchange process. The 
PTA signals in all three spectral arrays showed both fine structural changes and changes in 
the chemical shifts of certain signals. These changes could possibly be attributed to a second 
dynamic process occurring in solution. At this stage it is not certain whether the two processes 
are linked or not. 
Based on these observations, the rotation of the 2,6-diisopropylaniline ring is likely restricted 
by steric and/or electronic interactions at low temperature, hence, the methyls and methines 
are in two distinct environments. Whilst at higher temperature, the species in solution either 
takes on a less sterically strained conformation or the electronic interactions are overcome by 
the increased energy in the system, thus allowing the 2,6-diisopropylaniline ring to rotate about 
the N-C bond, resulting in the methyl and methine signals being equivalent. It is thought that 
the process by which the site-exchange is facilitated must involve the PTA ligand, as this 
process was not observed for the analogous PPh3 and PMe3 complexes [15;16]. 
As indicated before, the computational model described earlier in this chapter seems to 
support the experimental observations to some degree and suggests that a symmetric site-
exchange process occurs in solution (Scheme 3.2), most likely via rotation of the 2,6-
diisopropyl aniline ring about the N-C bond. This is suggested by the fact that the rotational 
energy barriers which were calculated approximate those reported for aryl ring rotation. 
However, despite a reasonable fit of the model, there was one apparent discrepancy in the 
variable temperature results for the PTA-based palladacycles, viz. the slight downfield shift in 
the methyl signals of the isopropyl groups as the temperature was increased (Figure 3.15). 
This was attributed to the effects of a second possible dynamic process occurring in solution. 
Therefore, the next step was to investigate the second process occurring in solution which 
was thought to be either a bond-breaking or -forming process. 
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3.2.3 Possible PTA ligand dissociation 
The fine structural and chemical shift changes observed in the variable temperature NMR 
spectra are indicative of either bond breaking or bond forming events, where the species 
before and after the bond breaking/forming process are different. Since the extent of the 
changes in the signals increased with increasing temperature, a bond breaking process was 
potentially more favoured, as increasing the temperature facilitates breaking of bonds. One of 
the possible bonds that could be involved in the bond breaking process is the Pd-P bond. 
The possible dissociation of the PTA ligand was thus considered, based largely on the 
changes observed in the imine signal. As stated earlier, the splitting of the imine signal is due 
to 4JH-P coupling between the imine proton and the PTA phosphorous atom. Thus, loss of the 
coupling at higher temperatures could be a consequence of possible PTA dissociation under 
these conditions. Should this be the case, one would expect that the PTA proton signals 
should change from those of the coordinated PTA ligand to those of the free PTA ligand. Thus, 
variable temperature 1H and 31P NMR spectra of C2 and C4 were recorded and compared to 
the NMR spectra of free PTA. The results of this study are discussed in the next section. 
 
3.2.3.1 PTA ligand dissociation 
In order to monitor the coordination of the PTA ligand, the 1H and 31P NMR spectra of the free 
ligand were recorded in deuterated TCE (Figure 3.19). The variable temperature 1H and 31P 
NMR spectra of C2 and C4 were also recorded in deuterated TCE in the range of 25 – 120 °C 
(Figures 3.20 - 3.23, respectively). 





Figure 3.19: 1H NMR spectrum (25 °C) of PTA in TCE-d2 with inset of 31P NMR spectrum (25 °C) of PTA in TCE-d2. 
 
The 1H NMR spectrum for the free PTA ligand shows two well resolved signals (Figure 3.19), 
viz. a doublet at 4.03 ppm (NCH2N) and a singlet at 4.56 ppm (PCH2N). Although unusual, the 
singlet resonance for the PCH2N signal has been reported previously [24]. The 31P NMR signal 
for free PTA occurs at -102.28 ppm (Figure 3.19 inset). 
The variable temperature 1H NMR spectra of C2 and C4 (Figures 3.20 and 3.22) showed the 
coalescence of the imine signal from a doublet to a singlet, accompanied by a slight downfield 
shift. Changes in the fine structure of the PTA signal at approximately 4.5-4.6 ppm were 
observed; however, the well resolved singlet and doublet of the free ligand in the region of 
4.0-4.6 ppm were not observed. More importantly, the 31P NMR signals of C2 and C4  
(Figures 3.21 and 3.23) both showed only a very slight downfield shift and broadening of the 
coordinated PTA signal at approximately -48 ppm, but no signals were observed at -102 ppm, 
the region for the free PTA ligand. 
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Figure 3.20: 1H NMR spectroscopic array (25-120 °C) of C2 in TCE-d2. 
 
 
Figure 3.21: 31P NMR spectroscopic array (25-120 °C) of C2 in TCE-d2 with inset of zoomed-in region. 
 





Figure 3.22: 1H NMR spectroscopic array (25-120°C) of C4 in TCE-d2. 
 
 
Figure 3.23: 31P NMR spectroscopic array (25-120 °C) of C4 in TCE-d2. 




Based on these observations, it was concluded that the change in the imine signal from a 
doublet (low temperature) to a singlet (high temperature) was not due to dissociation of the 
PTA ligand. Thus, there had to be an alternative bond breaking or bond forming process in 
solution to account for the observed changes in the signals for the imine and PTA protons in 
the variable temperature spectra. 
Close examination of the variable temperature 1H NMR spectra of C2 and C4 (Figures 3.20 
and 3.22) revealed that besides the isopropyl signals, the PTA signals showed significant 
changes in signal shape or fine structure accompanied by a 0.07 ppm downfield shift with 
increasing temperature. Since the proton signals of PTA showed significant changes and the 
31P signal showed almost no change besides peak broadening, a bond forming process was 
considered to try and account for the observed spectra. In a search of the literature, a few 
examples were found that describe processes in which PTA undergoes self-association. 
Therefore, PTA self-association was considered as a possibility (Scheme 3.3). The results of 
this investigation are discussed in the following section. 
 
Scheme 3.3: Possible PTA ligand self-association proposed as an alternative bond forming process, since PTA ligand 
dissociation does not occur. 
 
3.2.4 Possible PTA self-association 
From a literature investigation, a number of reports seemed to indicate that the PTA ligand 
has the ability to form hydrogen-bonded networks between its nitrogen atoms and solvated 
water molecules in crystals [25;26]. Furthermore, N+H···N bonding between PTA ligands has 
also been demonstrated (Figure 3.24) [25]. These interactions directed aggregation through 
hydrogen bond formation. Thus, an aggregation process via self-association of the PTA 
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Figure 3.24: N-H+···N interactions between six PTA ligands of [(TPA)4Au](PF6)·1.5HCl·H2O [25]. 
 
Weak, non-conventional C-H···O contacts in 2,6-bis(acylamino)pyridines [27] with a C-O bond 
distance of 3.405(3), as shown in Figure 3.25, have been reported in the literature. These non-
covalent interactions were also observed in non-covalent dimers of 2-acylaminopyrimidines, 
in addition to N-H···N hydrogen bonds, therefore, providing further stabilisation of the dimer. 
Since these weak C-H···O interactions exist, it is possible that there could be similar C-H···N 
interactions between two PTA ligands. 
 
Figure 3.25: An example of weak, non-conventional C-H···O interactions detected in 2,6-bis(acylamino)pyridines [27]. 
 
To establish whether PTA can self-associate, a simple NMR spectroscopy experiment was 
performed, in which an additional amount of PTA was added to a NMR sample containing a 
known amount of PTA. The 1H and 31P NMR spectra were recorded for the various 
concentrations of PTA and the chemical shift changes were monitored. The results of this 
study are shown in Figures 3.26 and 3.27. 









Figure 3.27: 31P NMR spectra of PTA (10 mg to 16.5 mg/ 106-175 mM) showing upfield shift with increasing concentration. 
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11.5 mg / 122 mM 
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From Figures 3.26 and 3.27, it appears as if there is some indication that PTA self-associates 
based on the fact that the chemical shifts of the PTA signals change with increasing 
concentration. It would however seem that the association (if indeed present) is very weak, 
since only small changes in the NMR spectra were observed. 
Work done by LaPlante et al. [28], showed that many potential drug compounds were able to 
aggregate (where aggregate is defined by IUPAC as an assemblage of primary particles 
exhibiting an identifiable collective behaviour) in aqueous media, leading to false-positives in 
high-throughput screening for biological activity. They stated that aggregators exhibit unusual 
NMR trends. Thus, they developed an NMR spectroscopy assay which distinguishes between 
aggregators and non-aggregators. The assay is a simple dilution assay and the results of such 
an assay are shown in Figure 3.28. By employing similar NMR spectroscopy experiments, it 
was attempted to probe the possibility of PTA self-association. 
 
Figure 3.28: Examples of the NMR spectroscopic assay where the 1H NMR spectra at various concentrations are  
shown [28]. 
 




3.2.4.1 PTA complex self-association 
Similar experiments to those employed by LaPlante [28] were conducted using the 
palladacycle complexes, where the NMR spectra of the compounds were recorded at different 
concentrations, ranging from dilute to saturated samples. The NMR spectra recorded for this 
assay are shown in Figures 3.29-3.31. 
Varying the concentration of the complex led to a variation in the degree of signal broadening 
of the isopropyl methyl signals (1.1-1.4 ppm) and a very slight downfield shift in the isopropyl 
methine (3.1-3.3 ppm) and imine (~8.4-8.5 ppm) signals (Figure 3.29 to 3.31). Unlike the other 
signals, the PTA signal (4.5-4.7 ppm) shifted slightly upfield with increasing concentration. It 
also showed fine structural changes. Furthermore, both the variable concentration- and 
variable temperature NMR spectroscopy experiments yielded spectra which, at face value, 
showed similar features with increasing temperature and concentration. It should, however, 
be pointed out that the broadening of the methyl signals of the isopropyl groups and the imine 
proton signal could possibly be a simple concentration effect (such as signal broadening due 
to increased viscosity) rather than being due to an aggregation process. Essentially, both 
these processes (increased viscosity and aggregation) could lead to the same spectral 
changes that were observed. 
 
Figure 3.29: 1H NMR spectroscopic array of C2 in CDCl3 (2-20 mg/ 6-56 mM), showing changing spectra for the different 










Figure 3.30: 1H NMR spectroscopic array of C4 in TCE-d2 (16-44 mg/ 46-127 mM), showing slight change in spectra for 
the different concentrations. 
 
 
Figure 3.31: 31P NMR spectroscopic array of C4 in TCE-d2 (16-44 mg/ 46-127 mM), showing slight shift and broadening in 

















The question then also arises whether the spectral changes observed with increasing 
concentration are linked to those changes seen in the variable temperature NMR experiments. 
Again, at face value, similar signal broadening is observed with both an increase in 
temperature on the one hand and an increase in concentration on the other. However, the 
extent of the changes is more dramatic in the case of temperature. If, as proposed, the signal 
broadening as a result of concentration changes is associated with molecular aggregation 
then, intuitively, one would reasonably expect that recording the spectra at higher 
temperatures would lead to less aggregation and consequently less signal broadening. If, 
however, one for example compares the low temperature spectrum of C2 with that of the high 
temperature (120 °C) spectrum in Figure 3.32, it is clear that at high temperature there is 
increased broadening which is contrary to what one would expect for the case of decreased 
association as a result of higher temperature. Thus, it is clear that the temperature and 
concentration effects are independent processes and that the temperature effects outweigh 
the concentration effects. 
Further confirmation that the two processes are independent can be seen when comparing 
the trends in the PTA signals. In the two cases, changing concentration and temperature 
(Figures 3.29 and 3.32, respectively; signals highlighted in grey), opposite trends were 
observed. For the concentration data, the PTA signal becomes less resolved with increasing 
concentration, but with increasing temperature, the signal becomes more resolved. The signal 
shapes for the lowest concentration and the highest temperature spectra are very similar. 
Additionally, the variable concentration spectra showed a slight upfield shift in the PTA signals 
with increasing concentration, whilst the variable temperature data showed a slight downfield 
shift in the signal with increasing temperature. As stated above, these observations suggest 
that the site-exchange process and the aggregation process are not linked. 





Figure 3.32: Variable temperature 1H NMR spectra of C2. The PTA signal is highlighted in grey. 
 
Having established that there was a concentration effect that could possibly involve PTA self-
association, the next step was to propose a likely structure for the aggregate. Computational 
modelling was used to determine the nature of the species and the intermolecular interactions. 
 
3.2.4.2 Self-associated aggregate via PTA ligands 
Based on the changes in the NMR spectra and the structural studies taken from the literature, 
it is suspected that there could possibly be non-covalent interactions between the PTA 
moieties of two distinct complexes (Figures 3.33 and 3.34), leading to some sort of non-
covalent dimer. The extent of dimerisation is expected to be greater at higher concentrations. 
 


















Figure 3.34: Possible dimerisation by association between two PTA ligands, forming a non-covalent dimer. 
 
In order to test the validity of the proposed non-covalent dimer and obtain a more concrete 
description of the intermolecular interactions, a computational study using density functional 
theory (DFT) was carried out by our collaborators to model the proposed self-association 
process via the PTA ligands. Some of the preliminary computational work is reported here. 
 
3.2.4.2.1 Monomer and dimer geometry optimisation and frequency scans of C2 
Geometry optimisation and frequency scans were performed with the initial geometry being 
constructed from 2D molecular structures of the mononuclear PTA-based palladacycle, C2. 
The monomer and dimer were both optimised successfully using the computational 
methodologies described in Section 3.4. Minima on the potential energy surface were 
identified and confirmed by the non-negative vibrational frequencies. The optimised geometry 
of the monomer is shown in Figure 3.35, where the 2,6-diisopropylaniline moiety has a slanted 
T-shaped configuration relative to the square planar metallocyclic ring (Figure 3.35, right). 
2 





Figure 3.35: Optimised geometry of the monomer shown from two angles. 
 
 
Figure 3.36: Optimised geometry of the PTA self-association aggregate. 
 
Similarly, the optimised geometry of the non-covalent dimer (Figure 3.36) also showed the 
slanted T-shaped configuration of the 2,6-diisopropylaniline moiety. Overall, there was very 
little change in the configuration of the monomer upon PTA complex self-association. This is 
best illustrated by the relatively small changes in the atomic bond distances upon dimer 
formation. Selected bond distances are reported in Table 3.5. The change in electron density 
upon aggregation was also determined and found to be relatively small with changes in the 
3rd and 4th decimals.




Table 3.5: Selected bond distances for the optimised monomer- and adduct geometries. 
Bond Pair 
Monomer 
(Bond distance in Å) 
Aggregate (Monomer 1) 
(Bond distance in Å) 
Aggregate (Monomer 2) 
(Bond distance in Å) 
Pd-C 2.018 2.019 2.019 
Pd-N 2.120 2.118 2.119 
Pd-P 2.259 2.259 2.259 
Pd-Cl 2.418 2.417 2.417 
N-C1 (imine) 1.297 1.296 1.297 
N-C2 (aniline ring) 1.422 1.423 1.423 
 
3.2.4.2.2 Non-covalent interaction analysis (NCI) 
Next, a non-covalent interaction (NCI-) analysis was performed [29] to calculate the inter- and 
intra-molecular topographical features of the electron density of the aggregate. It was hoped 
to gain further insight into specific regions of interest for non-covalent interactions and the 
relative strength of these interactions. In NCI analysis, the reduced density gradient (RDG) 
must be close to zero to indicate an attractive or repulsive interaction. Therefore, the RDG iso-
surface was constructed (Figure 3.37), where regions of attraction are illustrated in orange 
and regions of repulsion are indicated in blue. Regions of attraction (orange) may also indicate 
bond critical points or 2D minima in the electron density. 
 
Figure 3.37: Non-covalent interaction RDG iso-surface of the PTA self-association adduct, where s = 1 with signʎ2ρ(r) 
colour mapping, ρ(r) ϵ [-0.01 (orange); 0.01 (blue)]. 
 
From Figure 3.37, it is clear that there are some attractive non-covalent interactions between 
the monomers in the aggregate, however, compared to the electron density around the 
chloride in the Pd-Cl bond, these intermolecular interactions are relatively weak. Additionally, 




it is noteworthy, that the large isosurface between the Cl atom and the 2,6-diisopropylaniline 
ring may explain the hindered/restricted rotation about the N-C bond. It is also possible that 
there is an intramolecular interaction between the chloride ion and a methyl group, as seen by 
the pocket of red in the isosurface in the lower left-hand corner of Figure 3.37 (and to a lesser 
extent in the top right-hand side). This interaction may be responsible for the slanted T-shape 
of the monomers and more importantly, it could possibly be the intramolecular interaction 
which must be overcome for there to be free rotation about the N-C bond. 
 
In summary, the modelled non-covalent dimer is feasible based on the optimisation of the 
structure as a true energy minima on the potential energy surface. However, it is shown that 
there is very little configurational change in the monomer upon aggregation. Thus, it is unlikely 
that the broad methyl and imine signals could be accounted for by the formation of the 
aggregate. Instead, it is more likely that the broadening of the methyl signals of the isopropyl 
groups and the imine proton signal may be a concentration effect (such as signal broadening 
due to increased viscosity). Should this be the case, the temperature-induced site-exchange 
process and the aggregation process are not linked and it is purely coincidental that the 
variable temperature and variable concentration NMR spectra, at first glance, show similar 
trends. 
Due to the interesting and unusual nature of the work, this process is being investigated further 
by our collaborators with the aim of obtaining data which provides a complete understanding 
of this system; however, the extent of this additional computational work required is beyond 
the ambit of this project and thus only the preliminary results are reported here. Hence, the 
final conclusion on this process, as shown in Scheme 3.4, is that aggregation via PTA self-
association is feasible, as shown by the modelled data. However, there may be an alternative 
or additional concentration driven process occurring in solution which better or more fully 
explains the trends observed in the NMR spectra. 





Scheme 3.4: PTA ligand self-association proven to be feasible, but alternative or additional concentration driven processes 
need to be considered. 
 
3.2.5 Possible additional or alternative concentration driven process 
In Chapter 2, it was noted that mononuclear palladacycles showed the tendency to dimerise 
during the ionisation process when analysing these compounds by electrospray ionisation 
mass spectrometry. Thus, some of the ionisation fragments detected in the mass spectra of 
some of the mononuclear PTA-based palladacycles were dimeric in nature, where two metal 
centres are linked via a chloride bridge. Since dimerisation in solution is also a concentration 
driven process, this was considered as an alternative to the molecular aggregation described 
earlier. 
The simplest dimer that could form in solution is the µ-chloro palladacycle. To form this dimer, 
the phosphine ligand would have to dissociate and then two monomeric coordinatively 
unsaturated fragment species would combine to form the dimer (Figure 3.38). 
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This dimer, depicted in Figure 3.38, is identical to the chloro-bridged species which was used 
originally to form the PTA-based palladacycles. Thus, we compared the high concentration 1H 
NMR spectrum of C2 (Figure 3.39 – spectrum 2) with that of the corresponding bridged 
palladacycle, B2 (Figure 3.39 – spectrum 1). From Figure 3.39, it was clear that the imine 
proton chemical shift of the dimer, B2 (Figure 3.39 – spectrum 1) is approximately 0.3 ppm 
more upfield from the PTA-based palladacycle, C2, (Figure 3.39 – spectrum 2), whilst, the CH 
proton signal for the dimer (3.5 ppm) is further downfield from that of C2 (3.2 ppm). These 
findings, accompanied by the fact that the PTA ligand did not dissociate upon increasing 
concentration (Figures 3.30 and 3.31), led to the conclusion that the µ-chloro palladacycle 
without PTA as a ligand was not the species being formed in solution at higher concentrations. 
 
Figure 3.39: 1H NMR spectrum of C2 in CDCl3 (20 mg) - spectrum 2, showing the species detected at high concentration 
and 1H NMR spectrum of B2 in CDCl3 (10 mg) - spectrum 1. 
 
Since dimerisation via PTA ligand dissociation does not occur, another possibility viz. the 
dissociation of the imine ligand, as shown in Figure 3.40, was considered. Literature shows 
that a number of analogous palladacycles with various phosphine ligands and substituents on 
the phenyl ring (coordinated to the palladium) have been synthesised and employed in 
catalysis (Figure 3.41). Therefore, the coordination sphere is a stable conformation and the 
proposed dimer is plausible. The reversibility of the dimer formation may be questioned since 
the analogous dimers were stable enough to be isolated, but none of the reported systems 




have a substituent in the position of the imine, which could compete with the second chloride 
ligand for coordination to the palladium centre [30;31]. 
 
Figure 3.40: Proposed dimerisation via imine ligand dissociation. The dimerisation process represented here is not 
necessarily a single step process, there may be intermediates and/or transition states. 
 
Figure 3.41: Structure of reported chloro-bridged dimer with coordinated phosphine ligands [31]. 
 
The expected changes in the NMR spectra are discussed here, should the dimer in  
Figure 3.40 represent the high concentration species. Upon increasing the monomer 
concentration, there would be more monomer in solution, thus more dimer can form. 
Accompanying the formation of the proposed dimer is the loss of 4JH-P coupling of the imine 
proton signal, so that a singlet is expected on dimer formation. This correlates with what is 
found in the NMR experiments conducted at high concentrations. Furthermore, the change in 
the coordination around the palladium metal centre would lead to changes in the PTA proton 
and phosphorous signals. Finally, the dissociation of the Pd-N bond, would allow the 2,6-
diisopropylaniline moiety to move to a less sterically hindered position, thus allowing free 
rotation of the ring about the N-C bond, thus leading to increased broadening of the isopropyl 
methyl signals. These changes would also lead to shifts in the isopropyl methine and methyl 
signals. This situation is what is observed in the NMR of the free ligand, where the isopropyl 
methyls give rise to an individual doublet. 




Similarly, increased temperature would provide the energy required to break the Pd-N bond, 
thus facilitating the formation of the dimer in Figure 3.40. Hence, similar trends would be 
expected in the variable temperature and variable concentration NMR spectra. 
Comparison of these expected changes in the NMR spectra with the observed changes in the 
variable temperature and variable concentration NMR spectra show that this process 
correlates with most of the experimental observations. However, a much larger shift in the 
imine proton signal was expected upon dissociation. However, a closer comparison of the 
imine proton chemical shifts of various analogous ligands and compounds revealed an 
interesting trend. These 1H NMR imine proton shifts are summarised in Table 3.6. 
The compound, NC1 (Figure 3.42), reported in Table 3.6 is a non-cyclometallated analogue 
of C1, synthesised by cleaving the chloro-bridged palladacycle with excess PTA, instead of 
two equivalents, as used for the synthesis of C1. The two PTA ligands coordinated at the 
palladium centre, trans to each other, thus forcing the imine ligand to dissociate. Similar 
structures with PMe3 have been previously reported [16]. 
 
Figure 3.42: Chemical structure of NC1. 
 
Table 3.6: 1H NMR chemical shifts for the imine proton. 
Compound HC=N chemical shift (ppm) 
Change in chemical shift 
relative to C1 (ppm) 
L1 8.22 +0.23 
B1 7.75 -0.24 
C1 7.99 0.00 
NC1 8.49 +0.50 
 
The observed shift in the imine signal of palladacycle complexes with increasing temperature 
was a 0.05 ppm downfield shift. From Table 3.6, it was noted that the dissociation of the imine 
should lead to a downfield shift, whilst the formation of the chloro-bridged coordination should 
lead to an upfield shift. Since the changes in the coordination around the palladium centre in 
the two cases (free imine vs. chloro-bridged dimer) have opposite effects on the shielding of 




the imine proton, the change in the chemical shift as a result of dimerisation will be smaller 
than expected. 
Thus, the next step was to look for some evidence which could possibly support the formation 
of this dimer in solution. 
 
3.2.5.1 Possible dimerisation via imine dissociation 
In the previous section, it was argued that it was reasonably plausible that a dimer could form 
via dissociation of the imine ligand and that this species could possibly explain the 
experimentally observed variable temperature and concentration NMR data. However, some 
experimental evidence was required to prove that such dimers can indeed form. Since dimeric 
species have often been detected in the mass spectra of mononuclear palladium complexes 
[32;33], the higher m/z fragments in the ESI-MS spectra of the mononuclear palladacycles 
reported in this thesis were examined for evidence of the proposed dimer. 
A [M2-Cl]+ fragment was detected for some of the mononuclear palladacycles. This fragment 
represents the proposed dimer, M2, with the loss of a chloride ion (Figure 3.43). 
 
Figure 3.43: [M2-Cl]+ dimer fragment detected in high m/z regions of mass spectra of mononuclear palladacycles. Pd-N 
bond indicated as dashed line, as it is not possible to determine whether or not the bond is broken. 
 
The mass spectrum of C3 is shown in Figure 3.44 with the simulated fragmentation pattern. 
The observed fragmentation pattern matched the simulated pattern well. The [M2-Cl]+ 
fragments detected for the other mononuclear palladacycles are summarised in Table 3.7. 




Table 3.7: Dimer fragment, [M2-Cl]+, detected at high m/z values, for the mononuclear PTA-based palladacycles. 






Based on the detection of the [M2-Cl]+ fragment, the proposed dimerisation via dissociation of 
the imine ligand is feasible. 





Figure 3.44: Mass spectrum of C3 with showing [M2-Cl]+ cluster (purple) with inset of the simulated fragmentation pattern. 
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Scheme 3.5: Summary of the possible chemical exchange processes occurring in solution and detected by NMR 
spectroscopy. 
 
To summarise (Scheme 3.5), variable temperature NMR spectra showed that there is an 
exchange process occurring in solution. The process was identified as a symmetric two-site 
exchange and it was confirmed with a computational model that showed that the experimental 
data lie within the 95 % confidence limits. Furthermore, the calculated activation energies 
(ΔG#) were found to lie in the range for aryl ring rotations, thus the symmetric two-site 
exchange involved the rotation of the 2,6-diisopropylaniline moiety about the N-C bond with 
the isopropyl methyl signals in the NMR spectra clearly displaying line broadening due to the 
site-exchange process. 
A second process was also present, as observed by changes in the chemical shifts of signals 
with increasing temperature. Loss of 4JH-P coupling in the imine proton signal suggested that 
the PTA ligand dissociates, however, further NMR spectroscopy studies did not support this 
proposal. Next, non-covalent aggregation via PTA self-association was proposed. Both 
variable concentration NMR spectroscopy studies and the computationally modelled adduct 
showed that this process was feasible, but whether or not it could fully account for all the 
experimental observations was questioned. Therefore, alternative concentration driven 
processes were considered, specifically, dimerisation via ligand dissociation. Since it had 
already been established that the PTA ligand does not dissociate, the dissociation of the imine 
ligand was considered. Not only did the proposed dimerisation process account for all 
observed changes in the NMR spectra with variable concentration and temperature, but 
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spectrometry was used to confirm the formation of the dimer in solution, by detecting the dimer 
fragment with the loss of a chloride ion, [M2-Cl]+. 
With the dynamic motion in the NMR spectra elucidated, the next steps were to determine the 
role or influence of the PTA ligand and the ortho-substituents on the chemical exchange 
processes. 
 
3.2.6 PTA vs PPh3 and PMe3 
Having established that there are two, possibly three, chemical exchange processes occurring 
in solution, the next step was to determine why these processes were only observed for the 
TPA-based palladacycles and not their PPh3 and PMe3 counterparts. 
If at all likely to occur, the formation of the non-covalent dimer can be facilitated by PTA self-
association. It is likely that the nitrogen donor atoms in PTA would facilitate this process. 
Although, the computationally modelled dimer showed only weak intermolecular interaction, it 
was thought that the difference in electronegativity of the carbon and nitrogen atoms on the 
PTA facilitated the aligning of the monomers through areas of high and low electron density 
(Figures 3.33 and 3.37), therefore allowing close enough contact between the monomer units 
for these weak intermolecular interactions to occur. The proposed involvement of the nitrogen 
donor atoms in this process immediately eliminates the possibility of this process occurring in 
the analogous PPh3 and PMe3 analogues, as these phosphines do not contain atoms other 
than carbon and hydrogen in addition to the phosphorous, thus, there can be no significant 
differences in the electron density of the atoms in the phosphine, effectively preventing the 
sort of “close fit” illustrated in Figure 3.37. 
In order to determine why the site-exchange and the covalent dimer formation was only 
observed for the PTA series and not the analogous PPh3 and PMe3 series, the physical and 
chemical properties of the various phosphine ligands were compared (Table 3.8). 
Table 3.8 shows the various phosphine analogues, the 1H and 31P NMR spectroscopy data for 
the corresponding palladacycle complexes, as well as the pKa’s and cone angles of the 
phosphines. From examining the NMR spectra, it was clear that only the PTA analogue had 
broad NMR spectroscopic signals and that the nature of tertiary phosphine influenced the 
imine proton shifts [34-46]. Comparison of the pKa values and the NMR spectroscopic signals 
and chemical shifts shows that the basicity of the phosphines could not be used to explain the 
observed trends; however, differences in the cone angles [37] correlated with the chemical 
shifts and degree of broadening. The other significant difference between the phosphines 




studied was the presence of additional nitrogen donor atoms in PTA and absence of donor 
atoms, other than phosphorous, in PPh3 and PMe3. However, since similar covalent dimers, 
substituted with a range of phosphine ligands, none of which contain atoms other that carbon 
and hydrogen, was reported by Chaudhari et al. [31] (Figure 3.45), the nitrogen donor atoms 
in PTA could be ruled out as the factor responsible for facilitating or hindering dynamic 
chemical exchange processes. Thus, the property of PTA which is thought to facilitate the 
covalent dimer formation is the small cone angle and the related steric factor, which is smaller 
in this case. 
  
Figure 3.45: PTA-based palladacycle covalent dimer (left) compared to similar covalent dimers reported in the literature 
(right), where PR3 = PEt3, PMe2Ph, PMePh2 and PPh3 [31]. 
Since the reported structure in Figure 3.45 (right) does not have the bulky 2,6-
diisopropylaniline moiety on the phenyl ring, there is less steric hindrance about the square 
planar palladium system, thus allowing the dimer formation even with the bulky PPh3 ligand. 
Contrastingly, in the PTA-based palladacycle system in Figure 3.46 (left), the large 2,6-
diisopropylaniline moiety most likely occupies the same space required by larger phosphine 
ligands, thus preventing the dimer formation for bulkier phosphines, such as PPh3 and even 
the slightly smaller PMe3.  




Table 3.8: NMR spectroscopic data and properties for phosphine analogues. 
Phosphine PPh3 PMe3 PTA 
Structure 
   
1H iPr methyl signal 
and chemical shift 
(ppm) 
   
 
1.37 (d, 6H, 3JH-H 6.90 Hz); 
1.21 (d, 6H, 3JH-H 6.90 Hz) 
1.33(d, 6H, 3JH-H 6.75 Hz); 
1.13 (d, 6H, 3JH-H 6.90 Hz) 
1.08-1.39 (d, 12H, broad) 
1H imine 
chemical shift (ppm) 
8.11-8.13 8.00-8.03 7.96-7.99 
31P chemical shift 
(ppm) 
42.21 -4.28 -47.02 
pKa [35;36] 2.73 8.65 5.63 
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3.2.7 Role of ortho-substituents 
Since all of the palladacycles in the series showed different thermodynamic data for the 
symmetric site-exchange process (Table 3.3), the next section attempts to explain how the 
ortho-substituents could possibly affect the activation energy (ΔG#) for the site-exchange, as 
shown below in Table 3.9. The change in the activation energy for the various analogues is 
quite small when compared to the overall activation energy, but it is an effect than can be 
explained. Note that C3 data have been excluded as no thermodynamic data were obtained 
for this compound and C5 has been excluded as it is a para-substituted species. 
Table 3.9: Influence of ortho-substituents on activation energy for site-exchange compared with ortho-substituent 
properties from the literature. 
Complex ΔG# (kJ.mol-1)a Radius (Å)b Steric factorb 
C4 (2-Me) 57.86 1.73 0.52 
C1 (2-H) 60.01 - - 
C7 (2-NO2) 61.43 - - 
C8 (2-OMe) 64.69 1.47 0.35 
C6 (2-F) 64.63 1.39 0.31 
C2 (2-Cl) 68.30 1.89 0.61 
aExperimental data from Section 3.2.2; bLiterature data [38]. Note that radius refers to the iodic group 
radii derived from the ortho-substituted biphenyls. This value was used as an estimate of the size 
for the various groups. 
 
Simple steric and electronic effects were considered first. Steric effects were ruled out by using 
the size and steric factor data from literature. The literature data in Table 3.9 are from a report 
by Hussey and Diefenderfer [38]. This shows the radii of various ortho-substituents and their 
associated steric factors, where the steric factor is a relative term indicating the degree of 
hindrance caused by the group. The trend in Table 3.9 for the literature data does not 
correspond to the trend observed in the experimental ΔG# values calculated from the variable 
temperature NMR spectroscopy experiments. If electronic effects were the cause, then higher 
activation energy would have been expected for the electron-withdrawing groups due to 
reduced electron delocalisation, while lower activation energy (broad peaks) was expected for 
the electron-donating groups due to increased electron delocalisation. However the nitro- and 
fluoro-substituents, which are both strongly electronegative, have lower activation energies 
than the chloro-analogue. 
The so-called ortho effect was then considered, as it takes into account both steric and 
electronic effects of ortho-substituents, as well as resonance influences, using Hammet σo 
values [38]. Hammett σ values give an indication of the relative electron withdrawing or  




–donating ability of a substituent as compared to hydrogen, and is expressed as a ratio of  
log Ka’s. These values were initially created to explain why some aromatic substituted 
analogous were more readily reduced than others. Both σm and σp values were calculated for 
various substituents, σo values were not determined so readily due to the “ortho effect” where 
ortho-substituted aromatic compounds were more readily reduced than was predicted (ortho 
enhancement).This behaviour is ascribed to a change in electron density at the reaction site 
due to decreased resonance contributions and increased inductive contributions. In 1967, 
Hussey and Diefenderfer created a reaction series and calculated σo values for phenyl halides. 
In 1969, Tribble and Traynham [39] did similar work, calculating the values for a series of 
ortho-substituted phenols, using an improved method. They then compiled a table of these 
values, using their own data and those of similar systems in the literature. Relevant data from 
their table are shown in Table 3.10. Although the values differ for each data set, the trend 
remains the same - the values increase from the methoxy analogue to the nitro analogue. 
Note that if σo is zero there is no effect, if σo is positive the substituent is electron withdrawing 
and if σo is negative the substituent is electron donating. 
Table 3.10: Hammet σo values from work by Tribble and Traynham [39]. 
Ortho-substituent σo-a σo-b σo-c 
OMe -0.37 -0.23 -0.20 
Me -0.13 -0.03 -0.17 
H 0 0 0 
F 0.29 - - 
Cl 0.50 - 0.40 
Br 0.55 0.66 0.40 
NO2 - 1.20 - 
aPhenols in DMSO; bPhenols in HMPA; cAnilines in DMSO. 
 
Ignoring the nitro- and methoxy-analogues of the PTA series, the ortho effect trend fits 
observed NMR spectroscopy trends for the PTA-based palladacycles. The smaller the σo 
value, the broader the NMR spectroscopic signal. The deviation for the nitro- and methoxy-
analogues may be due to resonance effects since the reported values were determined for 
simple phenol and related systems, whilst the PTA systems involve conjugation and therefore 
possible resonance structures. 
 




3.3 Conclusions and future work 
A variety of peak shapes for the methyl signals of the isopropyl substituents in the PTA-based 
palladacycle series was observed and proven to be due to a reversible symmetric site-
exchange by way of variable temperature NMR spectroscopic studies and employing a 
computational model to describe the process. The free energy of activation (ΔG#) and other 
thermodynamic parameters for the two-site exchange process were calculated. The rotational 
energy barriers lie in the range of those observed for aryl group rotations, thus it was 
concluded that the 2,6-dissopropylaniline moiety rotates about the N-C bond. Variable 
temperature NMR spectra supported this finding. 
Slight deviations in the expected signal shifts were attributed to concentration-dependent 
molecular aggregation via association between the PTA ligands. A non-covalent aggregate 
was proposed and modelled. The model appears to fit the data to some degree, however 
further investigations are underway to attempt to confirm these initial findings. 
An alternative concentration and temperature dependent dimerisation process was also 
proposed which could possibly explain the observed NMR changes. For this covalent dimer 
to form, the imine ligand needs to dissociate and a µ-chloro dimer forms. This proposal was 
supported to some extent by literature precedence where related dimers are reported and the 
presence of corresponding dimer fragments in the ESI-MS spectra of the palladacycle 
complexes reported in Chapter 2. 
The ability of the mononuclear PTA-based palladacycles to undergo these processes was 
attributed to the nature of the phosphine ligand, PTA, specifically, the small cone angle and 
the nitrogen donor atoms of the ligand. Furthermore, we were able to show that the ortho effect 
could possibly account for the influence of the ortho-substituents on the rotational energy 
barrier for the site-exchange process. 
 
3.4 Materials and Methods 
General methods and synthetic details for the PTA-based palladacycles are reported in 
Chapter 2, Section 2.5. The synthesis of the non-cyclopalladated compound, NC1, is reported 
below. 
NMR (1H: 300 and 400 MHz; 13C: 300 MHz, 31P: 300 MHz) spectra were recorded on a Varian 
VNMRS 300 MHz or a Varian Unity Inova 400 MHz spectrometer at 273 K, unless otherwise 
specified, and chemical shifts are referenced to the residual protons of the deuterated solvents 




and external tetramethyl silane (TMS) for 1H and 13C NMR, whilst 31P NMR chemical shifts are 
referenced relative to external 85% phosphoric acid (H3PO4). Chemical shifts (δ) and coupling 
constants (J) are reported in ppm and Hertz (Hz), respectively. The data in brackets are as 
follows: multiplicity, number of atoms (as per integration), coupling constants, assignment of 
atoms (where ‘,’ denotes ‘and’ and ‘/’denotes ‘or’).The following abbreviations were used to 
describe multiplicity of signals: s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m 
= multiplet and (br) = broad signals. Variable temperature acquisitions were performed after 
30 minute thermal equilibration period at each temperature. Experimental NMR data were 
imported into NMRfitv12 for site-exchange modelling. Data obtained from modelling were 
exported to Microsoft Excel for further manipulation and plotting of graphs. Eyring plots were 
constructed using SciDAVis 1.D009 software [40]. 
 
Computational methods 
Note that all input files can be found in Section A2.3 of Appendix 2. 
All calculations employed the ORCA Density Functional program developed by Frank Neese 
[41]. Geometries were fully optimised and frequency scans were performed using the GGA-
PBE [42] DFT functional with an additional D3-Bekce-Johnson [43;44] dispersion correction. 
An effective core potential (ECP) functional basis set was employed for palladium. Other 
Gaussian type basis sets employed in these calculations are recorded in Table 3.11. 
Optimisation using an implicit solvent model, namely the conductor-like screening model 
(COSMO) [45] with the parameters of acetonitrile was done with the aforementioned 
combinations of functionals and basis sets. Both the monomer and dimer were characterised 
as true minima on the potential energy surface (PES), as was indicated by the non-negative 
vibrational frequencies. 
Table 3.11: Gaussian type basis sets and auxiliary basis sets. 
Atom Basis set Auxiliary Basis set 
Pd LANTZ [46] LAN(28) ECP [47] 
C Ahlrich Def2-TZVP [48;49] Def2-TZVP/J [50] 
H Ahlrich Def2-TZVP Def2-TZVP/J 
Cl Ahlrich ma-Def2-TZVP [49;51] Def2-TZVP/J 
N Ahlrich ma-Def2-TZVP Def2-TZVP/J 
P Ahlrich ma-Def2-TZVP Def2-TZVP/J 
 




The non-covalent interactions (NCI) [52] analysis were carried out using the AIMAII software 
package [53] on geometry optimised structures that were obtained with ORCA. Wave 
functional files (.wfx) used were created using Gaussian 09 [54]. 
 
Synthesis of non-cyclopalladated analogue, [Pd(PTA)2(C6H4)CH=N{2,6-(iPr)-
C6H3}Cl] 
[Pd(PTA)2(C6H4)CH=N{2,6-(iPr)-C6H3}Cl] (NC1) 
NC1 was synthesised by stirring a solution of B1 (0.100 g, 0.123 mmol) in dichloromethane  
(5 mL) in a Schlenk tube. PTA (0.077 g, 0.49 mmol, 4 equivalents) was added. The solution 
was stirred for 2 hours in an oil bath at ± 25 °C. The reaction mixture was filtered through 
celite. Solvent was removed to obtain a yellow oily residue. The product was obtained by 
layering with ether to promote precipitation. The solution was kept at room temperature 
overnight. The white solid was isolated by vacuum filtration and rinsed with ether. The solid 
was dried under high vacuum. Yield: 0.090 g, 58%. FT-IR (νC=N, cm-1) 1614.03.  
m.p.: > 200 °C. 1H NMR (599.98 MHz, CDCl3): δ 8.49 (s, 1H, CH=N); δ 7.95 (d, 1H,  
3JH-H 7.6 Hz, Ph); δ 7.39 (d, 1H, 3JH-H 6.5 Hz, Ph); δ 7.14-7.27 (m, 6H, Ph); δ 4.37 (dd, 12H, 
2JH-P 46 Hz and 4JH-P 13 Hz, P-CH2-N); δ 3.94 (s (br), 12H, N-CH2-N); δ 3.08-3.15 (m, 2H,  
iPr-CH);δ 1.27 (d, 12H, 3JH-H 6.5 Hz, CH3). 31P{1H} NMR (242.88 MHz, CDCl3): δ -63.37 (s). 
ESI-MS: [M+H]+ 722.2; [M-Cl]+ 684.2; [M-Cl-PTA]+ 527.2; [M-Cl-2PTA]+ 370.1; [M-Cl-
2PTA+MeCN]+ 411.1. Anal. Found: C, 47.7; H, 6.14; N, 12.6. Calc. for 
C31H46N7P2ClPd.1CH2Cl2: C, 47.7; H, 6.01; N, 12.2. 
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Synthesis and Characterisation 
 
4.1 Introduction 
The advantages of employing palladacycles in biological applications were previously 
described in Chapter 2. The main advantages being the rich coordination chemistry, facile 
synthesis, ease of handling and rapid library generation. The focus of Chapter 2 was the 
design and synthesis of mononuclear palladacycles, emphasising the use of lower molecular 
weight and water-soluble ligands, as a means to improve the water solubility. This chapter will 
discuss the design and synthesis of binuclear palladacycles, focusing of the choice of ligands 
and the use of water-soluble substituents to improve activity and enhance water solubility. 
 
4.1.1 Binuclear palladacycle anti-cancer agents previously reported in the literature 
Polymetallic species are by no means a new class of compounds in the field of 
chemotherapeutic agents or palladacycles. It has been suggested that the highly positively 
charged nature of polymetallic species in solution leads to stronger electrostatic interactions 
with DNA, thus making these complexes more active than their mononuclear counterparts [1]. 
The most well-known example of such complexes is the polymetallic platinum complex, 
[{trans-PtCl(NH3)2}2-(µ-trans-{Pt(NH3)2(NH2(CH2)6NH2)2})]4+ (BBR3464), a trinuclear complex 
which has shown in vitro and in vivo cytotoxicity. This complex has been evaluated in Stage I 
clinical trials and its activity has been ascribed to its ability to form flexible adducts with DNA 
[1]. 
Similarly, Rodrigues et al. reported a series of mono-, binuclear and cationic palladacycles 
with bisphosphinic ligands and amine functionalities [obtained from N,N-dimethyl-1-
phenethylamine (dmpa) ligands] [2]. Evaluation of the palladacycles as anti-cancer agents 
against syngeneic B16F10 murine melanoma, showed that the binuclear and cationic dppe 
analogues, [Pd2(S(-)C2,N-dmpa)2(µ-dppe)Cl2] and [Pd(S(-)C2,N-dmpa)(dppe)]Cl, were the most 
active compounds in vitro. However, in vivo, only the binuclear analogue was found to be 
active and, in agreement with the findings above, it was also more active than its monomeric 
analogue (Figure 4.1 and 4.2). This work suggests that binuclear palladacycles with bridging 




dppe ligands may be highly active anti-cancer agents, possibly forming flexible adducts with 
DNA through electrostatic interactions [2]. 
 
Figure 4.1: General structures for the monomeric and binuclear palladacycles, where PᴖP = dppe [2]. 
 
 
Figure 4.2: Binuclear dppe-bridged palladacycle, [Pd2(S(-)C2,N-dmpa)2(µ-dppe)Cl2], that showed the highest activity [2]. 
 
Following this work, Bincoletto et al., synthesised the dppf analogue, [Pd2(C2,NS(-)dmpa)2(µ-
dppf)Cl2], of the above complexes (Figure 4.3). Since ferrocene, on its own, is known for its 
anti-cancer properties, it could be incorporated into these binuclear palladacycles, in the form 
of dppf, to perhaps enhance the anti-cancer activity. Evaluation of this binuclear complex 
against Walker tumour-bearing rats showed a 90% inhibition of growth, again confirming that 
these bisphosphine-type ligands are promising scaffolds for palladacycles with potential 
application as anti-cancer agents [3]. 
Based on these publications and a number of other results obtained with similar µ-
bisphosphine palladacycle complexes, these ligands could be used to design binuclear 
palladacycles with significant anti-cancer activity. Thus, µ-bisphosphine ligands were 
incorporated into the palladacycle system to form binuclear palladacycles, similar to AJ5, with 
the potential to bind to DNA through electrostatic interactions. 
 





Figure 4.3: Ferrocene analogue [3] of the dppe palladacycle reported by Rodrigues et al. [2]. 
 
4.1.2 Influencing complex solubility by varying substituents on the ligands 
Recently, Albert et al., reported the significant effect that small structural changes, such as a 
linker molecule, can have on the cytotoxicity of potential drug compounds [1]. Two series of 
doubly cyclopalladated diimines, previously referred to in Chapter 1, were recently reported. 
Briefly, the design of these palladacycles was based on the need to balance both lipophilicity 
and reactivity, as the lipophilicity controls the degree of cellular uptake, whilst the kinetic 
reactivity determines the amount of metal which can bind to the DNA. As discussed in Chapter 
1, the reactivity of palladacycles can be controlled by strongly coordinating- or chelating 
ligands. Lipophilicity, on the other hand, is controlled by functional groups. To this end, the 
authors made use of two linker molecules, NCH2CH2N and N(CH2)2O(CH2)2O(CH2)2N, to vary 
flexibility, lipophilicity and hydrophilicity (Figure 4.4). 
 
Figure 4.4: General structure of the diimine palladacycles reported by Albert et al. [1]. 




Their results showed that all complexes with the shorter NCH2CH2N linker were inactive, whilst 
the complexes with the longer linker showed activity. This corresponds to the work on the 
trinuclear platinum complex, BBR3464, where the flexible adducts formed with DNA correlate 
with higher activity. Furthermore, the oxygen atoms present in the longer linker allowed for the 
possibility of hydrogen-bonding with water molecules which increased the hydrophilicity of the 
complex [1]. 
Given the findings reported by Albert et al. [1], it was decided to functionalise the benzylidene 
moieties in the binuclear palladacycles previously prepared by us, with ethylene glycol-type 
tethers with the aim of improving water solubility and facilitating interaction of the complex with 
biological targets via potential hydrogen bond formation. 
 
4.2 Synthetic routes 
Based on the information above and a comprehensive study of the literature, as well as the 
results obtained with AJ5, the following series of binuclear palladacycles, shown in Figure 4.5, 
was designed. 
 
Figure 4.5: General structures of binuclear palladacycles with µ-bisphosphine ligands, R, where R = dppm, dppe, dppp or 
dppf. Left = unsubstituted analogues and right = ethylene glycol-tethered analogues. 
 
The unsubstituted complexes, BC1-BC4, were synthesised in a three step process, similar to 
that used for the synthesis of the mononuclear palladacycles reported in Chapter 2. Briefly, 
the synthesis comprised of Schiff base condensation, cyclopalladation and finally, reaction 
with the bisphosphine ligands in a 1:1 ratio with the µ-chloro cyclopalladated complex. The 
Schiff base condensation reaction used to form the imine ligand, L1, and the cyclopalladation 
reaction to form the µ-chloro palladacycle, B1, is reported in Chapter 2, along with the 
BC1-BC4 BTC1-BTC4 




characterisation of these compounds. The final cleavage of the µ-chloro palladacycle with the 
various bisphosphines is shown in Scheme 4.1 and will be discussed in Section 4.3. 
 
Scheme 4.1: General synthetic scheme with bisphosphines, where PᴖP = dppm, dppe, dppp or dppf. 
 
The synthesis of the substituted or tethered analogues, BTC1-BTC4, was a four step process. 
Firstly, the aldehyde moiety was modified by adding an ethylene glycol-type tether, which 
could improve water solubility through hydrogen-bonding. Once the aldehyde was modified, 
the following three steps were the same as those for the unsubstituted series. The full four-
step synthesis is shown in Scheme 4.2 and will be discussed in Section 4.3. 
Finally, the bisphosphine ligands, 1,1-bis(diphenylphosphino)methane (dppm), dppe and 1,3-
bis(diphenylphosphino)propane (dppp) were chosen to compare the effect of the aliphatic 
chain on activity and solubility. This choice was partially inspired by a paper by Caires et al. 
[4]. They reported three binuclear palladacycles with the bisphosphine bridging ligands, dppe, 
dppp and dppb (Figure 4.6). Interestingly, the dppe and dppb analogues were far more active 
than the dppp complexes and the dppb analogue was more active than the dppe analogue 
across three cell lines. Their data suggest that in the systems synthesised, the aliphatic chain 
length influenced the anti-cancer activity through the formation of more or less favourable 
adducts. 
Furthermore, dppf was selected to allow the incorporation of ferrocene without significantly 
changing the structure of the designed palladacycles. The reason for incorporating ferrocene 
is its inherent anti-cancer activity. Thus, it could potentially enhance the anti-cancer activity of 
the complex, as reported by Bincoletto et al. (Figure 4.3) [3]. 
All novel compounds were characterised by FT-IR- and NMR (1H, 13C and 31P) spectroscopy, 
mass spectrometry, micro analysis and melting point and single crystal analysis, where 
applicable. In addition, the complex solubilities were determined in water, dimethyl sulfoxide 
and water/dimethyl sulfoxide mixtures. 
BC1-BC4 



















Figure 4.6: Bisphosphine bridged palladacycles reported by Caires et al. [4]. 
 
4.3 Results and discussion 
4.3.1 Functionalisation of 4-hydroxybenzaldehyde 
The functionalised aldehyde was synthesised by the method reported by Zhao et al. [5]. 4-
Hydroxybenzaldehyde was reacted with 2-(2-chloroethoxy)ethanol to form the functionalised 
aldehyde, 4-[2-(2-hydroxyethoxy)ethoxy]benzaldehyde (T1), as shown in Scheme 4.3. 
The product was isolated as a pale orange oil in a fair yield. At low temperatures, the oil 
solidified to a pale orange solid. The formation of the product was confirmed by FT-IR- and 1H 
NMR spectroscopy and was found to match the literature data [5]. 
 





Scheme 4.3: Synthesis of 4-[2-(2-hydroxyethoxy)ethoxy]benzaldehyde (T1). 
 
The FT-IR spectrum showed the carbonyl νC=0 band shifts from 1664 cm-1 for 4-
hydroxybenzaldehyde to 1679 cm-1 for the product. Furthermore, we observe the appearance 
of a band at 3428 cm-1, corresponding to an O-H stretch and thus accounting for the hydroxyl 
group on the tether. The phenyl alkyl ether stretches were observed at 1254 cm-1 and 1046 
cm-1 and the aliphatic ether stretch was observed at 1125 cm-1. 
The 1H NMR spectrum of the product showed an aldehyde signal at 9.84 ppm. The proton 
next to the phenyl alkyl ether occurs as a triplet at 4.18-4.20 ppm, the aliphatic ether protons 
occur in the region of 3.60-3.90 ppm. This corresponded to the reported values [5]. 
 
4.3.2 Preparation of Schiff base ligands 
The Schiff base ligand (T2) synthesis was adapted from the method described by Mungwe et 
al. [6]. The ligand was prepared by reacting 4-[2-(2-hydroxyethoxy)ethoxy]benzaldehyde (T1) 
with 2,6-diisopropylaniline in DCM, as shown in Scheme 4.4. A catalyst was required for this 
reaction to occur; thus, para-toluene sulfonic acid (pTSA) was added and the reaction was 
heated to 40 °C. The product was isolated as white needle crystals in a fair yield of 
approximately 60%. 
 
Scheme 4.4: Schiff base condensation of the tethered imine, T2. 
 
FT-IR spectroscopy was used to determine whether the imine had been formed successfully. 
The disappearance of the carbonyl (C=O) band and the appearance of the imine (C=N) band 
was monitored. The imine C=N stretch was observed at 1630 cm-1, with no evidence of the 
aldehyde C=O band at 1679 cm-1 (Figure 4.7). 
T1 
T2 T1 





Figure 4.7: FT-IR spectrum of T2 (4000-600 cm-1). 
 
These findings were confirmed by 1H NMR spectroscopy. The spectrum showed the imine 
signal at 8.12 ppm, which was the most deshielded signal in the spectrum. This signal was 
more upfield than the imine signal of L1, the unsubstituted analogue. The proton next to the 
phenyl alkyl ether was observed as a multiplet at 4.23-4.25 ppm, which was shifted 0.05 ppm 
downfield from the same signal in the aldehyde. The aliphatic ether protons appeared in the 
region of 3.7-4.0 ppm, a 0.1 ppm downfield shift from same signals in the aldehyde. The 
characteristic methine and methyl signals of the isopropyl substituents in the Schiff base 
ligands were observed at approximately 3.00 ppm and 1.18 ppm, respectively. These chemical 
shifts were similar to those observed for the unsubstituted ligand, L1. 
ESI-MS and elemental analysis were also used to confirm product formation and purity, 
respectively. The mass spectrum showed the molecular ion, [M+H]+, and the elemental 
analysis confirmed that the product was correct, with the incorporation of a small amount of 
water, which was also observed in the 1H NMR spectrum. 
A single crystal was grown from DCM layered with hexane at low temperature 
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Figure 4.8: ASU of T2, with thermal ellipsoids rendered at the 50% probability level. H atoms are rendered as spheres 
with arbitrary fixed radii. Selected non-H atoms are labelled. 
 
The asymmetric unit contains two independent molecules, A (top) and B (bottom), as shown 
in Figure 4.8. The molecules have the same composition, but slightly different conformations 
of the tether. Furthermore, although not shown in Figure 4.8, several atoms of the isopropyl 
groups closest to the tethers (labelled C10-C12 and C10A-C12A) were disordered over two 
positions. As observed in the crystal structure of B6, the disorder of the isopropyl groups is 
most likely via fluxional motion about a carbon (sp2)-carbon (sp3) bond axis. The major 
components have site-occupancy factors of 0.836(3) for A and 0.849(3) for B, whilst the minor 
components have site-occupancy factors of 0.151(3) and 0.164(3) for A and B, respectively. 
The different conformations of the two molecules are clearly reflected in the torsion angle C1-
N1-C13-C14 (τ) which is different for A (τA = -177.10(12)˚) and B (τB = 175.82(12)˚). These 
conformational differences result in different orientations and different packing. The molecules 
designated as A (orange) pack in a head-to-tail conformation, whilst those designated as B 
(purple) pack in a tail-to-tail fashion. Alternating columns of A and B are observed in the crystal 
packing (Figure 4.9) as an ⋯ABAB⋯ array of offset columns which repeats along the a-axis. 
The crystal structure also shows intermolecular hydrogen bonding involving the tethers of two 
B molecules. The terminal hydroxyl group of one molecule is hydrogen bonded to the ether 
oxygen atom of the other molecule (O3A-H3AA···O2A); thus forming a ring with an inversion 
centre and the Etter notation R22(10) [7]. These hydrogen bonds are bifurcate, as an additional 
interaction with the tether of an A molecule, as shown in Figure 4.10 is also observed. This is 




an interaction between the two terminal hydroxyl groups (O3-H3···O3A). The numerical data 
pertaining to these hydrogen bonds can be found in Table 4.1. 
 
Figure 4.9: Crystal packing of T2 along the a-axis showing columns of A (orange), B (purple) and the rings formed by tail-
to-tail packing of A. Inset (top left): Unit cell showing A and B in the ASU. Inset (bottom right): Partially packed unit cell 
showing columns of A and B. 
 
 
Figure 4.10: Hydrogen-bonding interactions in the crystal structure of T2. Hydrogen atoms have been omitted for clarity. 




Table 4.1: Hydrogen-bond parameters 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
O3—H3···O3Ai 0.88(3) 1.88(3) 2.748(2) 168(2) 
O3A—H3AA···O2Aii 0.87(3) 1.96(3) 2.790(2) 159(2) 
Note: D-H = proton donor group, A = proton acceptor atom; 
Symmetry codes: (i) -x+1, y+1/2, -z+3/2; (ii) -x+1, -y+1, -z+2. 
 
Similar hydrogen bonding was observed in the reported structure of an aza podand which was 
obtained by opening of the macrocycle of 4’,4”(5”)-dinitrodibenzo-18-crown-6 ethers with 
MeNH2 [8]. The centrosymmetric dimer, formed through bifurcate H-bonding in this case, is 
shown in Figure 4.11. Two O-H···O bonds were observed between the terminal hydroxyl group 
and the two ether oxygen atoms. The O(3)-H···O(2A) and O(3)-H···O(1A) bond distances 
were reported as 2.26(8) and 2.48(8) Å, whilst the angles at the hydrogen atom were reported 
as 124(7)° and 129(7)°, respectively. These bond distances are significantly shorter that those 
observed in the crystal structure of T2, suggesting that the intermolecular hydrogen bonding 
in T2 is quite weak. This could be attributed to the degree of disorder observed in the tether 
of T2, as confirmed by the large ellipsoids observed for O2 and O3 in Figure 4.8, whereas the 
reported structure, the aza podand dimer mentioned above, has a total of six intermolecular 
hydrogen bonds “locking” the tether in place, as indicated by the more uniformly sized 
ellipsoids observed throughout the structure (Figure 4.11). 
 
Figure 4.11: Structure of an aza podand showing dimer formation through bifurcate H-bonding. Thermal ellipsoids are 
drawn at 40% probability and hydrogen bonds are drawn as dashed lines [8]. 
 
Finally, it should be noted that the crystal structure included water. This water of crystallisation 
was also observed in the 1H NMR spectrum and the elemental analysis which calculated for 
C23H31NO3•0.9H2O, however; the solvent was “squeezed” out, as a satisfactory model could 
not be found. Further experimental crystallographic data can be found in Table 4.2 and 
additional geometric parameters can be found in Appendix 1, Tables A1.11 and A1.12.




Table 4.2: Experimental crystallographic data for T2. 
Parameter T2 
Chemical formula C23H31NO3 
Formula weight 369.49 
Temperature (K) 100(2) 
Wavelength (Å) 0.71073 
Crystal system Monoclinic 
Space group P21/c 
a (Å) 9.845(6) 
b (Å) 20.87(1) 
c (Å) 20.73(1) 
α (°) 90.000 
β (°) 90.54(1) 
γ (°) 90.000 
V (Å3) 4258(5) 
Z 8 
Dcalc [Mg/m3] 1.153 
Absorption coefficient (mm-1) 0.075 
F(000) 1600 
Final R indices [I>2σ(I)] R1 = 0.0468, wR2 = 0.1066 
Reflections collected 26919 
Completeness to θmax (%) 94.3 
Goodness-of-fit on F2 1.064 
Largest difference peak and hole (e Å-3) 0.359, -0.405 
 
 




4.3.3 µ-Chloro palladacycles 
Cyclopalladation of the Schiff base ligand, via electrophilic C-H bond activation, was carried 
out to obtain the μ-chloro bridged palladacycle. The synthesis was performed as described by 
Mungwe et al. [6], using two equivalents of Schiff base ligand, two equivalents of 
bis(acetonitrile)palladium dichloride and four equivalents of sodium acetate to form one 
equivalent of the palladacycle, T3 (Scheme 4.5) [6]. 
 
Scheme 4.5: Cyclopalladation of tethered imine, T2, to form tethered bridged complex, T3. 
 
In this way T3, a yellow crystalline solid, was isolated in a high yield. The material was found 
to be sparingly soluble in DCM and DMSO. The product’s structure was confirmed by FT-IR 
spectroscopy and ESI-MS. The use of other characterisation techniques was not possible due 
to the low solubility of the complex. 
The FT-IR spectrum showed the imine νC=N stretch at 1596 cm-1. This was a large shift to lower 
wavenumbers of approximately 30 cm-1 relative to the free ligand, as was expected for 
coordination to the metal through the imine nitrogen [9]. 
The mass spectrum showed a number of fragments, of which the most significant for 
confirming the formation of the product were the [M-Cl+2MeCN]+ and [(M/2)-Cl]2+ fragments 
at 1065 and 474.1 m/z (Figure 4.12). The simulated fragment pattern for the [M-Cl+2MeCN]+ 
fragment matches the fragment pattern of the base peak perfectly, whilst the [(M/2)-Cl]2+ 
fragment overlaps with a second fragment, thus obscuring the fragmentation pattern. 
T3 T2 
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4.3.4 Bisphosphine-bridged palladacycles 
With the μ-chloro bridged palladacycles, B1 and T3 in hand, the final synthetic step was to 
react these binuclear palladacycles with the various bisphosphines, to obtain the desired μ-
bisphosphine-bridged palladacycles. The synthetic details for this step are given in Scheme 
4.6. All compounds were isolated as crystalline or amorphous solids in acceptable to good 
yields (42-89%). Note that the characterisation data for AJ5, the previously reported binuclear 
palladacycle, have been included in the discussion to follow, for the sake of comparison. 
 
 
Scheme 4.6: General synthetic scheme for the reaction of the µ-chloro palladacycles with various bisphosphines to obtain 
the unsubstituted- (BC1-BC4) and the tethered binuclear palladacycles (BTC1-BTC4). 
 
FT-IR spectroscopy confirmed the successful displacement of the μ-chloro bridge with the μ-
bisphosphine bridge for all compounds. This was confirmed by the change in the νC=N stretch 
from 1599 cm-1 (B1) and 1596 cm-1 (T3) to slightly higher wavenumbers in the range of 1608-
1611 cm-1 for BC1-BC4 and 1605-1606 cm-1 for BTC1-BTC4 (Table 4.3). This shift can be 
explained by the fact that the phosphine ligand is a better sigma donor than the chloride ligand, 
thus resulting in increased electron density on the metal centre. Consequently, there is 
increased back donation from the metal to the ligands. Since tertiary phosphines are better pi-
acceptor ligand than the imine, there is less back donation onto the imine than in the case of 
the μ-chloro bridged palladacycles. Thus, the imine bond is stronger and the corresponding 
shift to higher wavenumbers is observed [10;11]. 
 
BC1-4: R’ = H (unsubstituted) 
BTC1-4: R' = -(OCH2CH2)2OH (tether) 
BC1 and BTC1: R = dppm 
AJ5 and BTC2: R = dppe 
BC3 and BTC3: R = dppp 
BC4 and BTC4: R = dppf 
B1: R’ = H 
T3: R’ = -(OCH2CH2)2OH 




Table 4.3: Analytical data for binuclear palladacycles, BC1-BC4 and BTC1-BTC4. 





BC1 1609 1161 246-249d 
AJ5c 1612 1175 257-260d 
BC3 1609 1189 245-248d 
BC4 1608 1331 181-186d 
BTC1 1606 1369 227-231e 
BTC2 1605 1381 158-162f 
BTC3 1605 1397 146-147f 
BTC4 1606 - 87.5-89.4d 
aIR spectra were recorded neat using an ATR accessory. bMelting points were recorded in glass capillaries 
and are reported as uncorrected. cData from previously published results [12]. dDecomposition without 
melting. eDecomposition, followed by melting. fMelting followed by decomposition. 
 
1H NMR spectroscopy was used to confirm that the correct products were isolated. The imine 
resonances were observed as a doublet in the range of 7.80-8.10 ppm. The fine structure of 
the signals are due to 4JH-P coupling between the imine proton and the phosphorous atom of 
the bisphosphine ligand. These imine resonances were shifted approximately 0.2 ppm 
downfield compared to the μ-chloro palladacycles. This could, once again, be explained by 
the fact that the phosphine ligands are better sigma donors than the chloride ligands. This led 
to increased electron density on the metal centres and subsequent back-donation to the pi-
acceptor ligands. Since the imine has more double bond character (due to the reduced degree 
of back-donation in the presence of the phosphine), it experiences greater anisotropic effects 
[10;11;13]. Both the multiplicity and the shift in the imine resonances confirmed coordination 
of the phosphine ligand. Tables 4.4 and 4.5 show the assignments of the signals in the 1H 
NMR spectra for the two series of palladacycles. It was clear from the tables that the tether in 
the substituted palladacycles, BTC1-BTC4, leads to shielding of the imine protons, as these 
signals are not shifted as far downfield as is the case for the unsubstituted palladacycles. This 
could be due to electron donating effects of the ether functionalities in the tether, resulting in 
shielding of the aromatic ring protons in the ortho and para positions [13]. 
Further evidence for coordination of the phosphine was observed by the increased complexity 
of the aromatic region due to the phenyl rings of the bisphosphine ligand which appear as 
broad multiplets in this region. Again, as with the imine signal, the aromatic signals of the 
tethered analogues were more shielded (5.62-8.14 ppm) than those of the unsubstituted 
analogues (6.07-8.13 ppm).  




The presence of only one bridging bisphosphine ligand could be confirmed by the signals 
resonances for these ligands in the aliphatic region. The chemical shift of the methylene 
protons of dppm was found at approximately 5.10 ppm, whilst dppe and dppp had resonances 
in the region of 1.60-3.03 ppm and the chemical shifts of the cyclopentadienyl rings of dppf 
are found in the region of 4.42-5.09 ppm. The remaining signals were assigned to the isopropyl 
groups, where the methine occurs in the region of 3.29-3.52 ppm, the methyls arise at 1.15-
1.49 ppm and the methylene protons of the tether occurred as 3-4 multiplets with chemical 
shifts in the region of 3.10-3.68 ppm (Figure 4.13 and 4.14). 
 
Figure 4.13: 1H NMR spectrum of BC3. 
 
13C NMR spectroscopy showed the same trend in chemical shifts as 1H NMR spectroscopy. 
The imine carbon signals were found in the region of 176-179 ppm for BC1-BC4 and 175-176 
ppm for BTC1-BTC4. The aromatic carbon coupled to the imine functionality (-CCH=N-) was 
found in the region of 158-161 ppm for all complexes and the ortho-mutilated carbon signal 
arose at approximately 145 ppm. For the tethered complexes, the aromatic carbon with the 
attached tether (-C-(OCH2CH2)2OH) arose at a chemical shift of 161-162 ppm. There were 
also a number of multiplets due to JC-P coupling in the aromatic region. The aliphatic region 
was not too complex with the resonances for the isopropyl methines and methyls occurring at 
27-28 ppm and 23-24 ppm, respectively. The chemical shifts of the aliphatic carbons of the 
bisphosphine ligand were observed in the range of 21-23 ppm and the cyclopentadienyl ring 
BC3 BA253.esp















































































































































signals of BTC4 were found at 75-77 ppm. The chemical shifts for the tether in BTC1-BTC4 
occurred in the region of 61-72 ppm. 
 
Figure 4.14: 1H NMR spectrum of BTC3. 
 
The 31P NMR spectra showed single resonances for each of the complexes in the chemical 
shift region of 31-40 ppm (Table 4.6). Thus, confirming the equivalence of the phosphines and 
the formation of a pure product. 
BTC3 BA260 recryst.esp



























































































































































Table 4.4: 1H NMR data for unsubstituted binuclear palladacycles, BC1-BC4. 
Complex CH=N Aromatic Region 
Aliphatic region 
P-(CH2)n-P (CH3)2CH CH(CH3)2 
BC1 7.99 (d, 2H, 4JH-P 7.0 Hz) 
8.10-8.13 (m, 8H); 7.27-7.29 (m, 4H); 
7.21-7.23 (m, 8H); 7.14-7.17 (m, 8H); 
6.90-6.92 (m, 2H); 6.55-6.57 (m, 2H); 
6.07-6.09 (m, 2H) 
5.09-5.13 (m, 2H) 3.40-3.47 (m, 4H) 
1.49 (d, 12H, 3JH-H 6.5 Hz) 
1.23 (d, 12H, 3JH-H 6.5 Hz) 
AJ5a 8.02 (d, 2H, 4JH-P 7.2 Hz) 
7.88-7.94 (m, 8H); 7.20-7.34 (m, 20H); 
6.93 (t, 2H, 3JH-H 7.34 Hz); 6.61 (t, 2H, 
3JH-H) 7.63 Hz); 6.34 (br. t, 2H, 4JH-P 
7.2 Hz) 
3.00 (br m, 4H) 3.37-3.46 (m, 4H) 
1.33 (d, 12H, 3JH-H 6.8 Hz) 
1.19 (d, 12H, 3JH-H 6.9Hz) 
BC3 8.02 (d, 2H, 4JH-P 7.6 Hz) 
7.76-7.79 (m, 8H); 7.33-7.39 (m, 6H); 
7.26-7.30 (m, 10H), 7.20 (d, 4H, 3JH-H 
7.6 Hz); 6.94-6.97 (m, 2H); 6.65-6.67 
(m, 2H); 6.44-6.46 (m, 2H) 
2.58-2.62 (m, 4H); 
1.60 (m, 2H) 
3.29-3.36 (m, 4H) 
1.32 (d, 12H, 3JH-H 6.5 Hz) 
1.18 (d, 12H, 3JH-H 7.0 Hz) 
BC4 8.06 (d, 2H, 4JH-P 7.6 Hz) 
7.60-7.64 (m, 8H); 7.36-7.40 (m, 6H); 
7.23-7.27 (m, 10H); 7.18 (d, 4H, 3JH-H 
7.6 Hz); 7.01-7.04 (m, 2H); 6.68-6.72 
(m, 2H); 6.35-6.38 (m, 2H) 
4.98 (br s, 4H, CP 
ring); 4.42-4.43 (m, 
4H, CP ring) 
3.37-3.44 (m, 4H) 
1.37 (d, 12H, 3JH-H 7.0 Hz) 
1.17 (d, 12H, 3JH-H 7.0 Hz) 
aData from references [12]. Spectra run in CDCl3 at 25 ˚C. Chemical shifts reported in ppm, referenced relative to residual solvent peak.
Stellenbosch University  https://scholar.sun.ac.za




Table 4.5: 1H NMR data for substituted binuclear palladacycles, BTC1-BTC4. 
Complex CH=N Aromatic Region 
Aliphatic region 
P-(CH2)n-P -(OCH2CH2)2OH (CH3)2CH CH(CH3)2 
BTC1 
7.89 (d, 2H, 4JH-P 
7.9 Hz) 
8.14-8.20 (m, 8H); 7.15-7.31 (m, 20H); 6.47 
(dd, 2H, 3JH-H 8.2 Hz and 4JH-H 2.2 Hz); 
5.62-5.65 (m, 2H) 
5.04-5.13 
(m, 2H) 
3.66-3.67 (m, 4H, Ph-OCH2-); 
3.39-3.52 (m, 8H, Ph-OCH2CH2- 
and -CH2CH2OH); 
3.16-3.19 (m, 4H, -CH2CH2OH) 
3.39-3.52 
(m, 4H) 
1.48 (d, 12H, 
3JH-H 6.8 Hz); 
1.24 (d, 12H, 




7.84-7.87 (m, 8H); 7.28-7.31 (m, 4H); 7.23-
7.26 (m, 12H); 7.17 (d, 4H, 3JH-H 7.6 Hz); 6.47 
(dd, 2H, 3JH-H 8.2 Hz and 4JH-H 2.3 Hz); 5.85-
5.86 (m, 2H) 
3.03 
(br d, 4H, 
3JH-H 2.3 Hz) 
3.60-3.61 (m, 4H, Ph-OCH2-); 
3.34-3.42 (m, 8H, Ph-OCH2CH2- 
and -CH2CH2OH); 3.11 (t, 4H, 3JH-
H 4.7 Hz, -CH2CH2OH) 
3.34-3.42 
(m, 4H) 
1.32 (d, 12H, 
3JH-H 7.0 Hz); 
1.17 (d, 12H, 
3JH-H 7.0 Hz) 
BTC3 
7.91 (d, 2H, 4JH-P 
7.6 Hz) 
7.77-7.80 (m, 8H); 7.39-7.41 (m, 4H); 7.31-
7.33 (m, 8H), 7.25-7.28 (m, 4H); 7.19 (d, 4H, 
3JH-H 7.6 Hz); 6.52 (dd, 2H, 3JH-H 8.2 Hz and 
4JH-H 2.3 Hz); 5.98-6.00 (m, 2H) 
2.59-2.64 
(m, 4H); 
1.60 (m, 2H) 
3.66-3.68 (m, 4H, Ph-OCH2-); 
3.47-3.48 (m, 4H, Ph-OCH2CH2-); 
3.43-3.45 (m, 4H, -CH2CH2OH); 
3.20-3.22 (m, 4H, -CH2CH2OH) 
3.31-3.38 
(m., 4H) 
1.30 (d, 12H, 
3JH-H 6.5 Hz) 
1.18 (d, 12H, 
3JH-H 7.0 Hz) 
BTC4 
7.95 (d, 2H, 4JH-P 
8.8 Hz) 
7.59-7.63 (m, 8H); 7.36-7.39 (m, 4H); 7.33-
7.34 (m, 2H); 7.24-7.27 (m, 8H); 7.22 (d, 2H, 
3JH-H 7.6 Hz); 7.16 (d, 4H, 3JH-H 7.3 Hz); 6.60 
(dd, 2H, 3JH-H 8.2 Hz and 4JH-H 2.3 Hz); 6.03 
(dd, 2H, 3JH-H 5.7 Hz and 4JH-H 2.3 Hz) 
5.09 (br s, 
4H, CP ring); 
4.42-4.43 
(m, 4H, CP 
ring) 
3.68-3.70 (m, 4H, Ph-OCH2-); 
3.52-3.54 (m, 8H, Ph-OCH2CH2- 
and -CH2CH2OH); 3.23 (br t, 4H, 
3JH-H 4.7 Hz, -CH2CH2OH) 
3.36-3.43 
(m, 4H) 
1.34 (d, 12H, 
3JH-H 7.0 Hz) 
1.16 (d, 12H, 
3JH-H 7.0 Hz) 
Spectra run in CDCl3 at 25 ˚C. Chemical shifts reported in ppm, referenced relative to residual solvent peak.
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Table 4.6: 31P NMR shifts of binuclear palladacycles, BC1-BC4 and BTC1-BTC4. 









*Data from previously published results [12]. 
 
ESI-MS was used as further confirmation that the correct product was formed. The molecular ion 
was not detected in any of the spectra; however, the [M-Cl]+ fragment, a common fragment in 
many palladium chloride complexes and also observed in the mononuclear palladacycle series, 
was detected for all complexes, except BTC4. This fragment confirms the correct product was 
formed. Another common fragment across the unsubstituted and tethered series was [M-2Cl-Pd-
L1/T2]+. This corresponds to the loss of the labile chloride ligands, followed by the loss of a 
palladium atom and the coordinated ligand [12]. This fragmentation pathway is shown in Figure 
4.15 and the various fragments are assigned in Table 4.7. 
 
Figure 4.15: Possible fragmentation pathway for BTC1 with major fragments assigned in Table 4.7. 
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The solubility of the compounds was tested in water, DMSO and a DMSO/water mixture, as 
reported in Chapter 2. Table 4.8 shows the results of this study. The binuclear complexes were 
found to be far more soluble in both DMSO and the water/DMSO mixture than the mononuclear 
complexes. In addition, the tethered series was generally more soluble than the unsubstituted 
series. Despite the increased solubility, all of the complexes were insoluble in water. 
Table 4.7: Ion fragments detected by ESI-MS for binuclear palladacycles, BC1-BC4 and BTC1-BTC4. 
Complex [M-Cl]+ [M-2Cl-Pd-L1/A2]+ 
BC1 1161 754 
AJ5* 1175 - 
BC3 1189 577 
BC4 1331 924 
BTC1 1369 858 
BTC2 1381 872 
BTC3 1397 886 
BTC4 - 1028 
*Data from previously published results [12]. 
 
Table 4.8: Solubilities for binuclear palladacycles, BC1-BC4 and BTC1-BTC4. 
Complex 
Solubility in water 
(mg/mL) 





AJ5 0 4.38 57 
BC1 0 6.32 62 
BC3 0 2.02 78 
BC4 0 57.2 91 
BTC1 0 2.85 28 
BTC2 0 32.6 76 
BTC3 0 76.0 54 
BTC4 0 53.7 98 
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4.4 Conclusions and future work 
Two series of binuclear palladacycles with bridging bisphosphine ligands were synthesised and 
fully characterised. The series with the ethylene glycol-type tether was found to be more soluble 
than the analogous unsubstituted series and the mononuclear PTA-based series. However, 
despite the improved solubility, none of the complexes were water-soluble. 
Incorporation of alternative water-soluble moieties should be investigated as a continuation of this 
work. Some possibilities include replacing 2,6-diisopropylaniline moiety with the more water-
soluble analogues, 4-aminophenol [14] and sulfanilic acid [15]. These analogues are less 
sterically hindered, more soluble and sulfanilic acid is currently used in medicinal applications as 
it has low toxicity. In addition to varying the aniline moiety, the tether can also be modified to be 
either shorter or longer (fewer or more oxygen atoms), thus allowing variation in the lipophilicity 
and hydrophilicity of the complexes [1]. 
 
4.5 Materials and Methods 
General methods are reported in Chapter 2, Section 2.5. 
 
Synthesis of unsubstituted binuclear palladacycles with μ-bisphosphine ligands 
[{PdCl(C6H4)CH=N(2,6-iPr2-C6H3)}2(μ-Ph2PCH2PPh2)] (BC1) 
BC1 was synthesised by preparing a solution of B1 (0.092 g, 0.11 mmol) in dichloromethane  
(5 mL) in a Schlenk tube. Dppm (0.044 g, 0.11 mmol) was added. The solution was stirred for  
6 hours in an oil bath at ± 25 °C. The reaction solution was filtered through celite and the solvent 
volume was reduced to obtain a slightly viscous yellow solution. The product was recrystallised 
by layering the dichloromethane solution with hexane at low temperature (-16 °C). The solution 
was kept at low temperature (-16 °C) overnight. The yellow crystals were isolated by vacuum 
filtration and rinsed with hexane. The material was dried under vacuum. Yield: 0.119 g, 88%. FT-
IR (νC=N, cm-1) 1609. m.p.: 246-249 °C. 1H NMR (599.99 MHz, CDCl3): δ 8.10-8.13 (m, 8H, Ph); δ 
7.99 (d, 2H, 4JH-P 7.0 Hz, CH=N); δ 7.27-7.29 (m, 4H, Ph); δ 7.21-7.23 (m, 8H, Ph); δ 7.14-7.17 
(m, 8H, Ph); δ 6.90-6.92 (m, 2H, Ph); δ 6.55-6.57 (m, 2H, Ph); δ 6.07-6.09 (m, 2H, Ph); δ 5.09-
5.13 (m, 2H, -PCH2P-); δ 3.40-3.47 (m, 4H, 
iPr-CH); δ 1.49 (d, 12H, 3JH-H 6.5 Hz, 
iPr-CH3); δ 1.23 
(d, 12H, 3JH-H 6.5 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 100.57 MHz): δ 176.27 (CH=N); δ 158.12 (-
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CCH=N-); δ 146.38 (o-metallated C); δ 144.46 (CAr); δ 139.88 (CAr); δ 136.67 (t, JC-P 4.6 Hz, CAr); 
δ 134.39 (t, JC-P 6.3 Hz, CAr); δ 129.54 (CAr); δ 129.33 (CAr); δ 127.56 (CAr); δ 126.89-126.99 (m, 
CAr); δ 126.07 (CAr); δ 123.01 (CAr); δ 121.87 (CAr); δ 27.54 (
iPr-CH); δ 23.64 (iPr-CH3); δ 22.04 (-
PCH2P-). 31P{1H} NMR (CDCl3, 161.89 MHz): δ 33.99 (s). ESI-MS: [M-Cl]+1161.25, [M-2Cl-Pd-
L1]+ 754.200, [M-2Cl-Pd-L1-(Ph)2PCH2P(Ph)2+MeCN]+ 411.11. Anal. Found: C, 61.8; H, 4.95; N, 
1.91. Calc. for C63H66Cl2N2P2Pd2•0.6CH2Cl2: C, 61.4; H, 5.44; N, 2.25. Solubility: DMSO 6.32 
mg/mL; 62% DMSO in water. 
 
[{PdCl(C6H4)CH=N(2,6-iPr2-C6H3)}2(μ-Ph2P(CH2)3PPh2)] (BC3) 
BC3 was synthesised as above, using dppp as the bridging bis(phosphine) and the quantities as 
indicated: B1 (0.092 g, 0.11 mmol), dichloromethane (5 mL) and dppp (0.047 g, 0.11 mmol). Yield: 
0.123 g, 89%. FT-IR (νC=N, cm-1) 1609. m.p.: 245-248 °C. 1H NMR (CDCl3, 599.99 MHz): δ 8.02 
(d, 2H, 4JH-P 7.6 Hz, CH=N); δ 7.76-7.79 (m, 8H, Ph); δ 7.33-7.39 (m, 6H, Ph); δ 7.26-7.30 (m, 
10H, Ph); δ 7.20 (d, 4H, 3JH-H 7.6 Hz, Ph); δ 6.94-6.97 (m, 2H, Ph); δ 6.65-6.67 (m, 2H, Ph); δ 
6.44-6.46 (m, 2H, Ph); δ 3.29-3.36 (m, 4H, iPr-CH); δ 2.58-2.62 (m, 4H, -PCH2CH2CH2P-); δ 1.60 
(m, 2H, -PCH2CH2CH2P-); δ 1.32 (d, 12H, 3JH-H 6.5 Hz, 
iPr-CH3); δ 1.18 (d, 12H, 3JH-H 7.0 Hz, 
iPr-
CH3). 13C{1H} NMR (CDCl3, 150.88 MHz): δ 176.73 (CH=N); δ 159.15 (-CCH=N-); δ 147.68 (o-
metallated C); δ 145.06 (CAr); δ 140.82 (m, CAr); δ 137.72-137.79 (m, CAr); δ 134.19 (t, JC-P 5.7 
Hz, CAr); δ 130.89 (CAr); δ 130.54 (m, CAr); δ 130.22 (m, CAr); δ 129.91 (CAr); δ 128.78 (CAr); δ 
128.34 (t, JC-P 5.7 Hz, CAr); δ 126.91 (CAr); δ 123.97 (CAr); δ 122.76 (CAr); δ 28.45 (
iPr-CH); δ 24.37 
(iPr-CH3); δ 23.16 (-PCH2CH2CH2P-); δ 21.36 (-PCH2CH2CH2P-). 31P{1H} NMR (CDCl3, 161.89 
MHz): δ 35.21 (s). ESI-MS: [M-Cl]+ 1189.28, [M-2Cl-Pd-L1]+ 782.232, [M-2Cl]2+ 577.156, [M-2Cl-
Pd-L1-(Ph)2P(CH2)3P(Ph)2+MeCN]+ 411.104. Anal. Found: C, 59.6; H, 5.05; N, 1.60. Calc. for 
C65H70Cl2N2P2Pd2•0.7H2O·1.3CH2Cl2: C, 59.2; H, 5.54; N, 2.08. Solubility: DMSO 2.02 mg/mL; 
78% DMSO in water. 
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BC4 was synthesised as above, using dppf as the bridging bis(phosphine) and the quantities as 
indicated: B1 (0.092 g, 0.11 mmol), dichloromethane (5 mL) and dppf (0.063 g, 0.11 mmol). Yield: 
0.072 g, 47%. FT-IR (νC=N, cm-1) 1608. m.p.: 181-186 °C. 1H NMR (CDCl3, 599.99 MHz): δ 8.06 
(d, 2H, 4JH-P 7.6 Hz, CH=N); δ 7.60-7.64 (m, 8H, Ph); δ 7.36-7.40 (m, 6H, Ph); 7.23-7.27 (m, 10H, 
Ph); δ 7.18 (d, 4H, 3JH-H 7.6 Hz, Ph); δ 7.01-7.04 (m, 2H, Ph); δ 6.68-6.72 (m, 2H, Ph); δ 6.35-
6.38 (m, 2H, Ph); δ 4.98 (br s, 4H, Cp ring); δ 4.42-4.43 (m, 4H, Cp ring); δ 3.37-3.44 (m, 4H, iPr-
CH); δ 1.37 (d, 12H, 3JH-H 7.0 Hz, 
iPr-CH3); δ 1.17 (d, 12H, 3JH-H 7.0 Hz, 
iPr-CH3). 13C{1H} NMR 
(CDCl3, 100.57 MHz): δ 177.25 (CH=N); δ 159.11 (-CCH=N-); δ 147.36 (o-metallated C); δ 145.44 
(CAr); δ 140.86 (CAr); δ 135.37 (t, JC-P 6.3 Hz, CAr); δ 130.53 (m, CAr); δ 130.31 (CAr); δ 128.54 
(CAr); δ 127.87-127.97 (m, CAr); δ 127.05 (CAr); δ 123.99 (CAr); δ 122.86 (CAr); δ 77.20 (m, Cp 
ring); δ 28.52 (iPr-CH); δ 24.62 (iPr-CH3); δ 23.02 (
iPr-CH3). 31P{1H} NMR (CDCl3, 161.89 MHz): 
δ 31.38 (s). ESI-MS: [M-Cl]+ 1331.22, [M-2Cl-Pd-L1]+ 924.186, [M-2Cl]2+ 648.133, [M-2Cl-Pd-L1-
{(Ph)2PC5H4FeC5H4P(Ph)2}+MeCN]+ 411.106. Anal. Found: C, 60.9; H, 4.79; N, 1.51. Calc. for 
C72H72Cl2FeN2P2Pd2•CH2Cl2: C, 60.4; H, 5.14; N, 1.93. Solubility: DMSO 57.2 mg/mL; 91% DMSO 
in water. 
 
Synthesis of binuclear palladacycles with 2-(2-hydroxyethoxy)ethoxy tether and 
μ-bisphosphine ligands 
4-[2-(2-Hydroxyethoxy)ethoxy]benzaldehyde (T1) 
T1 was synthesised by stirring a solution of 4-hydroxybenzaldehyde (1.22 g, 10.0 mmol) in dry 
acetonitrile (75.0 mL) in a 2-neck round bottom flask. 2-(2-Chloroethoxy)ethanol (1.24 g, 10.0 
mmol) was added to the solution, followed by potassium carbonate (6.50 g, 40.0 mmol). The 
resulting suspension was heated for 72 hours in an oil bath at ± 70 °C. The mixture was then 
cooled to room temperature and the solvent was removed under reduced pressure. The residue 
was dissolved in dichloromethane (100 mL) and the solution was washed with water (3 x 75 mL 
portions). The organic layer was dried over anhydrous magnesium sulphate after which the 
magnesium sulphate was removed by filtration. Solvent was removed from the filtrate to obtain 
an orange oily residue. The product was dried on high vacuum to remove any remaining solvent. 
Yield: 1.068 g, 65%. FT-IR (νC=O, cm-1) 1679; (νC-O, cm-1) 1254 (phenyl alkyl ether), 1046 (phenyl 
alkyl ether) and 1125 (aliphatic ether). 1H NMR (599.99 MHz, CDCl3): δ 9.84 (s, 1H, CH=O); δ 
7.78-7.81 (m, 2H, Ph); δ 6.98-7.00 (m, 2H, Ph); δ 4.19 (t, 2H, 3JH-H 4.7 Hz, Ph-OCH2CH2-); δ 3.87 
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T2 was synthesised by stirring T1 (0.365 g, 1.74 mmol) in chloroform (10.0 mL). 2,6-
Diisopropylaniline (0.327 mL, 1.74 mmol) was added, followed by a catalytic amount of pTSA (1 
crystal). The solution was refluxed for 24 hours at ± 55 °C. The product was purified by column 
chromatography with 2:1 ethyl acetate/hexane as eluent. The product-containing fractions were 
combined and the solvent was removed. The residue was dissolved in DCM, the solution was 
concentrated and then layered with hexane at room temperature. Fine, white needle crystals 
formed and were isolated by vacuum filtration. The crystals were dried under vacuum. Yield: 0.404 
g, 63%. FT-IR (νC=N, cm-1) 1630. m.p.: 89.8-94.5 °C. 1H NMR (399.99 MHz, CDCl3): δ 8.12 (s, 1H, 
CH=N); δ 7.85-7.87 (m, 2H, Ph); δ 7.15-7.17 (m, 2H, Ph); δ 7.08-7.12 (m, 1H, Ph); δ 7.04-7.07 
(m, 2H, Ph); δ 4.23-4.25 (m, 2H, Ph-OCH2CH2-); δ 3.91-3.94 (m, 2H, Ph-OCH2CH2-); δ 3.78-3.82 
(m, 2H, -CH2CH2OH); δ 3.70-3.72 (m, 2H, -CH2CH2OH); δ 2.94-3.04 (m, 2H, 
iPr-CH); δ 1.18 (d, 
12H, 3JH-H 6.6 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 599.99 MHz): δ 161.33 (CAr); δ 161.02 (CH=N); 
δ 149.38 (CAr); δ 137.77 (CAr); δ 130.19 (CAr); δ 129.34 (CAr); δ 123.88 (CAr); δ 122.94 (CAr); δ 
114.80 (CAr); δ 72.61 (-CH2CH2OH); δ 69.51 (Ph-OCH2CH2-); δ 67.58 (Ph-OCH2CH2-); δ 61.77 (-
CH2CH2OH); δ 28.48 (
iPr-CH); δ 24.81 (iPr-CH3); δ 23.10 (
iPr-CH3). ESI-MS: [M+H]+ 370.2. Anal. 
Found: C, 72.0; H, 8.95; N, 3.46. Calc. for C23H31NO3•0.9H2O: C, 71.6; H, 8.57; N, 3.63.  
 
[PdCl{4-[2-(2-hydroxyethoxy)ethoxy]}CH=N{2,6-iPr-C6H3}]2 (T3) 
T3 was synthesised by stirring a solution of bis(acetonitrile)palladium dichloride (0.100 g, 0.386 
mmol) in acetonitrile (5.00 mL). T2 (0.142 g, 0.386 mmol) and sodium acetate (0.063 g, 0.77 
mmol) were added to the solution. The resulting orange mixture was stirred for 18 hours in an oil 
bath at ± 25 °C. The solvent was removed to obtain a yellow oily residue which was dissolved in 
DCM (50.0 mL) and filtered through celite to remove any metallic palladium. The solvent volume 
was reduced and the solution was then layered with hexane at low temperature (-16 °C) to 
crystallise the product. The yellow crystalline solid was isolated by vacuum filtration and rinsed 
with hexane. The product was dried under vacuum. Yield: 0.156 g, 80%. FT-IR (νC=N, cm-1) 1597. 
m.p.: 150-154 °C. ESI-MS: [M-Cl+2MeCN]+ 1065; [(M/2)-Cl]2+ 474.1. Anal. Found: C, 53.6; H, 
5.98; N, 2.36. Calc. for C46H60Cl2N2O6Pd2: C, 54.1; H, 5.92; N, 2.74. 
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Synthesis of μ-bis(phosphines) palladacycles with bidentate phosphines and 
2-(2-hydroxyethoxy)ethoxy tether 
[(PdCl{4-[2-(2-hydroxyethoxy)ethoxy]}CH=N{2,6-iPr2-C6H3})2(μ-Ph2PCH2PPh2)] (BTC1) 
BTC1 was synthesised by stirring a solution of T3 (0.115 g, 0.113 mmol) in dichloromethane (5 
mL) in a Schlenk tube. Dppm (0.043 g, 0.11 mmol) was added. The solution was stirred for 6 
hours in an oil bath at ± 25 °C. The solvent volume was reduced by rotary evaporator to obtain a 
yellow oily residue. The product was recrystallised by layering the dichloromethane solution with 
hexane at low temperature. The solution was kept at low temperature (-16 °C) overnight. The off-
white solid was isolated by vacuum filtration and rinsed with hexane. The recrystallisation was 
repeated and the crystals were dried under vacuum. Yield: 0.080 g, 50%. FT-IR (νC=N, cm-1) 1606. 
m.p.: 227-231 °C. 1H NMR (299.74 MHz, CDCl3): δ 8.14-8.20 (m, 8H, Ph); δ 7.89 (d, 2H, 4JH-P 7.9 
Hz, CH=N); δ 7.15-7.31 (m, 20H, Ph); δ 6.47 (dd, 2H, 3JH-H 8.2 Hz and 4JH-H 2.2 Hz, Ph); δ 5.62-
5.65 (m, 2H, Ph); δ 5.04-5.13 (m, 2H, -PCH2P-); δ 3.66-3.67 (m, 4H, Ph-OCH2-); δ 3.39-3.52 (m, 
12H, Ph-OCH2CH2-, -CH2CH2OH and 
iPr-CH); δ 3.16-3.19 (m, 4H, -CH2CH2OH); δ 1.48 (d, 12H, 
3JH-H 6.8 Hz, 
iPr-CH3); δ 1.24 (d, 12H, 3JH-H 6.9 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 
175.87 (CH=N); δ 161.96 (CAr-OCH2CH2-); δ 159.55 (-CCH=N-); δ 145.54 (o-metallated C); δ 
141.21 (CAr); δ 140.33 (CAr); δ 135.44-135.61 (m, CAr); δ 130 (CAr); δ 129.93 (CAr); δ 128.02-
128.17 (m, CAr); δ 126.98 (CAr); δ 122.86 (CAr); δ 122.38 (t, JC-P 5.1 Hz, CAr); δ 112.11 (CAr); δ 
72.33 (-CH2CH2OH); δ 69.05 (Ph-OCH2CH2-); δ 66.68 (Ph-OCH2CH2-); δ 61.68 (-CH2CH2OH); δ 
28.55 (iPr-CH); δ 24.70 (iPr-CH3); δ 23.11 (-PCH2P-). 31P{1H} NMR (CDCl3, 161.89 MHz): δ 34.39 
(s). ESI-MS: [M-Cl]+ 1369.34, [M-2Cl-Pd-T2]+ 858.249, [M-2Cl-Pd-T2-
{(Ph)2PCH2P(Ph)2}+MeCN]+ 474.127, [M-2Cl-Pd-T2-{(Ph)2PCH2P(Ph)2}-C4H9O3+MeCN]+ 
411.105. Anal. Found: C, 59.8; H, 5.87; N, 1.47. Calc. for C71H82Cl2N2O6P2Pd2•H2O: C, 59.9; H, 
5.95; N, 1.97. Solubility: DMSO 2.85 mg/mL; 28% DMSO in water. 
 
[(PdCl{4-[2-(2-hydroxyethoxy)ethoxy]}CH=N{2,6-iPr2-C6H3})2(μ-Ph2P(CH2)2PPh2)] (BTC2) 
BTC2 was synthesised as above, using dppe as the bridging bis(phosphine) and the quantities 
as indicated: T3 (0.115 g, 0.113 mmol), dichloromethane (5.00 mL) and dppe (0.045 g, 0.11 
mmol). Yield: 0.108 g, 68%. FT-IR (νC=N, cm-1) 1605. m.p.: 158-162 °C. 1H NMR (599.99 MHz, 
CDCl3): δ 7.88-7.89 (m, 2H, CH=N); δ 7.84-7.87 (m, 8H, Ph); δ 7.28-7.31 (m, 4H, Ph); δ 7.23-
7.26 (m, 12H, Ph); δ 7.17 (d, 4H, 3JH-H 7.6 Hz, Ph); δ 6.47 (dd, 2H, 3JH-H 8.2 Hz and 4JH-H 2.3 Hz, 
Ph); δ 5.85-5.86 (m, 2H, Ph); δ 3.60-3.61 (m, 4H, Ph-OCH2-); δ 3.34-3.42 (m, 12H, Ph-OCH2CH2-
, -CH2CH2OH and 
iPr-CH); δ 3.11 (t, 12H, 3JH-H 4.7 Hz, -CH2CH2OH); δ 3.03 (br d, 4H, 3JH-H 2.3 
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Hz, -P(CH2)2P-); δ 1.32 (d, 12H, 3JH-H 7.0 Hz, 
iPr-CH3); δ 1.17 (d, 12H, 3JH-H 7.0 Hz, 
iPr-CH3). 
13C{1H} NMR (CDCl3, 75.38 MHz): δ 175.61 (CH=N); δ 162.43 (CAr-OCH2CH2-); δ 159.86 (-
CCH=N-); δ 145.09 (o-metallated C); δ 141.28 (CAr); δ 140.43 (CAr); δ 134.27-134.43 (m, CAr); δ 
130.71 (CAr); δ 130.04 (CAr); δ 128.39-128.53 (m, CAr); δ 126.78 (CAr); δ 122.78 (CAr); δ 122.37-
122.51 (m, JC-P, CAr); δ 112.23 (CAr); δ 72.33 (-CH2CH2OH); δ 69.05 (Ph-OCH2CH2-); δ 66.68 (Ph-
OCH2CH2-); δ 61.68 (-CH2CH2OH); δ 28.55 (
iPr-CH); δ 24.70 (iPr-CH3); δ 23.11 (-P(CH2)2P-). 
31P{1H} NMR (CDCl3, 161.89 MHz): δ 40.63 (s). ESI-MS: [M-Cl]+ 1381.38; [M-2Cl-Pd-T2]+ 
872.266, [M-2Cl-Pd-T2-{(Ph)2P(CH2)2P(Ph)2}+MeCN]+ 474.127, [M-2Cl-Pd-T2-
{(Ph)2P(CH2)2P(Ph)2}-C4H9O3+MeCN]+ 411.105. Anal. Found: C, 59.6; H, 6.04; N, 1.55. Calc. for 




BTC3 was synthesised as above, using dppp as the bridging bis(phosphine) and the quantities 
as indicated: T3 (0.115 g, 0.113 mmol), dichloromethane (5.00 mL) and dppp (0.047 g, 0.11 
mmol). Yield: 0.067 g, 42%. FT-IR (νC=N, cm-1) 1605. m.p.: 146-147 °C. 1H NMR (599.99 MHz, 
CDCl3): δ 7.91 (d, 2H, 4JH-P 7.6 Hz, CH=N); δ 7.77-7.80 (m, 8H, Ph); δ 7.39-7.41 (m, 4H, Ph); δ 
7.31-7.33 (m, 8H, Ph); δ 7.25-7.28 (m, 4H, Ph); δ 7.19 (d, 4H, 3JH-H 7.6 Hz, Ph); δ 6.52 (dd, 2H, 
3JH-H 8.2 Hz and 4JH-H 2.3 Hz, Ph); δ 5.98-6.00 (m, 2H, Ph); δ 3.66-3.68 (m, 4H, Ph-OCH2CH2-); δ 
3.47-3.48 (m, 4H, Ph-OCH2CH2-); δ 3.43-3.45 (m, 4H, -CH2CH2OH); δ 3.31-3.38 (m, 4H, 
iPr-CH); 
δ 3.20-3.22 (m, 4H, -CH2CH2OH); δ 2.59-2.64 (m, 4H, -PCH2CH2CH2P-); δ 1.60 (m, 2H, -
PCH2CH2CH2P-); δ 1.30 (d, 12H, 3JH-H 6.5 Hz, 
iPr-CH3); δ 1.18 (d, 12H, 3JH-H 7.0 Hz, 
iPr-CH3). 
13C{1H} NMR (CDCl3, 100.57 MHz): δ 175.71 (CH=N); δ 162.23 (CAr-OCH2CH2-); δ 160.10 (t, JC-
P 3.0 Hz, -CCH=N-); δ 145.47 (o-metallated C); δ 141.45 (CAr); δ 140.93 (CAr); δ 134.48-134.60 
(m, CAr); δ 130.99 (CAr); δ 130.76 (CAr); δ 130.41 (CAr); δ 130.30 (CAr); δ 128.76-128.86 (m, CAr); 
δ 127.08 (CAr); δ 123.03 (CAr); δ 122.78-122.89 (m, CAr); δ 112.39 (CAr); δ 72.61 (-CH2CH2OH); δ 
69.32 (Ph-OCH2CH2-); δ 67.14 (Ph-OCH2CH2-); δ 61.97 (-CH2CH2OH); δ 28.74 (
iPr-CH); δ 24.68 
(iPr-CH3); δ 23.48 (-PCH2CH2CH2P-); δ 21.62 (-PCH2CH2CH2P-). 31P{1H} NMR (CDCl3, 161.89 
MHz): δ 35.46 (s). ESI-MS: [M-Cl]+ 1397.37; [M-2Cl-Pd-T2]+ 886.280, [M-2Cl-Pd-T2-
{(Ph)2P(CH2)3P(Ph)2}+MeCN]+ 474.127. Anal. Found: C, 59.6; H, 5.94; N, 1.47. Calc. for 
C73H86Cl2N2O6P2Pd2•2H2O: C, 59.7; H, 6.17; N, 1.91. Solubility: DMSO 76.0 mg/mL; 54% DMSO 
in water. 
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BTC4 was synthesised as above, using dppf as the bridging bis(phosphine) and the amounts as 
indicated here: T3 (0.115 g, 0.113 mmol), dichloromethane (5.00 mL) and dppf (0.063 g, 0.11 
mmol). Yield: 0.115 g, 65%. FT-IR (νC=N, cm-1) 1605. m.p.: 87.5-89.4 °C. 1H NMR (599.99 MHz, 
CDCl3): δ 7.95 (d, 2H, 4JH-P 8.8 Hz, CH=N); δ 7.59-7.63 (m, 8H, Ph); δ 7.36-7.39 (m, 4H, Ph); δ 
7.33-7.34 (m, 2H, Ph); δ 7.24-7.27 (m, 8H, Ph); δ 7.22 (d, 2H, 3JH-H 7.6 Hz, Ph); δ 7.16 (d, 4H, 
3JH-H 7.3 Hz, Ph); δ 6.60 (dd, 2H, 3JH-H 8.2 Hz and 4JH-H 2.3 Hz, Ph); δ 6.03 (dd, 2H, JH-H 5.9 Hz 
and 2.34 Hz, Ph); δ 5.09 (br s, 4H, Cp ring); δ 4.42-4.43 (m, 4H, Cp ring); δ 3.68-3.70 (m, 4H, Ph-
OCH2-); δ 3.52-3.54 (m, 8H, Ph-OCH2CH2- and -CH2CH2OH); δ 3.36-3.43 (m, 4H, 3JH-H, 
iPr-CH); 
δ 3.23 (br t, 4H, 3JH-H 4.7 Hz, -CH2CH2OH); δ 1.34 (d, 12H, 3JH-H 7.0 Hz, 
iPr-CH3); δ 1.16 (d, 12H, 
3JH-H 7.0 Hz, 
iPr-CH3). 13C{1H} NMR (CDCl3, 75.38 MHz): δ 176.12 (CH=N); δ 161.58 (d, JC-P 2.2 
Hz, CAr-OCH2CH2-); δ 159.62 (d, JC-P 5.5 Hz, -CCH=N-); δ 145.14 (o-metallated C); δ 141.30 (CAr); 
δ 140.83 (CAr); δ 134.34-134.50 (m, CAr); δ 132.46 (CAr); δ 131.79 (CAr); δ 130.56 (CAr); δ 130.32 
(CAr); δ 127.89 (d, JC-P 10.5 Hz, CAr); δ 126.76 (CAr); δ 123.47 (d, JC-P 9.4 Hz, CAr); δ 122.67 (CAr); 
δ 112.17 (CAr); δ 76.91 (m, Cp ring); δ 75.72 (d, JC-P 8.06 Hz, Cp ring); δ 72.36 (-CH2CH2OH); δ 
69.13 (Ph-OCH2CH2-); δ 66.68 (Ph-OCH2CH2-); δ 61.68 (-CH2CH2OH); δ 28.48 (
iPr-CH); δ 24.81 
(iPr-CH3); δ 23.10 (
iPr-CH3). 31P{1H} NMR (CDCl3, 161.89 MHz): δ 31.38 (s). ESI-MS: [M-2Cl-Pd-
T2]+ 1028.23, [M-2Cl]2+ 752.179; [M-2Cl-Pd-T2-{(Ph)2PC5H4FeC5H4P(Ph)2}+MeCN]+ 474.127. 
Solubility: DMSO 53.7 mg/mL; 98% DMSO in water. 
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Biological evaluation and DNA binding 
studies of synthesised palladacycles 
 
5.1 Introduction 
5.1.1 In vitro studies 
In vitro studies are not a new phenomenon in cancer research. These cell culture-based 
experiments allow fast and efficient testing of potential drug candidates. Various aspects of drug 
candidates may be tested against many different human- and animal species cell lines. These 
include beneficial properties, such as the ability to prevent cell proliferation, and negative effects, 
such as toxicity. Importantly, in vitro assays are less expensive and do not have the ethical issues 
associated with in vivo testing [1]. 
One of the major drawbacks of in vitro studies is that the cell culture-based systems employed to 
conduct these tests are “over simplified” compared to actual biological systems. Hence, there is 
not always a direct correlation between in vitro and in vivo results. In cell cultures, each cell type 
is cultured and tested in isolation, whilst in the body, human and animal, there are interactions 
between the various systems or cell types which could affect the toxicity and or efficacy of the 
drug [2]. Despite this drawback, these studies are a valuable tool for initial screening of potential 
drug compounds. 
A great example of the value of in vitro testing is that of the Developmental Therapeutics Program 
(DTP) at the National Cancer Institute (NCI). This is a potential drug screening program which 
uses in vitro assays for the initial stages of testing, with the aim of keeping costs low and allowing 
a larger number of compounds to be screened per annum. The pre-screen is against three human 
cancer cell lines, MCF-7 breast cancer, NCI-H460 large-cell lung cancer and SF-268 glioblastoma 
cell lines. The next step involves the NCI60 human tumour cell line anti-cancer drug screen, where 
the drug compound is screened against 60 different human cancer cell lines [3]. Currently, 
approximately 2500 drugs per annum undergo this first stage of screening. Of these, only 2% will 
continue on to the second stage of testing which is in vivo testing, of which an even smaller 
fraction goes into clinical trials. Thus, the in vitro tests aid in the elimination of more than 98% of 
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potential drug candidates, allowing only the most promising drugs to move forward into clinical 
trials, which are both costly and time consuming [4]. 
Two of the most common in vitro assays were employed in this project; the first was a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay which is used to determine 
cell viability and half maximal inhibitory concentration (IC50) values. The second assay was a 
Western Blot to determine if there is any DNA damage or induction of apoptosis as a response to 
the potential drug compound. 
 
5.1.1.1 MTT assay 
The MTT assay is quite simple. Cells are cultured and then treated with the drug for a specific 
period of time. MTT, a yellow tetrazole, is then added to the cell culture. Viable cells will reduce 
the MTT to an insoluble purple formazan (Reaction Scheme 5.1). The formazan is then solubilised 
and quantified by absorbance spectroscopy. The more viable cells there are, the more formazan 
is produced and consequently, a higher absorbance value is obtained [5;6]. 
 
Scheme 5.1: Reduction of MTT to formazan. 
 
From these data, the half maximal inhibitory concentration (IC50) value was determined, as the 
concentration at which the compound inhibits growth of half of the treated cells, relative to the 
untreated cells [7]. 
 
5.1.1.2 Western Blot assay 
Western blotting is one of the most important techniques used in cell biology. It is used to detect 
specific proteins, isolated from a mixture (extracted from cells). The technique consists of three 
main steps, i) size separation by gel electrophoresis, ii) transfer of the separated proteins to a 
Yellow tetrazole Purple formazan 
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solid membrane and iii) labelling of the desired protein using primary and secondary antibodies 
to visualise the protein by various methods of detection, including colorimetric and radioactive 
detection, chemiluminescence and fluorescence [8]. The usefulness of this assay for evaluation 
of potential drugs is that it can be used to determine biochemical changes in the cells once 
exposed to (or treated with) the drug compound [9], as the presence of specific proteins provides 
information about the mode of anti-cancer activity [10;11]. The most important proteins which are 
employed as markers for potential anti-cancer drugs, are γ-H2AX, which, if present, is an 
indication of DNA damage and PARP, which if cleaved, is an indication that apoptosis has been 
induced. The presence of both of these proteins confirms that the drug targets DNA and induces 
cell death via apoptosis, the preferred mechanism of drug-induced cell death. 
Palladacycles have previously been shown to exert cytotoxicity by inducing DNA double strand 
cleavage [12;13]. This was determined by the presence of γ-H2AX in the cells. Additionally, 
induction of apoptosis by the drug can be detected by the presence of the cleaved PARP proteins, 
where the PARP proteins are usually cleaved from 116 KD to 86KD. Similar experiments were 
carried out by Ulukaya et al. [13]. They tested for apoptosis by looking for the presence of the 
cleaved caspase-3 protein using a Western blot assay, whilst DNA double strand breaks were 
tested for by a nuclear stain which detects γ-H2AX nuclear foci. The palladacycle, 
[PdCl(terpy)](sac)·2H2O, where terpy = 2,2’:6’2”-terpyridine and sac = saccarinate, tested by 
these authors showed both double strand breaks and induction of apoptosis at higher 
concentrations [13]. 
 
5.1.2 DNA binding studies 
DNA is a common target for many anti-cancer drugs. It controls cell growth, differentiation, 
replication and cell death. By binding to DNA, drug molecules can interfere with or inhibit 
transcription and replication processes which will lead to retarded or inhibited cell growth and 
division [14]. Current research seeks to understand and exploit the interactions between drug 
molecules and the DNA double helix, in order to use the information for rational drug design. 
Before understanding these interactions, they need to be identified and classified. This is where 
DNA binding studies come into play [15;16], as drug-DNA interactions influence the shape and 
conformation of both the drug and DNA molecules [14]. 
There are two types of drug-DNA binding: covalent- and non-covalent binding interactions [17]. 
Each of these will be discussed in more detail in the following sections. 
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5.1.2.1 Covalent binding 
Covalent bonding of a compound to DNA is a strong, irreversible interaction, leading to irreparable 
changes in the DNA structure, thus hindering DNA replication. Cisplatin is known to bind to DNA 
in this manner, thus forming intrastrand DNA adducts and interstrand crosslinks. The major 
binding type, occurring when cisplatin interacts with DNA, is an intrastrand 1,2-d(GpG) binding 
where the soft Pt2+ ion binds to the harder N7 atoms on sequential guanine nucleoside bases 
(Figure 5.1) [18]. The binding of cisplatin to DNA prevents replication, thus inducing apoptosis 
which consequently prevents cell division and therefore promoting the anti-tumour activity of the 
metallodrug. 
Similarly, Katsarou et al. reported the formation of an intrastrand GNG(G2C3G4)(N7-N7) chelation 
of the palladium complexes, trans-Cl2Pd(glyglyOH)2 and trans-Cl2Pd(glynvalOH)2 where glyglyOH 
and gly-L-nvalOH (glynvalOH) were the dipeptides employed as ligands, with the dodecamer 
d[CGCGAATTCGCG]2 duplex. Earlier studies of palladium compounds, [Pd(dien)(H2O)]2+, 
[Pd(en)(H2O)2]2+ and K2PdCl4, with this dodecamer showed preferential attack at the terminal 
region for the monofunctional species, with selectively binding to the G2 and G10 bases, whilst the 
bifunctional species bound selectively to the N7 atom of the G4 base, as observed by Katsarou et 
al. Furthermore, the hexaaqua palladium (II) species, [Pd(H2O)6]2+, showed selectivity for the G2 
and G4 bases [19;20]. These results suggested that there is, to some degree, a structure-activity 
relationship for the formation of palladium-DNA adducts. More importantly, these results show 
that palladium complexes can bind to DNA covalently and thus, palladium complexes can 
potentially prevent DNA replication and induce apoptosis, in a similar manner to cisplatin [21]. 
 
5.1.2.2 Non-covalent binding 
In contrast to covalent bonding, non-covalent interactions with DNA are weaker and thus, 
reversible. These interactions are usually preferred over covalent bonding, as covalent binding 
drugs, such as cisplatin, cause severe toxicity, whilst reversibly binding drugs could potentially be 
less toxic. There are three sub-classes of non-covalent interactions: intercalation, non-covalent 
groove binding (major and minor) and electrostatic binding, as shown in Figure 5.2 [23-26]. 
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Figure 5.1: DNA adducts formed with cisplatin [22]. 
 
5.1.2.2.1 Intercalation 
Intercalation is the most common type of DNA binding and hence, the most studied [15]. It occurs 
when a planar portion, usually an aromatic fragment, of a drug molecule binds between base 
pairs of the DNA double helix. Molecules that intercalate into the DNA double helix cause changes 
in the DNA. Such changes include elongation and unwinding of the helix [15;27]. There may also 
be increased stabilisation of the drug (and the DNA) in this adduct, provided by π-π stacking 
interactions and dipole-dipole interactions between the drug and the DNA [14-16;28]. Well known 
intercalators include ethidium bromide (Figure 5.3), anthracyclines and other heterocyclic dyes 
[16]. 
     
Figure 5.2: Computer generated (left) and diagrammatic (right) representations of the three types of DNA binding, where 
yellow represents intercalation, red represents groove binding and green represents electrostatic interactions [29]. 
 
Stellenbosch University  https://scholar.sun.ac.za




5.1.2.2.2 Non-covalent groove binding 
Groove binding is associated with hydrogen-bonding and van der Waals interactions of drug 
molecules with functional groups along the grooves in the DNA double helical structure [16]. The 
binding can be either in the major- or the minor groove in the DNA helix. 
Minor groove binding 
Most minor groove binders replace the “spine of hydration” (water molecules bound to DNA 
backbone), allowing them to fit well into the small space. Groove binders may just replace the 
water molecules bound to the DNA backbone, or there may be significant interactions between 
the DNA and the drug molecules which influence the shape and conformation of the DNA. These 
structures are stabilised by electrostatic, hydrophobic and hydrogen-bonding interactions. 
Hoechst 33258, a dye molecule, is a well-known minor groove binder (Figure 5.3) [14;28]. 
Major groove binder 
Methyl green, another organic dye, was the first reported major groove binder (Figure 5.3). A 
number of other natural products have also been identified as major groove binders. These 
species interact through intercalation between the base pairs in the major groove, whilst non-
covalent interactions are used to position the drug within the groove [25;28]. 
 
5.1.2.2.3 Electrostatic binding 
This type of binding is defined as the binding of a cationic drug molecule to the negatively charged 
phosphate groups in the DNA backbone. These interactions are non-selective and can occur 
anywhere along the sugar-phosphate backbone of DNA [16]. This mode of binding is more 
prevalent for cationic coordination compounds. One such example is L-[Ru(dpphen)3]2+ (where 
dpphen = 4,7-diphenyl-1,10-phenanthroline) (Figure 5.4), which was shown to bind to DNA 
exclusively through electrostatic interactions [26]. 
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Figure 5.3: Chemical structures of DNA intercalators and groove binders [14;16;28]. 
 
 
Figure 5.4: Structure of electrostatic DNA binder, L-[Ru(dpphen)3]2+ [26]. 
 
Ethidium bromide 
DNA intercalator Methyl green 
DNA major groove binder 
Hoechst 33258 
DNA minor groove binder 
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5.1.3 Analytical techniques for determining DNA binding interactions 
Various analytical techniques can be used to monitor the changes which occur in DNA and the 
drug molecules, as a result of the DNA binding interactions described above. These techniques 
include classical spectroscopic methods, electrophoresis, isothermal titration calorimetry and 
many others. The more classical and most commonly used techniques, electrophoresis, UV-, CD- 
and NMR spectroscopy, were employed in this project [24;30]. 
Electrophoresis 
Agarose gel electrophoresis is a simple and robust, yet very effective technique for determining 
whether DNA is the biological target for a potential drug compound. The ability of a compound to 
bind to DNA is determined by its ability to change the electrophoretic mobility of plasmid  
DNA [31]. 
Plasmid DNA has three different forms, namely: closed circular superhelical (ccc), open circular 
(oc) and linear. Each of these forms have a different electrophoretic mobility, based on its overall 
size and shape. The superhelical form is tightly coiled onto itself, making the overall physical size 
significantly smaller than the open circular form. Therefore, it migrates through the agarose gel 
significantly faster than the linear and open circular form. The linear form migrates faster than the 
open circular form, as its narrow shape allows it to pass through the channels in the gel easily. 
The open circular form has the slowest mobility due to its large floppy nature [32;33]. 
Recently, there have been a number of publications demonstrating the use of electrophoresis for 
determining DNA binding. Albert et al. incubated their diimine palladacycle compounds with 
pBluescript SK+ plasmid DNA at various concentrations (2.5-200 µM). Cisplatin and ethidium 
bromide were also included, as controls. The results from the agarose gel electrophoresis 
analysis are shown in Figure 5.5 [31]. 
Cisplatin showed significant changes in the electrophoretic mobility of both the open circular and 
superhelical forms of DNA. This was ascribed to the strong covalent bonding of cisplatin to DNA, 
specifically, the formation of cross-links. The non-covalent intercalation of ethidium bromide into 
the DNA helix was weaker and thus the changes in the electrophoretic mobility of DNA were far 
less significant. 
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Figure 5.5: Images of agarose gel showing the interaction of compounds with plasmid DNA, where 1 = DNA, 2 = 2.5 µM 
compound, 3 = 5 µM compound, 4 = 10 µM compound, 5 = 25 µM compound, 6 = 50 µM compound, 7 = 100 µM compound 
and 8 = 200 µM compound [31]. 
 
For cisplatin, the open circular (oc) band runs through the gel slightly faster for all concentrations, 
whist the superhelical (ccc) band changes significantly with increasing concentration. At low 
concentration, 2.5 µM, the ccc band was retarded to the point at which it coalesces with the open 
circular DNA. Therefore, only one broad band was observed in lane 2. This coalescence 
corresponded to complete removal of the supercoils so that the ccc form has changed to the oc 
form. This uncoiled DNA is called negatively supercoiled DNA and is considered to be an 
underwound form of DNA, as it has fewer coils than DNA in its natural state. Lanes 3 and 5 (5-25 
µM) show the separation of the bands again. The increase in the electrophoretic mobility of the 
ccc band is indicative of the conversion of the DNA from the negatively supercoiled form to the 
positively supercoiled or overwound form of DNA. Unlike the negatively supercoiled DNA, which 
has a right-handed supercoil, the positively supercoiled DNA has a left-handed supercoil [31;34]. 
Thus, the binding of cisplatin to DNA results in the uncoiling of DNA at lower concentrations, and 
at higher concentrations increased supercoiling with an opposite handedness is observed. 
As stated, ethidium bromide showed only slight retardation of both the open circular and 
superhelical bands [31]. This corresponded to the slight unwinding of the DNA helix upon 
intercalation. Furthermore, the extent of streaking observed is typically an indication of DNA 
damage (such as the unwinding due to intercalation); however, at a more fundamental level, 
streaking is a result of incomplete separation of DNA plasmids with slightly different forms, or in 
this case, slightly different degrees of DNA binding and therefore, unwinding. In order to separate 
these forms, a higher resolution separation was required. Polyacrylamide gels are often selected 
over agarose gels for separations requiring higher resolutions [35]. For the purpose of determining 
whether or not a drug compound binds to DNA, agarose gels are sufficient, as separation of the 
three forms of plasmid DNA is easily achieved. 
Reference 
compound 1 
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These authors studied the DNA binding of the palladacycle, Reference compound 1, and found 
that it showed the same trend as cisplatin, with coalescence (lane 5) followed by positive 
supercoiling (lane 6) (Figure 5.6). At higher concentrations (lane 7 and 8), little to no DNA was 
observed. This disappearance of the DNA bands was explained as the complete breakdown of 
the DNA as a result of interaction with the compound [31], resulting in insufficient amounts of DNA 
being present to interact with the staining dye and for any appreciable detection of DNA [31]. 
 
Figure 5.6: Structure of Reference compound 1, where Z = CH2CH2OCH2 [31]. 
 
UV-Vis spectroscopy 
UV-Vis spectroscopy can also be used to determine the interaction between drug molecules and 
DNA, by monitoring the changes in the absorbance of DNA or the drug. DNA has a characteristic 
absorbance maximum at approximately 260 nm. This absorbance is due to the purine and 
pyrimidine groups in the nucleoside bases which are chromophores. Comparison of the free drug 
and the drug-DNA complex should show the changes due to the interaction of the drug with the 
DNA, if there are any (Figure 5.7) [36]. The changes in the spectra could include bathochromic 
shifts in the absorption maxima of DNA and hypo- or hyperchromic effects. Weaker interacting 
drugs may show only hypo- or hyperchromic effects and no significant shifts in the absorbance 
maxima [24;36]. By recording a series of spectra, with increasing amounts of DNA, the drug-DNA 
association constants can be determined based on the quantitative changes. This is the most 
common method for determining drug-DNA interaction, as it is sensitive, simple and shows good 
reproducibility [24;30;36;37]. 
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Figure 5.7: UV absorption spectra showing the changes in absorbance of the free drug upon addition of DNA (from top to 
bottom), due to drug-DNA interactions. Inset: plot of (εa-εf)/(εb-εf) vs. DNA/M and the nonlinear least squares fit for the 
titration of DNA to the drug compound [36]. 
 
Circular dichroism spectroscopy 
Circular dichroism (CD) is defined as the difference in absorbance of left and right circularly 
polarised light. It is a very powerful technique for studying drug-DNA interactions. Its most 
attractive quality is the small amount of sample required. The CD spectrum of DNA shows two 
bands, a positive band at 260-280 nm due to base stacking and a negative band at approximately 
245 nm due to right-handed helicity of the double helical structure [25;31]. Achiral complexes (like 
most drug molecules) do not display a CD spectrum; however, when there is drug-DNA 
interaction, an induced CD (ICD) spectrum may be observed. Drug-DNA interaction causes 
changes in the conformation of the DNA helix and the drug molecule, which reflect as changes in 
the CD spectra or an induction of a spectrum, as the absorbance of light will differ. Changes in 
the CD spectra are most often observed as changes in intensities of the positive and negative 
bands and shifts in the wavelengths of the bands with varying drug- or DNA concentration. The 
observed spectra are due to the CD and ICD contributions of the DNA, the drug and the drug-
DNA complex, making interpretation of these changes quite complex. However, if an ICD is 
observed in the absorption band of an achiral ligand, it is evidence of drug-DNA interaction [25]. 
Based on the information above, in vitro evaluation of the complexes prepared and discussed in 
Chapters 2 and 4 was carried out to determine their potential as anti-cancer agents. Complexes 
showing biological activity were further subjected to DNA binding studies in order to determine 
the mode of activity. By studying the interactions between the palladacycles and DNA, it was 
hoped to gain insight and understanding into the role of various moieties and functional groups 
on the metallodrug in its DNA binding ability. 
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5.2 Results and Discussion 
5.2.1 In vitro results 
In vitro tests were performed to determine if the complexes prepared as part of this study were 
active as anti-cancer agents against human breast adenocarcinoma MCF7 (estrogen receptor 
positive) and MDA-MB231 (estrogen receptor negative) cell lines. These included cell viability 
tests using a MTT assay, and in some cases Western blots to test for DNA damage using γ-H2AX 
and PARP cleavage to determine whether or not apoptosis takes place. The complexes which 
were evaluated are shown in Figures 5.8 and 5.9. 
 
Figure 5.8: Mononuclear palladacycles evaluated as potential anti-cancer agents. 
 
 
Figure 5.9: Binuclear palladacycles evaluated as potential anti-cancer agents. Note that BC2 is the same complex as AJ5, the 
binuclear palladacycle with µ-dppe, however, this complex will only be referred to as AJ5 throughout this chapter. 
C1: R = 2-H 
C2: R = 2-Cl 
C3: R = 2-Br 
C4: R = 2-Me 
C5: R = 4-Me 
C6: R = 2-F 
C7: R = 2-NO2 
C8: R = 2-OMe 
BC1: R = dppm and R’ = H 
BC2 / AJ5: R = dppe and R’ = H 
BC3: R = dppp and R’ = H 
BC4: R = dppf and R’ = H 
BTC1: R = dppm and R’ = (OCH2CH2)2OH 
BTC2: R = dppe and R’ = (OCH2CH2)2OH 
BTC3: R = dppp and R’ = (OCH2CH2)2OH 
BTC4: R = dppf and R’ = (OCH2CH2)2OH 
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5.2.1.1 Cell viability assays 
The MTT assay data were plotted to show the percentage cell survival at various compound 
concentrations. For active compounds, a visible decrease in cell survival was observed with 
increasing compound concentration (Figure 5.10), whilst weakly active or inactive compounds 
showed little to no change in the cell survival (Figure 5.11). 
 
Figure 5.10: MTT assay data for active palladacycle, C2. 
 
 
Figure 5.11: MTT assay data for weakly active palladacycle, C1. 
 
As stated in the introduction, MTT assays are also used to determine the IC50 values of potential 
drug compounds. These values are summarised in Table 5.1. For this study, the obtained values 


















































MTT: Survival rate of C1 treated cells
MDA-MB-231
MCF7
MCF7 IC50 = 19 µM 
MDA-MB-231 IC50 = 17 µM 
MCF7 IC50 = 46 µM 
MDA-MB-231 IC50 = >54 µM 
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respective cell lines, as the aim of this project was to improve the solubility of the compounds, 
whilst maintaining the same level of activity. 
The most noticeable trend in Table 5.1, is that the binuclear palladacycles were more active (i.e. 
have lower IC50 values) than the mononuclear palladacycles. Although similar studies by da 
Rocha et al. and Higgins et al, showed that mononuclear palladacycles showed significantly lower 
IC50 values than the binuclear forms, this improvement in activity was accompanied by, and 
potentially as a result of, enhanced solubility [38;39]. Based on these and other reports, the 
solubility of the complexes in DMSO and the ability of the complexes to tolerate water (solubility 
in a mixture of water/DMSO) were compared. No direct correlation between the solubility and the 
activity was observed. Since mononuclear and binuclear palladacycles were being compared, the 
concentration of palladium present may also have had an effect on the activity, thus leading to 
enhanced activity with increasing metal concentration, especially in the case of the binuclear 
palladacycles. However, when the concentration plots were compared, it was observed that even 
at half of the IC50 value concentration, the binuclear palladacycles were more active than the 
mononuclear palladacycles. These findings agree with results reported in the literature and 
discussed in Chapter 4, where examples of binuclear and polymetallic species were shown to be 
more effective as anti-cancer agents. This enhanced activity is possibly due to improved 
electrostatic interactions when two or more metal centres are present and the formation of flexible 
DNA adducts, as explained in Chapter 4. 
Closer inspection of the mononuclear series showed that although these complexes were not as 
active as the binuclear complexes, C2, C3 and C5 exhibited IC50 values of less than 20 μM, which 
is still significant, as the IC50 values of cisplatin are approximately 19.6 μM for the MCF7 cell line 
and 43.5 μM for the MDA-MB231 cell line [40;41]. Thus, although these compounds are not as 
effective as AJ5 and the other binuclear complexes reported here, they are as and in some cases 
more effective than cisplatin. Importantly, these mononuclear palladacycles are also more active 
against the MDA-MB231 cell line (lower IC50 values obtained), which, from the IC50 values for 
cisplatin, is the more resistant cell line. This suggests that these compounds could be potential 
alternatives in cisplatin-resistant cell lines. 
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AJ5 0.18 ± 0.048 0.19 ± 0.015 4.38 57 
C1 >20 >20 8.32 66 
C2 19 ± 1.0 17 ± 1.6 1.91 72 
C3 11 ± 1.9 7.5 ± 1.0 2.34 72 
C4 inactive >20 6.72 69 
C5 16 ± 5.3 7.6 ± 3.5 12.3 49 
C6 >20 inactive 10.6 68 
C7 inactive inactive 0.459 57 
C8 >20 inactive 6.32 58 
BC1 2.7 ± 0.21 2.2 ± 0.19 6.32 62 
BC3 5.8 ± 0.28 5.0 ± 0.075 2.02 78 
BC4 inactive inactive 57.2 91 
BTC1 2.1 ± 0.21 2.5 ± 0.13 2.85 28 
BTC2 0.49 ± 0.02 0.58 ± 0.012 32.6 76 
BTC3 2.5 ± 0.26 2.3 ± 0.19 76.0 54 
BTC4 inactive inactive 53.7 98 
*Note that the IC50 values reported here are a statistical average and were not read directly from the representative 
MTT assay graphs in Figures 5.10 and 5.11. 
 
In contrast to the mononuclear complexes, the binuclear complexes do not appear to exhibit any 
significant selectivity between the two cell lines based on the data in Table 5.1. However, these 
compounds were far more active, with IC50 values well below those achieved with cisplatin and 
the mononuclear compounds, but not as low as the values reported for AJ5. Furthermore, the 
tethered compounds (BTC1-BTC4) do not appear to have significantly different activities to the 
unsubstituted compounds, despite the presence of the hydrophilic tether. The variation in activity 
can be correlated with the bisphosphine moiety instead. The results in Table 5.1 clearly show that 
dppe is the optimal bisphosphine ligand for these compounds, as both AJ5 and its tethered 
analogue, BTC2, are the most active compounds by quite a significant margin. The dppm and 
dppp compounds which differ from dppe by only one methylene group, have significantly higher 
IC50 values while the dppf analogues were found to be inactive. The inactivity of the dppf 
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compounds can be explained in terms of their solubility in the test medium, as both BC4 and 
BTC4 are highly soluble in DMSO (>50 mg/mL) and polar organic solvents, but they are 
completely intolerant of water, instantly precipitating upon addition of aqueous medium. 
Based on the IC50 values, further studies were carried out on the best/most representative 
palladacycle in each of the three series, C2 for the mononuclear compounds, AJ5 for the 
unsubstituted binuclear series and BTC2 for the tethered binuclear series. The choice of C2 over 
C3 for the mononuclear palladacycles was based on the instability of C3, as the latter compound 
tends to be slightly unstable. Furthermore, the next most active mononuclear palladacycle is C5; 
however, this is a para-substituted species, whilst the rest of the complexes in the series of ortho-
substituted. Therefore, C2, was selected as the most representative complex for the mononuclear 
series. 
 
5.2.1.2 Western blot assays 
Once the IC50 values were determined and the most promising compounds identified, Western 
blot assays were then used to determine how the active palladacycle complexes bring about the 
growth inhibition as determined by the MTT assay. Previous data showed that AJ5 induces both 
DNA damage and apoptosis [42]. The Western blot results for C2 and BTC2 are shown in Figures 
5.12 and 5.13. 
 
Figure 5.12: Western Blot showing γ-H2AX for C2 and BTC2, where UT = untreated. 
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Figure 5.13: Western Blot showing cleaved PARP for C2 and BTC2, where UT = untreated. 
 
As discussed in the introduction, the most important proteins which are employed as markers for 
potential anti-cancer drugs are γ-H2AX, which, if present, is an indication of DNA damage and 
PARP, which if cleaved, is an indication that apoptosis has been induced. In order to allow for 
relative quantification of the proteins being detected, a loading control, P38, was used to ensure 
that loading discrepancies are not interpreted as drug-induced changes. 
Figure 5.12 shows that there is little to no γ-H2AX for the untreated cells. This is expected, as  
γ-H2AX is a DNA damage response agent which gathers at the site of DNA double-strand breaks 
[42]. Treatment of the cells with C2 and BTC2 for 24 and 48 hours, respectively, show a significant 
amount of γ-H2AX. The results match those obtained for AJ5 [42]. 
Figure 5.13, shows the presence of PARP for both the untreated and treated cells at 0 and 24 
hours and little to no cleaved PARP. Drug-induced apoptosis leads to increased amounts of 
cleaved PARP, the molecular marker of apoptosis [42]. The presence of cleaved PARP (86 KD) 
in the cells after treatment with C2 and BTC2 for 24 hours indicates that both palladacycles induce 
apoptosis. Again, these data match that obtained for AJ5 [42]. The induction of apoptosis is 
preferable to necrosis, an alternative form of cell death. Necrosis is a detrimental mode of cell 
death, leading to inflammation in the host and often it is fatal. Apoptosis or programmed cell death 
is favourable, as it does not cause undesired negative effects and is usually beneficial to the host. 
Thus, making the mode of cell death caused by these palladacycles suited to their application as 
potential anti-cancer agents. 
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5.2.2 DNA binding studies 
The in vitro studies above show that not only are these palladacycles active as anti-cancer agents, 
but they induce both DNA damage and apoptosis. Thus, DNA binding studies were performed to 
probe these interactions further in order to gain insight and understanding into the activity 
demonstrated above. 
 
5.2.2.1 Agarose gel electrophoresis 
Electrophoresis was employed to determine whether the palladacycles cause DNA damage. 
Changes in the electrophoretic mobility of the various forms of plasmid DNA are considered to be 
evidence of metal-DNA binding [43]. Using the protocols reported by Frik et al. and Albert et al. 
[31;43], an assay was developed and the selected palladacycles along with cisplatin were 
evaluated. 
Initially, samples of both the mono- and binuclear palladacycles were prepared at the following 
three palladium concentrations: 10, 100 and 200 µM. The DNA was added and the concentration 
was kept constant at 0.4 µg/sample. The percentage solvent used for dissolution of the 
compounds (DMSO for palladacycles and saline for cisplatin) was also kept constant for all 
samples. Control samples of plasmid DNA with the same solvent system as for the compound-
containing samples were also prepared to ensure that the changes observed are due to complex-
DNA interaction and not solvent-DNA interaction. Samples were incubated overnight, after which 
loading dye was added and the gel was loaded and run. The gel was visualised by staining with 
ethidium bromide. Based on the initial results, another gel was run with a narrower concentration 
range (10-75 µM metal). The results of this study are shown in Figures 5.14 and 5.15  
(10-200 µM) and 5.16 and 5.17 (10-75 µM). 
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Figure 5.14: Interaction of pBluescript plasmid DNA (0.4 µg) in buffer (lane 3) and DNA in DMSO/buffer (lane 4) with 
increasing concentrations of compounds cisplatin, C2, AJ5 and BTC2. Gel stained with ethidium bromide stain (15 µL in 100 
mL 1x TBE buffer) after running. Lane 1: λ marker. 
 
 
Figure 5.15: More detailed depiction of gel, where all lanes contain DNA, as well as the components listed, unless otherwise 
stated. a) Lane 3: Saline. Lane 5: 200 µM (no DNA). Lane 6: 10 µM. Lane 7: 100 µM. Lane 8: 200 µM. b) Lane 4: DMSO. Lane 9: 
200 µM (no DNA). Lane 10: 10 µM. Lane 11: 100 µM. Lane 12: 200 µM. c) Lane 4: DMSO. Lane 13: 200 µM (no DNA). Lane 14: 
10 µM. Lane 15: 100 µM. Lane 16: 200 µM. d) Lane 4: DMSO. Lane 17: 200 µM (no DNA). Lane 18: 10 µM. Lane 19: 100 µM. 
Lane 20: 200 µM. 
a. Cisplatin b. C2 c. AJ5 d. BTC2 
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Figure 5.16: Interaction of pBluescript plasmid DNA (0.4 µg) in buffer (lane 3) and DNA in DMSO/buffer (lane 4) with 
increasing concentrations of compounds cisplatin, C2, AJ5 and BTC2. Gel stained with ethidium bromide stain (15 µL in 100 
mL 1x TBE buffer) after running. Lane 1: λ marker. 
 
 
Figure 5.17: More detailed depiction of gel, where all lanes contain DNA, as well as the components listed. a) Lane 3: Saline. 
Lane 5: 10 µM. Lane 6: 25 µM. Lane 7: 50 µM. Lane 8: 75 µM. b) Lane 4: DMSO. Lane 9: 10 µM. Lane 10: 25 µM. Lane 11: 50 
µM. Lane 12: 75 µM. c) Lane 4: DMSO. Lane 13: 10 µM. Lane 14: 25 µM. Lane 15: 50 µM. Lane 16: 75 µM. d) Lane 4: DMSO. 
Lane 17: 10 µM. Lane 18: 25 µM. Lane 19: 50 µM. Lane 20: 75 µM. 
a. Cisplatin b. C2 c. AJ5 d. BTC2 
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From Figure 5.14 and 5.15, it is clear that the palladacycles induce changes in the DNA; thus, it 
was concluded that all of the palladacycles tested bind to and damage the DNA [43]. Furthermore, 
these gels clearly show that the palladacycles induce far more significant changes in the DNA 
than cisplatin. Figures 5.16 and 5.17 show that the mononuclear palladacycle, C2, exhibits slightly 
different electrophoretic behaviour to the binuclear palladacycles, AJ5 and BTC2, based on the 
trends observed in the electrophoretic mobilities of the three forms of DNA. AJ5 and BTC2 also 
show distinctly different behaviour to cisplatin. Unlike cisplatin, both C2 and AJ5 showed 
precipitated DNA in the wells at higher concentrations. This suggested the formation of insoluble 
aggregates by condensation of the DNA. Electrostatic forces are often the driving force behind 
the formation of these aggregates [44;45]. Hoechst 33258-DNA aggregation (Figure 5.18) is an 
example of this process, taken from the literature [44]. 
 
Figure 5.18: Atomic force microscopy (AFM) images of (a) 1.5 µM Hoechst 33258-DNA complex showing random free 
complexes and (b) 60 µM Hoechst 33258-DNA complex showing condensed aggregate [44]. 
 
Figures 5.15a and 5.17a show the changes induced by cisplatin. Initially, the oc and ccc bands 
are retarded, whilst the linear fragment migrates slightly faster through the gel. The disappearance 
of the ccc band (Figure 5.17a, lane 7 and 8) is actually retardation, observed as streaking, until 
the ccc band coalesces with the oc and linear bands. At higher concentrations (Figure 5.15a, lane 
7 and 8), the ccc band migrates slightly faster through the gel. This is normally associated with a 
more condensed form of the DNA which can migrate through the gel faster than the control DNA 
in lane 3. This more condensed form of DNA is positively supercoiled DNA, which has a left-
handed supercoil. These data agree with literature findings, such as those discussed in the 
introduction, where the interaction of cisplatin with plasmid DNA was found to uncoil DNA at low 
concentrations but increases the extent of supercoiling of the DNA (recoil DNA with opposite 
handedness) at higher concentrations [31;43]. 
Lower concentration data for the mononuclear palladacycle, C2, show retardation and streaking 
of the oc band, whilst the linear band migrates slightly faster and becomes broader (Figure 5.17b, 
lane 12). The ccc band becomes more feint and migrates slightly faster, however, the change in 
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migration is minimal. The observed retarding (Figure 5.17b, lane 10-12) followed by increased 
electrophoretic mobility (Figure 5.15b, lane 10 and 11) of the oc band corresponds to unwinding 
of the DNA followed by the induction of positive (left-handed) supercoiling. Thus, as the 
concentration increases, the DNA is unwound and rewound tighter with a left-handed helix, thus 
allowing it to migrate through the gel faster [31;34;43]. Furthermore, this left-handed supercoiled 
DNA could correspond to Z-form DNA. This is an unfavourable form of DNA which has opposite 
handedness to normal B-form DNA (right-handed helix) and is more compact [46], explaining the 
ability to migrate through the gel faster than B-form DNA. Notably, C2 influences the oc band the 
most whilst cisplatin influenced the ccc band. This could be due to the size of the complexes, as 
the larger palladacycle structure may not be able to interact with the tightly coiled ccc plasmid. 
Higher concentration data for C2 (Figure 5.15b) show streaking and an increase in the 
electrophoretic mobility of the ccc band (lane 11). Eventually, no bands were discernible aside 
from a feint streak (lane 12). At lower concentrations, C2 appears to interact with DNA in a slightly 
different mode to the binuclear palladacycles, however, at higher concentrations, the 
palladacycles all exhibit the same trends. We propose that C2 exhibits the same type of interaction 
with DNA as the binuclear palladacycles, just not to the same extent (possibly due to the 
mononuclear nature of the complex). 
The binuclear palladacycles, AJ5 and BTC2, show similar trends to each other at all 
concentrations. The lower concentration data (Figures 5.17c and 5.17d) show increased 
electrophoretic mobilities for all of the bands, to a lesser or greater extent, with the degree of band 
fading becoming more obvious with increasing concentration; however, no initial unwinding of the 
DNA was observed. The higher concentration data (Figure 5.15c and d) show feint streaking 
(Figure 5.15c, lane 15) or no visible DNA (Figure 5.15c, lane 16 and Figure 5.15d, lane 19-20). 
The increased electrophoretic mobilities correspond to increased supercoiling of the DNA forms, 
making the fragments more compact and allowing easier passage through the gel [34]. 
The observed streaking and absence of observable DNA bands can be related to severe damage 
which can possibly be accounted for by a number of processes, viz. the formation of single strand 
DNA (ssDNA) to which the ethidium bromide stain cannot bind, competitive binding of the 
complexes and ethidium bromide to double-stranded DNA which could lead to the palladacycles 
saturating the ethidium bromide binding sites and preventing the stain from binding, loss of the 
3D superstructure of the DNA or even complete destruction of the DNA [31;47-49]. 
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To conclude, the agarose gel electrophoresis DNA binding assay showed that the palladacycles 
interact with DNA by a mode different to that of cisplatin. The complexes induced DNA 
aggregation which, based on literature, is most likely driven by electrostatic forces. Furthermore, 
the induction of positive supercoiling was observed. The tightly coiled DNA with left-handed 
helicity could correspond to Z-form DNA. Finally, the fading/disappearing DNA bands suggested 
conversion of the DNA to a form that cannot be stained by ethidium bromide, such as ssDNA or 
DNA that has lost its 3D superstructure or possibly been completely destroyed. Alternatively, there 
could be competitive binding of the palladacycles with ethidium bromide, such that the 
palladacycles saturate the ethidium bromide binding sites and consequently prevent staining of 
the DNA. 
To investigate the interactions of these complexes with DNA further, some spectroscopic 
techniques were employed. 
 
5.2.2.2 UV-Vis spectroscopy 
Generally, DNA binding studies by UV-Vis spectroscopy are carried out as absorbance titrations, 
where either the metal or DNA concentrations are kept constant while the other component is 
varied. We started out employing assays which had previously been utilised for the evaluation of 
DNA binding studies of metal compounds, such as the methods employed by Tarushi et al. and 
Cheng-Yong et al., however, these methods proved to be ineffective in the case of our compounds 
[16;50]. These interactions are usually monitored at a wavelength where only the DNA or the 
compound absorbs. Unfortunately such a wavelength did not exist for these novel palladacycles 
as the spectra of these compounds overlap with that of DNA. For this reason, many of our initial 
attempts failed, accompanied by the low solubility of the complexes, which necessitated the use 
of at least 10% DMSO to keep the compounds in solution. Inconclusive data was obtained or no 
apparent DNA binding was observed, which we knew could not be the case, based on the results 
of the Western blot assays and the electrophoresis study of DNA binding discussed earlier. 
While searching the literature, a less commonly employed method reported by Aslanoğlu and Öge 
for their work on the interaction of norepinephrine with DNA was discovered [51]. This method 
allowed for simple comparison and interpretation of the results, as it compares the summed 
absorbance obtained from pure compound and pure DNA solutions measured separately, where 
there is no interaction, to the absorbance of the solution containing a mixture of DNA and the 
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compound, where, it has already been proven that there is an interaction. Thus, any changes 
observed in the spectra are due to interaction of the compound with the DNA [51]. 
Since these DNA binding protocols are new to the laboratory and the method employed is not 
widely reported, it was decided to test the method using a known DNA binding compound as a 
model compound to ensure that the method is viable and that the DNA employed in the absence 
of a binding agent is not being denatured as a result of experimental conditions employed. The 
compounds also served as models for the type of DNA binding. Ethidium bromide, an intercalator 
[52], methylene blue, a semi-intercalator and electrostatic binder [53] and methyl green, a major 
groove binder [54] were included as references. The results for these experiments are shown in 
the appendix (Figures A3.1-A3.3) and will not be discussed unless pertinent to the interpretation 
of the interaction of the palladacycles with DNA. However, from the data it was ascertained that 
the assay is viable and that results resembling those reported in the literature, could be obtained. 
The DNA binding experiments were then carried out using C2, AJ5 and BTC2 with cisplatin, as 
a control for covalent binding. AJ5 was used as a benchmark for the novel complexes, as well as 
being representative of the unsubstituted binuclear series, whilst C2 and BTC2 were the 
representative compounds for the mononuclear and tethered binuclear series, respectively. The 
results are shown in Figures 5.19-5.22. Note that the samples containing both DNA and 
compound are denoted in the legends as DNA_Compound x, where x is the micromolar metal 
concentration. The spectra which represent the summed absorbance obtained from pure 
compound and pure DNA solutions measured separately, are denoted in the legends as  
(DNA) + (Compound x), where x is again the micromolar metal concentration. Note that blue 
arrows have been included on the graphs to highlight the changes observed due to DNA binding 
interactions. 
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Figure 5.19: UV-Vis spectra of cisplatin interaction with DNA and the summed absorbances of pure cisplatin and pure DNA at 




Figure 5.20: UV-Vis spectra of C2 interaction with DNA and the summed absorbances of pure C2 and pure DNA at various 
concentrations. Inset: Absorbance spectra of C2 (various concentrations) and DNA. 
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Figure 5.21: UV-Vis spectra of AJ5 interaction with DNA and the summed absorbances of pure AJ5 and pure DNA at various 
concentrations. Inset: Absorbance spectra of AJ5 (various concentrations) and DNA. 
 
Figure 5.22: UV-Vis spectra of BTC2 interaction with DNA and the summed absorbances of pure BTC2 and pure DNA at 
various concentrations. Inset: Absorbance spectra of BTC2 (various concentrations) and DNA. 
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For cisplatin, a hypochromic effect was observed. The summed spectra showed no change with 
increasing metal concentration, as cisplatin does not absorb in this region, whilst the samples 
containing both DNA and cisplatin showed a hypochromic effect. As expected, the sample with a 
higher concentration of cisplatin showed a larger hypochromic effect than the lower concentration 
sample. The extent of interaction with DNA (hypochromism) is greater than the change in 
absorbance due to varying metal concentration, as can be seen by comparing the change in 
absorbance between the 5 and 10 µM samples and the summed spectra. The samples 
experience a small change in absorbance due to increasing metal concentration (0.005 AU) 
compared to the overall hypochromic effect relative to the summed spectra (0.013 AU). This 
correlated to the strength of DNA-binding rather than the type, as it is well known that cisplatin 
forms covalent bonds with DNA. Furthermore, comparison of the cisplatin spectra with the known 
binders showed that none of the known binders exhibit hypochromism to this extent. 
All three palladacycles show the same effect in the UV-Vis spectra – hypochromism. In contrast 
to cisplatin, the degree of hypochromism is far less than the change in absorbance due to the 
changes in metal concentration. This suggests that these compounds do not bind as strongly to 
DNA. Thus, the binding observed here corresponds to the formation of weaker non-covalent 
bonds rather than the covalent bonds observed for cisplatin. Based on the literature, 
hypochromism is an indication of either groove or electrostatic binding [24;30;37;55]. This was 
confirmed by comparison with the spectra obtained for methylene blue and methyl green (Figures 
A3.2 and A3.3 in the appendix), where methylene blue, with intercalation and electrostatic 
interactions, showed hyperchromism and methyl green, with groove binding interactions, showed 
hypochromism. The reason for the observation of hyperchromism, rather than hypochromism for 
methylene blue, is that intercalation causes more significant changes in the structure of the DNA 
helix, which are then more easily detected by UV-Vis spectroscopy [53]. 
Both C2 and AJ5 showed a deviation from the hypochromic effect at higher concentrations. This 
was due to the formation of a precipitate at these high concentrations. Not only was this visible to 
the naked eye, during the experiment, but by recording the absorbance at 620 nm, non-zero 
absorbances were observed which were indicative of the presence of particles in solution [56]. 
The recorded data are shown in Table 5.2. 
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Table 5.2: Absorbances values recorded at 620 nm. 
Sample A620 (nm)* 
DNA 0 
C2 50 0 
C2 75 0 
C2 100 0.3 
C2 125 0.3 
DNA_C2 50 0 
DNA_C2 75 0 
DNA_C2 100 0 
DNA_C2 125 0.4 
AJ5 20 0 
AJ5 30 0 
AJ5 40 0 
AJ5 50 0.001 
DNA_AJ5 20 0 
DNA_AJ5 30 0 
DNA_AJ5 40 0 
DNA_AJ5 50 0 
*Non-zero absorbances are indicated in red text. 
The presence of a precipitate corresponds to the formation of insoluble aggregates, as observed 
in the electrophoresis data. Thus, the next step in this study was to try to determine if the DNA 
binding mode was groove- or electrostatic binding. Thus, CD spectroscopy was employed, as it 
is more sensitive to changes in the DNA structure than UV-Vis spectroscopy. 
 
5.2.2.3 CD spectroscopy 
Based on the success of the UV-Vis spectroscopy studies, the same method was employed for 
the CD spectroscopy studies. There were two reasons for selecting this method. Firstly, the 
method was used very successfully for the UV-Vis spectra and the Chirascan instrument used 
allowed for simultaneous recording of CD and UV-Vis data, thus, the two sets of UV-Vis data 
could be compared to ensure that the experiment was successful. Secondly, the sensitivity of this 
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technique is advantageous; however, the more complex results are far more difficult to 
understand and interpret. Thus, having the summed data for comparison with the data where 
there are various spectral changes due to interaction of the compound with DNA aids in the 
interpretation of the data. Furthermore, as stated in the protocol by Garbett et al., the spectra 
should be recorded at wavelengths where no signal overlap occurs, as overlapping signals make 
interpretation difficult, as the signals may result from an induced CD (ICD) spectrum or structural 
changes in the DNA [57]. 
The known DNA binding compounds, ethidium bromide, methylene blue and methyl green, were 
again included, to ensure that the method was effective. These results are shown in the appendix 
(Figures A3.4 – A3.6) and will not be discussed unless pertinent to the interpretation of the 
interaction of the palladacycles with DNA. From the data, it was ascertained that the assay works 
and that the literature trends could be replicated. 
The DNA binding experiments were then carried out on C2, AJ5 and BTC2 with cisplatin, as a 
control for covalent binding. AJ5 was used as a benchmark for the novel complexes, as well as 
being representative of the unsubstituted binuclear series, whilst C2 and BTC2 were the 
representative compounds for the mononuclear and tethered binuclear series, respectively. The 
results are shown in Figures 5.23-5.26. 
After the data were collected, it was confirmed that the compounds themselves do not have CD 
spectra. This was expected, as the compounds are achiral. Therefore, the summed spectra are 
not included in the results, as the spectra are the same as that of DNA on its own. As in the case 
of the UV-Vis spectroscopic studies, the samples containing both DNA and compound are 
denoted in the legends as DNA_Compound x, where x is the micromolar metal concentration. 
For cisplatin, there is an overall decrease in the intensity of the positive band (284 nm), which 
corresponds to a decrease in the base stacking. The negative band (244 nm) shows an increase 
intensity which corresponds to an increase in the helicity of the DNA [58;59]. The observed 
changes in the DNA signal intensities correspond a transformation of the DNA from the B→C 
form with increased helicity, as reported for cisplatin in the literature [59]. 
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Figure 5.23: CD spectra of cisplatin interaction with DNA at various metal concentrations. 
 
Figure 5.24: CD spectra of C2 interaction with DNA at various metal concentrations. 
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Figure 5.25: CD spectra of AJ5 interaction with DNA at various metal concentrations. 
 
Figure 5.26: CD spectra of BTC2 interaction with DNA at various metal concentrations. 
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Upon interaction of the palladacycles with DNA, there was a decrease in the intensity of both the 
positive and negative bands. The changes are more pronounced for C2 and BTC2 and in fact, 
these two complexes show fairly similar trends. In both cases there was a clear shift in the 
negative bands of C2 and BTC2, to higher wavelengths. The decreased intensity of both the 
positive and negative bands are an indication of decreased base stacking and helicity. At higher 
metal concentrations (50-125 µM), C2 and BTC2 showed CD spectra which have almost 
indiscernible positive and negative bands. Initially, these results were thought to be ambiguous, 
however, when considered with the lower concentration data, the results could most likely be 
correlated to a number of different possible effects, including the formation of ssDNA, a 
transformation in the DNA from B→Z form or the formation of achiral aggregates. 
Comparison of these results with those usually obtained for the known DNA binders appears to 
indicate that the same trends were observed as is the case for the known major groove binder, 
methyl green. Despite the similarity in the observed trends, the negative bands of the CD spectra 
for the interaction of the palladacycles (more specifically C2 and BTC2) with DNA showed a shift 
to higher wavenumbers, which was not the case for the groove binder, methyl green. Therefore, 
groove binding was unlikely as no shift in the negative band was expected. Furthermore, these 
compounds do not have the curved shape observed for reported groove binders (Figure 5.3). 
Since the electrophoresis results suggested the formation of aggregates, driven by electrostatic 
forces, and the UV-Vis spectra showed hypochromism which suggests either groove- or 
electrostatic binding, these palladacycles most likely bind to DNA through electrostatic 
interactions. 
Next, NMR spectroscopy was attempted with the hope of gaining further insight into the interaction 
of the palladacycles with DNA. 
 
5.2.2.4 Attempt to study DNA binding via NMR spectroscopy 
Based on the various analytical techniques explored above, it would appear that the palladacycles 
bind to DNA through weak non-covalent interactions and that at high metal concentrations, the 
formation of insoluble metal-DNA aggregates were observed. However, experiments to determine 
whether these weak interactions were groove or electrostatic in nature were inconclusive. Thus, 
NMR spectroscopy was employed in an attempt to gain greater insight into the nature of the weak 
interactions between the palladacycles and DNA. C6, the fluoro analogue, was selected for this 
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experiment, as it is one of the more soluble complexes (in DMSO), as well as affording the 
opportunity to monitor a second nucleus, the NMR active fluorine-19 nucleus (19F). 
19F and 31P NMR spectra were recorded for C6, the fluoro-analogue, with varying ratios of salmon 
sperm DNA. C6 was chosen, as it was one of the more soluble complexes and allowed the 
recording of spectra for both nuclei. All samples were prepared in 20% D2O in DMSO-d6 to ensure 
that C6 remained in solution. DNA:metal ratios of 1:10, 1:4, 1:2 and 1:1 were investigated. 
All 19F NMR spectroscopic signals were observed as broad singlets. The chemical shifts are 
recorded in Table 5.3. The 31P NMR spectra are shown in Figures 5.27-5.29. 
Table 5.3: 19F NMR spectroscopic data. 
Sample (DNA:C6) 19F NMR signal shift (ppm) 
DNA No signal 






No changes were observed in the 19F NMR signal of C6, which was observed as a broad signal 
at -109.5 ppm. No 19F-1H coupling was observed, however, this was attributed to the very low 
concentration of the sample. 
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Figure 5.27: 31P NMR spectra of C6 (spectrum 1), DNA (spectrum 2) and various DNA:C6 ratios (spectra 3-6). 
 
Figure 5.28: 31P NMR spectra of C6 (spectrum 1), DNA (spectrum 2) and various DNA:C6 ratios (spectra 3-6) in the range of 0.5 
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Figure 5.29: 31P NMR spectra of C6 (spectrum 1), DNA (spectrum 2) and various DNA:C6 ratios (spectra 3-6). Only the C6 signal 
is shown. Inset of 1:1 DNA:C6 in the range of 40-45 ppm showing broad second signal. 
 
The 31P NMR spectra showed no dramatic shifts in the DNA and C6 signals, however, a new 
broad signal started appearing at approximately -41 ppm, just downfield of the C6 signal at a 1:1 
ratio of DNA to C6 (Figure 5.27). Closer inspection of the DNA signals showed an overall upfield 
shift of both signals (a singlet at approximately -0.3 ppm and a multiplet at -0.80 - -0.65 ppm) from 
the free DNA to the metal-DNA complex. Increasing the metal led to an upfield shift of these 
signals (Figure 5.28). The complex 31P signal broadened, shifted slightly downfield with increasing 
DNA concentration (Figure 5.29). A new signal starts appearing at -41.25 ppm with increasing 
DNA concentration (Figure 5.29 inset). 
Considering the 31P NMR signals for both the DNA and metal complex, the slight changes 
observed in the NMR spectra could possibly suggest very weak interactions between the 
palladacycle and DNA, however, the formation of a new 31P signal in the region of the complex 
signal confirms that the DNA does interact with and change the complex, leading to the formation 
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In order to ascertain the mode of DNA binding, all the DNA binding study data must be taken 
together. The evaluation of the data is discussed in the section below. 
Electrophoresis showed that the palladacycles bind to the DNA by a mode different to that of 
cisplatin. The mononuclear compound, C2, exhibited a slightly different electrophoretic behaviour 
to that of the binuclear compounds, AJ5 and BTC2, at lower metal concentrations, whilst all three 
palladacycles showed fairly similar trends at higher metal concentration. The palladacycles were 
thought to induce positive supercoiling, so that the DNA has a left-handed supercoil and migrates 
through the gel faster than the DNA control [34]. This left-handed supercoiled DNA could 
correspond to Z-form DNA which has the opposite handedness to normal B-form DNA and is 
more compact. The presence of precipitated DNA in the wells at higher concentrations suggested 
the formation of insoluble aggregates by condensation of the DNA helix through electrostatic 
interactions [44;45]. Finally, the observed streaking and absence of observable DNA bands at 
higher metal concentration was attributed to possible competitive electrostatic binding to DNA 
(between the complex and ethidium bromide stain), loss of 3D superstructure and/or complete 
DNA destruction. 
The formation of smaller, more flexible ssDNA was unlikely, since C2 and AJ5 showed 
precipitation of material in the wells which suggested the formation of large insoluble aggregates. 
The UV-Vis spectroscopic data (reported in Section 5.2.2.2) were used to verify this, as the 
conversion from double strand DNA (dsDNA) to ssDNA is expected to be observed as a 40% 
hyperchromic shift at 260 nm in the UV-Vis spectrum. The UV-Vis spectra did not show any such 
hyperchromic effects, thus, ssDNA formation was ruled out. 
Next, possible competitive electrostatic DNA binding was considered and thought to be 
improbable, as ethidium bromide is an intercalator and the UV- and CD spectroscopic data did 
not show the same DNA binding trends as ethidium bromide (Figures A3.1 and A3.4). However, 
literature reports showed that ethidium bromide has a secondary electrostatic binding site [48;49]. 
Therefore, it was possible that the palladacycles could block the electrostatic binding site, thus 
lowering the fluorescence and leading to the observed band fading. 
Loss of the 3D superstructure and or complete destruction of the DNA could also explain the 
absence of observable DNA, as these changes to the structure of the DNA will prevent ethidium 
bromide from binding and visualising the DNA. Furthermore, the data obtained here resembles 
the data for Reference compound 1 reported by Albert et al. [31] and discussed in Section 5.1.3 
of the introduction (Figure 5.5). The active diimine palladacycle showed no observable DNA at 
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high complex concentrations. This could possibly be attributed to destruction of the DNA. 
However, for the palladacycles evaluated in this chapter, the NMR spectroscopy data showed 
only slight changes in the DNA signals upon interaction with the palladacycles at various 
DNA:palladacycle ratios. Therefore, loss of 3D structure and complete destruction of the DNA are 
unlikely. 
Furthermore, UV-Vis spectroscopic data showed that all three palladacycles induce the same 
effect in the absorbance spectra – hypochromism. Based on the literature, hypochromism is an 
indication of either groove or electrostatic binding. Additionally, both C2 and AJ5 showed a 
deviation from the hypochromic effect at higher concentrations. This was due to the presence of 
a precipitate. The presence of a precipitate corresponds to the formation of insoluble aggregates, 
as observed in the electrophoresis data. 
Thus, from the electrophoresis and UV-Vis spectroscopy data, the palladacycles could possibly 
induce the following DNA binding types: Z-form DNA, insoluble aggregates, competitive 
electrostatic binding forces and groove binding. The formation of ssDNA and loss of 3D structure 
and/or complete destruction of the DNA were ruled out. 
The CD spectroscopy, like UV-Vis spectroscopy, showed similar data for all three palladacycles. 
Upon interaction with DNA, there was a decrease in the intensity of both the positive and negative 
bands of the CD spectra of DNA, which indicated decreased base stacking and helicity. The 
changes were more pronounced for C2 and BTC2 and there was also a clear shift in the negative 
bands, to higher wavelengths. The data suggested possible formation of ssDNA, a transformation 
in the DNA from B→Z form or the formation of achiral aggregates. 
From the electrophoresis and UV-Vis spectroscopy data, ssDNA formation was ruled out. Thus, 
only a transformation in the DNA from B→Z form or the formation of achiral aggregates were 
considered. 
Z-form DNA has an inverted CD spectrum of B-form DNA, due to opposite handedness of the B- 
and Z-form helices [34;55]. So the CD spectrum of Z-form DNA would exhibit a positive band at 
approximately 260 nm and a negative band at approximately 290 nm [60]. Although the CD 
spectra show a shift in the negative band to higher wavenumbers, no shift in the positive band 
was observed. Despite the decreasing band intensities with increasing metal concentration, a 
complete B→Z form transition was not observed, however, the electrophoresis data also 
suggested the possible formation of Z-form DNA. 
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Finally, the formation of achiral aggregates was quite possible, as these aggregates would not 
have a CD spectrum. The loss of band intensities with increasing metal concentration could 
correspond to the formation of achiral aggregates. More importantly, the formation of insoluble 
aggregates was observed in both the electrophoresis and UV-Vis spectroscopic data. 
Finally, the 31P NMR spectra showed subtle shifts in the DNA signals and no clear changes in the 
complex signal, however, a new signal starts appearing at -41.25 ppm with increasing metal 
concentration. Taken together, these data suggest very weak interactions between the 
palladacycle and DNA as very little change was observed in the NMR spectra. 
Thus, from all the DNA binding study data, discussed in Sections 5.2.2.1-5.2.2.4, it was concluded 
that the palladacycles induce the formation of insoluble aggregates. Additionally, a B→Z form 
transformation in the DNA is possible. Of the possible groove and electrostatic binding forces, the 
most likely driving force behind the formation of insoluble aggregates and a B→Z form transition 
is electrostatic binding. 
Since the palladacycles are neutral, the nature of the proposed electrostatic interaction is 
uncertain, however, from the NMR experiments, it is clear that PTA ligand dissociation does not 
occur, as no signal for the free phosphine at -102 ppm is detected when C6 is examined in 
solution. Thus, it is proposed that the Pd-Cl bond undergoes hydrolysis to form the aquated 
species, which is cationic in nature (Figure 5.30), however, further studies are required to confirm 
this structure. Similar hydrolysis processes are reported throughout the literature for platinum anti-
cancer agents [59]. 
 
Figure 5.30: Proposed aquated species which is cationic in nature. 
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5.2.3 Quantitative DNA binding studies 
In an attempt to establish whether the DNA binding constants could be determined, an alternative 
UV-Vis spectroscopic assay was investigated. The work carried out by Yang et al. [61] was used 
as a starting point to develop the assay. 
Absorption titrations of the palladacycles, C2, AJ5 and BTC2 were carried out in 10% DMSO in 
tris-HCl buffer using a fixed palladium concentration (10 µM). Aliquots (2-10 µL) of DNA stock 
solution (1.0 mM) were added to both the sample and reference (10% DMSO in buffer) cuvettes 
in order to eliminate the absorbance of the DNA. Samples were mixed by inversion and then 
recorded after a 5 minute incubation period. According to literature, the titrations should be 
continued until the absorbance remains unchanged for four titrations, however, in the case of 
these palladacycles precipitation was observed before this point of binding saturation was 
achieved. Unfortunately, the precipitate caused interference with the absorbance trends and the 
experiment had to be aborted. Figure 5.31 is a representative graph of the data obtained. 
 
Figure 5.31: UV-Vis spectra of AJ5 titrated with DNA at various concentrations. The [DNA]:[M] ratio represented with black 
dots indicates the ratio at which precipitation was observed. 
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Based on the inability to obtain a point of DNA binding saturation due to the low solubility of the 
complexes and/or the formation of insoluble DNA aggregates, binding constants could not be 




In vitro studies show that the binuclear palladacycles were far more active than the mononuclear 
palladacycles. This was most likely due to the low solubility of the mononuclear complexes. The 
significantly lower IC50 values of the binuclear palladacycles were attributed to improved solubility 
and the ability to form flexible adducts with DNA. Furthermore, the presence of two metal centres 
could result in improved electrostatic interactions with the DNA. Interestingly, the mononuclear 
complexes were more cytotoxic towards human breast adenocarcinoma MDA-MB231 (triple 
negative) cells which are notoriously difficult to treat, whilst the binuclear complexes showed no 
selectivity between the different cell lines. Western blot assays showed that the palladacycles 
induce DNA double strand breaks and apoptosis. 
DNA binding studies using electrophoresis and various spectroscopic techniques suggested that 
all of the palladacycles interact with DNA in a similar manner. The data obtained from these 
studies showed that the palladacycles bind to DNA in a mode different to that of cisplatin. The 
data also showed that the palladacycles induced the formation of insoluble aggregates and that 
the palladacycles possibly induce a B→Z form transition in the DNA. Furthermore, considering 
the data obtained and the reported literature trends, the results of this study suggested that the 
most likely form of DNA binding present is an electrostatic binding mode. Since the palladacycles 
are neutral, the nature of the proposed electrostatic interaction is uncertain, however, from the 
NMR data, it is clear that PTA ligand dissociation can be ruled out. Furthermore, hydrolysis of the 
Pd-Cl bond was proposed, as this process would result in a cationic species, but further studies 
are required to probe this experimentally. 
 
5.4 Materials and Methods 
Calf thymus DNA (CT DNA), ethidium bromide and trisodium citrate, 
tris(hydroxymethyl)aminomethane were obtained from Sigma Aldrich. Salmon sperm DNA 
solution was obtained from Thermo Scientific. Boric acid and DMSO were obtained from Merck. 
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Sodium chloride and bromophenol blue were obtained from Saarchem. Glycerin was obtained 
from BARRS Industrial Enterprises. Methylene blue was obtained from Riedel de Haan and 
methyl green was obtained from Dr. Theodore Schuchardt. Agarose gel was obtained from Bio-
Rad, pBluescript cultures and EcoR 1+Hind III λ marker were obtained from the Microbiology 
department at Stellenbosch University. Distilled water was used to prepare buffers for DNA 
binding. All buffers were prepared according to standard protocols. 
In vitro assays were carried out at the Tbox laboratory at the UCT Medical School, with the 
assistance of Prof. Prince and her students. Human MCF7 breast adenocarcinoma (estrogen 
receptor positive) cells were maintained in RPMI 1640 medium and human breast 
adenocarcinoma MDA-MB231 (triple negative) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM). Both were obtained from Highveld Biological, Lyndhurst, South Africa. 
Both media were supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
μg/mL streptomycin and 1 mM sodium pyruvate. Cells were maintained at 37˚C in a 5% CO2 – 
95% air-humidified incubator. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyyltetrazolium bromide 
(MTT) assay was obtained from Roche, USA. Hybond ECL membranes were obtained from 
Amersham Biosciences. The primary antibodies PARP ½ (sc-7150) and phospo-H2AX (#2577) 
were obtained from Santa Cruz, California, USA, whilst the p38 antibody (M0800) was obtained 
from Sigma Aldrich. Antibody-reactive proteins were visualised using the chemiluminescence 
reaction (ECL) detection system from Thermo Scientific, Hudson, NH, USA. 
Physiological saline solution, 1x TBE buffer, tris-HCl buffer (pH 7.2) [62], 1x loading dye and 
ethidium bromide stain (10 mg/mL) were prepared according to standard protocols. Plasmid DNA 
concentration was determined using a NanoDrop ND1000. Agarose gel electrophoresis was 
carried out in a horizontal midi gel apparatus system, from OMEG Scientific, connected to an 
Enduro 250V power supply. Photographs of the gel were taken in a dark room by UV light with a 
Fujifilm Finepix S2000HD camera. Photographs were processed using ImageJ 1.50b software 
[63]. A GBC UV/VIS 920 spectrometer was used to determine DNA concentration and UV-Vis 
spectra. Spectra were recorded in the range of 200-630 nm. A 10.00 mm path quartz cuvette was 
used with 300 nm.min-1/ 0.133 nm step size and 2 nm slit width. Simultaneous CD and UV-Vis 
spectra were recorded on a Chirascan-plus CD spectrometer. Spectra were recorded in the range 
of 200-400 nm. A 10.00 mm path quartz cuvette was used with a scan speed of 0.3 nm s-1, a step 
of 1 nm, response time: 0.3 s and spectral band width of 1.0 nm. Three accumulations were 
recorded for each sample. 
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Note that all DNA binding studies were carried out at metal concentrations and not complex 
concentrations, to ensure that the mononuclear and binuclear palladacycle data were 
comparable. 
 
In vitro studies 
Cytotoxicity (MTT) assay 
The complex solutions were prepared by dissolution in DMSO to obtain 5 mM stock solutions. 
Solutions were stored at room temperature for no more than a week. Human MCF7 breast 
adenocarcinoma cells in RPMI 1640 medium and human breast adenocarcinoma MDA-MB231 
cells in DMEM were seeded in 96-well plates at 3-6 x 10-3 cells per well. After 48 hours, the cells 
were treated with various concentrations of complex (0-1 μM) or the vehicle for 48 hours. The 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyyltetrazolium bromide (MTT) assay was then used, as 
described by the manufacturer’s instructions: 10 μL of MTT solution was added to each well. Well 
plates were then incubated at 37 °C for 4 h. This was followed by addition of 100 μL solubilisation 
buffer (10% SDS in 0.01 M HCl) and incubation overnight at 37 °C. Absorbance at 585 nm was 
then determined for each well and the mean cell viability was calculated as a percentage of the 
mean vehicle control. The experiments were performed in triplicate and the data were used to 
determine the half maximal inhibitory concentration values (IC50). 
 
Western Blot assays 
The complex solutions were prepared by dissolution in DMSO to obtain 0.1 and 0.2 μM stock 
solutions. Solutions were stored at room temperature for no more than a week. Human MCF7 
breast adenocarcinoma cells in RPMI 1640 medium were plated in 6 cm petri dishes at 6 x 105 
cells per plate. The cells were treated with the complex solutions for 24 or 48 hours. Cells were 
then lysed using whole cell lysis buffer (0.5 M tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol and 0.02% bromophenol blue). Samples were boiled for 10 minutes. The 
proteins were resolved using SDS/PAGE (8-15% gels) as required. They were then transferred 
to Hybond ECL membranes which were then incubated with primary antibodies against PARP ½ 
(sc-7150), phospho-H2AX (#2577) and p38 (M0800).Thereafter, the membranes were incubated 
with HRP-conjugated secondary antibodies (1:5000). The antibody-reactive proteins were 
visualised with a chemiluminescence reaction (ECL) detection system. 
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DNA binding studies 
Agarose gel electrophoresis 
High concentration gels 
pBluescript plasmid was isolated with a Zyppy plasmid isolation kit, following the product protocol. 
DNA concentration was determined and adjusted to 40 µg/mL with 1x TBE buffer. Stock solutions 
(34, 340 and 680 M) of palladacycles were prepared in DMSO and stock solutions of cisplatin 
were prepared in physiological saline solution and kept in the dark. Samples (15 µL) were 
prepared with constant DNA volume (10 µL) and the metal concentration was varied by adding 
the different stock solutions (5 µL) to obtain samples with final metal concentrations of 10, 100 
and 200 µM. Compound control samples were prepared with buffer (10 µL) and the highest metal 
concentration (5 µL 680 M stock), to ensure that compounds to not fluoresce. DNA controls were 
prepared with DNA stock (10 µL) and DMSO or saline (5 µL) to ensure determine the effect of 
these reagents on the DNA. All samples were incubated in the dark for 22 hours at 37 °C. 
Low concentration gels 
pBluescript plasmid was isolated with a Zyppy plasmid isolation kit, following the product protocol. 
DNA concentration was determined and adjusted to 32 µg/mL with 1x TBE buffer. For the high 
concentration gels, stock solutions (33, 83, 166 and 249 M) of palladacycles were prepared in 
DMSO and stock solutions of cisplatin were prepared in physiological saline solution and kept in 
the dark. Samples (20 µL) were prepared with constant DNA volume (12.5 µL) and the metal 
concentration was varied by adding the different stock solutions (6.25 µL) to obtain samples with 
final metal concentrations of 10, 25, 50 and 75 µM. DNA controls were prepared with DNA stock 
(12.5 µL) and DMSO or saline (6.25 µL) to ensure determine the effect of these reagents on the 
DNA. All samples were incubated in the dark for 22 hours at 37 °C. 
 
Agarose gel (0.800 g/100 mL) was prepared in 1x TBE buffer. Gel was allowed to set at room 
temperature for at least 1 hour. Loading dye (2 µL) was added to each sample. Samples were 
loaded and a λ marker was included. Gels were run for 3 hours at 80 V in 1x TBE buffer. The gel 
was then stained in 1x TBE buffer containing ethidium bromide stain (15 µL) for 15 min, followed 
by destaining in water for 5 min. Gels were then photographed under UV light (254 nm). 
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(Qualitative) UV-Vis spectroscopy 
Calf thymus DNA was reconstituted in tris-HCl buffer (pH 7.2) for 48 hours at room temperature. 
DNA concentration was determined spectrophotometrically, as described by Sigma, and adjusted 
to 0.5 mM with tris-HCl buffer. Stock solutions (0.5 mM or 1.25 mM) of palladacycles were 
prepared in DMSO and stock solutions of cisplatin were prepared in physiological saline solution 
and kept in the dark. Samples (4.0 mL) were prepared with constant DNA volume (0.4 mL) and 
the metal concentration was varied by adding different volumes of the stock solution (0.0 - 0.4 
mL) to obtain samples with final metal concentrations of 2.5-7.5 µM (cisplatin), 25-125 µM (C2) 
and 10-50 µM (AJ5 and BTC2). Solubilising agents were added in various quantities  
(0.0 – 1.0 mL) to ensure a constant percentage in all samples. Finally, buffer was added to bring 
the sample volume to a total of 4 mL. Compound control samples were prepared in the same way, 
no DNA was added. All samples were incubated in the dark for 1 hour at 25 °C. Samples were 
scanned and the data recorded for further processing. 
Attempted quantitative UV-Vis spectroscopy 
Calf thymus DNA was reconstituted as described above and its concentration adjusted to 1.0 mM 
with tris-HCl buffer. Stock solutions (0.1 mM metal) of palladacycles were prepared in DMSO. 
Samples (3.0 mL) were prepared with constant metal concentration (10 µM; 0.3 mL of 0.1 mM 
stock solution) and constant buffer volume (2.7 mL) to obtain samples with final metal 
concentrations of 10 µM. The DNA concentration was varied by adding different volumes of the 
stock solution (2-10 µL). All samples were mixed by inversion of the cuvettes and were then 
incubated in the cell holder for 5 minutes at 25 °C. Samples were scanned and the data recorded 
for further processing. 
 
CD spectroscopy 
Calf thymus DNA was reconstituted and the concentration was determined as for the UV-Vis 
spectroscopy assay. Samples (1.0 mL) were prepared as described above, however, the 
quantities were adjusted to obtain a final sample volume of 1 mL. All samples were incubated in 
the dark for 1 hour at 25 °C. Samples were scanned at 25 °C and the data recorded for further 
processing. 
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Attempted DNA binding study via NMR spectroscopy 
Salmon sperm DNA solution (10 mg/mL) was used as received. A stock solution of C6 in DMSO-
d6 (2 mg/mL) was prepared. Samples were prepared as 20% D2O in DMSO-d6 with a total volume 
of 1 mL. Samples were scanned at 25 °C and the data recorded for further processing. NMR (19F 
and 31P: 400 MHz) spectra were recorded on Varian NMR spectrometer at 273 K and chemical 
shifts are referenced relative to external standards. Trichlorofluoromethane (CFCl3) was used for 
the 19F NMR and 85% phosphoric acid (H3PO4) for 31P NMR. Chemical shifts (δ) and coupling 
constants (J) are reported in ppm and Hertz (Hz), respectively. 
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Conclusions and future work 
 
6.1 Concluding remarks 
Mononuclear and binuclear (unsubstituted and substituted) palladacycles, were designed and 
synthesised based on the structure and properties of AJ5 (Figure 6.1), a binuclear palladacycle 
with significant anti-cancer activity [1;2]. 
 
Figure 6.1: Promising palladacycle, AJ5. 
The mononuclear series of novel PTA-based palladacycles was synthesised and characterised 
successfully. Despite the fact that the complexes are mononuclear and have a water-soluble 
phosphine ligand, PTA, they were found to be insoluble in water and generally less soluble than 
AJ5 in organic solvents. Variable temperature 1H NMR spectroscopy showed that these 
palladacycles exhibit a reversible symmetric site-exchange of the methyls of the isopropyl groups 
via rotation of the 2,6-diisopropylaniline moiety about the N-C bond. This was confirmed by 
employing a computational model which showed that the experimental data lie within the 95% 
confidence limits. Slight deviations in the expected signal shifts were attributed to concentration-
dependent chemical exchange processes, of which dimerisation by imine ligand dissociation was 
supported by literature precedence and ESI-MS dimer fragments, and the formation of a non-
covalent dimer by PTA self-association was shown to be feasibly by a computational model of the 
aggregate. The ability of these species to undergo chemical exchange processes was linked to 
the tertiary phosphine ligand, PTA, specifically, its small cone angle and the nitrogen donor atoms. 
AJ5 
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Furthermore, the “ortho effect” was shown to account for the influence of the ortho-substituents 
on the free energy of activation. 
Two series of binuclear palladacycles with bridging bisphosphine ligands and in the case of the 
substituted series, an ethylene glycol-type tether, were successfully synthesised and 
characterised. As expected, the substituted complexes showed significantly improved solubility in 
organic solvents compared to the unsubstituted complexes and AJ5. However, in spite of the 
enhanced solubility in non-aqueous media, none of the binuclear palladacycles were water-
soluble. 
In vitro evaluation of the mono- and binuclear palladacycles was performed against mammalian 
breast cancer cell lines, MCF7 and MDA-MB231. These studies showed that most of the 
complexes are cytotoxic, with the binuclear palladacycles showing better activity than the 
mononuclear palladacycles. IC50 values of some of the palladacycles were better than those of 
cisplatin (below 20 μM) and the IC50 values for the substituted-binuclear palladacycle, BTC2 
(Figure 6.2), were found to be comparable to those of AJ5. The complexes were found to induce 
DNA damage and apoptosis. DNA binding studies were carried out on the most active 
palladacycle in each series to determine the mode of action. DNA binding studies by ultraviolet-
visible-, circular dichroism- and NMR spectroscopy suggest that all of the palladacycles bind to 
DNA in a mode different from cisplatin. The most likely mode of DNA binding was identified as an 
electrostatic binding mode. Thus, the formation of a cationic species was proposed to form via 
hydrolysis of the Pd-Cl bond (Figure 6.3), a commonly reported process for platinum anti-cancer 
agents. Additionally, attempts were made to determine the DNA binding constants of the 
palladacycles, however these quantitative studies were aborted, as the compounds were not 
suitably soluble. 
 
Figure 6.2: Modified palladacycle, BTC2. 
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Figure 6.3: Proposed cationic species which can bind to DNA through electrostatic interactions. 
 
In summary, a range of palladacycles with varying degrees of solubility and water-tolerance were 
design and synthesised successfully. A number of these palladacycles are more active, in vitro, 
than cisplatin, whilst BTC2, a binuclear dppe-bridged palladacycle with an ethylene glycol-type 
tether, exhibits comparable biological activity to AJ5 and was found to be more soluble than AJ5. 
Furthermore, the results from the in vitro assays were used to identify the most promising 
palladacycles in each of the three series and then employed these palladacycles in DNA binding 
studies in an attempt determine their mode of action. The most likely mode of action was 
determined to be an electrostatic DNA binding mode. 
 
6.2 Future work 
From the review in Chapter 1, entitled “Palladium and its complexes as potential anti-cancer 
agents”, it is clear that palladium complexes could provide viable alternatives to the current metal-
based anti-cancer drugs, both in terms of reduced toxicity and the ability to overcome cisplatin 
drug resistance. The literature provides a vast library of these palladium complexes, including 
some examples where the palladium complexes are significantly more active than cisplatin, yet 
not as toxic. Despite the overwhelming number of promising palladium complexes in the literature, 
there has been limited success with these complexes beyond the laboratory. This lack of 
advancement has been ascribed to the absence of data regarding the mode of action of these 
drugs. This need for more in-depth information justifies the ongoing research in this field. 
The aim of this project was to synthesise novel water-soluble palladacycles for testing as anti-
cancer agents. The approach employed was to impart enhanced water solubility to the palladium 
complexes by introducing hydrophilic functional groups on the aldehyde starting materials. 
Furthermore, the bridged palladacycles were cleaved with the hydrophilic tertiary phosphine, PTA 
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In terms of the latter aim, initially the use of the water-soluble phosphine, PTA, as a ligand was 
investigated, but this did not lead to any significant enhancement of water solubility of the 
complexes. In contrast to this, the incorporation of the hydrophilic ethylene glycol-type tether led 
to a considerable increase in solubility without significantly altering the biological activity of the 
compounds. However, complete water-solubility was not achieved. Comparison of the solubilities 
and biological activity of the palladacycles (Figure 6.4) allowed us to come to the following 
conclusions: The most soluble complexes (in DMSO), BC4 and BTC4, were completely inactive 
as they did not tolerate water well, whilst the most water tolerant (lowest % DMSO in water/DMSO 
mixture required to keep complex in solution) complex, BTC1, was also not the most active 
complex. Furthermore, comparison of the data for the mononuclear palladacycles show that C2 
and C3 are the most active biologically, yet both complexes have low solubility and low water 
tolerance. Similarly, AJ5 which has significant biological activity has low solubility, but better water 
tolerance. Contrastingly, BTC2 has high solubility but low water tolerance, yet its biological activity 
in on par with that of AJ5. These data confirmed that water-solubility is not the main factor 
controlling biological activity. 
From the literature, it is known that the lipophilicity of compounds influences tissue permeability. 
As reported by Garcia et al., tissue permeability of a compound affects the localisation of the 
compound in the targeted tissue and the capacity of the compound to bind to biomolecules, 
making it one of the most influential properties for biological activity. Therefore, the lipophilicity of 
the palladacycles should be determined and compared with the biological data to see if there is a 
correlation. The simplest method for determining the lipophilicity is by using a shake-flask method. 
The n-octanol/water partition coefficient (log Po/w) is measured and the higher the value, the more 
lipophilic the compound [3-5]. Should there be a correlation, the data can be used to improve the 
design of these palladacycles. 
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Figure 6.4: Biological activity and solubility trends of palladacycles, where palladacycles are grouped according to phosphine 
ligands. The mononuclear palladacycles are grouped in a black box, whilst the binuclear palladacycles are grouped in white 
boxes. For the solubility trends, dark blue represents solubility in DMSO and light blue represents water tolerance in 
water/DMSO mixtures 
 
Furthermore, the incorporation of alternative water-soluble moieties should also be investigated 
for the mononuclear palladacycles. Some possibilities include replacing the 2,6-diisopropylaniline 
moiety with more soluble analogues, such as 4-aminophenol [6] and sulfanilic acid [7]. These 
analogues are also less sterically hindered, so perhaps a series of palladacycles can be prepared 
where the effects of varying solubility and steric bulk of the aniline ring moiety on the solubility 
and biological activity of the palladacycles are evaluated, as shown in Figure 6.5. Should this be 
effective, it could be implemented for the binuclear palladacycles as well. 
 
Figure 6.5: Proposed series of palladacycles with different aniline moieties, varying both solubility (R) and steric bulk. 
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Furthermore, the lipophilicity and hydrophilicity of BTC2 (and the other palladacycles) can be 
varied, by changing the length and consequently the oxygen atom content of the ethylene glycol-
type tether [8]. Since the tether did not appear to influence the biological activity of the 
palladacycles, this may be an effective way in which to tweak the solubility to facilitate easier in 
vitro testing of the palladacycles. 
 
6.2.2 NMR spectroscopy study to confirm the concentration dependent processes 
As mentioned in the conclusions above, three chemical exchange processes were proposed to 
occur in the PTA palladacycle system, a site-exchange, PTA-self aggregation and dimerisation 
by imine ligand dissociation. Both the site-exchange and dimerisation processes were attributed 
to the small cone angle of PTA, whilst the aggregation process via PTA self-association was 
attributed to the presence of the nitrogen donor atoms and the consequent distribution of electron 
density on the ligand surface. The site-exchange process was proven satisfactorily, but the 
concentration dependent processes were a bit more complex. Both processes were shown to be 
feasibly and the dimerisation was supported by literature precedence and the detection of 
corresponding dimer fragments in the ESI-MS data, but the shifts in the imine signal were smaller 
than expected. Furthermore, no experimental support was obtained for the aggregation via PTA 
self-association. 
Thus, further modelling studies are proposed, where the changes in bond distances and electron 
density on the atoms are studied more in-depth. Furthermore, the site-exchange computational 
model should also be adjusted to include parameters that account for the observed concentration 
effects, possible aggregation and dimerisation via dissociation of the imine ligand. This would 
require rewriting of the calculations for the in-house program, NMRfitv12, used for modelling the 
site-exchange process, which is outside the scope of this project. However, obtaining a fit for all 
three processes occurring simultaneously or for the site-exchange occurring simultaneously with 
either an aggregation process or a dimerisation process would provide more concrete evidence 
to support these proposals. 
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6.2.3 DNA binding studies 
Based on the literature review in Chapter 1, it is clear that there is still very little known about the 
mode of action of palladium compounds, despite the large quantity of data highlighting the 
potential of these compounds as anti-cancer agents. This gap in the understanding of the mode 
of action of palladium compounds has been offered as the reason why the progress of palladium 
compounds has not progressed beyond pre-clinical work. Therefore, as stated in the aims of this 
project, the DNA binding studies were carried out to determine the mode of action of the 
palladacycles and hopefully provide insight into the role of the various moieties and functional 
groups in the interaction of these metallodrugs with DNA. The four techniques employed each 
pointed to a number of different DNA binding interactions, but taken together, the results 
suggested an electrostatic DNA binding mode, for which a possible active species – an aquated 
cationic species – was proposed. Thus, it is proposed that hydrolysis studies be performed on the 
palladacycles. 
A very simple assay was developed by Cui and Mester for the hydrolysis and detection of cisplatin 
and its hydrates [9], where varying concentrations of cisplatin were incubated in water at 37 °C 
for 1,2,3,4,5 and 24 hours. Samples were analysed by both ESI-MS and the results were further 
confirmed with LC/ESI-MS. Cisplatin and its hydrates were unambiguously identified with LC/ESI-
MS. This would be a simple way to determine if the proposed cationic species forms. 
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Crystallography data for 
Chapter 2 and Chapter 4 
 
A1.1 Crystal data for L7 
Table A1.1: Bond distances (Å) in the crystal structure of L7. 
C1A—C2A 1.395(2) C14A—C15A 1.525(2) 
C1A—C6A 1.399(2) C14A—C16A 1.534(2) 
C1A—C7A 1.480(2) C14A—H14A 1.0000 
C1B—C2B 1.398(2) C14B—C15B 1.532(2) 
C1B—C6B 1.393(2) C14B—C16B 1.525(5) 
C1B—C7B 1.485(2) C14B—H14B 1.0000 
C2A—C3A 1.383(2) C15A—H15A 0.9800 
C2B—C3B 1.385(2) C15A—H15B 0.9800 
C3A—C4A 1.383(2) C15A—H15C 0.9800 
C3A—H3A 0.9500 C15B—H15D 0.9800 
C3B—C4B 1.384(2) C15B—H15E 0.9800 
C3B—H3B 0.9500 C15B—H15F 0.9800 
C4A—C5A 1.390(2) C16A—H16A 0.9800 
C4A—H4A 0.9500 C16A—H16B 0.9800 
C4B—C5B 1.389(2) C16A—H16C 0.9800 
C4B—H4B 0.9500 C16B—H16D 0.9800 
C5A—C6A 1.385(2) C16B—H16E 0.9800 
C5A—H5A 0.9500 C16B—H16F 0.9800 
C5B—C6B 1.387(2) C17A—C18A 1.530(2) 
C5B—H5B 0.9500 C17A—C19A 1.527(2) 
C6A—H6A 0.9500 C17A—H17A 1.0000 
C6B—H6B 0.9500 C17B—C18B 1.533(2) 
C7A—H7A 0.9500 C17B—C19B 1.537(2) 
C7B—H7B 0.9500 C17B—H17B 1.0000 
C8A—C9A 1.405(2) C18A—H18D 0.9800 
C8A—C13A 1.403(2) C18A—H18E 0.9800 
C8B—C9B 1.407(2) C18A—H18F 0.9800 
C8B—C13B 1.407(2) C18B—H18G 0.9800 
C9A—C10A 1.390(2) C18B—H18H 0.9800 
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C9A—C17A 1.518(2) C18B—H18I 0.9800 
C9B—C10B 1.396(2) C19A—H19D 0.9800 
C9B—C17B 1.520(2) C19A—H19E 0.9800 
C10A—C11A 1.387(2) C19A—H19F 0.9800 
C10A—H10A 0.9500 C19B—H19G 0.9800 
C10B—C11B 1.381(2) C19B—H19H 0.9800 
C10B—H10B 0.9500 C19B—H21I 0.9800 
C11A—C12A 1.384(2) N1A—C2A 1.472(2) 
C11A—H11A 0.9500 N1A—O2A 1.232(2) 
C11B—C12B 1.387(2) N1B—C2B 1.467(2) 
C11B—H11B 0.9500 N1B—O2B 1.226(2) 
C12A—C13A 1.398(2) N2A—C7A 1.263(2) 
C12A—H12A 0.9500 N2A—C8A 1.431(2) 
C12B—C13B 1.396(2) N2B—C7B 1.268(2) 
C12B—H12B 0.9500 N2B—C8B 1.431(2) 
C13A—C14A 1.522(2) O1A—N1A 1.225(2) 
C13B—C14B 1.523(2) O1B—N1B 1.229(1) 
 
Table A1.2: Bond angles (°) in the crystal structure of L7. 
O1A—N1A—O2A 124.5(1) O2B—N1B—O1B 123.4(1) 
O1A—N1A—C2A 117.6(1) O2B—N1B—C2B 118.0(1) 
O2A—N1A—C2A 117.9(1) O1B—N1B—C2B 118.7(1) 
C2A—C1A—C6A 116.8(1) C6B—C1B—C2B 116.8(1) 
C2A—C1A—C7A 122.1(1) C6B—C1B—C7B 118.3(1) 
C6A—C1A—C7A 121.0(1) C2B—C1B—C7B 124.8(1) 
C7A—N2A—C8A 116.9(1) C7B—N2B—C8B 118.1(1) 
C3A—C2A—C1A 123.5(1) C3B—C2B—C1B 122.9(1) 
C3A—C2A—N1A 116.8(1) C3B—C2B—N1B 117.5(1) 
C1A—C2A—N1A 119.7(1) C1B—C2B—N1B 119.5(1) 
C2A—C3A—C4A 118.2(1) C4B—C3B—C2B 118.8(1) 
C2A—C3A—H3A 120.9 C4B—C3B—H3B 120.6 
C4A—C3A—H3A 120.9 C2B—C3B—H3B 120.6 
C3A—C4A—C5A 120.2(1) C3B—C4B—C5B 119.9(1) 
C3A—C4A—H4A 119.9 C3B—C4B—H4B 120.1 
C5A—C4A—H4A 119.9 C5B—C4B—H4B 120.1 
C6A—C5A—C4A 120.6(1) C6B—C5B—C4B 120.3(1) 
C6A—C5A—H5A 119.7 C6B—C5B—H5B 119.8 
C4A—C5A—H5A 119.7 C4B—C5B—H5B 119.8 
C5A—C6A—C1A 120.7(1) C5B—C6B—C1B 121.3(1) 
C5A—C6A—H6A 119.7 C5B—C6B—H6B 119.4 
C1A—C6A—H6A 119.7 C1B—C6B—H6B 119.4 
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N2A—C7A—C1A 121.1(1) N2B—C7B—C1B 119.5(1) 
N2A—C7A—H7A 119.4 N2B—C7B—H7B 120.2 
C1A—C7A—H7A 119.4 C1B—C7B—H7B 120.2 
C13A—C8A—C9A 121.7(1) C9B—C8B—C13B 122.3(1) 
C13A—C8A—N2A 121.3(1) C9B—C8B—N2B 116.9(1) 
C9A—C8A—N2A 116.9(1) C13B—C8B—N2B 120.4(1) 
C10A—C9A—C8A 118.2(1) C10B—C9B—C8B 117.6(1) 
C10A—C9A—C17A 122.1(1) C10B—C9B—C17B 122.4(1) 
C8A—C9A—C17A 119.8(1) C8B—C9B—C17B 119.9(1) 
C11A—C10A—C9A 121.1(1) C11B—C10B—C9B 121.1(1) 
C11A—C10A—H10A 119.5 C11B—C10B—H10B 119.4 
C9A—C10A—H10A 119.5 C9B—C10B—H10B 119.4 
C12A—C11A—C10A 119.8(1) C10B—C11B—C12B 120.2(1) 
C12A—C11A—H11A 120.1 C10B—C11B—H11B 119.9 
C10A—C11A—H11A 120.1 C12B—C11B—H11B 119.9 
C11A—C12A—C13A 121.4(1) C11B—C12B—C13B 121.3(1) 
C11A—C12A—H12A 119.3 C11B—C12B—H12B 119.3 
C13A—C12A—H12A 119.3 C13B—C12B—H12B 119.3 
C12A—C13A—C8A 117.6(1) C12B—C13B—C8B 117.2(1) 
C12A—C13A—C14A 119.7(1) C12B—C13B—C14B 122.0(1) 
C8A—C13A—C14A 122.7(1) C8B—C13B—C14B 120.6(1) 
C13A—C14A—C15A 111.5(1) C13B—C14B—C16B 114.2(1) 
C13A—C14A—C16A 110.7(1) C13B—C14B—C15B 109.7(1) 
C15A—C14A—C16A 110.7(1) C16B—C14B—C15B 109.6(1) 
C13A—C14A—H14A 108.0 C13B—C14B—H14B 107.7 
C15A—C14A—H14A 108.0 C16B—C14B—H14B 107.7 
C16A—C14A—H14A 108.0 C15B—C14B—H14B 107.7 
C14A—C15A—H15A 109.5 C14B—C15B—H15E 109.5 
C14A—C15A—H15B 109.5 C14B—C15B—H15F 109.5 
H15A—C15A—H15B 109.5 H15E—C15B—H15F 109.5 
C14A—C15A—H15C 109.5 C14B—C15B—H15D 109.5 
H15A—C15A—H15C 109.5 H15E—C15B—H15D 109.5 
H15B—C15A—H15C 109.5 H15F—C15B—H15D 109.5 
C14A—C16A—H16A 109.5 C14B—C16B—H16D 109.5 
C14A—C16A—H16B 109.5 C14B—C16B—H16F 109.5 
H16A—C16A—H16B 109.5 H16D—C16B—H16F 109.5 
C14A—C16A—H16C 109.5 C14B—C16B—H16E 109.5 
H16A—C16A—H16C 109.5 H16D—C16B—H16E 109.5 
H16B—C16A—H16C 109.5 H16F—C16B—H16E 109.5 
C9A—C17A—C19A 111.7(1) C9B—C17B—C18B 113.0(1) 
C9A—C17A—C18A 112.6(1) C9B—C17B—C19B 112.0(1) 
C19A—C17A—C18A 110.6(1) C18B—C17B—C19B 109.6(1) 
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C9A—C17A—H17A 107.2 C9B—C17B—H17B 107.3 
C19A—C17A—H17A 107.2 C18B—C17B—H17B 107.3 
C18A—C17A—H17A 107.2 C19B—C17B—H17B 107.3 
C17A—C18A—H18D 109.5 C17B—C18B—H18G 109.5 
C17A—C18A—H18F 109.5 C17B—C18B—H18I 109.5 
H18D—C18A—H18F 109.5 H18G—C18B—H18I 109.5 
C17A—C18A—H18E 109.5 C17B—C18B—H18H 109.5 
H18D—C18A—H18E 109.5 H18G—C18B—H18H 109.5 
H18F—C18A—H18E 109.5 H18I—C18B—H18H 109.5 
C17A—C19A—H19D 109.5 C17B—C19B—H19G 109.5 
C17A—C19A—H19E 109.5 C17B—C19B—H19H 109.5 
H19D—C19A—H19E 109.5 H19G—C19B—H19H 109.5 
C17A—C19A—H19F 109.5 C17B—C19B—H21I 109.5 
H19D—C19A—H19F 109.5 H19G—C19B—H21I 109.5 
H19E—C19A—H19F 109.5 H19H—C19B—H21I 109.5 
 
 
A1.2 Crystal data for B6 
Table A1.3: Bond distances (Å) in the crystal structure of B6. 
C1—C2 1.384(3) C14—C15 1.529(4) 
C1—C6 1.413(2) C14—C16 1.521(4) 
C1—C7 1.438(2) C14—C21 1.526(2) 
C2—C3 1.374(3) C14—C22 1.526(2) 
C3—C4 1.389(3) C17—C18 1.522(3) 
C4—C5 1.392(3) C17—C19 1.525(3) 
C5—C6 1.389(2) Cl1—Pd1i 2.3193(4) 
C8—C9 1.399(2) F1—C2 1.361(2) 
C8—C13 1.399(2) N(1)—C(7) 1.292(2) 
C9—C10 1.385(3) N1—C8 1.439(2) 
C9—C17 1.519(3) Pd(1)—C(6) 1.975(2) 
C10—C11 1.385(3) Pd(1)—Cl(A) 2.4454(5) 
C11—C12 1.382(3) Pd(1)—Cl(1)i 2.3192(4) 
C12—C13 1.395(3) Pd(1)—N(1) 2.015(1) 
C13—C14 1.521(3)   
Symmetry code:  (i) -x, -y, -z. 
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Table A1.4: Bond angles (°) in the crystal structure of B6. 
C2—C1—C6 119.5(2) C12—C13—C8 117.1(2) 
C2—C1—C7 125.1(2) C12—C13—C14 121.2(2) 
C6—C1—C7 115.3(2) C13—C14—C15 112.0(3) 
C3—C2—C1 122.7(2) C13—C14—C21 111(1) 
F1—C2—C1 118.4(2) C13—C14—C22 113(1) 
F1—C2—C3 118.9(2) C16—C14—C13 110.9(3) 
C2—C3—C4 117.3(2) C16—C14—C15 110.8(3) 
C3—C4—C5 122.0(2) C16—C14—C21 125(1) 
C6—C5—C4 120.0(2) C22—C14—C15 97.2(8) 
C1—C6—Pd1 112.2(1) C22—C14—C21 112(1) 
C5—C6—C1 118.5(2) C9—C17—C18 111.9(2) 
C5—C6—Pd1 129.2(1) C9—C17—C19 110.7(2) 
N1—C7—C1 115.6(2) C18—C17—C19 111.4(2) 
C9—C8—N1 117.6(2) Pd1i—Cl1—Pd1 92.75(2) 
C13—C8—C9 123.2(2) C7—N1—C8 121.4(2) 
C13—C8—N1 119.1(2) C7—N1—Pd1 115.5(1) 
C8—C9—C17 121.7(2) C8—N1—Pd1 123.0(1) 
C10—C9—C8 117.1(2) C(6)—Pd(1)—Cl(1)i 95.33(5) 
C10—C9—C17 121.2(2) C(6)—Pd(1)—Cl(A) 177.25(5) 
C11—C10—C9 121.4(2) C(6)—Pd(1)—N(1) 81.37(7) 
C12—C11—C10 120.2(2) Cl(1)i—Pd(1)—Cl(1) 87.25(2) 
C11—C12—C13 121.1(2) N(1)—Pd(1)—Cl(A) 96.06(4) 
C8—C13—C14 121.8(2) N(1)—Pd(1)—Cl(1)i 176.68(4) 
Symmetry code:  (i) -x, -y, -z. 
 
A1.3 Crystal data for C1 
Table A1.5: Bond distances (Å) in the crystal structure of C1. 
C1B—C2B 1.398(4) C18A—H18B 0.9810 
C1B—C6B 1.419(3) C18A—H18C 0.9800 
C1B—C7B 1.443(4) C18B—H18D 0.9800 
C2A—C1A 1.399(3) C18B—H18E 0.9800 
C2A—C3A 1.385(3) C18B—H18F 0.9790 
C2A—H2A 0.9500 C19A—H19A 0.9800 
C2B—C3B 1.391(4) C19A—H19B 0.9810 
C2B—H2B 0.9500 C19A—H19C 0.9790 
C3A—H3A 0.9510 C19B—H19D 0.9800 
C3B—H3B 0.9490 C19B—H19E 0.9800 
C4A—C3A 1.388(4) C19B—H19F 0.9790 
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C4A—C5A 1.389(4) C20A—H20A 0.9890 
C4A—H4A 0.9490 C20A—H20B 0.9910 
C4B—C3B 1.382(4) C20B—H20C 0.9890 
C4B—C5B 1.393(4) C20B—H20D 0.9900 
C4B—H4B 0.9500 C21A—H21A 0.9900 
C5A—H5A 0.9500 C21A—H21B 0.9910 
C5B—H5B 0.9500 C21B—H21C 0.9900 
C6A—C1A 1.417(3) C21B—H21D 0.9910 
C6A—C5A 1.398(3) C22A—H22A 0.9890 
C6B—C5B 1.398(4) C22A—H22B 0.9900 
C7A—C1A 1.447(3) C22B—H22C 0.9900 
C7A—H7A 0.9490 C22B—H22D 0.9900 
C7B—H7B 0.9490 C23A—H23A 0.9900 
C8B—C9B 1.394(4) C23A—H23B 0.9890 
C8B—C13B 1.408(4) C23B—H23C 0.9890 
C9A—C8A 1.397(4) C23B—H23D 0.9900 
C9B—C10B 1.393(3) C24A—H24A 0.9900 
C9B—C14B 1.525(4) C24A—H24B 0.9910 
C10A—C9A 1.392(3) C24B—H24C 0.9890 
C10A—H10A 0.9500 C24B—H24D 0.9900 
C10B—H10B 0.9500 C25A—H25A 0.9910 
C11A—C10A 1.381(4) C25A—H25B 0.9890 
C11A—C12A 1.381(4) C25B—H25C 0.9910 
C11A—H11A 0.9500 C25B—H25D 0.9900 
C11B—C10B 1.380(4) N1A—C7A 1.275(3) 
C11B—C12B 1.384(4) N1A—C8A 1.441(3) 
C11B—H11B 0.9500 N1B—C7B 1.286(3) 
C12A—C13A 1.388(4) N1B—C8B 1.448(3) 
C12A—H12A 0.9500 N2A—C20A 1.471(3) 
C12B—H12B 0.9500 N2A—C23A 1.473(4) 
C13A—C8A 1.403(4) N2A—C25A 1.462(4) 
C13A—C17A 1.514(4) N2B—C22B 1.479(3) 
C13B—C12B 1.392(3) N2B—C24B 1.462(4) 
C13B—C17B 1.521(4) N2B—C25B 1.469(4) 
C14A—C9A 1.511(4) N3A—C21A 1.477(3) 
C14A—C15A 1.523(4) N3A—C23A 1.473(3) 
C14A—C16A 1.528(4) N3A—C24A 1.468(4) 
C14A—H14A 1.000 N3B—C20B 1.475(3) 
C14B—C15B 1.528(4) N3B—C23B 1.477(3) 
C14B—C16B 1.516(4) N3B—C25B 1.459(3) 
C14B—H14B 1.001 N4A—C22A 1.476(3) 
C15A—H15A 0.9800 N4A—C24A 1.468(4) 
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C15A—H15B 0.9800 N4A—C25A 1.467(4) 
C15A—H15C 0.9800 N4B—C21B 1.464(3) 
C15B—H15D 0.9800 N4B—C23B 1.459 (4) 
C15B—H15E 0.9800 N4B—C24B 1.471(4) 
C15B—H15F 0.9800 P1A—C20A 1.840(3) 
C16A—H16A 0.9800 P1A—C21A 1.834(3) 
C16A—H16B 0.9790 P1A—C22A 1.842(3) 
C16A—H16C 0.9790 P1B—C20B 1.842(3) 
C16B—H16D 0.9810 P1B—C21B 1.848(3) 
C16B—H16E 0.9800 P1B—C22B 1.850(3) 
C16B—H16F 0.9800 Pd1A—C6A 2.011(3) 
C17A—C18A 1.509(4) Pd1A—Cl1A 2.3750(8) 
C17A—C19A 1.520(5) Pd1A—N1A 2.101(2) 
C17A—H17A 1.001 Pd1A—P1A 2.2176(8) 
C17B—C18B 1.534(4) Pd1B—C6B 2.015(3) 
C17B—C19B 1.527(4) Pd1B—Cl1B 2.3701(8) 
C17B—H17B 1.000 Pd1B—N1B 2.112(2) 
C18A—H18A 0.9790 Pd1B—P1B 2.2220(8) 
 
Table A1.6: Bond angles (°) in the crystal structure of C1. 
C2A—C1A—C6A 122.4(2) H18D—C18B—H18E 109.5 
C2A—C1A—C7A 121.8(2) H18F—C18B—H18D 109.5 
C6A—C1A—C7A 115.8(2) H18F—C18B—H18E 109.4 
C2B—C1B—C6B 122.5(2) C17A—C19A—H19A 109.5 
C2B—C1B—C7B 121.2(2) C17A—C19A—H19B 109.5 
C6B—C1B—C7B 116.3(2) C17A—C19A—H19C 109.6 
C1A—C2A—H2A 120.0 H19A—C19A—H19B 109.5 
C3A—C2A—C1A 119.9(2) H19C—C19A—H19A 109.4 
C3A—C2A—H2A 120.1 H19C—C19A—H19B 109.4 
C1B—C2B—H2B 120.0 C17B—C19B—H19D 109.4 
C3B—C2B—C1B 120.0(2) C17B—C19B—H19E 109.5 
C3B—C2B—H2B 120.0 C17B—C19B—H19F 109.5 
C2A—C3A—H3A 120.6 H19D—C19B—H19F 109.4 
C4A—C3A—C2A 118.8(2) H19E—C19B—H19D 109.4 
C4A—C3A—H3A 120.6 H19E—C19B—H19F 109.6 
C2B—C3B—H3B 120.7 H20A—C20A—H20B 107.9 
C4B—C3B—C2B 118.5(3) N2A—C20A—H20A 109.1 
C4B—C3B—H3B 120.8 N2A—C20A—H20B 109.1 
C3A—C4A—C5A 121.3(2) N2A—C20A—P1A 112.5(2) 
C3A—C4A—H4A 119.4 P1A—C20A—H20A 109.1 
C5A—C4A—H4A 119.3 P1A—C20A—H20B 109.1 
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C3B—C4B—C5B 121.6(3) H20C—C20B—H20D 108.0 
C3B—C4B—H4B 119.2 N3B—C20B—H20C 109.3 
C5B—C4B—H4B 119.2 N3B—C20B—H20D 109.3 
C4A—C5A—C6A 121.8(2) N3B—C20B—P1B 111.5(2) 
C4A—C5A—H5A 119.1 P1B—C20B—H20C 109.3 
C6A—C5A—H5A 119.1 P1B—C20B—H20D 109.3 
C4B—C5B—C6B 121.8(3) H21A—C21A—H21B 107.9 
C4B—C5B—H5B 119.1 N3A—C21A—H21A 109.1 
C6B—C5B—H5B 119.1 N3A—C21A—H21B 109.1 
C1A—C6A—Pd1A 111.9(2) N3A—C21A—P1A 112.5(2) 
C5A—C6A—C1A 115.9(2) P1A—C21A—H21A 109.1 
C5A—C6A—Pd1A 132.1(2) P1A—C21A—H21B 109.1 
C1B—C6B—Pd1B 111.8(2) H21C—C21B—H21D 108.1 
C5B—C6B—C1B 115.6(2) N4B—C21B—H21C 109.3 
C5B—C6B—Pd1B 132.5(2) N4B—C21B—H21D 109.3 
C1A—C7A—H7A 120.9 N3B—C21B—P1B 111.6(2) 
N1A—C7A—C1A 118.2(2) P1B—C21B—H21C 109.3 
N1A—C7A—H7A 120.9 P1B—C21B—H21D 109.3 
C1B—C7B—H7B 120.9 H22A—C22A—H22B 108.1 
N1B—C7B—C1B 118.1(2) N4A—C22A—H22A 109.4 
N1B—C7B—H7B 121.0 N4A—C22A—H22B 109.5 
C9A—C8A—C13A 122.7(2) N4A—C22A—P1A 111.0(2) 
C9A—C8A—N1A 118.9(2) P1A—C22A—H22A 109.5 
C13A—C8A—N1A 118.3(2) P1A—C22A—H22B 109.4 
C9B—C8B—C13B 122.3(2) H22C—C22B—H22D 108.0 
C9B—C8B—N1B 120.6(2) N2B—C22B—H22C 109.2 
C13B—C8B—N1B 117.1(2) N2B—C22B—H22D 109.2 
C8A—C9A—C14A 121.9(2) N2B—C22B—P1B 112.0(2) 
C10A—C9A—C8A 117.4(2) P1B—C22B—H22C 109.2 
C10A—C9A—C14A 120.6(2) P1B—C22B—H22D 109.2 
C8B—C9B—C14B 121.4(2) H23A—C23A—H23B 107.6 
C10B—C9B—C8B 117.3(2) N2A—C23A—H23A 108.6 
C10B—C9B—C14B 121.2(2) N2A—C23A—H23B 108.6 
C9A—C10A—H10A 119.3 N2A—C23A—N3A 114.5(2) 
C11A—C10A—C9A 121.3(3) N3A—C23A—H23A 108.6 
C11A—C10A—H10A 119.4 N3A—C23A—H23B 108.6 
C9B—C10B—H10B 119.3 H23C—C23B—H23D 107.5 
C11B—C10B—C9B 121.5(3) N3B—C23B—H23C 108.4 
C11B—C10B—H10B 119.2 N3B—C23B—H23D 108.4 
C10A—C11A—C12A 119.9(3) N4B—C23B—H23C 108.4 
C10A—C11A—H11A 120.0 N4B—C23B—H23D 108.3 
C12A—C11A—H11A 120.1 N4B—C23B—N3B 115.6(2) 
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C10B—C11B—C12B 120.2(2) H24A—C24A—H24B 107.4 
C10B—C11B—H11B 119.9 N3A—C24A—H24A 108.4 
C12B—C11B—H11B 119.9 N3A—C24A—H24B 108.4 
C11A—C12A—C13A 121.6(3) N4A—C24A—H24A 108.4 
C11A—C12A—H12A 119.2 N4A—C24A—H24B 108.4 
C13A—C12A—H12A 119.2 N4A—C24A—N3A 115.5(2) 
C11B—C12B—C13B 120.6(3) H24C—C24B—H24D 107.6 
C11B—C12B—H12B 119.7 N4B—C24B—H24C 108.6 
C13B—C12B—H12B 119.7 N4B—C24B—H24D 108.6 
C8A—C13A—C17A 122.0(2) N2B—C24B—H24C 108.7 
C12A—C13A—C8A 117.1(3) N2B—C24B—H24D 108.7 
C12A—C13A—C17A 120.9(3) N2B—C24B—N4B 114.3(2) 
C8B—C13B—C17B 120.7(2) H25A—C25A—H25B 107.6 
C12B—C13B—C8B 117.8(2) N2A—C25A—H25A 108.6 
C12B—C13B—C17B 121.5(2) N2A—C25A—H25B 108.6 
C9A—C14A—C15A 110.1(2) N2A—C25A—N4A 114.5(2) 
C9A—C14A—C16A 112.0(2) N4A—C25A—H25A 108.6 
C9A—C14A—H14A 107.9 N4A—C25A—H25B 108.7 
C15A—C14A—C16A 111.0(3) H25C—C25B—H25D 107.6 
C15A—C14A—H14A 107.8 N2B—C25B—H25C 108.5 
C16A—C14A—H14A 107.8 N2B—C25B—H25D 108.6 
C9B—C14B—C15B 109.5(2) N3B—C25B—N2B 114.8(2) 
C9B—C14B—H14B 108.0 N3B—C25B—H25C 108.5 
C15B—C14B—H14B 108.1 N3B—C25B—H25D 108.6 
C16B—C14B—C9B 113.1(2) C7A—N1A—C8A 120.4(2) 
C16B—C14B—C15B 109.8(3) C7A—N1A—Pd1A 113.0(2) 
C16B—C14B—H14B 108.1 C8A—N1A—Pd1A 126.5(2) 
C14A—C15A—H15A 109.5 C7B—N1B—C8B 119.0(2) 
C14A—C15A—H15B 109.4 C7B—N1B—Pd1B 112.7(2) 
C14A—C15A—H15C 109.4 C8B—N1B—Pd1B 128.1(2) 
H15A—C15A—H15B 109.5 C20A—N2A—C23A 111.4(2) 
H15A—C15A—H15C 109.5 C25A—N2A—C20A 110.5(2) 
H15C—C15A—H15B 109.5 C25A—N2A—C23A 108.3(2) 
C14B—C15B—H15D 109.5 C24B—N2B—C22B 110.2(2) 
C14B—C15B—H15E 109.4 C24B—N2B—C25B 108.7(2) 
C14B—C15B—H15F 109.4 C25B—N2B—C22B 111.4(2) 
H15D—C15B—H15E 109.5 C23A—N3A—C21A 110.7(2) 
H15D—C15B—H15F 109.5 C24A—N3A—C21A 110.4(2) 
H15F—C15B—H15E 109.5 C24A—N3A—C23A 107.7(2) 
C14A—C16A—H16A 109.4 C20B—N3B—C23B 111.6(2) 
C14A—C16A—H16B 109.4 C25B—N3B—C20B 110.8(2) 
C14A—C16A—H16C 109.5 C25B—N3B—C23B 107.4(2) 
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H16B—C16A—H16A 109.4 C24A—N4A—C22A 111.5(2) 
H16B—C16A—H16C 109.5 C25A—N4A—C22A 110.9(2) 
H16C—C16A—H16A 109.6 C25A—N4A—C24A 108.5(2) 
C14B—C16B—H16D 109.4 C21B—N4B—C24B 111.1(2) 
C14B—C16B—H16E 109.4 C23B—N4B—C21B 111.3(2) 
C14B—C16B—H16F 109.5 C23B—N4B—C24B 108.1(2) 
H16E—C16B—H16D 109.6 C20A—P1A—C22A 97.7(1) 
H16E—C16B—H16F 109.5 C20A—P1A—Pd1A 116.83(9) 
H16F—C16B—H16D 109.5 C21A—P1A—C20A 97.62(1) 
C13A—C17A—C19A 112.7(3) C21A—P1A—C22A 100.2(1) 
C13A—C17A—H17A 107.7 C21A—P1A—Pd1A 115.20(9) 
C18A—C17A—C13A 112.1(3) C22A—P1A—Pd1A 124.6(9) 
C18A—C17A—C19A 108.9(3) C20B—P1B—Pd1B 116.96(9) 
C18A—C17A—H17A 107.6 C20B—P1B—C21B 100.4(1) 
C19A—C17A—H17A 107.6 C20B—P1B—C22B 97.8(1) 
C13B—C17B—C18B 112.9(2) C21B—P1B—Pd1B 121.8(1) 
C13B—C17B—C19B 111.1(2) C21B—P1B—C22B 97.2(1) 
C13B—C17B—H17B 107.6 C22B—P1B—Pd1B 118.2(9) 
C18B—C17B—C19B 109.9(2) C6A—Pd1A—Cl1A 173.27(8) 
C18B—C17B—H17B 107.6 C6A—Pd1A—N1A 81.01(9) 
C19B—C17B—H17B 107.6 C6A—Pd1A—P1A 94.53(7) 
C17A—C18A—H18A 109.5 N1A—Pd1A—Cl1A 93.87(6) 
C17A—C18A—H18B 109.5 N1A—Pd1A—P1A 170.68(6) 
C17A—C18A—H18C 109.4 P1A—Pd1A—Cl1A 91.16(3) 
H18A—C18A—H18C 109.5 C6B—Pd1B—Cl1B 174.08(8) 
H18B—C18A—H18A 97(4) C6B—Pd1B—N1B 81.01(9) 
H18B—C18A—H18C 109.5 C6B—Pd1B—P1B 95.20(8) 
C17B—C18B—H18D 109.5 N1B—Pd1B—Cl1B 93.34(6) 
C17B—C18B—H18E 109.5 N1B—Pd1B—P1B 173.52(6) 
C17B—C18B—H18F 109.5 P1B—Pd1B—Cl1B 90.59(2) 
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A1.4 Crystal data for C2 
Table A1.7: Bond distances (Å) in the crystal structure of C2. 
C1A—C2A 1.398(2) C17B—C19B 1.535(2) 
C2A—C3A 1.400(2) C17B—H17B 1.0000 
C2A—H2A 0.9500 C18A—H18A 0.9800 
C2B—C1B 1.398(2) C18A—H18B 0.9800 
C2B—C3B 1.399(2) C18A—H18C 0.9800 
C2B—H2B 0.9500 C18B—H18D 0.9800 
C3A—H3A 0.9500 C18B—H18E 0.9800 
C3B—H3B 0.9500 C18B—H18F 0.9800 
C4A—C3A 1.390(2) C19A—H19D 0.9800 
C4A—H4A 0.9500 C19A—H19E 0.9800 
C4B—C3B 1.387(2) C19A—H19F 0.9800 
C4B—H4B 0.9500 C19B—H19A 0.9800 
C5A—C4A 1.387(2) C19B—H19B 0.9800 
C5B—C4B 1.385(2) C19B—H19C 0.9800 
C6A—C1A 1.428(2) C20A—H20C 0.9900 
C6A—C5A 1.397(2) C20A—H20D 0.9900 
C6B—C1B 1.422(2) C20B—H20A 0.9900 
C6B—C5B 1.399(2) C20B—H20B 0.9900 
C7A—C6A 1.452(2) C20B—N27 1.470(2) 
C7A—H7A 0.9500 C21A—H21A 0.9900 
C7A—N1A 1.287(2) C21A—H21B 0.9900 
C7B—C6B 1.456(2) C21B—H21C 0.9900 
C7B—H7B 0.9500 C21B—H21D 0.9900 
C8A—C9A 1.406(2) C22A—H22C 0.9900 
C8A—C13A 1.403(2) C22A—H22D 0.9900 
C9A—C10A 1.396(2) C22B—H22A 0.9900 
C9A—C14A 1.523(2) C22B—H22B 0.9900 
C9B—C8B 1.405(2) C23A—H23A 0.9900 
C9B—C10B 1.398(2) C23A—H23B 0.9900 
C10A—C11A 1.380(2) C23B—H23C 0.9900 
C10A—H10A 0.9500 C23B—H23D 0.9900 
C10B—C11B 1.382(2) C24A—H24C 0.9900 
C10B—H10B 0.9500 C24A—H24D 0.9900 
C11A—H11A 0.9500 C24B—H24A 0.9900 
C11B—H11B 0.9500 C24B—H24B 0.9900 
C12A—C11A 1.385(2) C25A—H25C 0.9900 
C12A—H12A 0.9500 C25A—H25D 0.9900 
C12B—C11B 1.389(2) C25B—H25A 0.9900 
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C12B—H12B 0.9500 C25B—H25B 0.9900 
C13A—C12A 1.395(2) Cl2A—C5A 1.746(1) 
C13A—C17A 1.519(2) Cl2B—C5B 1.744(2) 
C13B—C8B 1.404(2) N1A—C8A 1.441(2) 
C13B—C12B 1.393(2) N2A—C20A 1.473(2) 
C13B—C17B 1.515(2) N2A—C21A 1.465(2) 
C14A—C15A 1.524(2) N2A—C24A 1.473(2) 
C14A—C15C 1.523(2) N3—C7B 1.284(2) 
C14A—C16A 1.524(2) N3—C8B 1.441(2) 
C14A—C16C 1.524(2) N3A—C21A 1.472(2) 
C14A—H14A 1.0000 N3A—C22A 1.475(2) 
C14B—C9B 1.523(2) N3A—C25A 1.468(2) 
C14B—C15B 1.530(2) N4A—C23A 1.473(2) 
C14B—C16B 1.532(2) N4A—C24A 1.468(2) 
C14B—H14B 1.0000 N4A—C25A 1.469(2) 
C15A—H15D 0.9800 N21—C21B 1.467(2) 
C15A—H15E 0.9800 N21—C22B 1.477(2) 
C15A—H15F 0.9800 N21—C25B 1.475(2) 
C15B—H15A 0.9800 N27—C21B 1.466(2) 
C15B—H15B 0.9800 N27—C24B 1.476(2) 
C15B—H15C 0.9800 N34—C23B 1.472(2) 
C15C—H15G 0.9800 N34—C24B 1.474(2) 
C15C—H15H 0.9800 N34—C25B 1.468(2) 
C15C—H15I 0.9800 P1A—C20A 1.838(1) 
C16A—H16D 0.9800 P1A—C22A 1.844(1) 
C16A—H16E 0.9800 P1A—C23A 1.847(1) 
C16A—H16F 0.9800 P1B—C20B 1.852(1) 
C16B—H16A 0.9800 P1B—C22B 1.845(1) 
C16B—H16B 0.9800 P1B—C23B 1.840(1) 
C16B—H16C 0.9800 Pd1A—C1A 2.005(1) 
C16C—H16G 0.9800 Pd1A—Cl1A 2.3667(3) 
C16C—H16H 0.9800 Pd1A—N1A 2.092(1) 
C16C—H16I 0.9800 Pd1A—P1A 2.2321(3) 
C17A—C18A 1.526(2) Pd1B—C1B 2.005(1) 
C17A—C19A 1.529(2) Pd1B—Cl1B 2.3721(3) 
C17A—H17A 1.0000 Pd1B—N3 2.092(1) 
C17B—C18B 1.529(2) Pd1B—P1B 2.2404(3) 
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Table A1.8: Bond angles (°) in the crystal structure of C2. 
C2A—C1A—C6A 117.1(1) C17A—C18A—H18C 109.5 
C2A—C1A—Pd1A 131.34(9) H18A—C18A—H18B 109.5 
C6A—C1A—Pd1A 111.55(9) H18A—C18A—H18C 109.5 
C2B—C1B—C6B 117.5(1) H18B—C18A—H18C 109.5 
C2B—C1B—Pd1B 130.7(1) C17B—C18B—H18D 109.5 
C6B—C1B—Pd1B 111.63(9) C17B—C18B—H18E 109.5 
C1A—C2A—C3A 121.3(1) C17B—C18B—H18F 109.5 
C1A—C2A—H2A 119.4 H18D—C18B—H18E 109.5 
C3A—C2A—H2A 119.4 H18D—C18B—H18F 109.5 
C1B—C2B—C3B 121.3(1) H18E—C18B—H18F 109.5 
C1B—C2B—H2B 119.4 C17A—C19A—H19D 109.5 
C3B—C2B—H2B 119.4 C17A—C19A—H19E 109.5 
C2A—C3A—H3A 119.4 C17A—C19A—H19F 109.5 
C4A—C3A—C2A 121.2(1) H19D—C19A—H19E 109.5 
C4A—C3A—H3A 119.4 H19D—C19A—H19F 109.5 
C2B—C3B—H3B 119.4 H19E—C19A—H19F 109.5 
C4B—C3B—C2B 121.2(1) C17B—C19B—H19A 109.5 
C4B—C3B—H3B 119.4 C17B—C19B—H19B 109.5 
C3A—C4A—H4A 120.9 C17B—C19B—H19C 109.5 
C5A—C4A—C3A 118.3(1) H19A—C19B—H19B 109.5 
C5A—C4A—H4A 120.9 H19A—C19B—H19C 109.5 
C3B—C4B—H4B 121.0 H19B—C19B—H19C 109.5 
C5B—C4B—C3B 118.1(1) H20C—C20A—H20D 107.9 
C5B—C4B—H4B 121.0 N2A—C20A—H20C 109.1 
C4A—C5A—C6A 121.6(1) N2A—C20A—H20D 109.1 
C4A—C5A—Cl2A 118.1(1) N2A—C20A—P1A 112.37(8) 
C6A—C5A—Cl2A 120.4(1) P1A—C20A—H20C 109.1 
C4B—C5B—C6B 122.1(1) P1A—C20A—H20D 109.1 
C4B—C5B—Cl2B 117.6(1) H20A—C20B—H20B 107.9 
C6B—C5B—Cl2B 120.3(1) N27—C20B—H20A 109.2 
C1A—C6A—C7A 115.8(1) N27—C20B—H20B 109.2 
C5A—C6A—C1A 120.4(1) N27—C20B—P1B 112.19(9) 
C5A—C6A—C7A 123.8(1) P1B—C20B—H20A 109.2 
C1B—C6B—C7B 116.2(1) P1B—C20B—H20B 109.2 
C5B—C6B—C1B 119.8(1) H21A—C21A—H21B 107.6 
C5B—C6B—C7B 124.0(1) N2A—C21A—H21A 108.6 
C6A—C7A—H7A 121.3 N2A—C21A—H21B 108.6 
N1A—C7A—C6A 117.5(1) N2A—C21A—N3A 114.5(1) 
N1A—C7A—H7A 121.3 N3A—C21A—H21A 108.6 
C6B—C7B—H7B 121.6 N3A—C21A—H21B 108.6 
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N3—C7B—C6B 116.9(1) H21C—C21B—H21D 107.6 
N3—C7B—H7B 121.6 N21—C21B—H21C 108.7 
C9A—C8A—N1A 119.0(1) N21—C21B—H21D 108.7 
C13A—C8A—C9A 122.3(1) N27—C21B—H21C 108.7 
C13A—C8A—N1A 118.4(1) N27—C21B—H21D 108.7 
C9B—C8B—N3 119.1(1) N27—C21B—N21 114.4(1) 
C13B—C8B—C9B 122.5(1) H22C—C22A—H22D 108.1 
C13B—C8B—N3 118.1(1) N3A—C22A—H22C 109.5 
C8A—C9A—C14A 122.6(1) N3A—C22A—H22D 109.5 
C10A—C9A—C8A 117.2(1) N3A—C22A—P1A 110.79(9) 
C10A—C9A—C14A 120.0(1) P1A—C22A—H22C 109.5 
C8B—C9B—C14B 122.6(1) P1A—C22A—H22D 109.5 
C10B—C9B—C8B 117.2(1) H22A—C22B—H22B 108.0 
C10B—C9B—C14B 120.1(1) N21—C22B—H22A 109.3 
C9A—C10A—H10A 119.2 N21—C22B—H22B 109.3 
C11A—C10A—C9A 121.6(1) N21—C22B—P1B 111.45(9) 
C11A—C10A—H10A 119.2 P1B—C22B—H22A 109.3 
C9B—C10B—H10B 119.2 P1B—C22B—H22B 109.3 
C11B—C10B—C9B 121.6(1) H23A—C23A—H23B 107.9 
C11B—C10B—H10B 119.2 N4A—C23A—H23A 109.2 
C10A—C11A—C12A 119.9(1) N4A—C23A—H23B 109.2 
C10A—C11A—H11A 120.1 N4A—C23A—P1A 111.86(9) 
C12A—C11A—H11A 120.1 P1A—C23A—H23A 109.2 
C10B—C11B—C12B 119.9(1) P1A—C23A—H23B 109.2 
C10B—C11B—H11B 120.0 H23C—C23B—H23D 107.9 
C12B—C11B—H11B 120.0 N34—C23B—H23C 109.2 
C11A—C12A—C13A 121.2(1) N34—C23B—H23D 109.2 
C11A—C12A—H12A 119.4 N34—C23B—P1B 111.98(9) 
C13A—C12A—H12A 119.4 P1B—C23B—H23C 109.2 
C11B—C12B—C13B 121.1(1) P1B—C23B—H23D 109.2 
C11B—C12B—H12B 119.4 H24C—C24A—H24D 107.7 
C13B—C12B—H12B 119.4 N2A—C24A—H24C 108.8 
C8A—C13A—C17A 121.0(1) N2A—C24A—H24D 108.8 
C12A—C13A—C8A 117.6(1) N4A—C24A—H24C 108.8 
C12A—C13A—C17A 121.3(1) N4A—C24A—H24D 108.8 
C8B—C13B—C17B 120.1(1) N4A—C24A—N2A 113.9(1) 
C12B—C13B—C8B 117.7(1) H24A—C24B—H24B 107.6 
C12B—C13B—C17B 122.1(1) N27—C24B—H24A 108.7 
C9A—C14A—C15A 112.4(2) N27—C24B—H24B 108.7 
C9A—C14A—C15C 115.3(7) N34—C24B—H24A 108.7 
C9A—C14A—C16A 111.0(3) N34—C24B—H24B 108.7 
C9A—C14A—C16C 107.4(7) N34—C24B—N27 114.2(1) 
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C9A—C14A—H14A 107.7 H25C—C25A—H25D 107.6 
C15A—C14A—C16A 110.1(3) N3A—C25A—H25C 108.6 
C15A—C14A—H14A 107.7 N3A—C25A—H25D 108.6 
C15C—C14A—C16C 110.4(9) N3A—C25A—N4A 114.5(1) 
C16A—C14A—H14A 107.7 N4A—C25A—H25C 108.6 
C9B—C14B—C15B 109.9(1) N4A—C25A—H25D 108.6 
C9B—C14B—C16B 112.9(1) H25A—C25B—H25B 107.7 
C9B—C14B—H14B 107.9 N21—C25B—H25A 108.8 
C15B—C14B—C16B 110.3(1) N21—C25B—H25B 108.8 
C15B—C14B—H14B 107.9 N34—C25B—H25A 108.8 
C16B—C14B—H14B 107.9 N34—C25B—H25B 108.8 
C14A—C15A—H15D 109.5 N34—C25B—N21 113.7(1) 
C14A—C15A—H15E 109.5 C7A—N1A—C8A 120.2(1) 
C14A—C15A—H15F 109.5 C7A—N1A—Pd1A 113.17(8) 
H15D—C15A—H15E 109.5 C8A—N1A—Pd1A 125.38(8) 
H15D—C15A—H15F 109.5 C21A—N2A—C20A 110.6(1) 
H15E—C15A—H15F 109.5 C21A—N2A—C24A 108.5(1) 
C14B—C15B—H15A 109.5 C24A—N2A—C20A 111.3(1) 
C14B—C15B—H15B 109.5 C7B—N3—C8B 121.2(1) 
C14B—C15B—H15C 109.5 C7B—N3—Pd1B 113.75(8) 
H15A—C15B—H15B 109.5 C8B—N3—Pd1B 124.07(8) 
H15A—C15B—H15C 109.5 C21A—N3A—C22A 111.7(1) 
H15B—C15B—H15C 109.5 C25A—N3A—C21A 108.5(1) 
C14A—C15C—H15G 109.5 C25A—N3A—C22A 111.2(1) 
C14A—C15C—H15H 109.5 C24A—N4A—C23A 111.0(1) 
C14A—C15C—H15I 109.5 C24A—N4A—C25A 108.1(1) 
H15G—C15C—H15H 109.5 C25A—N4A—C23A 111.6(1) 
H15G—C15C—H15I 109.5 C21B—N21—C22B 111.6(1) 
H15H—C15C—H15I 109.5 C21B—N21—C25B 108.7(1) 
C14A—C16A—H16D 109.5 C25B—N21—C22B 111.3(1) 
C14A—C16A—H16E 109.5 C20B—N27—C24B 111.1(1) 
C14A—C16A—H16F 109.5 C21B—N27—C20B 111.2(1) 
H16D—C16A—H16E 109.5 C21B—N27—C24B 108.1(1) 
H16D—C16A—H16F 109.5 C23B—N34—C24B 111.6(1) 
H16E—C16A—H16F 109.5 C25B—N34—C23B 111.0(1) 
C14B—C16B—H16A 109.5 C25B—N34—C24B 108.7(1) 
C14B—C16B—H16B 109.5 C20A—P1A—C22A 99.33(6) 
C14B—C16B—H16C 109.5 C20A—P1A—C23A 97.01(6) 
H16A—C16B—H16B 109.5 C20A—P1A—Pd1A 115.28(4) 
H16A—C16B—H16C 109.5 C22A—P1A—C23A 99.19(7) 
H16B—C16B—H16C 109.5 C22A—P1A—Pd1A 122.85(4) 
C14A—C16C—H16G 109.5 C23A—P1A—Pd1A 118.52(4) 
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C14A—C16C—H16H 109.5 C20B—P1B—Pd1B 109.70(4) 
C14A—C16C—H16I 109.5 C22B—P1B—C20B 97.92(6) 
H16G—C16C—H16H 109.5 C22B—P1B—Pd1B 127.99(4) 
H16G—C16C—H16I 109.5 C23B—P1B—C20B 98.49(6) 
H16H—C16C—H16I 109.5 C23B—P1B—C22B 98.43(6) 
C13A—C17A—C18A 111.6(1) C23B—P1B—Pd1B 118.93(4) 
C13A—C17A—C19A 112.5(1) C1A—Pd1A—Cl1A 173.38(4) 
C13A—C17A—H17A 107.2 C1A—Pd1A—N1A 81.36(5) 
C18A—C17A—C19A 110.8(1) C1A—Pd1A—P1A 95.61(4) 
C18A—C17A—H17A 107.2 N1A—Pd1A—Cl1A 92.05(3) 
C19A—C17A—H17A 107.2 N1A—Pd1A—P1A 169.84(3) 
C13B—C17B—C18B 113.3(1) P1A—Pd1A—Cl1A 90.98(1) 
C13B—C17B—C19B 111.0(1) C1B—Pd1B—Cl1B 170.57(4) 
C13B—C17B—H17B 107.3 C1B—Pd1B—N3 81.32(5) 
C18B—C17B—C19B 110.5(1) C1B—Pd1B—P1B 100.54(4) 
C18B—C17B—H17B 107.3 N3—Pd1B—Cl1B 93.67(3) 
C19B—C17B—H17B 107.3 N3—Pd1B—P1B 166.21(3) 
C17A—C18A—H18A 109.5 P1B—Pd1B—Cl1B 86.23(1) 
C17A—C18A—H18B 109.5   
 
 
A1.5 Crystal data for C4 
Table A1.9: Bond distances (Å) in the crystal structure of C4. 
C1A—C2A 1.408(3) C17B—C19B 1.531(3) 
C1A—C6A 1.426(3) C20B—N2B 1.478(3) 
C1A—C7A 1.442(3) C26A—C2A 1.510(3) 
C1B—C2B 1.410(3) C26B—C2B 1.508(3) 
C1B—C6B 1.420(3) N1A—C7A 1.279(3) 
C1B—C7B 1.444(3) N1A—C8A 1.440(3) 
C3A—C2A 1.383(3) N1B—C7B 1.283(3) 
C3A—C4A 1.388(3) N1B—C8B 1.447(3) 
C3B—C2B 1.387(3) N2A—C20A 1.478(3) 
C3B—C4B 1.384(3) N2A—C23A 1.468(3) 
C5A—C4A 1.392(3) N2A—C25A 1.461(3) 
C5B—C4B 1.390(3) N2B—C23B 1.470(3) 
C6A—C5A 1.392(3) N2B—C25B 1.476(3) 
C6B—C5B 1.396(3) N3A—C21A 1.473(3) 
C8A—C9A 1.399(3) N3A—C23A 1.467(3) 
C8A—C13A 1.392(3) N3A—C24A 1.463(3) 
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C8B—C9B 1.394(3) N3B—C21B 1.474(3) 
C8B—C13B 1.395(3) N3B—C23B 1.471(3) 
C9A—C10A 1.396(4) N3B—C24B 1.466(3) 
C9A—C14A 1.520(4) N4A—C22A 1.467(3) 
C9B—C10B 1.395(3) N4A—C24A 1.475(3) 
C9B—C14B 1.511(3) N4A—C25A 1.468(3) 
C10A—C11A 1.377(4) N4B—C22B 1.468(3) 
C10B—C11B 1.387(3) N4B—C24B 1.463(3) 
C12A—C11A 1.382(4) N4B—C25B 1.465(3) 
C12B—C11B 1.383(3) P1A—C20A 1.842(2) 
C13A—C12A 1.388(3) P1A—C21A 1.848(3) 
C13B—C12B 1.399(3) P1A—C22A 1.844(2) 
C13B—C17B 1.512(3) P1B—C20B 1.845(2) 
C14A—C15A 1.463(4) P1B—C21B 1.845(2) 
C14A—C16A 1.441(5) P1B—C22B 1.849(2) 
C14B—C15B 1.510(4) Pd1A—C6A 2.022(2) 
C14B—C15C 1.74(2) Pd1A—Cl1A 2.3832(6) 
C14B—C16B 1.513(4) Pd1A—N1A 2.089(2) 
C14B—C16C 1.48(2) Pd1A—P1A 2.2229(6) 
C17A—C13A 1.515(3) Pd1B—C6B 2.018(2) 
C17A—C18A 1.527(3) Pd1B—Cl1B 2.3773(6) 
C17A—C19A 1.531(3) Pd1B—N1B 2.087(2) 
C17B—C18B 1.521(4) Pd1B—P1B 2.2347(6) 
 
Table A1.10: Bond angles (°) in the crystal structure of C4. 
C2A—C1A—C6A 123.0(2) C13B—C17B—C19B 111.4(2) 
C2A—C1A—C7A 121.9(2) C18B—C17B—C19B 111.6(2) 
C6A—C1A—C7A 115.0(2) N2A—C20A—P1A 111.7(2) 
C2B—C1B—C6B 123.3(2) N2B—C20B—P1B 112.0(2) 
C2B—C1B—C7B 121.5(2) N3A—C21A—P1A 111.4(2) 
C6B—C1B—C7B 115.0(2) N3B—C21B—P1B 111.7(2) 
C1A—C2A—C26A 121.5(2) N4A—C22A—P1A 112.0(2) 
C3A—C2A—C1A 118.2(2) N4B—C22B—P1B 111.7(2) 
C3A—C2A—C26A 120.2(2) N3A—C23A—N2A 114.4(2) 
C1B—C2B—C26B 121.9(2) N2B—C23B—N3B 114.3(2) 
C3B—C2B—C1B 117.5(2) N3A—C24A—N4A 115.0(2) 
C3B—C2B—C26B 120.5(2) N4B—C24B—N3B 114.9(2) 
C2A—C3A—C4A 120.3(2) N2A—C25A—N4A 114.6(2) 
C4B—C3B—C2B 120.7(2) N4B—C25B—N2B 113.8(2) 
C3A—C4A—C5A 120.7(2) C7A—N1A—C8A 117.9(2) 
C3B—C4B—C5B 120.9(2) C7A—N1A—Pd1A 113.3(2) 
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C4A—C5A—C6A 122.0(2) C8A—N1A—Pd1A 128.8(2) 
C4B—C5B—C6B 121.5(2) C7B—N1B—C8B 117.7(2) 
C1A—C6A—Pd1A 112.0(2) C7B—N1B—Pd1B 112.9(2) 
C5A—C6A—C1A 115.8(2) C8B—N1B—Pd1B 129.2(1) 
C5A—C6A—Pd1A 132.2(2) C23A—N2A—C20A 111.3(2) 
C1B—C6B—Pd1B 112.1(2) C25A—N2A—C20A 111.1(2) 
C5B—C6B—C1B 116.0(2) C25A—N2A—C23A 108.3(2) 
C5B—C6B—Pd1B 131.6(2) C23B—N2B—C20B 111.0(2) 
N1A—C7A—C1A 118.8(2) C23B—N2B—C25B 108.3(2) 
N1B—C7B—C1B 118.9(2) C25B—N2B—C20B 111.4(2) 
C9A—C8A—N1A 118.7(2) C23A—N3A—C21A 110.8(2) 
C13A—C8A—C9A 122.6(2) C24A—N3A—C21A 111.6(2) 
C13A—C8A—N1A 118.7(2) C24A—N3A—C23A 108.3(2) 
C9B—C8B—C13B 122.7(2) C23B—N3B—C21B 110.7(2) 
C9B—C8B—N1B 118.2(2) C24B—N3B—C21B 111.6(2) 
C13B—C8B—N1B 119.0(2) C24B—N3B—C23B 108.2(2) 
C8A—C9A—C14A 121.9(2) C22A—N4A—C24A 110.9(2) 
C10A—C9A—C8A 117.1(2) C22A—N4A—C25A 110.6(2) 
C10A—C9A—C14A 120.9(3) C25A—N4A—C24A 108.5(2) 
C8B—C9B—C10B 117.5(2) C24B—N4B—C22B 111.8(2) 
C8B—C9B—C14B 120.5(2) C24B—N4B—C25B 108.6(2) 
C10B—C9B—C14B 122.0(2) C25B—N4B—C22B 110.9(2) 
C11A—C10A—C9A 121.4(3) C20A—P1A—C21A 97.7(2) 
C11B—C10B—C9B 121.0(2) C20A—P1A—C22A 97.8(1) 
C10A—C11A—C12A 119.5(2) C20A—P1A—Pd1A 118.84(8) 
C12B—C11B—C10B 120.1(2) C21A—P1A—Pd1A 121.63(8) 
C11A—C12A—C13A 121.7(2) C22A—P1A—C21A 99.8(1) 
C11B—C12B—C13B 120.9(2) C22A—P1A—Pd1A 116.56(8) 
C8A—C13A—C17A 120.4(2) C20B—P1B—C21B 97.7(1) 
C12A—C13A—C8A 117.2(2) C20B—P1B—C22B 97.6(1) 
C12A—C13A—C17A 122.3(2) C20B—P1B—Pd1B 116.87(8) 
C8B—C13B—C12B 117.5(2) C21B—P1B—C22B 99.7(1) 
C8B—C13B—C17B 121.5(2) C21B—P1B—Pd1B 118.11(8) 
C12B—C13B—C17B 121.0(2) C22B—P1B—Pd1B 122.28(8) 
C15A—C14A—C9A 112.4(3) C6A—Pd1A—Cl1A 173.80(7) 
C16A—C14A—C9A 116.4(3) C6A—Pd1A—N1A 80.88(8) 
C16A—C14A—C15A 121.3(3) C6A—Pd1A—P1A 95.02(7) 
C9B—C14B—C15C 105.0(5) N1A—Pd1A—Cl1A 93.11(5) 
C9B—C14B—C16B 112.1(2) N1A—Pd1A—P1A 175.89(5) 
C15B—C14B—C9B 112.4(2) P1A—Pd1A—Cl1A 90.98(2) 
C15B—C14B—C16B 113.7(3) C6B—Pd1B—Cl1B 171.62(6) 
C16C—C14B—C9B 106.7(9) C6B—Pd1B—N1B 81.02(8) 
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C16C—C14B—C15C 101(1) C6B—Pd1B—P1B 96.04(6) 
C13A—C17A—C18A 112.6(2) N1B—Pd1B—Cl1B 91.87(5) 
C13A—C17A—C19A 112.0(2) N1B—Pd1B—P1B 176.45(5) 
C18A—C17A—C19A 111.2(2) P1B—Pd1B—Cl1B 91.21(2) 
C13B—C17B—C18B 110.9(2)   
 
 
A1.6 Crystal data for T2 
Table A1.11: Bond distances (Å) in the crystal structure of T2. 
C1—C2 1.403(2) C12A—H12H 0.9800 
C1—C6 1.409(2) C12A—H12I 0.9800 
C1A—C2A 1.405(2) C12B—H12D 0.9800 
C1A—C6A 1.409(2) C12B—H12E 0.9800 
C2—C3 1.389(2) C12B—H12F 0.9800 
C2—C7 1.523(2) C12C—H12J 0.9800 
C2A—C3A 1.396(2) C12C—H12K 0.9800 
C2A—C7A 1.518(2) C12C—H12L 0.9800 
C3—C4 1.382(2) C13—C14 1.469(2) 
C3—H3A 0.9500 C13—H13 0.9500 
C3A—C4A 1.380(2) C13A—C14A 1.465(2) 
C3A—H3AB 0.9500 C13A—H13A 0.9500 
C4—C5 1.385(2) C14—C15 1.400(2) 
C4—H4 0.9500 C14—C19 1.396(2) 
C4A—C5A 1.384(2) C14A—C15A 1.393(2) 
C4A—H4A 0.9500 C14A—C19A 1.400(2) 
C5—C6 1.391(2) C15—C16 1.379(2) 
C5—H5 0.9500 C15—H15 0.9500 
C5A—C6A 1.394(2) C15A—C16A 1.385(2) 
C5A—H5A 0.9500 C15A—H15A 0.9500 
C6—C10 1.522(2) C16—C17 1.394(2) 
C6A—C10A 1.520(2) C16—H16 0.9500 
C7—C8 1.523(2) C16A—C17A 1.397(2) 
C7—C9 1.528(2) C16A—H16A 0.9500 
C7—H7 1.0000 C17—C18 1.395(2) 
C7A—C8A 1.528(2) C17A—C18A 1.391(2) 
C7A—C9A 1.531(2) C18—C19 1.383(2) 
C7A—H7A 1.0000 C18—H18 0.9500 
C8—H8A 0.9800 C18A—C19A 1.380(2) 
C8—H8B 0.9800 C18A—H18A 0.9500 
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C8—H8C 0.9800 C19—H19 0.9500 
C8A—H8AA 0.9800 C19A—H19A 0.9500 
C8A—H8AB 0.9800 C20—C21 1.512(2) 
C8A—H8AC 0.9800 C20—H20A 0.9900 
C9—H9A 0.9800 C20—H20B 0.9900 
C9—H9B 0.9800 C20A—C21A 1.503(2) 
C9—H9C 0.9800 C20A—H20C 0.9900 
C9A—H9AA 0.9800 C20A—H20D 0.9900 
C9A—H9AB 0.9800 C21—H21A 0.9900 
C9A—H9AC 0.9800 C21—H21B 0.9900 
C10—C11 1.510(2) C21A—H21C 0.9900 
C10—C11B 1.523(3) C21A—H21D 0.9900 
C10—C12 1.535(2) C22—C23 1.497(2) 
C10—C12B 1.507(3) C22—H22A 0.9900 
C10—H10 1.0000 C22—H22B 0.9900 
C10—H10A 1.0000 C22A—C23A 1.504(2) 
C10A—C11A 1.507(2) C22A—H22C 0.9900 
C10A—C11C 1.525(4) C22A—H22D 0.9900 
C10A—C12A 1.527(2) C23—H23A 0.9900 
C10A—C12C 1.507(4) C23—H23B 0.9900 
C10A—H10B 1.0000 C23A—H23C 0.9900 
C10A—H10C 1.0000 C23A—H23D 0.9900 
C11—H11A 0.9800 N1—C1 1.425(2) 
C11—H11B 0.9800 N1—C13 1.273(2) 
C11—H11C 0.9800 N1A—C1A 1.425(2) 
C11A—H11G 0.9800 N1A—C13A 1.272(2) 
C11A—H11H 0.9800 O1—C17 1.361(2) 
C11A—H11I 0.9800 O1—C20 1.434(2) 
C11B—H11D 0.9800 O1A—C17A 1.364(2) 
C11B—H11E 0.9800 O1A—C20A 1.430(2) 
C11B—H11F 0.9800 O2—C21 1.420(2) 
C11C—H11J 0.9800 O2—C22 1.427(2) 
C11C—H11K 0.9800 O2A—C21A 1.426(2) 
C11C—H11L 0.9800 O2A—C22A 1.431(2) 
C12—H12A 0.9800 O3—C23 1.411(3) 
C12—H12B 0.9800 O3—H3 0.88(3) 
C12—H12C 0.9800 O3A—C23A 1.422(2) 
C12A—H12G 0.9800 O3A—H3AA 0.87(3) 
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Table A1.12: Bond angles (°) in the crystal structure of T2. 
C2—C1—C6 121.5(1) C10—C12—H12B 109.5 
C2—C1—N1 118.4(1) C10—C12—H12C 109.5 
C6—C1—N1 119.9(1) H12A—C12—H12B 109.5 
C2A—C1A—C6A 121.8(1) H12A—C12—H12C 109.5 
C2A—C1A—N1A 118.5(1) H12B—C12—H12C 109.5 
C6A—C1A—N1A 119.5(1) C10A—C12A—H12G 109.5 
C1—C2—C7 120.2(1) C10A—C12A—H12H 109.5 
C3—C2—C1 118.3(1) C10A—C12A—H12I 109.5 
C3—C2—C7 121.5(1) H12G—C12A—H12H 109.5 
C1A—C2A—C7A 120.6(1) H12G—C12A—H12I 109.5 
C3A—C2A—C1A 117.9(1) H12H—C12A—H12I 109.5 
C3A—C2A—C7A 121.5(1) C10—C12B—H12D 109.5 
C2—C3—H3A 119.4 C10—C12B—H12E 109.5 
C4—C3—C2 121.2(1) C10—C12B—H12F 109.5 
C4—C3—H3A 119.4 H12D—C12B—H12E 109.5 
C2A—C3A—H3AB 119.5 H12D—C12B—H12F 109.5 
C4A—C3A—C2A 121.1(1) H12E—C12B—H12F 109.5 
C4A—C3A—H3AB 119.5 C10A—C12C—H12J 109.5 
C3—C4—C5 120.0(1) C10A—C12C—H12K 109.5 
C3—C4—H4 120.0 C10A—C12C—H12L 109.5 
C5—C4—H4 120.0 H12J—C12C—H12K 109.5 
C3A—C4A—C5A 120.3(1) H12J—C12C—H12L 109.5 
C3A—C4A—H4A 119.8 H12K—C12C—H12L 109.5 
C5A—C4A—H4A 119.8 C14—C13—H13 118.6 
C4—C5—C6 121.2(1) N1—C13—C14 122.8(1) 
C4—C5—H5 119.4 N1—C13—H13 118.6 
C6—C5—H5 119.4 C14A—C13A—H13A 118.3 
C4A—C5A—C6A 121.1(1) N1A—C13A—C14A 123.4(1) 
C4A—C5A—H5A 119.4 N1A—C13A—H13A 118.3 
C6A—C5A—H5A 119.4 C15—C14—C13 119.0(1) 
C1—C6—C10 120.3(1) C19—C14—C13 122.3(1) 
C5—C6—C1 117.9(1) C19—C14—C15 118.6(1) 
C5—C6—C10 121.7(1) C15A—C14A—C13A 122.5(1) 
C1A—C6A—C10A 120.6(1) C15A—C14A—C19A 118.4(1) 
C5A—C6A—C1A 117.8(1) C19A—C14A—C13A 119.0(1) 
C5A—C6A—C10A 121.7(1) C14—C15—H15 119.6 
C2—C7—C8 113.0(1) C16—C15—C14 120.8(1) 
C2—C7—C9 110.5(1) C16—C15—H15 119.6 
C2—C7—H7 107.4 C14A—C15A—H15A 119.5 
C8—C7—C9 110.9(1) C16A—C15A—C14A 121.1(1) 
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C8—C7—H7 107.4 C16A—C15A—H15A 119.5 
C9—C7—H7 107.4 C15—C16—C17 120.0(1) 
C2A—C7A—C8A 112.4(1) C15—C16—H16 120.0 
C2A—C7A—C9A 112.1(1) C17—C16—H16 120.0 
C2A—C7A—H7A 107.2 C15A—C16A—C17A 119.5(1) 
C8A—C7A—C9A 110.4(1) C15A—C16A—H16A 120.3 
C8A—C7A—H7A 107.2 C17A—C16A—H16A 120.3 
C9A—C7A—H7A 107.2 C16—C17—C18 119.9(1) 
C7—C8—H8A 109.5 O1—C17—C16 115.3(1) 
C7—C8—H8B 109.5 O1—C17—C18 124.8(1) 
C7—C8—H8C 109.5 C18A—C17A—C16A 120.3(1) 
H8A—C8—H8B 109.5 O1A—C17A—C16A 124.1(1) 
H8A—C8—H8C 109.5 O1A—C17A—C18A 115.6(1) 
H8B—C8—H8C 109.5 C17—C18—H18 120.2 
C7A—C8A—H8AA 109.5 C19—C18—C17 119.6(1) 
C7A—C8A—H8AB 109.5 C19—C18—H18 120.2 
C7A—C8A—H8AC 109.5 C17A—C18A—H18A 120.2 
H8AA—C8A—H8AB 109.5 C19A—C18A—C17A 119.5(1) 
H8AA—C8A—H8AC 109.5 C19A—C18A—H18A 120.2 
H8AB—C8A—H8AC 109.5 C14—C19—H19 119.5 
C7—C9—H9A 109.5 C18—C19—C14 121.0(1) 
C7—C9—H9B 109.5 C18—C19—H19 119.5 
C7—C9—H9C 109.5 C14A—C19A—H19A 119.4 
H9A—C9—H9B 109.5 C18A—C19A—C14A 121.2(1) 
H9A—C9—H9C 109.5 C18A—C19A—H19A 119.4 
H9B—C9—H9C 109.5 C21—C20—H20A 110.1 
C7A—C9A—H9AA 109.5 C21—C20—H20B 110.1 
C7A—C9A—H9AB 109.5 H20A—C20—H20B 108.5 
C7A—C9A—H9AC 109.5 O1—C20—C21 107.8(1) 
H9AA—C9A—H9AB 109.5 O1—C20—H20A 110.1 
H9AA—C9A—H9AC 109.5 O1—C20—H20B 110.1 
H9AB—C9A—H9AC 109.5 C21A—C20A—H20C 110.4 
C6—C10—C11B 111.8(4) C21A—C20A—H20D 110.4 
C6—C10—C12 113.9(1) H20C—C20A—H20D 108.6 
C6—C10—H10 107.5 O1A—C20A—C21A 106.8(1) 
C6—C10—H10A 104.3 O1A—C20A—H20C 110.4 
C11—C10—C6 110.1(1) O1A—C20A—H20D 110.4 
C11—C10—C12 110.2(1) C20—C21—H21A 108.7 
C11—C10—H10 107.5 C20—C21—H21B 108.7 
C11B—C10—H10A 104.3 H21A—C21—H21B 107.6 
C12—C10—H10 107.5 O2—C21—C20 114.3(1) 
C12B—C10—C6 116.3(4) O2—C21—H21A 108.7 
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C12B—C10—C11B 114.2(6) O2—C21—H21B 108.7 
C12B—C10—H10A 104.3 C20A—C21A—H21C 110.0 
C6A—C10A—C11C 107.8(5) C20A—C21A—H21D 110.0 
C6A—C10A—C12A 114.4(1) H21C—C21A—H21D 108.4 
C6A—C10A—H10B 106.4 O2A—C21A—C20A 108.3(1) 
C6A—C10A—H10C 106.0 O2A—C21A—H21C 110.0 
C11A—C10A—C6A 111.6(1) O2A—C21A—H21D 110.0 
C11A—C10A—C12A 111.0(2) C23—C22—H22A 110.0 
C11A—C10A—H10B 106.4 C23—C22—H22B 110.0 
C11C—C10A—H10C 106.0 H22A—C22—H22B 108.4 
C12A—C10A—H10B 106.4 O2—C22—C23 108.6(1) 
C12C—C10A—C6A 113.1(5) O2—C22—H22A 110.0 
C12C—C10A—C11C 117.0(8) O2—C22—H22B 110.0 
C12C—C10A—H10C 106.0 C23A—C22A—H22C 109.9 
C10—C11—H11A 109.5 C23A—C22A—H22D 109.9 
C10—C11—H11B 109.5 H22C—C22A—H22D 108.3 
C10—C11—H11C 109.5 O2A—C22A—C23A 109.0(1) 
H11A—C11—H11B 109.5 O2A—C22A—H22C 109.9 
H11A—C11—H11C 109.5 O2A—C22A—H22D 109.9 
H11B—C11—H11C 109.5 C22—C23—H23A 109.0 
C10A—C11A—H11G 109.5 C22—C23—H23B 109.0 
C10A—C11A—H11H 109.5 H23A—C23—H23B 107.8 
C10A—C11A—H11I 109.5 O3—C23—C22 112.9(2) 
H11G—C11A—H11H 109.5 O3—C23—H23A 109.0 
H11G—C11A—H11I 109.5 O3—C23—H23B 109.0 
H11H—C11A—H11I 109.5 C22A—C23A—H23C 109.6 
C10—C11B—H11D 109.5 C22A—C23A—H23D 109.6 
C10—C11B—H11E 109.5 H23C—C23A—H23D 108.1 
C10—C11B—H11F 109.5 O3A—C23A—C22A 110.2(1) 
H11D—C11B—H11E 109.5 O3A—C23A—H23C 109.6 
H11D—C11B—H11F 109.5 O3A—C23A—H23D 109.6 
H11E—C11B—H11F 109.5 C13—N1—C1 118.5(1) 
C10A—C11C—H11J 109.5 C13A—N1A—C1A 118.3(1) 
C10A—C11C—H11K 109.5 C17—O1—C20 118.7(1) 
C10A—C11C—H11L 109.5 C17A—O1A—C20A 118.2(1) 
H11J—C11C—H11K 109.5 C21—O2—C22 114.0(1) 
H11J—C11C—H11L 109.5 C21A—O2A—C22A 112.5(1) 
H11K—C11C—H11L 109.5 C23—O3—H3 107(2) 
C10—C12—H12A 109.5 C23A—O3A—H3AA 114(2) 
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A1.7 CIFCHECK reports 
A1.7.1 CIFCHECK report for L7 
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A1.7.2 CIFCHECK report for B6 
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A1.7.3 CIFCHECK report for C1 
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A1.7.4 CIFCHECK report for C2 
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A1.7.5 CIFCHECK report for C4 
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A1.7.6 CIFCHECK report for T2 
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Additional NMR spectroscopy study 
data 
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Figure A2.2: 1H NMR spectroscopic array of C2 in CDCl3 (20 – 40 °C). 
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Figure A2.4: 1H NMR spectroscopic array of C4 in CDCl3 (-50 – 40 °C). 
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Figure A2.6: 1H NMR spectroscopic array of C6 in CDCl3 (-20 – 40 °C). 
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Figure A2.8: 1H NMR spectroscopic array of C8 in CDCl3 (-50 – 40 °C). 
 
 
Figure A2.9: 1H NMR (25 °C) of C2 in TCE-d2 showing no change after cooling, heating and cooling again. Note that the slight 
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Figure A2.10: Eyring plot of C1 in CDCl3. 
Dataset: Experimental 
Function: A*x+B 
R2 = 0.9926 
B = 11.52 ± 0.4020 
A = -3874 ± 111.3 
Dataset: 95% Confidence limit (+) 
Dataset: 95% Confidence limit (-) 
Function: A*x+B 
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Figure A2.11: Eyring plot of C2 in CDCl3. 
 
Figure A2.12: Eyring plot of C4 in CDCl3. 
Dataset: Experimental 
Function: A*x+B 
R2 = 0.9998 
B = 12.46 ± 0.2389 
A = -5125 ± 73.60 
Dataset: 95% Confidence limit (+) 




R2 = 0.9940 
B = 15.78 ± 0.4302 
A = -4780 ± 117.9 
Dataset: 95% Confidence limit (+) 
Dataset: 95% Confidence limit (-) 
Function: A*x+B 
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Figure A2.13: Eyring plot of C5 in CDCl3. 
 
Figure A2.14: Eyring plot of C6 in CDCl3. 
Dataset: Experimental 
Function: A*x+B 
R2 = 0.9967 
B = 12.86 ± 0.3548 
A = -4271 ± 99.69 
Dataset: 95% Confidence limit (+) 




R2 = 0.9966 
B = 11.87 ± 0.3639 
A = -4526 ± 107.3 
Dataset: 95% Confidence limit (+) 
Dataset: 95% Confidence limit (-) 
Function: A*x+B 
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Figure A2.15: Eyring plot of C7 in CDCl3. 
 
Figure A2.16: Eyring plot of C8 in CDCl3.  
Dataset: Experimental 
Function: A*x+B 
R2 = 0.9918 
B = 12.51 ± 0.5084 
A = -4315 ± 148.6 
Dataset: 95% Confidence limit (+) 




R2 = 0.9955 
B = 12.83 ± 0.4879 
A = -4795 ± 144.1 
Dataset: 95% Confidence limit (+) 
Dataset: 95% Confidence limit (-) 
Function: A*x+B 
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Additional DNA binding study data 
 




Figure A3.1: UV-Vis spectra of ethidium bromide interaction with DNA, the summed absorbances of ethidium bromide and 
DNA, and DNA. 
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Figure A3.3: UV-Vis spectra of methyl green interaction with DNA, the summed absorbances of methyl green and DNA, and 
DNA. 
  
Stellenbosch University  https://scholar.sun.ac.za




A3.2 CD spectroscopic data 
 
Figure A3.4: CD spectra of ethidium bromide interaction with DNA at various concentrations. 
 
Figure A3.5: CD spectra of methylene blue interaction with DNA at various concentrations. 
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Figure A3.6: CD spectra of methyl green interaction with DNA at various concentrations. 
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